0001213900-24-09841810-Q Modular Medical, Inc. 20241114202411141605491605491605490 0001213900-24-098418 10-Q 54 20240930 20241114 20241114 Modular Medical, Inc. 0001074871 3841 870620495 NV 0331 10-Q 34 001-41277 241461927 16772 WEST BERNARDO DRIVE SAN DIEGO CA 92127 858-800-3500 16772 WEST BERNARDO DRIVE SAN DIEGO CA 92127 BEAR LAKE RECREATION INC 19981208 10-Q 1 ea0220455-10q_modular.htm QUARTERLY REPORT Â Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549Â Â FORM 10-Q Â (Mark One) â˜’ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Â For the quarterly period ended September 30, 2024 Â or Â â˜ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Â For the transition period from Â toÂ Commission file number: 000-49671 Â MODULAR MEDICAL, INC. (Exact Name of Registrant as Specified in its Charter) Â Nevada Â 87-0620495 (State or Other Jurisdiction of Incorporation or Organization) Â (I.R.S. Employer Identification No.) Â 10740 Thornmint Road, San Diego, CA 92127 (Address of Principal Executive Offices) (Zip Code) Â (858) 800-3500 (Registrantâ€™s telephone number, including area code) Â Securities registered pursuant to Section 12(b) of the Act: Â Title of each class Â Trading symbol(s) Â Name of each exchange on which registered Common Stock Par Value $.001 per Share Â MODD Â The Nasdaq Stock Market, LLC Â Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Â â˜’ Yes â˜ No Â Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Â â˜’ Yes â˜ No Â Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act. Â Large accelerated filer â˜ Accelerated filer â˜ Non-accelerated Filer â˜’ Smaller reporting company â˜’ Â Emerging growth company â˜ Â If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. â˜ Â Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Â â˜ Yes â˜’ No Â The number of outstanding shares of the registrantâ€™s common stock, par value $0.001 per share, was 34,571,939 as of November 13, 2024. Â Â Â Â Â MODULAR MEDICAL,Â INC. Â FORMÂ 10-Q SEPTEMBERÂ 30, 2024 Â TABLE OF CONTENTS Â PARTÂ I â€” FINANCIAL INFORMATION 1 Â Â Â Item 1. Financial Statements (Unaudited): 1 Â Â Â Â Condensed Consolidated Balance Sheets as of SeptemberÂ 30, 2024 and MarchÂ 31, 2024 1 Â Â Â Â Condensed Consolidated Statements of Operations for the three and six monthsÂ ended September 30, 2024 and September 30, 2023 2 Â Â Â Â Condensed Consolidated Statements of Stockholdersâ€™ Equity for the three and six months endedÂ September 30, 2024 and 2023 3 Â Â Â Â Condensed Consolidated Statements of Cash Flows for the six months ended September 30, 2024 and 2023 4 Â Â Â Â Notes to Condensed Consolidated Financial Statements 5 Â Â Â Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations 14 Â Â Â Item 3. Quantitative and Qualitative Disclosures about Market Risk 17 Â Â Â Item 4. Controls and Procedures 17 Â Â Â PARTÂ II â€” OTHER INFORMATION 18 Â Â Â Item 1. Legal Proceedings 18 Â Â Â Item 1A. Risk Factors 18 Â Â Â Item 2. Unregistered Sales of Equity Securities 18 Â Â Â Item 3. Defaults Upon Senior Securities 18 Â Â Â Item 4. Mine Safety Disclosures 18 Â Â Â Item 5. Other Information 18 Â Â Â Item 6. Exhibits 19 Â Â Â Signatures 20 Â i Â Â Â Part I â€” FINANCIAL INFORMATION Â Item 1. Financial Statements Â Modular Medical, Inc. Condensed Consolidated Balance Sheets (In thousands, except par value) Â Â Â September 30, 2024 (Unaudited)Â Â March 31, 2024Â ASSETSÂ Â Â Â Â Â CURRENT ASSETSÂ Â Â Â Â Â Cash and cash equivalentsÂ $3,893Â Â $9,232Â Prepaid expenses and otherÂ Â 283Â Â Â 465Â TOTAL CURRENT ASSETSÂ Â 4,176Â Â Â 9,697Â Â Â Â Â Â Â Â Property and equipment, netÂ Â 3,641Â Â Â 2,975Â Right of use asset, netÂ Â 954Â Â Â 1,135Â TOTAL ASSETSÂ $8,771Â Â $13,807Â Â Â Â Â Â Â Â Â LIABILITIES AND STOCKHOLDERSâ€™ EQUITYÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â CURRENT LIABILITIESÂ Â Â Â Â Â Â Accounts payableÂ $501Â Â $802Â Accrued expensesÂ Â 345Â Â Â 280Â Short-term lease liabilitiesÂ Â 398Â Â Â 373Â TOTAL CURRENT LIABILITIESÂ Â 1,244Â Â Â 1,455Â Â Â Â Â Â Â Â Long-term lease liabilitiesÂ Â 611Â Â Â 817Â TOTAL LIABILITIESÂ Â 1,855Â Â Â 2,272Â Â Â Â Â Â Â Â Commitments and Contingencies (Note 7)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â STOCKHOLDERSâ€™ EQUITYÂ Â Â Â Â Â Â Preferred Stock, $0.001 par value, 5,000 shares authorized, none issued and outstandingÂ Â â€"Â Â Â â€"Â Common Stock, $0.001 par value, 100,000 shares authorized; 34,370 and 32,464 shares issued and outstanding as of September 30, 2024 and March 31, 2024, respectivelyÂ Â 34Â Â Â 32Â Additional paid-in capitalÂ Â 81,904Â Â Â 77,432Â Accumulated deficitÂ Â (75,022)Â Â (65,929) TOTAL STOCKHOLDERSâ€™ EQUITYÂ Â 6,916Â Â Â 11,535Â TOTAL LIABILITIES AND STOCKHOLDERSâ€™ EQUITYÂ $8,771Â Â $13,807Â Â The accompanying notes are an integral part of these condensed consolidated financial statements. Â 1 Â Â Modular Medical, Inc. Condensed Consolidated Statements of Operations (Unaudited) (In thousands, except per share data) Â Â Â Three Months Ended September 30,Â Â Six Months Ended September 30,Â Â Â Â 2024 Â Â Â 2023Â Â 2024Â Â 2023Â Operating expensesÂ Â Â Â Â Â Â Â Â Â Â Â Â Research and developmentÂ $3,702Â Â $3,159Â Â $6,907Â Â $5,927Â General and administrativeÂ Â 1,294Â Â Â 1,031Â Â Â 2,309Â Â Â 2,014Â Total operating expensesÂ Â 4,996Â Â Â 4,190Â Â Â 9,216Â Â Â 7,941Â Loss from operationsÂ Â (4,996)Â Â (4,190)Â Â (9,216)Â Â (7,941) Other incomeÂ Â 42Â Â Â 9Â Â Â 125Â Â Â 23Â Loss before income taxesÂ Â (4,954)Â Â (4,181)Â Â (9,091)Â Â (7,918) Provision for income taxesÂ Â 2Â Â Â 2Â Â Â 2Â Â Â 2Â Net lossÂ $(4,956)Â $(4,183)Â $(9,093)Â $(7,920) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net loss per shareÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Basic and dilutedÂ $(0.14)Â $(0.19)Â $(0.27)Â $(0.40) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Shares used in computing net loss per shareÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Basic and dilutedÂ Â 34,338Â Â Â 22,445Â Â Â 34,114Â Â Â 19,786Â Â The accompanying notes are an integral part of these condensed consolidated financial statements. Â 2 Â Â Modular Medical, Inc. Condensed Consolidated Statements of Stockholdersâ€™ Equity (Unaudited) (In thousands) Â Â Â Common StockÂ Â Additional Paid-InÂ Â AccumulatedÂ Â Stockholdersâ€™Â Â Â SharesÂ Â AmountÂ Â CapitalÂ Â DeficitÂ Â EquityÂ Balance as of March 31, 2024Â Â 32,464Â Â $32Â Â $77,432Â Â $(65,929)Â $11,535Â Shares issued for servicesÂ Â 10Â Â Â â€"Â Â Â 15Â Â Â â€"Â Â Â 15Â Exercise of warrantsÂ Â 55Â Â Â â€"Â Â Â 68Â Â Â â€"Â Â Â 68Â Issuances under equity incentive planÂ Â 32Â Â Â â€"Â Â Â 6Â Â Â â€"Â Â Â 6Â Stock-based compensationÂ Â â€"Â Â Â â€"Â Â Â 529Â Â Â â€"Â Â Â 529Â Net lossÂ Â â€"Â Â Â â€"Â Â Â â€"Â Â Â (4,137)Â Â (4,137) Balance as of June 30, 2024Â Â 32,561Â Â $32Â Â $78,050Â Â $(70,066)Â $8,016Â Shares issued for servicesÂ Â 20Â Â Â â€"Â Â Â 35Â Â Â â€"Â Â Â 35Â Exercise of warrantsÂ Â 939Â Â Â 1Â Â Â 844Â Â Â â€"Â Â Â 845Â At-the-market sales of stock, netÂ Â 825Â Â Â 1Â Â Â 1,922Â Â Â â€"Â Â Â 1,923Â Issuances under equity incentive planÂ Â 25Â Â Â â€"Â Â Â 9Â Â Â â€"Â Â Â 9Â Stock-based compensationÂ Â â€"Â Â Â â€"Â Â Â 1,044Â Â Â â€"Â Â Â 1,044Â Net lossÂ Â â€"Â Â Â â€"Â Â Â â€"Â Â Â (4,956)Â Â (4,956) Balance as of September 30, 2024Â Â 34,370Â Â $34Â Â $81,904Â Â $(75,022)Â $6,916Â Â Â Â Common StockÂ Â Additional Paid-InÂ Â AccumulatedÂ Â Stockholdersâ€™Â Â Â SharesÂ Â AmountÂ Â CapitalÂ Â DeficitÂ Â EquityÂ Balance as of March 31, 2023Â Â 10,949Â Â $11Â Â $53,524Â Â $(48,459)Â $5,076Â Issuance of common stock and warrants in equity offering, netÂ Â 10,139Â Â Â 10Â Â Â 9,723Â Â Â â€"Â Â Â 9,733Â Issuances under equity incentive planÂ Â 7Â Â Â â€"Â Â Â 6Â Â Â â€"Â Â Â 6Â Stock-based compensationÂ Â â€"Â Â Â â€"Â Â Â 478Â Â Â â€"Â Â Â 478Â Net lossÂ Â â€"Â Â Â â€"Â Â Â â€"Â Â Â (3,737)Â Â (3,737) Balance as of June 30, 2023Â Â 21,095Â Â $21Â Â $63,731Â Â $(52,196)Â $11,556Â Shares issued for servicesÂ Â 2Â Â Â â€"Â Â Â 1Â Â Â â€"Â Â Â 1Â Issuances under equity incentive planÂ Â 27Â Â Â â€"Â Â Â 7Â Â Â â€"Â Â Â 7Â Stock-based compensationÂ Â â€"Â Â Â â€"Â Â Â 557Â Â Â â€"Â Â Â 557Â Net lossÂ Â â€"Â Â Â â€"Â Â Â â€"Â Â Â (4,183)Â Â (4,183) Balance as of September 30, 2023Â Â 21,124Â Â $21Â Â $64,296Â Â $(56,379)Â $7,938Â Â The accompanying notes are an integral part of these condensed consolidated financial statements. Â 3 Â Â Modular Medical, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited) (In thousands) Â Â Â Six Months Ended September 30,Â Â Â 2024Â Â 2023Â CASH FLOWS FROM OPERATING ACTIVITIESÂ Â Â Â Â Â Net lossÂ $(9,093)Â $(7,920) Adjustments to reconcile net loss to net cash used in operating activities:Â Â Â Â Â Â Â Stock-based compensation expenseÂ Â 1,588Â Â Â 1,048Â Depreciation and amortizationÂ Â 456Â Â Â 153Â Shares for servicesÂ Â 26Â Â Â 11Â Changes in assets and liabilities:Â Â Â Â Â Â Â Prepaid expenses and other assetsÂ Â 64Â Â Â 105Â Lease right-of-use assetÂ Â 182Â Â Â 168Â Accounts payable and accrued expensesÂ Â (355)Â Â 137Â Change in lease liabilityÂ Â (182)Â Â (186) Net cash used in operating activitiesÂ Â (7,314)Â Â (6,484) Â Â Â Â Â Â Â Â CASH FLOWS FROM INVESTING ACTIVITIESÂ Â Â Â Â Â Purchases of property and equipmentÂ Â (1,003)Â Â (718) Net cash used in investing activitiesÂ Â (1,003)Â Â (718) Â Â Â Â Â Â Â Â CASH FLOWS FROM FINANCING ACTIVITIESÂ Â Â Â Â Â Proceeds from at-the-market sales of stock, netÂ Â 1,923Â Â Â â€"Â Proceeds from exercise of common stock purchase warrantsÂ Â 1,055Â Â Â â€"Â Proceeds from issuance of common stock and warrants, netÂ Â â€"Â Â Â 9,733Â Net cash provided by financing activitiesÂ Â 2,978Â Â Â 9,733Â Â Â Â Â Â Â Â Net increase (decrease) in cash and cash equivalentsÂ Â (5,339)Â Â 2,531Â Â Â Â Â Â Â Â Cash and cash equivalents at beginning of periodÂ Â 9,232Â Â Â 3,799Â Â Â Â Â Â Â Â Cash and cash equivalents at end of periodÂ $3,893Â Â $6,330Â Â The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. Â 4 Â Â MODULAR MEDICAL, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) Â NOTE 1 â€" THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Â Modular Medical, Inc. (the Company) was incorporated in Nevada in October 1998 under the name Bear Lake Recreation, Inc. The Company had no material business operations from 2002 until approximately 2017 when it acquired all of the issued and outstanding shares of Quasuras, Inc., a Delaware corporation (Quasuras), and changed its name from Bear Lake Recreation, Inc. to Modular Medical, Inc. Â The Company is a pre-revenue, medical device company focused on the design, development and eventual commercialization of innovative insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. Through the creation of an innovative two-part patch pump, its initial product, the MODD1, the Company seeks to fundamentally alter the trade-offs between cost and complexity and access to the higher standards of care requiring considerable motivation that presently available insulin pumps provide. By simplifying and streamlining the user experience from introduction, prescription, reimbursement, training and day-to-day use, the Company seeks to expand the wearable insulin delivery device market beyond the highly motivated â€œsuper usersâ€ and expand the category into the mass market. The product seeks to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets. In January 2024, the Company submitted a 510(k) premarket notification to the United States Food and Drug Administration (FDA) for the MODD1, and, in September 2024, the Company received FDA clearance to market and sell its MODD1 pump in the United States. Â Liquidity and Going Concern Â The Company does not currently have revenues to generate cash flows to cover operating expenses. Since its inception, the Company has incurred operating losses and negative cash flows in each year due to costs incurred in connection with its operations. The Company expects to continue to incur operating losses for the foreseeable future and incur cash outflows from operations as it continues to invest in the development and commercialization of its products. The Company expects that its research and development and general and administrative expenses will continue to increase, and, as a result, it will eventually need to generate significant revenue to achieve profitability. When considered with its current operating plan, these conditions raise substantial doubt about the Companyâ€™s ability to continue as a going concern within one year after the date that these financial statements are issued. In addition, the Companyâ€™s independent registered public accounting firm, in its report on the consolidated financial statements as of and for the year ended March 31, 2024, expressed substantial doubt about the Companyâ€™s ability to continue as a going concern. These condensed consolidated financial statements do not include any adjustments that might result from this uncertainty. Implementation of the Companyâ€™s plans and its ability to continue as a going concern will depend upon the Companyâ€™s ability to raise additional capital, through the sale of additional equity or debt securities, to support its future operations. There can be no assurance that such additional capital, whether in the form of debt or equity financing, will be sufficient or available and, if available, that such capital will be offered on terms and conditions acceptable to the Company. The Companyâ€™s operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital expenditures. The Companyâ€™s future capital requirements and the adequacy of its available funds will depend on many factors, including the Companyâ€™s ability to successfully commercialize its MODD1 product, competing technological and market developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement its product offering. If the Company is unable to secure additional capital, it may be required to curtail its product commercialization and research and development initiatives and take additional measures to reduce costs in order to conserve its cash.Â 5 Â Â Basis of Presentation Â The Companyâ€™s fiscal year ends on March 31 of each calendar year. Each reference to a fiscal year in these notes to the condensed consolidated financial statements refers to the fiscal year ended March 31 of the calendar year indicated (for example, fiscal 2025 refers to the fiscal year ending March 31, 2025). The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Quasuras. All significant intercompany transactions and balances have been eliminated in consolidation. Â The accompanying condensed consolidated financial statements are unaudited and have been prepared in accordance with generally accepted accounting principles in the United States (GAAP) and with the rules and regulations of the United States Security and Exchange Commission (SEC) regarding interim financial reporting. The condensed consolidated balance sheet as of March 31, 2024 has been derived from the audited consolidated financial statements at that date. Certain information and disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted in accordance with these rules and regulations of the SEC. The information in this report should be read in conjunction with the Companyâ€™s consolidated financial statements and notes thereto included in its most recent annual report on Form 10-K filed with the SEC. Â In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Companyâ€™s financial position, results of operations and cash flows for the interim periods presented. The operating results for the six months ended September 30, 2024 are not necessarily indicative of the results that may be expected for the year ending March 31, 2025 or for any other future period. Â Use of Estimates Â The preparation of the accompanying condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of revenues and expenses during the reporting period. Estimates may include those pertaining to accruals, stock-based compensation and income taxes. Actual results could differ from those estimates. Â Reportable Segment Â The Company operates in one business segment and uses one measurement of profitability for its business. Â Research and Development Â The Company expenses research and development expenditures as incurred. Â Â Concentration of Credit Risk Â Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash held in demand deposit accounts. The Company maintains a portion of its cash in demand deposit accounts at high credit quality financial institutions within the United States, which are insured by the Federal Deposit Insurance Corporation (FDIC) up to limits of approximately $250,000. No reserve has been made in the financial statements for any possible loss due to financial institution failure.Â 6 Â Â Risks and Uncertainties Â The Company is subject to risks from, among other things, competition associated with the industry in general, other risks associated with financing, liquidity requirements, rapidly changing customer requirements, limited operating history, pandemics, wars and acts of terrorism and the volatility of public markets. The Company may be unable to access the capital markets, and additional capital may only be available to the Company on terms that could be significantly detrimental to its existing stockholders and to its business. Â Â Cash and Cash Equivalents Â Cash and cash equivalents include cash held in demand deposit and money market accounts, certificates of deposit and all highly liquid debt instruments with original maturities of three months or less. Â Property and Equipment Â Property and equipment are recorded at historical cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally three to five years. Depreciation is recorded in operating expenses in the consolidated statements of operations. Leasehold improvements and assets acquired through finance leases are amortized over the shorter of their estimated useful life or the lease term, and amortization is recorded in operating expenses in the consolidated statements of operations. Construction-in-process includes machinery and equipment and is stated at cost and not depreciated. Depreciation on construction-in-process commences when the assets are ready for their intended use and placed into service. Â Fair Value of Financial Instruments Â The Company measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels: Â â—Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets. Â Â â— Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. Â Â â— Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement. Â Due

to their short-term nature, the carrying values of cash equivalents, accounts payable and accrued expenses, approximate fair value. Â Leases Â The Companyâ€™s right-of-use assets consist of leased assets recognized in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) No. 842, Leases, which requires lessees to recognize a lease liability and a corresponding lease asset for virtually all lease contracts. Right-of-use assets represent the Companyâ€™s right to use an underlying asset for the lease term and the lease liability represents the Companyâ€™s obligation to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the consolidated balance sheets and are expensed on a straight-line basis over the lease term in the consolidated statement of operations and comprehensive loss. The Company determines the lease term by agreement with the lessor. In cases where the lease does not provide an implicit interest rate, the Company uses the Companyâ€™s incremental borrowing rate based on the information available at commencement date in determining the present value of future payments.Â 7 Â Â Stock-Based Compensation Â The Company periodically issues stock options, restricted stock units and stock awards to employees and non-employees. The Company accounts for such awards based on FASB ASC Topic 718, whereby the value of the award is measured on the date of grant and recognized as compensation expense on a straight-line basis over the requisite service period, usually the vesting period. With respect to performance-based awards, the Company assesses the probability of achieving the requisite performance criteria before recognizing compensation expense. The fair value of the Companyâ€™s stock options is estimated using the Black-Scholes-Merton Option Pricing (Black Scholes) model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the options, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes model. The assumptions used in the Black-Scholes model could materially affect compensation expense recorded in future periods. Â Per-Share Amounts Â Basic net loss per share is computed by dividing loss for the period by the weighted-average number of shares of common stock outstanding (WASO) during the period. In addition, the Company includes the number of shares of common stock issuable under pre-funded warrants as outstanding for purposes of the WASO calculation. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period. Potentially dilutive common shares consist of incremental shares of common stock issuable upon the exercise of stock options and exercise of warrants. Â Â The following table sets forth securities outstanding which were excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive (in thousands). Â Â Â Six Months Ended September 30,Â Â Â 2024Â Â 2023Â Options to purchase common stockÂ Â 4,531Â Â Â 2,913Â Unvested restricted stock unitsÂ Â 146Â Â Â 229Â Common stock purchase warrantsÂ Â 10,430Â Â Â 11,892Â TotalÂ Â 15,107Â Â Â 15,034Â Â Reclassifications Â Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations or cash flows. Â Comprehensive Loss Â Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may include certain changes in equity that are excluded from net loss. For the three and six months ended September 30, 2024 and 2023, the Companyâ€™s comprehensive loss was the same as its net loss. Â Recently Issued Accounting Pronouncements Â In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires disclosure of incremental segment information on an annual and interim basis. ASU No. 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and it requires retrospective application to all prior periods presented in the financial statements. The Company is currently evaluating the impact that this ASU will have on the presentation of its consolidated financial statements. Â In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which expands disclosures in an entityâ€™s income tax rate reconciliation table and disclosures regarding cash taxes paid both in the U.S. and foreign jurisdictions. The update will be effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact that this ASU will have on the presentation of its consolidated financial statements. Â In November 2024, the FASB issued ASU No. 2024-03, Income Statement â€“ Reporting Comprehensive Income â€“ Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The new standard requires disclosures about specific types of expenses included in the expense captions presented on the face of the income statement as well as disclosures about selling expenses. The standard is effective for the Company for annual periods beginning April 1, 2027 and interim periods beginning April 1, 2028, with early adoption permitted. The standard may be applied either prospectively to financial statements issued for reporting periods after the effective date or retrospectively to any or all prior periods presented in the financial statements. The Company is evaluating the impact that this ASU will have on the presentation of its consolidated financial statements.Â Â 8 Â Â NOTE 2 â€“ CONSOLIDATED BALANCE SHEET DETAIL Â Â Â SeptemberÂ 30, 2024Â Â March 31, 2024Â Â Â Â (in thousands)Â Property and equipment, netÂ Â Â Â Â Â Machinery and equipmentÂ $4,540Â Â $3,209Â Computer equipment and softwareÂ Â 66Â Â Â 66Â Construction-in-processÂ Â 74Â Â Â 283Â Leasehold improvementsÂ Â 33Â Â Â 33Â Office equipmentÂ Â 46Â Â Â 63Â Â Â Â 4,759Â Â Â 3,654Â Less:Â Â accumulated depreciation and amortizationÂ Â (1,118)Â Â (679) TotalÂ $3,641Â Â $2,975Â Â Â Â SeptemberÂ 30, 2024Â Â March 31, 2024Â Â Â Â (in thousands)Â Accrued expensesÂ Â Â Â Â Â Accrued wages and employee benefitsÂ $265Â Â $243Â OtherÂ Â 80Â Â Â 37Â TotalÂ $345Â Â $280Â Â NOTE 3 â€“ LEASES Â Â Thornmint Road, San Diego, CAÂ Â The 48-month lease term commenced February 1, 2023, and the lease provides for an initial base monthly rent of $36,000 with annual rent increases of approximately 4%. In addition to the minimum lease payments, the Company is responsible for property taxes, insurance and certain other operating costs. A discount rate of 8%, which approximated the Companyâ€™s incremental borrowing rate, was used to measure the lease asset and liability. The Company obtained a right-of-use asset of approximately $1,560,000 in exchange for its obligations under the operating lease. Â Future minimum payments under the facility operating lease, as of September 30, 2024, are listed in the table below (in thousands). Â Annual Fiscal YearsÂ Â Â 2025Â $228Â 2026Â Â 470Â 2027Â Â 405Â Total future lease paymentsÂ $1,103Â Less:Â Imputed interestÂ Â (94) Present value of lease liabilityÂ $1,009Â Â Cash paid for amounts included in the measurement of lease liabilities was approximately $225,000 and $257,000 for the six months ended September 30, 2024 and 2023, respectively. Rent expense was approximately $225,000 for each of the six month periods ended September 30, 2024 and 2023, respectively and $113,000 for each of the three month periods ended September 30, 2024 and 2023. Â 9 Â Â NOTE 4 â€“ STOCKHOLDERSâ€™ EQUITY Â ATM Offering Â In November 2023, the Company entered into a Sales Agreement (the ATM Agreement) with Leerink Partners LLC (Leerink) under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock through an â€œat the market offeringâ€ program under which Leerink will act as sales agent or principal. The ATM Agreement provides that Leerink will be entitled to compensation for its services equal to 3.0% of the gross proceeds from sales of any shares of common stock under the ATM Agreement. The Company has no obligation to sell any shares under the ATM Agreement and may, at any time, suspend solicitation and offers under the ATM Agreement. During the three and six months ended September 30, 2024, under the ATM Agreement, the Company sold 824,514 shares of common stock for proceeds of approximately $1,933,000, which was net of commissions and legal fees of approximately $82,000. Â Common Stock Purchase Warrants Â As of September 30, 2024, the Company had the following common stock purchase warrants outstanding (share amounts in thousands): Â Â Â Number of SharesÂ Â Exercise PriceÂ Â ExpirationÂ Balance as of March 31, 2024Â Â 12,521Â Â Â Â Â Â Â Â Â Warrants exercisedÂ Â (55)Â $1.22Â Â Â May 2028Â Balance as of June 30, 2024Â Â 12,466Â Â Â Â Â Â Â Â Â Warrants exercisedÂ Â (252)Â $0.01Â Â Â â€”Â Warrants exercisedÂ Â (649)Â $1.22Â Â Â May 2028Â Warrants exercisedÂ Â (39)Â $1.32Â Â Â May 2027Â Balance as of September 30, 2024Â Â 11,526Â Â Â Â Â Â Â Â Â Â As of March 31, 2024, the Company had the following warrants outstanding (share amounts in thousands): Â TypeÂ Number of SharesÂ Â Exercise PriceÂ Â ExpirationÂ Common stockÂ Â 1,348Â Â $0.01Â Â Â â€”Â Common stockÂ Â 4,421Â Â Â 1.22Â Â Â May 2028Â Common stockÂ Â 535Â Â Â 1.32Â Â Â May 2027Â Common stockÂ Â 768Â Â Â 6.00Â Â Â JanuaryÂ 2027Â -Â FebruaryÂ 2027Â Common stockÂ Â 4,011Â Â Â 6.60Â Â Â February 2027Â Common stockÂ Â 1,438Â Â $6.60Â Â Â November 2027Â TotalÂ Â 12,521Â Â Â Â Â Â Â Â Â Â The outstanding pre-funded warrants with an exercise price of $0.01 per share were included in the weighted average shares outstanding calculation for each of the three and six month periods ended September 30, 2024 and 2023. At March 31, 2024, the Company had a receivable from its transfer agent for approximately $142,000 for the proceeds from warrants exercised prior to March 31, 2024. The receivable was recorded in the prepaid and other line in the consolidated balance sheet at March 31, 2024 and was collected during the three months ended June 30, 2024. Â Other Â During the six months ended September 30, 2024 and 2023, the Company issued 30,000 and 1,429 shares of common stock with fair values of approximately $51,000 and $1,400, respectively to service providers. Â 10 Â Â NOTE 5 â€“ STOCK-BASED COMPENSATION Â Amended 2017 Equity Incentive Plan Â In October 2017, the Board approved the 2017 Equity Incentive Plan (the Plan), as amended, with 1,000,000 shares of common stock reserved for issuance. In January 2020 and August 2021, the Board approved increases in the number of shares reserved for issuance by 333,334 and 1,333,334 shares, respectively. In January 2023 and February 2024, the Companyâ€™s stockholders approved increases in the number of shares reserved for issuance under the Plan by an additional 2,000,000 and 3,000,000 shares, respectively. Under the Plan, eligible employees, directors and consultants may be granted a broad range of awards, including stock options, stock appreciation rights, restricted stock, performance-based awards and restricted stock units. The Plan is administered by the Board or, in the alternative, a committee designated by the Board.Â Â Stock-Based Compensation Expense Â Stock options granted by the Company generally vest over 36 months and have a 10-year term. As of September 30, 2024, the unamortized compensation cost related to stock options was approximately $1,763,000 and is expected to be recognized as expense over a weighted-average period of approximately 1.8 years. Â In October 2023, under its Two-Part FDA Submission and Clearance Milestone Bonus Program (the Bonus Program), the Company granted stock options to purchase 909,533 shares of common stock, which were subject to vesting based upon the achievement of certain performance milestones by the Company and continued service by the optionees. In January 2024, options to purchase 625,326 shares (net of forfeitures), which were granted under part one of the Bonus Program, vested upon the Companyâ€™s submission to the FDA. In August 2024, options to purchase 242,307 shares (net of forfeitures), which were granted under part two of the Bonus Program, were canceled, as the Company did not receive clearance from the FDA for its MODD1 product by August 1, 2024. In August 2024, the Company granted new options to purchase 339,298 shares (the Clearance Options), which were subject to vesting based upon the Companyâ€™s receipt of clearance from the FDA for its MODD1 product by December 31, 2024 and continued service by the optionees. The Clearance options vested in full in September 2024 upon the Companyâ€™s receipt of clearance from the FDA for its MODD1 product. Â The weighted-average grant date fair value of options granted was $1.41Â and $1.00 per share for the six months ended September 30, 2024 and 2023, respectively, and $1.51 and $1.02 for the three months ended September 30, 2024 and 2023, respectively. The following assumptions were used in the fair-value method calculations: Â Â Â Three Months Ended September 30,Â Â SixÂ MonthsÂ Ended September 30,Â Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Risk-free interest ratesÂ Â 3.4%Â -Â 4.1%Â Â Â 4.4%Â -Â 4.6%Â Â Â 3.5%Â -Â 4.4%Â Â Â 3.5%Â -Â 4.6%Â VolatilityÂ Â 114% - 117%Â Â Â 127%Â Â 114% - 123%Â Â Â 82.6% - 152.2%Â Expected life (years)Â Â 5.0 â€“ 5.7Â Â Â 5.0 â€“ 5.7Â Â Â 5.0 â€“ 5.7Â Â Â 5.0 â€“ 6.2Â Â The fair values of options at the grant date were estimated utilizing the Black-Scholes valuation model, which includes simplified methods to establish the fair term of options, as well as average volatility. The risk-free interest rate was derived from the Daily Treasury Yield Curve Rates, as published by the U.S. Department of the Treasury as of the grant date for terms equal to the expected terms of the options. A dividend yield of zero was applied because the Company has never paid dividends and has no intention to pay dividends in the foreseeable future. The Company accounts for forfeitures as they occur. Â The following table summarizes the activity in the shares available for grant under the Plan during the six months ended September 30, 2024: Â Â Â Â Â Â Options OutstandingÂ Â Â Â Â Â Â Â Â WeightedÂ Â Â SharesÂ Â Â Â Â AverageÂ Â Â AvailableÂ Â Number ofÂ Â ExerciseÂ Â Â for GrantÂ Â SharesÂ Â PricesÂ Balance at March 31, 2024Â Â 3,648,651Â Â Â 3,689,341Â Â $Â Â Â Â Â Â Â Â Â 3.70Â Share awardsÂ Â (3,875)Â Â â€”Â Â Â 1.56Â Options grantedÂ Â (682,375)Â Â 682,375Â Â Â 1.52Â Options exercisedÂ Â â€”Â Â Â (7,530)Â Â 1.08Â Options cancelled and returned to the PlanÂ Â 42,230Â Â Â (42,230)Â Â 2.62Â Balance at June 30, 2024Â Â 3,004,631Â Â Â 4,321,956Â Â $3.36Â Share awardsÂ Â (3,875)Â Â â€”Â Â Â 2.28Â Options grantedÂ Â (483,673)Â Â 483,673Â Â Â 1.81Â Options cancelled and returned to the PlanÂ Â 274,901Â Â Â (274,901)Â Â 1.51Â Balance at September 30, 2024Â Â 2,791,984Â Â Â 4,530,728Â Â $3.33Â Â 11 Â Â A stock option was exercised on a cashless basis for 7,530 shares of common stock during the six months ended September 30, 2024. There were no stock options exercised during the six months ended September 30, 2023. During the six months ended September 30, 2024 and 2023, the Company awarded 7,750 and 12,640 shares, respectively, and for the three months ended September 30, 2024 and 2023, the Company awarded 3,875 and 6,265 shares, respectively, to its non-employee directors under the Companyâ€™s outside director compensation plan. For the six months ended September 30, 2024 and 2023, the Company recorded stock-based compensation expense for these share awards of approximately $15,000 and $13,000, respectively, and for the three months ended September 30, 2024 and 2023, the Company recorded stock-based compensation expense for these share awards of approximately $9,000 and $7,000, respectively. Â A summary of restricted stock unit (RSU) activity under the Plan is presented below. Â Â Â Â Â Â Weighted AverageÂ Â Â Number of SharesÂ Â Grant-Date Fair ValueÂ Non-vested shares at March 31, 2024Â Â 187,499Â Â $Â Â 0.91Â VestedÂ Â (20,832)Â $0.91Â Non-vested shares at June 30, 2024Â Â 166,667Â Â $0.91Â VestedÂ Â (20,833)Â $0.91Â Non-vested shares at September 30, 2024Â Â 145,834Â Â $0.91Â Â The total intrinsic value of RSUs outstanding as of September 30, 2024 was approximately $328,000. The unamortized compensation cost at September 30, 2024 was approximately $94,000 related to RSUs and is expected to be recognized as expense over a period of approximately 1.75 years. Â The following table summarizes the range of outstanding and exercisable options as of September 30, 2024: Â Â Â Options Outstanding Â Â Options Exercisable Â Range of Exercise Price Â Number Outstanding Â Â Weighted Average Remaining Contractual Life (in Years) Â Â Weighted Average Exercise Price Â Â Number Exercisable Â Â Weighted Average Exercise Price Â Â Aggregate Intrinsic value Â $0.93 - $2.28 Â Â 3,098,454 Â Â Â 8.41 Â Â $ 1.57 Â Â Â 2,640,918 Â Â $ 1.55 Â Â $ 1,839,613 Â $3.95 - $7.51 Â Â 933,145 Â Â Â 6.69 Â Â $ 5.30 Â Â Â 836,533 Â Â $ 5.42 Â Â Â â€” Â $8.61 - $17.70 Â Â 499,129 Â Â Â 6.73 Â Â $ 10.56 Â Â Â 490,036 Â Â $ 10.56 Â Â Â â€” Â $0.93 - $17.70 Â Â 4,530,728 Â Â Â 7.87 Â Â $ 3.33 Â Â Â 3,967,487 Â Â $ 3.48 Â Â $Â 1,839,613 Â Â The intrinsic value per share is calculated as the excess of the closing price of the common stock on the Companyâ€™s principal trading market over the exercise price of the option. Â NOTE 6 â€“ INCOME TAXES Â The Company determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the Companyâ€™s assets and liabilities using tax rates in effect for the year in which the Company expects the differences to affect taxable income. A valuation allowance is established for any deferred tax assets for which it is more likely than not that all or a portion of the deferred tax assets will not be realized. Based on the available information and other factors, management believes it is more likely than not that its federal and state net deferred tax assets will not be fully realized, and the Company has recorded a full valuation allowance. Â The Company files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations. All tax returns for fiscal 2016 to fiscal 2023 may be subject to examination by the U.S. federal and state tax authorities. As of September 30, 2024, the Company has not recorded any liability for unrecognized tax benefits related to uncertain tax positions. Â 12 Â Â NOTE 7 â€“ COMMITMENTS AND CONTINGENCIES Â Litigations, Claims and Assessments Â In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements. Â Indemnification Â In the ordinary course of business, the Company enters into contractual arrangements under which it may agree to indemnify the counterparties from any losses incurred relating to breach of representations and warranties, failure to perform certain covenants, or claims and losses arising from certain events as outlined within the particular contract, which may include, for example, losses arising from litigation or claims relating to past performance. Such indemnification clauses may not be subject to maximum loss clauses. The Company has also entered into indemnification agreements with its officers and directors. No amounts were reflected in the Companyâ€™s consolidated financial statements for the three and six months ended September 30, 2024 and 2023 related to these indemnifications. The Company has not estimated the maximum potential amount of indemnification liability under these agreements due to the limited history of prior claims and the unique facts and circumstances applicable to each particular agreement. To date, the Company has not made any payments related to these indemnification agreements. Â Purchase Obligations Â The Companyâ€™s primary purchase obligations include purchase orders for machinery and equipment. At September 30, 2024, the Company had outstanding purchase orders for machinery and equipment and related expenditures of approximately $990,000. Â In December 2023, the Company signed a device integration agreement with a provider of connected-care and remote monitoring diabetes technology solutions. As of September 30, 2024, the Company had a remaining obligation under the device integration agreement of approximately $400,000Â over three years for technology license fees. Â NOTE 8 â€“ RELATED PARTY TRANSACTIONS Â A family member of one of the Companyâ€™s executive officers is an employee of the Company. During the three months ended September 30, 2024 and 2023, the Company paid the family member approximately $43,365 and $28,954, respectively, which includes the aggregate grant date fair values, as determined pursuant to FASB ASC Topic 718, of stock options granted during each period. During the six months ended September 30, 2024

and 2023, the Company paid the family member approximately $100,625 and $63,754, respectively, which includes the aggregate grant date fair values, as determined pursuant to FASB ASC Topic 718, of stock options granted during each period. Â 13 Â Â Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations Â This Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the accompanying condensed consolidated financial statements and notes included in this Quarterly Report on Form 10-Q (this Report). This Report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which include, without limitation, statements about the market for our technology, our strategy, competition, expected financial performance and capital raising efforts, and other aspects of our business identified in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission on June 21, 2024 and in other reports that we file from time to time with the Securities and Exchange Commission. Any statements about our business, financial results, financial condition and operations contained in this Report that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words â€œbelieves,â€ â€œanticipates,â€ â€œexpects,â€ â€œintends,â€ â€œplans,â€ â€œprojects,â€ or similar expressions are intended to identify forward-looking statements. Our actual results could differ materially from those expressed or implied by these forward-looking statements as a result of various factors, including the risk factors described under Item 1A of our Annual Report on Form 10-K for the year ended March 31, 2024. These forward-looking statements represent our intentions, plans, expectations, assumptions and beliefs about future events and are subject to risks, uncertainties and other factors including, without limitation, the direct and indirect effects of coronavirus disease 2019, or COVID-19, as well as inflationary risks, including the risk that the cost of certain of the Companyâ€™s components is increasing, and related issues that may arise therefrom. Many of those factors are outside of our control and could cause actual results to differ materially from those expressed or implied by those forward-looking statements. In light of these risks, uncertainties and assumptions, the events described in the forward-looking statements might not occur or might occur to a different extent or at a different time than we have described. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this Report. All subsequent written and oral forward-looking statements concerning other matters addressed in this Report and attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this Report. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, a change in events, conditions, circumstances or assumptions underlying such statements, or otherwise. Â Our fiscal year ends on March 31 of each calendar year. Each reference to a fiscal year in this Report, refers to the fiscal year ended March 31 of the calendar year indicated (for example, fiscal 2025 refers to the fiscal year ending March 31, 2025). Unless the context requires otherwise, references to â€œwe,â€ â€œus,â€ â€œour,â€ and the â€œCompanyâ€ refer to Modular Medical, Inc. and its consolidated subsidiary. Â Company Overview Â We are a pre-revenue medical device company focused on the design, development and commercialization of innovative insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. Through the creation of a novel two-part patch pump, our initial product, the MODD1, we seek to fundamentally alter the trade-offs between cost and complexity and access to the higher standards of care that presently-available insulin pumps provide. By simplifying and streamlining the user experience from introduction, prescription, reimbursement, training and day-to-day use, we seek to expand the wearable insulin delivery device market beyond the highly motivated â€œsuper usersâ€ and expand the category into the mass market. The product seeks to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets. In January 2024, we submitted a 510(k) premarket notification to the United States Food and Drug Administration (â€œFDAâ€) for our MODD1 insulin pump, and, in September 2024, we received FDA clearance to market and sell our MODD1 pump in the United States. Â Historically, we have financed our operations principally through private placements and public offerings of our common stock and sales of convertible promissory notes. Based on our current operating plan, substantial doubt about our ability to continue as a going concern for a period of at least one year from the date that the financial statements included in Item 1 of this Report are issued exists. Our ability to continue as a going concern depends on our ability to raise additional capital, through the sale of equity or debt securities, to support our future operations. If we are unable to secure additional capital, we will be required to curtail our research and development initiatives and take additional measures to reduce costs. We have provided additional disclosure in Note 1 to the consolidated financial statements in Item 1 of this Report and under Liquidity below.Â Â 14 Â Â Critical Accounting Policies and Estimates Â The discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these condensed consolidated financial statements requires us to make certain estimates and judgments that affect the reported amounts of assets, liabilities, and expenses. On an ongoing basis, we make these estimates based on our historical experience and on assumptions that we consider reasonable under the circumstances. Actual results may differ from these estimates and reported results could differ under different assumptions or conditions. Our significant accounting policies and estimates are disclosed in Note 1 of the Notes to Consolidated Financial Statements in our Annual Report on Form 10-K for the year ended March 31, 2024. As of September 30, 2024, there have been no material changes to our significant accounting policies and estimates. Â Results of Operations Â Research and Development Â Â Â September 30,Â Â ChangeÂ Â Â 2024Â Â 2023Â Â 2023 to 2024Â Â Â (dollar amounts in thousands)Â Research and development â€“ Three months endedÂ $3,702Â Â $3,159Â Â $543Â Â Â 17.1% Research and development â€“ Six months endedÂ $6,907Â Â $5,927Â Â $980Â Â Â 16.5% Â Our research and development, or R&D, expenses include personnel, consulting, testing, materials and supplies, depreciation and amortization and other operational costs associated with the pre-FDA clearance production of our insulin pump product. We expense R&D costs as they are incurred. Â R&D expenses increased for the three months ended September 30, 2024 compared with the same period of 2023, primarily due to increased stock-based compensation expense of $0.5 million, employee-related costs of approximately $0.2 million and increased depreciation expense of approximately $0.2 million. These increases were partially offset by decreases of approximately $0.2 million in consulting expenses and $0.2 million in material costs. Â R&D expenses increased for the six months ended September 30, 2024 compared with the same period of 2023, primarily due to increased stock-based compensation costs of approximately $0.5 million, increased employee-related costs of approximately $0.4 million, an increase in depreciation expense of approximately $0.3 million and an increase in travel-related and other costs of approximately $0.1 million. These increases were partially offset by an approximately $0.3 million decrease in material and supplies costs. Our full-time R&D employee headcount increased to 42 at September 30, 2024 from 39 at September 30, 2023. R&D expenses included stock-based compensation expenses of approximately $0.8 million and $0.4 million for the three-months ended September 30, 2024 and 2023, respectively, and $1.2 million and $0.7 million for the six-month periods ended September 30, 2024 and 2023, respectively. We expect research and development expenses to increase in the second half of fiscal 2025, as we commence initial activities in support of commercialization of our MODD1 product. Â 15 Â Â General and Administrative Â Â Â September 30,Â Â ChangeÂ Â Â 2024Â Â 2023Â Â 2023 to 2024Â Â Â (dollar amounts in thousands)Â General and administrative â€“ Three months endedÂ $1,294Â Â $1,031Â Â $263Â Â Â 25.5% General and administrative â€“ Six months endedÂ $2,309Â Â $2,014Â Â $295Â Â Â 14.6% Â General and administrative, or G&A, expenses consist primarily of personnel and related overhead costs for facilities, finance, human resources, legal, marketing and general management. Â G&A expenses increased for the three months ended September 30, 2024 compared with the same period of 2023, primarily as a result of increases in professional service, recruiting, legal and consulting expenses of approximately $0.3 million. Â G&A expenses increased for the six months ended September 30, 2024 compared with the same period of 2023, primarily as a result of an increase in legal and professional services expenses of approximately $0.3 million and stock-based compensation expense of approximately $0.1 million, partially offset by decreases in travel-related and other costs of $0.1 million. G&A expenses included stock-based compensation expenses of approximately $0.2 million for each of the three-month periods ended September 30, 2024 and 2023, and $0.4 million and $0.3 million for the six months ended September 30, 2024 and 2023, respectively. We expect G&A expenses to increase in the second half of fiscal 2025, as we commence initial activities in support of commercialization of our MODD1 product. Â Liquidity and Capital Resources; Changes in Financial ConditionÂ Â We do not currently have revenues to generate cash flows to cover operating expenses. Since our inception, we have incurred operating losses and negative cash flows in each year due to costs incurred in connection with our operations. For the six months ended September 30, 2024 and year ended March 31, 2024, we incurred net losses of approximately $9.1 million and $17.5 million, respectively. At September 30, 2024, we had a cash balance of $3.9 million and an accumulated deficit of approximately $75 million. We expect to continue to incur operating losses for the foreseeable future and incur cash outflows from operations, as we continue to invest in the development and commercialization of our products. We expect that our expenses will continue to increase, and, as a result, we will eventually need to generate significant revenue to achieve profitability. When considered with our current operating plan, these conditions raise substantial doubt about our ability to continue as a going concern for a period of at least one year from the date that the financial statements included in Item 1 of this Report are issued. Our financial statements do not include adjustments to the amounts and classification of assets and liabilities that may be necessary should we be unable to continue as a going concern. Our operating needs include the planned costs to operate our business, including amounts required to fund continued research and development activities, working capital and capital expenditures. Our ability to continue as a going concern depends on our ability to raise additional capital, through the sale of equity or debt securities to support our future operations. During the three months ended March 31, 2024, we completed an offering of shares of common stock for net proceeds of approximately $10.3 million, which includes the proceeds from the underwriterâ€™s exercise of the overallotment. In November 2023, we entered into a Sales Agreement (the â€œATM Agementâ€) with Leerink Partners LLC (â€œLeerinkâ€) under which we may offer and sell, from time to time at our sole discretion, shares of our common stock (subject to availability on our shelf registration statement) through an â€œat the market offeringâ€ program under which Leerink will act as sales agent or principal. During the three months ended September 30, 2024, we sold 824,514 shares of common stock for net proceeds of approximately $1.9 million under the ATM Agreement. Subject to market conditions, we expect to resume sales under the ATM during the remainder of fiscal 2025, however, the potential net proceeds from such future sales are unknown. In addition, during the three months ended September 30, 2024, we received a total of approximately $0.8 million of proceeds from the exercise of common stock purchase warrants issued in a public offering we completed in May 2023. Our future capital requirements and the adequacy of our available funds will depend on many factors, including, without limitation, our ability to successfully commercialize our MODD1 product, competing technological and market developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement our product offerings. If we are unable to secure additional capital timely, we may be required to curtail product commercialization and R&D initiatives, reduce headcount and take additional measures to reduce costs in order to conserve our cash. Â For the six months ended September 30, 2024, we used approximately $7.3 million of cash in operating activities, which primarily resulted from our net loss of approximately $9.1 million and net changes in operating assets and liabilities of approximately $0.3 million, as adjusted for stock-based compensation expenses of approximately $1.6 million, depreciation and amortization expenses of approximately $0.5 million and other immaterial adjustments. For the six months ended six September 30, 2023, we used approximately $6.5 million in operating activities, which primarily resulted from our net loss of approximately $7.9 million and net changes in operating assets and liabilities of approximately $0.2 million, as adjusted for stock-based compensation expenses of approximately $1.0 million, net changes in operating assets and liabilities of approximately $0.2 million and depreciation and amortization expenses of approximately $0.2 million.Â Â 16 Â Â For the six months ended September 30, 2024 and 2023, cash used in investing activities of approximately $1.0 million and $0.7 million, respectively, was for the purchase of property and equipment. Â Cash provided by financing activities of approximately $3.0 million for the six months ended September 30, 2024 was attributable to proceeds from the at-the-market sales of stock and exercise of common stock purchase warrants. Cash provided by financing activities of $9.7 million for the six months ended September 30, 2023 was attributable to net proceeds from the issuance of common stock and common stock purchase warrants in a public offering, net of underwriting fees and issuance costs. Â Purchase Obligations Â Our primary purchase obligations include purchase orders for machinery and equipment. At September 30, 2024, we had outstanding purchase orders for machinery and equipment and related expenditures of approximately $1.0 million. Â In December 2023, we signed a device integration agreement with a provider of connected-care and remote monitoring diabetes technology solutions. As of September 30, 2024, we had a remaining obligation under the device integration agreement of approximately $0.4 millionÂ over three years for technology license fees. Â Recently Issued Accounting Pronouncements Â Recently issued accounting pronouncements are detailed in Note 1 in the Notes to the Condensed Consolidated Financial Statements included in Item 1 of this Report. Â Item 3. Quantitative and Qualitative Disclosures about Market Risk Â Not required. Â Item 4. Controls and Procedures Â Disclosure Controls and Procedures. Â Our management is responsible for establishing and maintaining adequate internal control over our financial reporting. Because of inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate. Â Under the supervision and with the participation of our management, including our Chief Executive Officer, we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934. Based on this evaluation, our management concluded that, as of September 30, 2024, our disclosure controls and procedures were effective. Â Changes in Internal Control over Financial Reporting. Â During the three months ended September 30, 2024, there was no change in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. Â 17 Â Â Part II â€“ OTHER INFORMATION Â Item 1. Legal Proceedings Â We are not currently involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. To our knowledge, there is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of us or our subsidiary, threatened against or affecting us, our common stock, our subsidiary or our subsidiaryâ€™s officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect. Â Item 1A. Risk Factors Â We face many significant risks in our business, some of which are unknown to us and not presently foreseen. These risks could have a material adverse impact on our business, financial condition and results of operations in the future. There are no material changes to the risk factors set forth under Item 1A of our Annual Report on Form 10-K for the year ended March 31, 2024, which we filed with the SEC on June 21, 2024. Â Item 2. Unregistered Sales of Equity Securities and Use of Proceeds Â Recent Sales of Unregistered Securities Â On September 30, 2024, we issued 20,833 shares to one of our non-employee directors upon vesting of a restricted stock unit award granted under our Amended and Restated 2017 Equity Incentive Plan. On August 26, 2024, we issued 20,000 shares of our common stock to a service provider. The aforementioned issuances were made pursuant to exemptions from registration pursuant to Section 4(2) and/or Rule 506 of Regulation D of the Securities Act. Â Item 3. Defaults Upon Senior Securities Â There has been no default in the payment of principal, interest, or a sinking or purchase fund installment, or any other material default, with respect to any indebtedness of ours. Â Item 4. Mine Safety Disclosures Â Not applicable. Â Item 5. Other Information Â None. Â 18 Â Â Item 6. Exhibits Â Exhibit Â Â Â Reference Â Â Â Filed or Furnished Number Â Exhibit Description Â Form Â Exhibit Â FilingÂ Date Â Herewith 31.1 Â Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Â Â Â Â Â Â Â Â X 31.2 Â Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Â Â Â Â Â Â Â X 32.1 Â Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Â Â Â Â Â Â Â Â X 101 Â The following financial information from Modular Medical, Inc.â€™s quarterly report on Form 10-Q for the period ended September 30, 2024, filed with the SEC on November 13, 2024, formatted in Inline Extensible Business Reporting Language (Inline XBRL): (i) the Condensed Consolidated Statements of Operations for the three and six months ended September 30, 2024 and 2023, (ii) the Condensed Consolidated Balance Sheets as of September 30 2024 and March 31, 2024, (iii) the Condensed Consolidated Statements of Stockholdersâ€™ Equity for the three and Â six months ended September 30, 2024 and 2023, (iv) the Condensed Consolidated Statements of Cash Flows for the six months ended September 30, 2024 and 2023, and (v) Notes to Condensed Consolidated Financial Statements. Â Â Â Â Â Â Â Â X 104 Â Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). Â Â Â Â Â Â Â Â X Â 19 Â Â SIGNATURES Â Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Â Â MODULAR MEDICAL, INC. Â Â Â Date: November 14, 2024 By: /s/ James E. Besser Â Â James E. Besser Â Â Chief Executive Officer Â Â (Principal Executive Officer) Â Â Â By: /s/ Paul DiPerna Â Â Paul DiPerna Â Â Chairman, President, Chief Financial Officer and Treasurer Â Â (Principal Financial Officer) Â 20 false --03-31 Q2 2025 0001074871 0001074871 2024-04-01 2024-09-30 0001074871 2024-11-13 0001074871 2024-09-30 0001074871 2024-03-31 0001074871 2024-07-01 2024-09-30 0001074871 2023-07-01 2023-09-30 0001074871 2023-04-01 2023-09-30 0001074871 us-gaap:CommonStockMember 2024-03-31 0001074871 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001074871 us-gaap:RetainedEarningsMember 2024-03-31

0001074871 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001074871 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001074871 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001074871 2024-04-01 2024-06-30 0001074871 us-gaap:CommonStockMember 2024-06-30 0001074871 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001074871 us-gaap:RetainedEarningsMember 2024-06-30 0001074871 2024-06-30 0001074871 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001074871 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001074871 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001074871 us-gaap:CommonStockMember 2024-09-30 0001074871 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001074871 us-gaap:RetainedEarningsMember 2024-09-30 0001074871 us-gaap:CommonStockMember 2023-03-31 0001074871 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001074871 us-gaap:RetainedEarningsMember 2023-03-31 0001074871 2023-03-31 0001074871 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001074871 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001074871 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001074871 2023-04-01 2023-06-30 0001074871 us-gaap:CommonStockMember 2023-06-30 0001074871 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001074871 us-gaap:RetainedEarningsMember 2023-06-30 0001074871 2023-06-30 0001074871 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001074871 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001074871 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001074871 us-gaap:CommonStockMember 2023-09-30 0001074871 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001074871 us-gaap:RetainedEarningsMember 2023-09-30 0001074871 2023-09-30 0001074871 srt:MinimumMember 2024-09-30 0001074871 srt:MaximumMember 2024-09-30 0001074871 us-gaap:StockOptionMember 2024-04-01 2024-09-30 0001074871 us-gaap:StockOptionMember 2023-04-01 2023-09-30 0001074871 modd:UnvestedRestrictedStockUnitsMember 2024-04-01 2024-09-30 0001074871 modd:UnvestedRestrictedStockUnitsMember 2023-04-01 2023-09-30 0001074871 us-gaap:WarrantMember 2024-04-01 2024-09-30 0001074871 us-gaap:WarrantMember 2023-04-01 2023-09-30 0001074871 us-gaap:MachineryAndEquipmentMember 2024-09-30 0001074871 us-gaap:MachineryAndEquipmentMember 2024-03-31 0001074871 us-gaap:ComputerEquipmentMember 2024-09-30 0001074871 us-gaap:ComputerEquipmentMember 2024-03-31 0001074871 us-gaap:ConstructionInProgressMember 2024-09-30 0001074871 us-gaap:ConstructionInProgressMember 2024-03-31 0001074871 us-gaap:LeaseholdImprovementsMember 2024-09-30 0001074871 us-gaap:LeaseholdImprovementsMember 2024-03-31 0001074871 us-gaap:OfficeEquipmentMember 2024-09-30 0001074871 us-gaap:OfficeEquipmentMember 2024-03-31 0001074871 modd:ThornmintRoadSanDiegoCAMember 2024-09-30 0001074871 2023-02-01 2023-02-01 0001074871 2023-02-01 0001074871 2023-11-30 2023-11-30 0001074871 us-gaap:WarrantMember 2023-04-01 2024-03-31 0001074871 us-gaap:WarrantMember us-gaap:CommonStockMember 2024-04-01 2024-09-30 0001074871 us-gaap:WarrantMember us-gaap:CommonStockMember 2023-04-01 2023-09-30 0001074871 us-gaap:WarrantMember 2024-03-31 0001074871 us-gaap:WarrantMember 2024-04-01 2024-06-30 0001074871 us-gaap:WarrantMember 2024-06-30 0001074871 us-gaap:WarrantMember modd:WarrantOneMember 2024-07-01 2024-09-30 0001074871 us-gaap:WarrantMember modd:WarrantTwoMember 2024-07-01 2024-09-30 0001074871 us-gaap:WarrantMember modd:WarrantThreeMember 2024-07-01 2024-09-30 0001074871 us-gaap:WarrantMember 2024-09-30 0001074871 us-gaap:WarrantMember us-gaap:CommonStockMember 2024-03-31 0001074871 us-gaap:WarrantMember us-gaap:CommonStockMember 2023-04-01 2024-03-31 0001074871 us-gaap:WarrantMember modd:CommonStockOneMember 2024-03-31 0001074871 us-gaap:WarrantMember modd:CommonStockOneMember 2023-04-01 2024-03-31 0001074871 us-gaap:WarrantMember modd:CommonStockTwoMember 2024-03-31 0001074871 us-gaap:WarrantMember modd:CommonStockTwoMember 2023-04-01 2024-03-31 0001074871 us-gaap:WarrantMember modd:CommonStockThreeMember 2024-03-31 0001074871 us-gaap:WarrantMember modd:CommonStockThreeMember 2023-04-01 2024-03-31 0001074871 us-gaap:WarrantMember modd:CommonStockFourMember 2024-03-31 0001074871 us-gaap:WarrantMember modd:CommonStockFourMember 2023-04-01 2024-03-31 0001074871 us-gaap:WarrantMember modd:CommonStockFiveMember 2024-03-31 0001074871 us-gaap:WarrantMember modd:CommonStockFiveMember 2023-04-01 2024-03-31 0001074871 modd:TwoThousandAndSeventeenEquityIncentivePlanMember 2017-10-31 2017-10-31 0001074871 modd:TwoThousandAndSeventeenEquityIncentivePlanMember 2020-01-31 0001074871 modd:TwoThousandAndSeventeenEquityIncentivePlanMember 2021-08-31 0001074871 modd:TwoThousandAndSeventeenEquityIncentivePlanMember 2023-01-31 0001074871 modd:TwoThousandAndSeventeenEquityIncentivePlanMember 2024-02-28 0001074871 modd:MilestoneBonusProgramMember 2023-10-31 2023-10-31 0001074871 2024-01-31 2024-01-31 0001074871 2024-08-31 2024-08-31 0001074871 us-gaap:StockCompensationPlanMember 2024-04-01 2024-09-30 0001074871 us-gaap:StockCompensationPlanMember 2023-04-01 2023-09-30 0001074871 us-gaap:StockCompensationPlanMember 2024-07-01 2024-09-30 0001074871 us-gaap:StockCompensationPlanMember 2023-07-01 2023-09-30 0001074871 modd:NonemployeeDirectorsMember 2024-07-01 2024-09-30 0001074871 modd:NonemployeeDirectorsMember 2023-07-01 2023-09-30 0001074871 modd:NonemployeeDirectorsMember 2024-04-01 2024-09-30 0001074871 modd:NonemployeeDirectorsMember 2023-04-01 2023-09-30 0001074871 us-gaap:RestrictedStockUnitsRSUMember 2024-09-30 0001074871 srt:MinimumMember 2024-07-01 2024-09-30 0001074871 srt:MaximumMember 2024-07-01 2024-09-30 0001074871 srt:MinimumMember 2023-07-01 2023-09-30 0001074871 srt:MaximumMember 2023-07-01 2023-09-30 0001074871 srt:MinimumMember 2024-04-01 2024-09-30 0001074871 srt:MaximumMember 2024-04-01 2024-09-30 0001074871 srt:MinimumMember 2023-04-01 2023-09-30 0001074871 srt:MaximumMember 2023-04-01 2023-09-30 0001074871 us-gaap:RestrictedStockUnitsRSUMember 2024-03-31 0001074871 us-gaap:RestrictedStockUnitsRSUMember 2024-04-01 2024-06-30 0001074871 us-gaap:RestrictedStockUnitsRSUMember 2024-06-30 0001074871 us-gaap:RestrictedStockUnitsRSUMember 2024-07-01 2024-09-30 0001074871 srt:MinimumMember modd:zeroPointNineThreeToTwoPointTwoEightMember 2024-09-30 0001074871 srt:MaximumMember modd:zeroPointNineThreeToTwoPointTwoEightMember 2024-09-30 0001074871 modd:zeroPointNineThreeToTwoPointTwoEightMember 2024-09-30 0001074871 modd:zeroPointNineThreeToTwoPointTwoEightMember 2024-04-01 2024-09-30 0001074871 srt:MinimumMember modd:ThreePointNineFiveToSevenPointFiveOneMember 2024-09-30 0001074871 srt:MaximumMember modd:ThreePointNineFiveToSevenPointFiveOneMember 2024-09-30 0001074871 modd:ThreePointNineFiveToSevenPointFiveOneMember 2024-09-30 0001074871 modd:ThreePointNineFiveToSevenPointFiveOneMember 2024-04-01 2024-09-30 0001074871 srt:MinimumMember modd:EightPointSixOneToSeventeenPointSevenZeroMember 2024-09-30 0001074871 srt:MaximumMember modd:EightPointSixOneToSeventeenPointSevenZeroMember 2024-09-30 0001074871 modd:EightPointSixOneToSeventeenPointSevenZeroMember 2024-09-30 0001074871 modd:EightPointSixOneToSeventeenPointSevenZeroMember 2024-04-01 2024-09-30 0001074871 srt:MinimumMember modd:ZeroPointNineThreeToSeventeenPointSevenZeroMember 2024-09-30 0001074871 srt:MaximumMember modd:ZeroPointNineThreeToSeventeenPointSevenZeroMember 2024-09-30 0001074871 modd:ZeroPointNineThreeToSeventeenPointSevenZeroMember 2024-09-30 0001074871 modd:ZeroPointNineThreeToSeventeenPointSevenZeroMember 2024-04-01 2024-09-30 0001074871 modd:DeviceIntegrationAgreementMember 2024-09-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares modd:segment xbrli:pure EX-31.1 2 ea022045501ex31-1_modular.htm CERTIFICATION Exhibit 31.1 Â CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Â I, James E. Besser, certify that: Â 1.I have reviewed this Quarterly Report on Form 10-Q of Modular Medical, Inc. for the period ended September 30, 2024; Â 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report; Â 4.The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Â (a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â (b)Designed such internal controls over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â (c)Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; Â (d)Disclosed in this report any change in the registrantâ€™s internal controls over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and Â 5.The registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): Â (a)All significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â Â (b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â /s/Â James E. Besser Date: November 14, 2024 James E. Besser Â Chief Executive Officer Â Â EX-31.2 3 ea022045501ex31-2_modular.htm CERTIFICATION Exhibit 31.2 Â CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Â I, Paul M. DiPerna, certify that: Â 1.I have reviewed this Quarterly Report on Form 10-Q of Modular Medical, Inc. for the period ended September 30, 2024; Â 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report; Â 4.The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Â (a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â (b)Designed such internal controls over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â (c)Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; Â (d)Disclosed in this report any change in the registrantâ€™s internal controls over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and Â 5.The registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): Â (a)All significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â (b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â /s/Â Paul M. DiPerna Date: November 14, 2024 Paul M. DiPerna Â Chairman, President, Chief Financial Officer and Treasurer Â Â EX-32.1 4 ea022045501ex32-1_modular.htm CERTIFICATION Exhibit 32.1 Â CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Â In connection with the Quarterly Report on Form 10-Q of Modular Medical, Inc. (the â€œCompanyâ€) for the period ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), each of James E. Besser, Chief Executive Officer of the Company, and Paul M. DiPerna, Chairman, President, Chief Financial Officer and Treasurer, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of his knowledge, that: Â 1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities and Exchange Act of 1934, as amended; and Â 2.The information contained in the Report fairly presents, in all material respects, the financial condition and the results of operations of the Company. Â By: /s/Â James E. Besser Date: November 14, 2024 Â James E. Besser Â Â Chief Executive Officer Â Â Â By: /s/Â Paul M. DiPerna Date: November 14, 2024 Â Paul M. DiPerna Â Â Chairman, President, Chief Financial Officer and Treasurer Â Â This certification accompanies this Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, or otherwise required, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Â EX-101.SCH 5 modd-20240930.xsd XBRL SCHEMA FILE 995301 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 995302 - Statement - Condensed Consolidated Balance Sheets (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 995303 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:definitionLink link:calculationLink 995304 - Statement - Condensed Consolidated Statements of Stockholdersâ€™ Equity (Unaudited) link:presentationLink link:definitionLink link:calculationLink 995305 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 995306 - Disclosure - The Company and Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 995307 - Disclosure - Consolidated Balance Sheet Detail link:presentationLink link:definitionLink link:calculationLink 995308 - Disclosure - Leases link:presentationLink link:definitionLink link:calculationLink 995309 - Disclosure - Stockholdersâ€™ Equity link:presentationLink link:definitionLink link:calculationLink 995310 - Disclosure - Stock-Based Compensation link:presentationLink link:definitionLink link:calculationLink 995311 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 995312 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 995313 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 996000 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 996001 - Disclosure - The Company and Summary of Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 996002 - Disclosure - Consolidated Balance Sheet Detail (Tables) link:presentationLink link:definitionLink link:calculationLink 996003 - Disclosure - Leases (Tables) link:presentationLink link:definitionLink link:calculationLink 996004 - Disclosure - Stockholdersâ€™ Equity (Tables) link:presentationLink link:definitionLink link:calculationLink 996005 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:definitionLink link:calculationLink 996006 - Disclosure - The Company and Summary of Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 996007 - Disclosure - The Company and Summary of Significant Accounting Policies (Details) - Schedule of Diluted Net Loss Per Share link:presentationLink link:definitionLink link:calculationLink 996008 - Disclosure - Consolidated Balance Sheet Detail (Details) - Schedule of Property and Equipment, Net link:presentationLink link:definitionLink link:calculationLink 996009 - Disclosure - Consolidated Balance Sheet Detail (Details) - Schedule of Accrued Expenses link:presentationLink link:definitionLink link:calculationLink 996010 - Disclosure - Leases (Details) link:presentationLink link:definitionLink link:calculationLink 996011 - Disclosure - Leases (Details) - Schedule of Future Minimum Payments Under the Facility Operating Lease link:presentationLink link:definitionLink link:calculationLink 996012 - Disclosure - Stockholdersâ€™ Equity (Details) link:presentationLink link:definitionLink link:calculationLink 996013 - Disclosure - Stockholdersâ€™ Equity (Details) - Schedule of Warrants Outstanding link:presentationLink link:definitionLink link:calculationLink 996014 - Disclosure - Stock-Based Compensation (Details) link:presentationLink link:definitionLink link:calculationLink 996015 - Disclosure - Stock-Based Compensation (Details) - Schedule of Assumptions were used in the Fair-Value Method link:presentationLink link:definitionLink link:calculationLink 996016 - Disclosure - Stock-Based Compensation (Details) - Schedule of Activity in the Shares link:presentationLink link:definitionLink link:calculationLink 996017 - Disclosure - Stock-Based Compensation (Details) - Schedule of RSU Activity under the Plan link:presentationLink link:definitionLink link:calculationLink 996018 - Disclosure - Stock-Based Compensation (Details) - Schedule of Outstanding and Exercisable Options link:presentationLink link:definitionLink link:calculationLink 996019 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 996020 - Disclosure - Related Party Transactions (Details) link:presentationLink

link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 6 modd-20240930_cal.xml XBRL CALCULATION FILE EX-101.DEF 7 modd-20240930_def.xml XBRL DEFINITION FILE EX-101.LAB 8 modd-20240930_lab.xml XBRL LABEL FILE TOTAL CURRENT ASSETS TOTAL ASSETS TOTAL CURRENT LIABILITIES TOTAL LIABILITIES TOTAL STOCKHOLDERSâ€™ EQUITY Balance Balance TOTAL LIABILITIES AND STOCKHOLDERSâ€™ EQUITY Total operating expenses Loss from operations Loss before income taxes Net loss Net loss Balance (in Shares) Balance (in Shares) Equity Components [Axis] Net cash used in operating activities Net cash used in investing activities Net cash provided by financing activities Net increase (decrease) in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash and cash equivalents The Company and Summary of Significant Accounting Policies [Abstract] Antidilutive Securities [Axis] Consolidated Balance Sheet Detail [Abstract] Long-Lived Tangible Asset [Axis] Total Property and equipment, net Schedule of Accrued Expenses [Abstract] Total Accrued expenses Leases [Abstract] Schedule of Future Minimum Payments Under the Facility Operating Lease [Abstract] Total future lease payments Stockholdersâ€™ Equity [Abstract] STOCKHOLDERSâ€™ EQUITY Number of Shares, balance Number of Shares, Common stock Class of Stock [Axis] Class of Warrant or Right [Axis] Stock-Based Compensation [Abstract] Statistical Measurement [Axis] Shares Available for Grant, Beginning Balance Shares Available for Grant, Ending Balance Number of Shares, Beginning Balance Number of Shares, Ending Balance Number Outstanding (in Shares) Weighted Average Exercise Price, Beginning Balance (in Dollars per share) Weighted Average Exercise Price, Ending Balance (in Dollars per share) Weighted Average Exercise Price Number of Shares, Beginning Balance Number of Shares, Ending Balance Weighted Average Grant-Date Fair Value, Beginning Balance Weighted Average Grant-Date Fair Value, Ending Balance Exercise Price Range [Axis] Income Taxes [Abstract] Commitments and Contingencies [Abstract] Related Party Transactions [Abstract] ASSETS CURRENT ASSETS Prepaid expenses and other Right of use asset, net LIABILITIES AND STOCKHOLDERSâ€™ EQUITY CURRENT LIABILITIES Accounts payable Short-term lease liabilities Long-term lease liabilities Commitments and Contingencies (Note 7) Preferred Stock, $0.001 par value, 5,000 shares authorized, none issued and outstanding Preferred stock, par value (in Dollars per share) Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common Stock, $0.001 par value, 100,000 shares authorized; 34,370 and 32,464 shares issued and outstanding as of September 30, 2024 and March 31, 2024, respectively Common stock, par value (in Dollars per share) Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Additional paid-in capital Accumulated deficit Operating expenses Research and development General and administrative Other income Provision for income taxes Net loss per share Basic (in Dollars per share) Diluted (in Dollars per share) Shares used in computing net loss per share Basic (in Shares) Diluted (in Shares) Shares issued for services Shares issued for services (in Shares) Exercise of warrants Exercise of warrants (in Shares) Number of Shares, Options exercised Total number of options granted Issuances under equity incentive plan Issuances under equity incentive plan (in Shares) Shares approved under equity incentive plan Stock-based compensation At-the-market sales of stock, net At-the-market sales of stock, net (in Shares) Issuance of common stock shares (in Shares) Issuance of common stock and warrants in equity offering, net Issuance of common stock and warrants in equity offering, net (in Shares) CASH FLOWS FROM OPERATING ACTIVITIES Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation expense Depreciation and amortization Shares for services Changes in assets and liabilities: Lease right-of-use asset Accounts payable and accrued expenses Change in lease liability CASH FLOWS FROM INVESTING ACTIVITIES CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from at-the-market sales of stock, net Proceeds from exercise of common stock purchase warrants Proceeds from issuance of common stock and warrants, net Prepaid expenses and other assets Purchases of property and equipment Common Stock Common stock [Member] Common Stock [Member] Additional Paid-In Capital Accumulated Deficit THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Schedule of Diluted Net Loss Per Share Anti-dilutive total CONSOLIDATED BALANCE SHEET DETAIL Schedule of Property and Equipment, Net Property and equipment, net Property and equipment, gross Schedule of Accrued Expenses Accrued expenses Accrued wages and employee benefits Other LEASES Schedule of Future Minimum Payments Under the Facility Operating Lease 2025 2026 2027 Present value of lease liability STOCKHOLDERSâ€™ EQUITY Schedule of Warrants Outstanding Number of Shares, Warrants exercised Exercise Price, Warrants exercised (in Dollars per share) Weighted Average Exercise Price, Options exercised (in Dollars per share) Expiration Dates, Warrants exercised Exercise Price, Common stock (in Dollars per share) Expiration Dates, Common stock STOCK-BASED COMPENSATION Schedule of Assumptions were used in the Fair-Value Method Risk-free interest rates Volatility Expected life (years) Schedule of Activity in the Shares Shares Available for Grant, Share awards Number of Shares, Share awards Weighted Average Exercise Price, Share awards (in Dollars per share) Shares Available for Grant, Options granted Number of Shares, Options granted Weighted Average Exercise Price, Options granted (in Dollars per share) Weighted-average grant date fair value of options granted (in Dollars per share) Shares Available for Grant, Options exercised Shares Available for Grant, Options cancelled and returned to the Plan Weighted Average Exercise Price, Options cancelled and returned to the Plan (in Dollars per share) Schedule of RSU Activity under the Plan Weighted Average Grant-Date Fair Value, Vested Schedule of Outstanding and Exercisable Options Range of Exercise Price Weighted Average Remaining Contractual Life (in Years) Number Exercisable (in Shares) Weighted Average Exercise Price Aggregate Intrinsic value (in Dollars) INCOME TAXES COMMITMENTS AND CONTINGENCIES RELATED PARTY TRANSACTIONS Less: accumulated depreciation and amortization Less: Imputed interest Number of Shares, Options cancelled and returned to the Plan Number of Shares, Vested Options to purchase common stock [Member] Unvested restricted stock units [Member] Common stock purchase warrants [Member] Warrant [Member] Machinery and equipment [Member] Computer equipment and software [Member] Construction-in-process [Member] Leasehold improvements [Member] Office equipment [Member] Warrants exercised [Member] Warrants exercised [Member] Warrants exercised [Member] Common stock [Member] Common stock [Member] Common stock [Member] Common stock [Member] Common stock [Member] Minimum [Member] Maximum [Member] Restricted Stock Units (RSUs) [Member] $0.93 - $2.28 [Member] $3.95 - $7.51 [Member] $8.61 - $17.70 [Member] $0.93 - $17.70 [Member] Lease Contractual Term [Axis] Plan Name [Axis] Title and Position [Axis] Purchase Commitment, Excluding Long-Term Commitment [Axis] Business segment (in segment) FDIC insured amount (in Dollars) Estimated useful lives Lease term Rent expense Annual rent increases percentage Discount rate Obtained a right-of-use asset Cash paid Compensation services equal percentage Shares sold (in Shares) Net proceeds Legal fees Exercise price of the pre-funded warrants (in Dollars per share) Aggregate proceeds Common stock fair value Number of shares reserved Contractual term Unamortized compensation cost (in Dollars) Weighted average period Options granted Options cancelled Options granted Option exercised Shares issued Stock-based compensation (in Dollars) Total intrinsic value (in Dollars) Expense over a period Purchase obligations Company paid amount Liquidity and Going Concern Basis of Presentation Use of Estimates Reportable Segment Research and Development Concentration of Credit Risk Risks and Uncertainties Cash and Cash Equivalents Property and Equipment Fair Value of Financial Instruments Leases Stock-Based Compensation Per-Share Amounts Reclassifications Comprehensive Loss Recently Issued Accounting Pronouncements Thornmint Road, San Diego, CA [Member] 2017 Equity Incentive Plan [Member] Milestone Bonus Program [Member] Stock-Based Compensation [Member] Non-employee Directors [Member] Device Integration Agreement [Member] Equity Component [Domain] Statement [Table] Statement [Line Items] Antidilutive Securities, Name [Domain] Antidilutive Security, Excluded EPS Calculation [Table] Schedule of Diluted Net Loss Per Share [Line Items] Long-Lived Tangible Asset [Domain] Property, Plant and Equipment [Table] Schedule of Property and Equipment, Net [Line Items] Class of Stock [Domain] Class of Warrant or Right [Domain] Class of Warrant or Right [Table] Schedule of Warrants Outstanding [Line Items] Statistical Measurement [Domain] Stock-Based Compensation (Details) - Schedule of Assumptions were used in the Fair-Value Method [Table] Schedule of Assumptions were used in the Fair-Value Method [Line Items] Stock-Based Compensation (Details) - Schedule of Activity in the Shares [Table] Schedule of Activity in the Shares [Line Items] Award Type [Domain] Stock-Based Compensation (Details) - Schedule of RSU Activity under the Plan [Table] Schedule of RSU Activity Under the Plan [Line Items] Exercise Price Range [Domain] Stock-Based Compensation (Details) - Schedule of Outstanding and Exercisable Options [Table] Schedule of Outstanding and Exercisable Options [Line Items] The Company and Summary of Significant Accounting Policies (Details) [Table] The Company and Summary of Significant Accounting Policies [Line Items] Lease Contractual Term [Domain] Leases (Details) [Table] Leases [Line Items] Stockholdersâ€™ Equity (Details) [Table] Stockholdersâ€™ Equity [Line Items] Title and Position [Domain] Plan Name [Domain] Stock-Based Compensation (Details) [Table] Stock-Based Compensation [Line Items] Purchase Commitment, Excluding Long-Term Commitment [Domain] Commitments and Contingencies (Details) [Table] Commitments and Contingencies [Line Items] Related Party Transactions (Details) [Table] Related Party Transactions [Line Items] The price per of exercise price of the pre-funded warrants. Expiration common stock. Expiration dates warrants exercised. Lease right-of-use asset. Amount of issuance of common stock and warrants in equity offering, net. Number of Issuance of common stock and warrants in equity offering, net. The shares of options cancelled. The shares of options granted. Number of shares warrants exercised. Represent the percentage of annual rent increases. Disclosure of accounting policy for risks and uncertainties. Shares available for grant, options granted. Options cancelled and returned to the plan, shares available for grant. Shares Available for Grant options exercised. Represent the share for share based compensation arrangement by share based payment award share awards shares available for grant in share awards. The amount of share awards in share based arrangement by share awards. Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Number of share options (or share units) exercised during the current period. Compensation services equal. Schedule Of Rsu Activity Under The Plan Abstract Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Number of Operating Segments Payments for Rent Use of Estimates, Policy [Policy Text Block] Assets [Abstract] Commitments and Contingencies Comprehensive Income, Policy [Policy Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Common Stock, Value, Issued Proceeds from Issuance of Warrants Earnings Per Share, Diluted Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Retained Earnings [Member] Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Vested Number Of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Lessee, Leases [Policy Text Block] Weighted Average Number of Shares Outstanding, Basic [Abstract] compensation Services Equal Milestone Bonus Program Member Operating Lease, Payments Weighted Average Number of Shares Outstanding, Basic Property, Plant and Equipment, Net [Abstract] Increase (Decrease) in Prepaid Expense and Other Assets Expiration Common Stock Stock Issued During Period, Value, New Issues Net Of Forfeitures Options Granted Statement of Stockholders' Equity [Abstract] Exercise Price Of The Prefunded Warrants Basis of Accounting, Policy [Policy Text Block] Increase (Decrease) in Operating Lease Liability Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Income Tax Expense (Benefit) Income Statement [Abstract] Stock Issued During Period, Shares, New Issues Accounts Payable and Accrued Liabilities, Current [Abstract] Lessee, Operating Leases [Text Block] Number Of Shares Warrants Exercised New Accounting Pronouncements, Policy [Policy Text Block] Supplemental Balance Sheet Disclosures [Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding Additional Paid in Capital Operating Expenses [Abstract] Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled And Returned To The Plan Shares Available For Grant Earnings Per Share, Basic Net Cash Provided by (Used in) Operating Activities [Abstract] Assets Liabilities Share-Based Payment Arrangement, Option and Stock Appreciation Rights, Activity [Table Text Block] Research and Development Expense Preferred Stock, Shares Issued Construction in Progress [Member] Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Share Based Compensations Arrangements By Share Based Payment Share Awards In Period Weighted Average Exercise Price Minimum [Member] Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Common Stock, Shares, Outstanding Stock Issued During Period, Shares, Issued for Services Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price Retained Earnings (Accumulated Deficit) Net Cash Provided by (Used in) Investing Activities Common Stock Four Member Eight Point Six One To Seventeen Point Seven Zero Member Payments to Acquire Property, Plant, and Equipment Nonemployee Directors Member Share-Based Payment Arrangement [Policy Text Block] Preferred Stock, Shares Authorized Machinery and Equipment [Member] Preferred Stock, Shares Outstanding Device Integration Agreement Member Property, Plant and Equipment, Net Prepaid Expense and Other Assets, Current Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Net Cash Provided by (Used in) Financing Activities Accounts Payable, Current Accrued Employee Benefits, Current Maximum [Member] Sharebased Compensation Arrangement By Sharebased Payment Award Option Outstanding Weighted Average Remaining Contractual Term2 Common Stock, Shares Authorized Unvested Restricted Stock Units Member Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Property, Plant and Equipment, Gross Operating Lease, Liability, Noncurrent Stock Issued During Period, Value, Employee Benefit Plan Other Accrued Liabilities, Current Warrant [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Share-Based Payment Arrangement [Member] Concentration Risk, Credit Risk, Policy [Policy Text Block] Schedule of Accrued Liabilities [Table Text Block] Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Share-Based Payment Arrangement, Expense Net Cash Provided by (Used in) Financing Activities [Abstract] Additional Paid-in Capital [Member] Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold Other Income Leasehold Improvements [Member] Operating Income (Loss) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Three Point Nine Five To Seven Point Five One Member Net Cash Provided by (Used in) Investing Activities [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Schedule Of Outstanding And Exercisable Options Abstract Operating Lease, Liability Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Granted Available For Grant Issuance Of Common Stock And Warrants In Equity Offering Netin Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Depreciation, Depletion and Amortization, Nonproduction Common Stock [Member] Reclassification, Comparability Adjustment [Policy Text Block] Expiration Dates Warrants Exercisedin Dollars Per Share Segment Reporting, Policy [Policy Text Block] Statement of Cash Flows [Abstract] Property, Plant and Equipment, Useful Life Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract] Class of Warrant or Right, Outstanding Operating Lease, Liability, Current Lessee, Operating Lease, Liability, to be Paid, Year Two Income Tax Disclosure [Text Block] Common Stock, Capital Shares Reserved for Future Issuance Warrant Two Member Stock Issued During Period Shares Stock Option Exercised Defined Benefit Plan, Assumptions [Table Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Increase Decrease Lease Rightofuse Asset Related Party Transactions Disclosure [Text Block] Schedule Of Warrants Outstanding Abstract Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number Financing Receivable, Unamortized Loan Cost (Fee) Liabilities, Current [Abstract] Net Cash Provided by (Used in) Operating Activities Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Issuance of Stock and Warrants for Services or Claims APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Legal Fees Equity Option [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Office Equipment [Member] Stock Issued During Period, Shares, Other Share-Based Payment Arrangement [Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares Warrant Three Member Fair Value of Financial Instruments, Policy [Policy Text Block] Lessee, Operating Lease, Term of Contract Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Substantial Doubt about Going Concern [Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Equity, Attributable to Parent Increase (Decrease) in Accounts Payable and Accrued Liabilities Share Based Compensation Arrangement By Share Based Payment Award Share Awards Shares Available For Exercised In Share Awards Computer Equipment [Member] Stock Issued During Period, Value, Stock Options Exercised Property, Plant and Equipment, Policy [Policy Text Block] Restricted Stock Units (RSUs) [Member] Stock Issued During Period, Value, Issued for Services Schedule Of Activity In The Shares Abstract General and Administrative Expense Cash and Cash Equivalents, Policy [Policy Text Block] Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Earnings Per Share [Abstract] Lessee, Operating Lease, Discount Rate Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Common Stock Two Member Common Stock, Par or Stated Value Per Share Earnings Per Share, Policy [Policy Text Block] Common Stock, Shares, Issued Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period,

Weighted Average Exercise Price Thornmint Road San Diego CAMember Weighted Average Number of Shares Outstanding, Diluted Common Stock Five Member Share Based Compensation Arrangement By Share Based Payment Share Award In Period Gross Share Based Compensation Arrangement By Share Based Payment Award Share Awards Shares Available For Grant In Share Awards Stock Issued During Period, Shares, Employee Benefit Plan Cash, FDIC Insured Amount Lessee, Operating Lease, Liability, to be Paid Two Thousand And Seventeen Equity Incentive Plan Member Share-Based Payment Arrangement, Option, Activity [Table Text Block] Equity [Text Block] Purchase Obligation Sale of Stock, Number of Shares Issued in Transaction Proceeds from Warrant Exercises Assets, Current [Abstract] Property, Plant and Equipment [Table Text Block] Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Common Stock Three Member Liabilities, Current Operating Expenses Equity, Fair Value Adjustment Statement of Financial Position [Abstract] Proceeds from Debt, Net of Issuance Costs Issuance Of Common Stock And Warrants In Equity Offering Net Risks And Uncertainties Policy Text Block Accrued Liabilities, Current Schedule Of Diluted Net Loss Per Share Abstract Research and Development Expense, Policy [Policy Text Block] Liabilities and Equity [Abstract] Shares, Outstanding Commitments and Contingencies Disclosure [Text Block] Lessee, Operating Lease, Liability, to be Paid, Year One Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Proceeds from Issuance of Common Stock Common Stock One Member Net Of Forfeitures Options Cancelled Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Zero Point Nine Three To Seventeen Point Seven Zero Member Schedule Of Assumptions Were Used In The Fair Value Method Abstract Class of Warrant or Right, Exercise Price of Warrants or Rights Preferred Stock, Value, Issued Schedule Of Property And Equipment Net Abstract Liabilities and Equity Lessee, Operating Lease, Liability, Undiscounted Excess Amount Percentage Of Annual Rent Increases Share-Based Payment Arrangement, Noncash Expense Warrant One Member Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term zero Point Nine Three To Two Point Two Eight Member Preferred Stock, Par or Stated Value Per Share Operating Lease, Right-of-Use Asset Assets, Current Proceeds from Other Equity EX-101.PRE 9 modd-20240930_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Cover - shares 6 Months Ended Sep. 30, 2024 Nov. 13, 2024 Document Information [Line Items] Â Â Document Type 10-Q Â Document Quarterly Report true Â Document Transition Report false Â Entity Interactive Data Current No Â Amendment Flag false Â Document Period End Date Sep. 30, 2024 Â Document Fiscal Year Focus 2025 Â Document Fiscal Period Focus Q2 Â Entity Information [Line Items] Â Â Entity Registrant Name MODULAR MEDICAL, INC. Â Entity Central Index Key 0001074871 Â Entity File Number 000-49671 Â Entity Tax Identification Number 87-0620495 Â Entity Incorporation, State or Country Code NV Â Current Fiscal Year End Date --03-31 Â Entity Current Reporting Status Yes Â Entity Shell Company false Â Entity Filer Category Non-accelerated Filer Â Entity Small Business true Â Entity Emerging Growth Company false Â Entity Contact Personnel [Line Items] Â Â Entity Address, Address Line One 10740 Thornmint Road Â Entity Address, City or Town San Diego Â Entity Address, State or Province CA Â Entity Address, Postal Zip Code 92127 Â Entity Phone Fax Numbers [Line Items] Â Â City Area Code (858) Â Local Phone Number 800-3500 Â Entity Listings [Line Items] Â Â Title of 12(b) Security Common Stock Par Value $.001 per Share Â Trading Symbol MODD Â Security Exchange Name NASDAQ Â Entity Common Stock, Shares Outstanding Â 34,571,939 X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_DocumentInformationLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_EntityContactPersonnelLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_EntityInformationLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_EntityListingsLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_EntityPhoneFaxNumbersLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 12 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets - USD ($) $ in Thousands Sep. 30, 2024 Mar. 31, 2024 CURRENT ASSETS Â Â Cash and cash equivalents $ 3,893 $ 9,232 Prepaid expenses and other 283 465 TOTAL CURRENT ASSETS 4,176 9,697 Property and equipment, net 3,641 2,975 Right of use asset, net 954 1,135 TOTAL ASSETS 8,771 13,807 CURRENT LIABILITIES Â Â Accounts payable 501 802 Accrued expenses 345 280 Short-term lease liabilities 398 373 TOTAL CURRENT LIABILITIES 1,244 1,455 Long-term lease liabilities 611 817 TOTAL LIABILITIES 1,855 2,272 Commitments and Contingencies (Note 7) STOCKHOLDERSâ€™ EQUITY Â Â Preferred Stock, $0.001 par value, 5,000 shares authorized, none issued and outstanding Common Stock, $0.001 par value, 100,000 shares authorized; 34,370 and 32,464 shares issued and outstanding as of September 30, 2024 and March 31, 2024, respectively 34 32 Additional paid-in capital 81,904 77,432 Accumulated deficit (75,022) (65,929) TOTAL STOCKHOLDERSâ€™ EQUITY 6,916 11,535 TOTAL LIABILITIES AND STOCKHOLDERSâ€™ EQUITY $ 8,771 $ 13,807 X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4:

http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -

Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting

Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 13 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares shares in Thousands Sep. 30, 2024 Mar. 31, 2024 Statement of Financial Position [Abstract] Â Â Preferred stock, par value (in Dollars per share) $ 0.001 $ 0.001 Preferred stock, shares authorized 5,000 5,000 Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value (in Dollars per share) $ 0.001 $ 0.001 Common stock, shares authorized 100,000 100,000 Common stock, shares issued 34,370 32,464 Common stock, shares outstanding 34,370 32,464 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 14 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands 3 Months Ended 6 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Operating expenses Â Â Â Â Research and development $ 3,702 $ 3,159 $ 6,907 $ 5,927 General and administrative 1,294 1,031 2,309 2,014 Total operating expenses 4,996 4,190 9,216 7,941 Loss from operations (4,996) (4,190) (9,216) (7,941) Other income 42 9 125 23 Loss before income taxes (4,954) (4,181) (9,091) (7,918) Provision for income taxes 2 2 2 2 Net loss $ (4,956) $ (4,183) $ (9,093) $ (7,920) Net loss per share Â Â Â Â Basic (in Dollars per share) $ (0.14) $ (0.19) $ (0.27) $ (0.4) Diluted (in Dollars per share) $ (0.14) $ (0.19) $ (0.27) $ (0.4) Shares used in computing net loss per share Â Â Â Â Basic (in Shares) 34,338 22,445 34,114 19,786 Diluted (in Shares) 34,338 22,445 34,114 19,786 X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of revenue and income classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column E)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column E)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(1)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_OtherIncome Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 15 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Stockholdersâ€™ Equity (Unaudited) - USD ($) $ in Thousands Common Stock Additional Paid-In Capital Accumulated Deficit Total Balance at Mar. 31, 2023 $ 11 $ 53,524 $ (48,459) $ 5,076 Balance (in Shares) at Mar. 31, 2023 10,949,000 Â Â Â Issuance of common stock and warrants in equity offering, net $ 10 9,723 9,733 Issuance of common stock and warrants in equity offering, net (in Shares) 10,139,000 Â Â Â Issuances under equity incentive plan 6 6 Issuances under equity incentive plan (in Shares) 7,000 Â Â Â Stock-based compensation 478 478 Net loss (3,737) (3,737) Balance at Jun. 30, 2023 $ 21 63,731 (52,196) 11,556 Balance (in Shares) at Jun. 30, 2023 21,095,000 Â Â Â Balance at Mar. 31, 2023 $ 11 53,524 (48,459) 5,076 Balance (in Shares) at Mar. 31, 2023 10,949,000 Â Â Â Net loss Â Â Â (7,920) Balance at Sep. 30, 2023 $ 21 64,296 (56,379) 7,938 Balance (in Shares) at Sep. 30, 2023 21,124,000 Â Â Â Balance at Jun. 30, 2023 $ 21 63,731 (52,196) 11,556 Balance (in Shares) at Jun. 30, 2023 21,095,000 Â Â Â Shares issued for services 1 1 Shares issued for services (in Shares) 2,000 Â Â Â Issuances under equity incentive plan 7 7 Issuances under equity incentive plan (in Shares) 27,000 Â Â Â Stock-based compensation 557 557 Net loss (4,183) (4,183) Balance at Sep. 30, 2023 $ 21 64,296 (56,379) 7,938 Balance (in Shares) at Sep. 30, 2023 21,124,000 Â Â Â Balance at Mar. 31, 2024 $ 32 77,432 (65,929) 11,535 Balance (in Shares) at Mar. 31, 2024 32,464,000 Â Â Â Shares issued for services 15 15 Shares issued for services (in Shares) 10,000 Â Â Â Exercise of warrants 68 $ 68 Exercise of warrants (in Shares) 55,000 Â Â 7,530 Issuances under equity incentive plan 6 $ 6 Issuances under equity incentive plan (in Shares) 32,000 Â Â Â Stock-based compensation 529 529 Net loss (4,137) (4,137) Balance at Jun. 30, 2024 $ 32 78,050 (70,066) 8,016 Balance (in Shares) at Jun. 30, 2024 32,561,000 Â Â Â Balance at Mar. 31, 2024 $ 32 77,432 (65,929) 11,535 Balance (in Shares) at Mar. 31, 2024 32,464,000 Â Â Â Net loss Â Â Â (9,093) Balance at Sep. 30, 2024 $ 34 81,904 (75,022) 6,916 Balance (in Shares) at Sep. 30, 2024 34,370,000 Â Â Â Balance at Jun. 30, 2024 $ 32 78,050 (70,066) 8,016 Balance (in Shares) at Jun. 30, 2024 32,561,000 Â Â Â Shares issued for services 35 35 Shares issued for services (in Shares) 20,000 Â Â Â Exercise of warrants $ 1 844 845 Exercise of warrants (in Shares) 939,000 Â Â Â At-the-market sales of stock, net $ 1 1,922 1,923 At-the-market sales of stock, net (in Shares) 825,000 Â Â Â Issuances under equity incentive plan 9 9 Issuances under equity incentive plan (in Shares) 25,000 Â Â Â Stock-based compensation 1,044 1,044 Net loss (4,956) (4,956) Balance at Sep. 30, 2024 $ 34 $ 81,904 $ (75,022) $ 6,916 Balance (in Shares) at Sep. 30, 2024 34,370,000 Â Â Â X - DefinitionAmount of issuance of common stock and warrants in equity offering, net. + ReferencesNo definition available. + Details Name: modd_IssuanceOfCommonStockAndWarrantsInEquityOfferingNet Namespace Prefix: modd_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of Issuance of common stock and warrants in equity offering, net. + ReferencesNo definition available. + Details Name: modd_IssuanceOfCommonStockAndWarrantsInEquityOfferingNetinShares Namespace Prefix: modd_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodValueIssuedForServices Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 16 R6.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands 6 Months Ended Sep. 30, 2024 Sep. 30, 2023 CASH FLOWS FROM OPERATING ACTIVITIES Â Â Net loss $ (9,093) $ (7,920) Adjustments to reconcile net loss to net cash used in operating activities: Â Â Stock-based compensation expense 1,588 1,048 Depreciation and amortization 456 153 Shares for services 26 11 Changes in assets and liabilities: Â Â Prepaid expenses and other assets 64 105 Lease right-of-use asset 182 168 Accounts payable and accrued expenses (355) 137 Change in lease liability (182) (186) Net cash used in operating activities (7,314) (6,484) CASH FLOWS FROM INVESTING ACTIVITIES Â Â Purchases of property and equipment (1,003) (718) Net cash used in investing activities (1,003) (718) CASH FLOWS FROM FINANCING ACTIVITIES Â Â Proceeds from at-the-market sales of stock, net 1,923 Proceeds from exercise of common stock purchase warrants 1,055 Proceeds from issuance of common stock and warrants, net 9,733 Net cash provided by financing activities 2,978 9,733 Net increase (decrease) in cash and cash equivalents (5,339) 2,531 Cash and cash equivalents at beginning of period 9,232 3,799 Cash and cash equivalents at end of period $ 3,893 $ 6,330 X - DefinitionLease right-of-use asset. + ReferencesNo definition available. + Details Name: modd_IncreaseDecreaseLeaseRightofuseAsset Namespace Prefix: modd_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_DepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in obligation for operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_IncreaseDecreaseInOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionFair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -

Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from the issuance of equity classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromOtherEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 17 R7.htm IDEA: XBRL DOCUMENT v3.24.3 The Company and Summary of Significant Accounting Policies 6 Months Ended Sep. 30, 2024 The Company and Summary of Significant Accounting Policies [Abstract] Â THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES NOTE 1 â€“ THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Â Modular Medical, Inc. (the Company) was incorporated in Nevada in October 1998 under the name Bear Lake Recreation, Inc. The Company had no material business operations from 2002 until approximately 2017 when it acquired all of the issued and outstanding shares of Quasuras, Inc., a Delaware corporation (Quasuras), and changed its name from Bear Lake Recreation, Inc. to Modular Medical, Inc. Â The Company is a pre-revenue, medical device company focused on the design, development and eventual commercialization of innovative insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. Through the creation of an innovative two-part patch pump, its initial product, the MODD1, the Company seeks to fundamentally alter the trade-offs between cost and complexity and access to the higher standards of care requiring considerable motivation that presently available insulin pumps provide. By simplifying and streamlining the user experience from introduction, prescription, reimbursement, training and day-to-day use, the Company seeks to expand the wearable insulin delivery device market beyond the highly motivated â€œsuper usersâ€ and expand the category into the mass market. The product seeks to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets. In January 2024, the Company submitted a 510(k) premarket notification to the United States Food and Drug Administration (FDA) for the MODD1, and, in September 2024, the Company received FDA clearance to market and sell its MODD1 pump in the United States. Â Liquidity and Going Concern Â The Company does not currently have revenues to generate cash flows to cover operating expenses. Since its inception, the Company has incurred operating losses and negative cash flows in each year due to costs incurred in connection with its operations. The Company expects to continue to incur operating losses for the foreseeable future and incur cash outflows from operations as it continues to invest in the development and commercialization of its products. The Company expects that its research and development and general and administrative expenses will continue to increase, and, as a result, it will eventually need to generate significant revenue to achieve profitability. When considered with its current operating plan, these conditions raise substantial doubt about the Companyâ€™s ability to continue as a going concern within one year after the date that these financial statements are issued. In addition, the Companyâ€™s independent registered public accounting firm, in its report on the consolidated financial statements as of and for the year ended March 31, 2024, expressed substantial doubt about the Companyâ€™s ability to continue as a going concern. These condensed consolidated financial statements do not include any adjustments that might result from this uncertainty. Implementation of the Companyâ€™s plans and its ability to continue as a going concern will depend upon the Companyâ€™s ability to raise additional capital, through the sale of additional equity or debt securities, to support its future operations. There can be no assurance that such additional capital, whether in the form of debt or equity financing, will be sufficient or available and, if available, that such capital will be offered on terms and conditions acceptable to the Company. The Companyâ€™s operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital expenditures. The Companyâ€™s future capital requirements and the adequacy of its available funds will depend on many factors, including the Companyâ€™s ability to successfully commercialize its MODD1 product, competing technological and market developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement its product offering. If the Company is unable to secure additional capital, it may be required to curtail its product commercialization and research and development initiatives and take additional measures to reduce costs in order to conserve its cash.Â Basis of Presentation Â The Companyâ€™s fiscal year ends on March 31 of each calendar year. Each reference to a fiscal year in these notes to the condensed consolidated financial statements refers to the fiscal year ended March 31 of the calendar year indicated (for example, fiscal 2025 refers to the fiscal year ending March 31, 2025). The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Quasuras. All significant intercompany transactions and balances have been eliminated in consolidation. Â The accompanying condensed consolidated financial statements are unaudited and have been prepared in accordance with generally accepted accounting principles in the United States (GAAP) and with the rules and regulations of the United States Security and Exchange Commission (SEC) regarding interim financial reporting. The condensed consolidated balance sheet as of March 31, 2024 has been derived from the audited consolidated financial statements at that date. Certain information and disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted in accordance with these rules and regulations of the SEC. The information in this report should be read in conjunction with the Companyâ€™s consolidated financial statements and notes thereto included in its most recent annual report on Form 10-K filed with the SEC. Â In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Companyâ€™s financial position, results of operations and cash flows for the interim periods presented. The operating results for the six months ended September 30, 2024 are not necessarily indicative of the results that may be expected for the year ending March 31, 2025 or for any other future period. Â Use of Estimates Â The preparation of the accompanying condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of revenues and expenses during the reporting period. Estimates may include those pertaining to accruals, stock-based compensation and income taxes. Actual results could differ from those estimates. Â Reportable Segment Â The Company operates in one business segment and uses one measurement of profitability for its business. Â Research and Development Â The Company expenses research and development expenditures as incurred. Â Â Concentration of Credit Risk Â Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash held in demand deposit accounts. The Company maintains a portion of its cash in demand deposit accounts at high credit quality financial institutions within the United States, which are insured by the Federal Deposit Insurance Corporation (FDIC) up to limits of approximately $250,000. No reserve has been made in the financial statements for any possible loss due to financial institution failure.Â Risks and Uncertainties Â The Company is subject to risks from, among other things, competition associated with the industry in general, other risks associated with financing, liquidity requirements, rapidly changing customer requirements, limited operating history, pandemics, wars and acts of terrorism and the volatility of public markets. The Company may be unable to access the capital markets, and additional capital may only be available to the Company on terms that could be significantly detrimental to its existing stockholders and to its business. Â Â Cash and Cash Equivalents Â Cash and cash equivalents include cash held in demand deposit and money market accounts, certificates of deposit and all highly liquid debt instruments with original maturities of three months or less. Â Property and Equipment Â Property and equipment are recorded at historical cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally three to five years. Depreciation is recorded in operating expenses in the consolidated statements of operations. Leasehold improvements and assets acquired through finance leases are amortized over the shorter of their estimated useful life or the lease term, and amortization is recorded in operating expenses in the consolidated statements of operations. Construction-in-process includes machinery and equipment and is stated at cost and not depreciated. Depreciation on construction-in-process commences when the assets are ready for their intended use and placed into service. Â Fair Value of Financial Instruments Â The Company measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels: Â â—Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets. Â Â â— Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. Â Â â— Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement. Â Due to their short-term nature, the carrying values of cash equivalents, accounts payable and accrued expenses, approximate fair value. Â Leases Â The Companyâ€™s right-of-use assets consist of leased assets recognized in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) No. 842, Leases, which requires lessees to recognize a lease liability and a corresponding lease asset for virtually all lease contracts. Right-of-use assets represent the Companyâ€™s right to use an underlying asset for the lease term and the lease liability represents the Companyâ€™s obligation to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the consolidated balance sheets and are expensed on a straight-line basis over the lease term in the consolidated statement of operations and comprehensive loss. The Company determines the lease term by agreement with the lessor. In cases where the lease does not provide an implicit interest rate, the Company uses the Companyâ€™s incremental borrowing rate based on the information available at commencement date in determining the present value of future payments.Â Stock-Based Compensation Â The Company periodically issues stock options, restricted stock units and stock awards to employees and non-employees. The Company accounts for such awards based on FASB ASC Topic 718, whereby the value of the award is measured on the date of grant and recognized as compensation expense on a straight-line basis over the requisite service period, usually the vesting period. With respect to performance-based awards, the Company assesses the probability of achieving the requisite performance criteria before recognizing compensation expense. The fair value of the Companyâ€™s stock options is estimated using the Black-Scholes-Merton Option Pricing (Black Scholes) model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the options, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes model. The assumptions

used in the Black-Scholes model could materially affect compensation expense recorded in future periods. Â Per-Share Amounts Â Basic net loss per share is computed by dividing loss for the period by the weighted-average number of shares of common stock outstanding (WASO) during the period. In addition, the Company includes the number of shares of common stock issuable under pre-funded warrants as outstanding for purposes of the WASO calculation. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period. Potentially dilutive common shares consist of incremental shares of common stock issuable upon the exercise of stock options and exercise of warrants. Â Â The following table sets forth securities outstanding which were excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive (in thousands). Â Â Â Six Months Ended September 30,Â Â Â 2024Â Â 2023Â Options to purchase common stockÂ Â 4,531Â Â Â 2,913Â Unvested restricted stock unitsÂ Â 146Â Â Â 229Â Common stock purchase warrantsÂ Â 10,430Â Â Â 11,892Â TotalÂ Â 15,107Â Â Â 15,034Â Â Reclassifications Â Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations or cash flows. Â Comprehensive Loss Â Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may include certain changes in equity that are excluded from net loss. For the three and six months ended September 30, 2024 and 2023, the Companyâ€™s comprehensive loss was the same as its net loss. Â Recently Issued Accounting Pronouncements Â In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires disclosure of incremental segment information on an annual and interim basis. ASU No. 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and it requires retrospective application to all prior periods presented in the financial statements. The Company is currently evaluating the impact that this ASU will have on the presentation of its consolidated financial statements. Â In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which expands disclosures in an entityâ€™s income tax rate reconciliation table and disclosures regarding cash taxes paid both in the U.S. and foreign jurisdictions. The update will be effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact that this ASU will have on the presentation of its consolidated financial statements. Â In November 2024, the FASB issued ASU No. 2024-03, Income Statement â€" Reporting Comprehensive Income â€" Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The new standard requires disclosures about specific types of expenses included in the expense captions presented on the face of the income statement as well as disclosures about selling expenses. The standard is effective for the Company for annual periods beginning April 1, 2027 and interim periods beginning April 1, 2028, with early adoption permitted. The standard may be applied either prospectively to financial statements issued for reporting periods after the effective date or retrospectively to any or all prior periods presented in the financial statements. The Company is evaluating the impact that this ASU will have on the presentation of its consolidated financial statements.Â X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 250 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/250/tableOfContent + Details Name: us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 18 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Consolidated Balance Sheet Detail 6 Months Ended Sep. 30, 2024 Consolidated Balance Sheet Detail [Abstract] Â CONSOLIDATED BALANCE SHEET DETAIL NOTE 2 â€" CONSOLIDATED BALANCE SHEET DETAIL Â Â Â SeptemberÂ 30, 2024Â Â March 31, 2024Â Â Â Â (in thousands)Â Property and equipment, netÂ Â Â Â Â Â Machinery and equipmentÂ $4,540Â Â $3,209Â Computer equipment and softwareÂ Â 66Â Â Â 66Â Construction-in-processÂ Â 74Â Â Â 283Â Leasehold improvementsÂ Â 33Â Â Â 33Â Office equipmentÂ Â 46Â Â Â 63Â Â Â Â 4,759Â Â Â 3,654Â Less:Â Â accumulated depreciation and amortizationÂ Â (1,118)Â Â (679) TotalÂ $3,641Â Â $2,975Â Â Â Â SeptemberÂ 30, 2024Â Â March 31, 2024Â Â Â (in thousands)Â Accrued expensesÂ Â Â Â Â Â Accrued wages and employee benefitsÂ $265Â Â $243Â OtherÂ Â 80Â Â Â 37Â TotalÂ $345Â Â $280Â X - ReferencesNo definition available. + Details Name: us-gaap_BalanceSheetRelatedDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/210/tableOfContent + Details Name: us-gaap_SupplementalBalanceSheetDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 19 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Leases 6 Months Ended Sep. 30, 2024 Leases [Abstract] Â LEASES NOTE 3 â€" LEASES Â Â Thormmint Road, San Diego, CAÂ Â The 48-month lease term commenced February 1, 2023, and the lease provides for an initial base monthly rent of $36,000 with annual rent increases of approximately 4%. In addition to the minimum lease payments, the Company is responsible for property taxes, insurance and certain other operating costs. A discount rate of 8%, which approximated the Companyâ€™s incremental borrowing rate, was used to measure the lease asset and liability. The Company obtained a right-of-use asset of approximately $1,560,000 in exchange for its obligations under the operating lease. Â Future minimum payments under the facility operating lease, as of September 30, 2024, are listed in the table below (in thousands). Â Annual Fiscal YearsÂ Â Â 2025Â $228Â 2026Â Â 470Â 2027Â Â 405Â Total future lease paymentsÂ $1,103Â Less:Â Imputed interestÂ Â (94) Present value of lease liabilityÂ $1,009Â Â Cash paid for amounts included in the measurement of lease liabilities was approximately $225,000 and $257,000 for the six months ended September 30, 2024 and 2023, respectively. Rent expense was approximately $225,000 for each of the six month periods ended September 30, 2024 and 2023, respectively and $113,000 for each of the three month periods ended September 30, 2024 and 2023. X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/842-20/tableOfContent + Details Name: us-gaap_LesseeOperatingLeasesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R10.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholdersâ€™ Equity 6 Months Ended Sep. 30, 2024 Stockholdersâ€™ Equity [Abstract] Â STOCKHOLDERSâ€™ EQUITY NOTE 4 â€" STOCKHOLDERSâ€™ EQUITY Â ATM Offering Â In November 2023, the Company entered into a Sales Agreement (the ATM Agreement) with Leerink Partners LLC (Leerink) under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock through an â€œat the market offeringâ€ program under which Leerink will act as sales agent or principal. The ATM Agreement provides that Leerink will be entitled to compensation for its services equal to 3.0% of the gross proceeds from sales of any shares of common stock under the ATM Agreement. The Company has no obligation to sell any shares under the ATM Agreement and may, at any time, suspend solicitation and offers under the ATM Agreement. During the three and six months ended September 30, 2024, under the ATM Agreement, the Company sold 824,514 shares of common stock for proceeds of approximately $1,933,000, which was net of commissions and legal fees of approximately $82,000. Â Common Stock Purchase Warrants Â As of September 30, 2024, the Company had the following common stock purchase warrants outstanding (share amounts in thousands): Â Â Â Number of SharesÂ Â Exercise PriceÂ Â ExpirationÂ Balance as of March 31, 2024Â Â 12,521Â Â Â Â Â Â Â Â Â Warrants exercisedÂ Â (55)Â $1.22Â Â Â May 2028Â Balance as of June 30, 2024Â Â 12,466Â Â Â Â Â Â Â Â Â Warrants exercisedÂ Â (252)Â $0.01Â Â Â â€"Â Warrants exercisedÂ Â (649)Â $1.22Â Â Â May 2028Â Warrants exercisedÂ Â (39)Â $1.32Â Â Â May 2027Â Balance as of September 30, 2024Â Â 11,526Â Â Â Â Â Â Â Â Â As of March 31, 2024, the Company had the following warrants outstanding (share amounts in thousands): Â TypeÂ Number of SharesÂ Â Exercise PriceÂ Â ExpirationÂ Common stockÂ Â 1,348Â Â $0.01Â Â Â â€"Â Common stockÂ Â 4,421Â Â Â 1.22Â Â Â May 2028Â Common stockÂ Â 535Â Â Â 1.32Â Â Â May 2027Â Common stockÂ Â 768Â Â Â 6.00Â Â JanuaryÂ 2027Â -Â FebruaryÂ 2027Â Common stockÂ Â 4,011Â Â Â 6.60Â Â Â February 2027Â Common stockÂ Â 1,438Â Â $6.60Â Â Â November 2027Â TotalÂ Â 12,521Â Â Â Â Â Â Â Â Â Â The outstanding pre-funded warrants with an exercise price of $0.01 per share were included in the weighted average shares outstanding calculation for each of the three and six month periods ended September 30, 2024 and 2023. At March 31, 2024, the Company had a receivable from its transfer agent for approximately $142,000 for the proceeds from warrants exercised prior to March 31, 2024. The receivable was recorded in the prepaid and other line in the consolidated balance sheet at March 31, 2024 and was collected during the three months ended June 30, 2024. Â Other Â During the six months ended September 30, 2024 and 2023, the Company issued 30,000 and 1,429 shares of common stock with fair values of approximately $51,000 and $1,400, respectively to service providers. X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R11.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation 6 Months Ended Sep. 30, 2024 Stock-Based Compensation [Abstract] Â STOCK-BASED COMPENSATION NOTE 5 â€" STOCK-BASED COMPENSATION Â Amended 2017 Equity Incentive Plan Â In October 2017, the Board approved the 2017 Equity Incentive Plan (the Plan), as amended, with 1,000,000 shares of common stock reserved for issuance. In January 2020 and August 2021, the Board approved increases in the number of shares reserved for issuance by 333,334 and 1,333,334 shares, respectively. In January 2023 and February 2024, the Companyâ€™s stockholders approved increases in the number of shares reserved for issuance under the Plan by an additional 2,000,000 and 3,000,000 shares, respectively. Under the Plan, eligible employees, directors and consultants may be granted a broad range of awards, including stock options, stock appreciation rights, restricted stock, performance-based awards and restricted stock units. The Plan is administered by the Board or, in the alternative, a committee designated by the Board.Â Â Stock-Based Compensation Expense Â Stock options granted by the Company generally vest over 36 months and have a 10-year term. As of September 30, 2024, the unamortized compensation cost related to stock options was approximately $1,763,000 and is expected to be recognized as expense over a weighted-average period of approximately 1.8 years. Â In October 2023, under its Two-Part FDA Submission and Clearance Milestone Bonus Program (the Bonus Program), the Company granted stock options to purchase 909,533 shares of common stock, which were subject to vesting based upon the achievement of certain performance milestones by the Company and continued service by the optionees. In January 2024, options to purchase 625,326 shares (net of forfeitures), which were granted under part one of the Bonus Program, vested upon the Companyâ€™s submission to the FDA. In August 2024, options to purchase 242,307 shares (net of forfeitures), which were granted under part two of the Bonus Program, were canceled, as the Company did not receive clearance from the FDA for its MODD1 product by August 1, 2024. In August 2024, the Company granted new options to purchase 339,298 shares (the Clearance Options), which were subject to vesting based upon the Companyâ€™s receipt of clearance from the FDA for its MODD1 product by December 31, 2024 and continued service by the optionees. The Clearance options vested in full in September 2024 upon the Companyâ€™s receipt of clearance from the FDA for its MODD1 product. Â The weighted-average grant date fair value of options granted was $1.41Â and $1.00 per share for the six months ended September 30, 2024 and 2023, respectively, and $1.51 and $1.02 for the three months ended September 30, 2024 and 2023, respectively. The following assumptions were used in the fair-value method calculations: Â Â Â Three Months Ended September 30,Â Â SixÂ MonthsÂ Ended September 30,Â Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Risk-free interest ratesÂ Â 3.4%Â -Â 4.1%Â Â Â 4.4%Â -Â 4.6%Â Â Â 3.5%Â -Â 4.4%Â Â Â 3.5%Â -Â 4.6%Â VolatilityÂ Â 114% - 117%Â Â Â 127%Â Â Â 114% - 123%Â Â Â 82.6% - 152.2%Â Expected life (years)Â Â 5.0 â€" 5.7Â Â Â 5.0 â€" 5.7Â Â Â 5.0 â€" 5.7Â Â Â 5.0 â€" 6.2Â Â The fair values of options at the grant date were estimated utilizing the Black-Scholes valuation model, which includes simplified methods to establish the fair term of options, as well as average volatility. The risk-free interest rate was derived from the Daily Treasury Yield Curve Rates, as published by the U.S. Department of the Treasury as of the grant date for terms equal to the expected terms of the options. A dividend yield of zero was applied because the Company has never paid dividends and has no intention to pay dividends in the foreseeable future. The Company accounts for forfeitures as they occur. Â The following table summarizes the activity in the shares available for grant under the Plan during the six months ended September 30, 2024: Â Â Â Â Â Â Options OutstandingÂ Â Â Â Â Â Â Â Â WeightedÂ Â Â SharesÂ Â Â Â Â AverageÂ Â Â AvailableÂ Â Number ofÂ Â ExerciseÂ Â Â for GrantÂ Â SharesÂ Â PricesÂ Balance at March 31, 2024Â Â 3,648,651Â Â Â 3,689,341Â Â $Â Â Â Â Â Â Â Â Â 3.70Â Share awardsÂ Â (3,875)Â Â â€"Â Â Â 1.56Â Options grantedÂ Â (682,375)Â Â 682,375Â Â Â 1.52Â Options exercisedÂ Â â€"Â Â Â (7,530)Â Â 1.08Â Options cancelled and returned to the PlanÂ Â 42,230Â Â Â (42,230)Â Â 2.62Â Balance at June 30, 2024Â Â 3,004,631Â Â Â 4,321,956Â Â $3.36Â Share awardsÂ Â (3,875)Â Â â€"Â Â Â 2.28Â Options grantedÂ Â (483,673)Â Â 483,673Â Â Â 1.81Â Options cancelled and returned to the PlanÂ Â 274,901Â Â Â (274,901)Â Â 1.51Â Balance at September 30, 2024Â Â 2,791,984Â Â

Â 4,530,728Â Â $3.33Â Â A stock option was exercised on a cashless basis for 7,530 shares of common stock during the six months ended September 30, 2024. There were no stock options exercised during the six months ended September 30, 2023. During the six months ended September 30, 2024 and 2023, the Company awarded 7,750 and 12,640 shares, respectively, and for the three months ended September 30, 2024 and 2023, the Company awarded 3,875 and 6,265 shares, respectively, to its non-employee directors under the Companyâ€™s outside director compensation plan. For the six months ended September 30, 2024 and 2023, the Company recorded stock-based compensation expense for these share awards of approximately $15,000 and $13,000, respectively, and for the three months ended September 30, 2024 and 2023, the Company recorded stock-based compensation expense for these share awards of approximately $9,000 and $7,000, respectively. Â A summary of restricted stock unit (RSU) activity under the Plan is presented below. Â Â Â Â Â Â Weighted AverageÂ Â Â Number of SharesÂ Â Grant-Date Fair ValueÂ Non-vested shares at March 31, 2024Â Â 187,499Â Â $Â Â 0.91Â VestedÂ Â (20,832)Â $0.91Â Non-vested shares at June 30, 2024Â Â 166,667Â Â $0.91Â VestedÂ Â (20,833)Â $0.91Â Non-vested shares at September 30, 2024Â Â 145,834Â Â $0.91Â Â The total intrinsic value of RSUs outstanding as of September 30, 2024 was approximately $328,000. The unamortized compensation cost at September 30, 2024 was approximately $94,000 related to RSUs and is expected to be recognized as expense over a period of approximately 1.75 years. Â The following table summarizes the range of outstanding and exercisable options as of September 30, 2024: Â Â Â Options Outstanding Â Â Options Exercisable Â Range of Exercise Price Â Number Outstanding Â Â Weighted Average Remaining Contractual Life (in Years) Â Â Weighted Average Exercise Price Â Â Number Exercisable Â Â Weighted Average Exercise Price Â Â Aggregate Intrinsic value Â $0.93 - $2.28 Â Â 3,098,454 Â Â Â 8.41 Â Â $ 1.57 Â Â Â 2,640,918 Â Â $ 1.55 Â Â $ 1,839,613 Â $3.95 - $7.51 Â Â 933,145 Â Â Â 6.69 Â Â $ 5.30 Â Â Â 836,533 Â Â $ 5.42 Â Â Â â€” Â $8.61 - $17.70 Â Â 499,129 Â Â Â 6.73 Â Â $ 10.56 Â Â Â 490,036 Â Â $ 10.56 Â Â Â â€” Â $0.93 - $17.70 Â Â 4,530,728 Â Â Â 7.87 Â Â $ 3.33 Â Â Â 3,967,487 Â Â $ 3.48 Â Â $Â 1,839,613 Â Â The intrinsic value per share is calculated as the excess of the closing price of the common stock on the Companyâ€™s principal trading market over the exercise price of the option. X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 22 R12.htm IDEA: XBRL DOCUMENT v3.24.3 Income Taxes 6 Months Ended Sep. 30, 2024 Income Taxes [Abstract] Â INCOME TAXES NOTE 6 â€“ INCOME TAXES Â The Company determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the Companyâ€™s assets and liabilities using tax rates in effect for the year in which the Company expects the differences to affect taxable income. A valuation allowance is established for any deferred tax assets for which it is more likely than not that all or a portion of the deferred tax assets will not be realized. Based on the available information and other factors, management believes it is more likely than not that its federal and state net deferred tax assets will not be fully realized, and the Company has recorded a full valuation allowance. Â The Company files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations. All tax returns for fiscal 2016 to fiscal 2023 may be subject to examination by the U.S. federal and state tax authorities. As of September 30, 2024, the Company has not recorded any liability for unrecognized tax benefits related to uncertain tax positions. X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details Name: us-gaap_IncomeTaxDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R13.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies 6 Months Ended Sep. 30, 2024 Commitments and Contingencies [Abstract] Â COMMITMENTS AND CONTINGENCIES NOTE 7 â€“ COMMITMENTS AND CONTINGENCIES Â Litigations, Claims and Assessments Â In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements. Â Indemnification Â In the ordinary course of business, the Company enters into contractual arrangements under which it may agree to indemnify the counterparties from any losses incurred relating to breach of representations and warranties, failure to perform certain covenants, or claims and losses arising from certain events as outlined within the particular contract, which may include, for example, losses arising from litigation or claims relating to past performance. Such indemnification clauses may not be subject to maximum loss clauses. The Company has also entered into indemnification agreements with its officers and directors. No amounts were reflected in the Companyâ€™s consolidated financial statements for the three and six months ended September 30, 2024 and 2023 related to these indemnifications. The Company has not estimated the maximum potential amount of indemnification liability under these agreements due to the limited history of prior claims and the unique facts and circumstances applicable to each particular agreement. To date, the Company has not made any payments related to these indemnification agreements. Â Purchase Obligations Â The Companyâ€™s primary purchase obligations include purchase orders for machinery and equipment. At September 30, 2024, the Company had outstanding purchase orders for machinery and equipment and related expenditures of approximately $990,000. Â In December 2023, the Company signed a device integration agreement with a provider of connected-care and remote monitoring diabetes technology solutions. As of September 30, 2024, the Company had a remaining obligation under the device integration agreement of approximately $400,000Â over three years for technology license fees. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R14.htm IDEA: XBRL DOCUMENT v3.24.3 Related Party Transactions 6 Months Ended Sep. 30, 2024 Related Party Transactions [Abstract] Â RELATED PARTY TRANSACTIONS NOTE 8 â€“ RELATED PARTY TRANSACTIONS Â A family member of one of the Companyâ€™s executive officers is an employee of the Company. During the three months ended September 30, 2024 and 2023, the Company paid the family member approximately $43,365 and $28,954, respectively, which includes the aggregate grant date fair values, as determined pursuant to FASB ASC Topic 718, of stock options granted during each period. During the six months ended September 30, 2024 and 2023, the Company paid the family member approximately $100,625 and $63,754, respectively, which includes the aggregate grant date fair values, as determined pursuant to FASB ASC Topic 718, of stock options granted during each period. X - ReferencesNo definition available. + Details Name: us-gaap_RelatedPartyTransactionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(e)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/850/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1 + Details Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R15.htm IDEA: XBRL DOCUMENT v3.24.3 Pay vs Performance Disclosure - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Sep. 30, 2024 Jun. 30, 2024 Sep. 30, 2023 Jun. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Pay vs Performance Disclosure Â Â Â Â Â Â Net Income (Loss) $ (4,956) $ (4,137) $ (4,183) $ (3,737) $ (9,093) $ (7,920) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13:

http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 26 R16.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended Sep. 30, 2024 Trading Arrangements, by Individual Â Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 27 R17.htm IDEA: XBRL DOCUMENT v3.24.3 Accounting Policies, by Policy (Policies) 6 Months Ended Sep. 30, 2024 The Company and Summary of Significant Accounting Policies [Abstract] Â Liquidity and Going Concern Liquidity and Going ConcernThe Company does not currently have revenues to generate cash flows to cover operating expenses. Since its inception, the Company has incurred operating losses and negative cash flows in each year due to costs incurred in connection with its operations. The Company expects to continue to incur operating losses for the foreseeable future and incur cash outflows from operations as it continues to invest in the development and commercialization of its products. The Company expects that its research and development and general and administrative expenses will continue to increase, and, as a result, it will eventually need to generate significant revenue to achieve profitability. When considered with its current operating plan, these conditions raise substantial doubt about the Companyâ€™s ability to continue as a going concern within one year after the date that these financial statements are issued. In addition, the Companyâ€™s independent registered public accounting firm, in its report on the consolidated financial statements as of and for the year ended March 31, 2024, expressed substantial doubt about the Companyâ€™s ability to continue as a going concern. These condensed consolidated financial statements do not include any adjustments that might result from this uncertainty. Implementation of the Companyâ€™s plans and its ability to continue as a going concern will depend upon the Companyâ€™s ability to raise additional capital, through the sale of additional equity or debt securities, to support its future operations. There can be no assurance that such additional capital, whether in the form of debt or equity financing, will be sufficient or available and, if available, that such capital will be offered on terms and conditions acceptable to the Company. The Companyâ€™s operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital expenditures. The Companyâ€™s future capital requirements and the adequacy of its available funds will depend on many factors, including the Companyâ€™s ability to successfully commercialize its MODD1 product, competing technological and market developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement its product offering. If the Company is unable to secure additional capital, it may be required to curtail its product commercialization and research and development initiatives and take additional measures to reduce costs in order to conserve its cash.Â Basis of Presentation Basis of PresentationThe Companyâ€™s fiscal year ends on March 31 of each calendar year. Each reference to a fiscal year in these notes to the condensed consolidated financial statements refers to the fiscal year ended March 31 of the calendar year indicated (for example, fiscal 2025 refers to the fiscal year ending March 31, 2025). The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Quasuras. All significant intercompany transactions and balances have been eliminated in consolidation.The accompanying condensed consolidated financial statements are unaudited and have been prepared in accordance with generally accepted accounting principles in the United States (GAAP) and with the rules and regulations of the United States Security and Exchange Commission (SEC) regarding interim financial reporting. The condensed consolidated balance sheet as of March 31, 2024 has been derived from the audited consolidated financial statements at that date. Certain information and disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted in accordance with these rules and regulations of the SEC. The information in this report should be read in conjunction with the Companyâ€™s consolidated financial statements and notes thereto included in its most recent annual report on Form 10-K filed with the SEC.In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Companyâ€™s financial position, results of operations and cash flows for the interim periods presented. The operating results for the six months ended September 30, 2024 are not necessarily indicative of the results that may be expected for the year ending March 31, 2025 or for any other future period. Use of Estimates Use of Estimates The preparation of the accompanying condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of revenues and expenses during the reporting period. Estimates may include those pertaining to accruals, stock-based compensation and income taxes. Actual results could differ from those estimates. Reportable Segment Reportable Segment The Company operates in one business segment and uses one measurement of profitability for its business. Research and Development Research and DevelopmentThe Company expenses research and development expenditures as incurred. Concentration of Credit Risk Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash held in demand deposit accounts. The Company maintains a portion of its cash in demand deposit accounts at high credit quality financial institutions within the United States, which are insured by the Federal Deposit Insurance Corporation (FDIC) up to limits of approximately $250,000. No reserve has been made in the financial statements for any possible loss due to financial institution failure.Â Risks and Uncertainties Risks and Uncertainties The Company is subject to risks from, among other things, competition associated with the industry in general, other risks associated with financing, liquidity requirements, rapidly changing customer requirements, limited operating history, pandemics, wars and acts of terrorism and the volatility of public markets. The Company may be unable to access the capital markets, and additional capital may only be available to the Company on terms that could be significantly detrimental to its existing stockholders and to its business. Cash and Cash Equivalents Cash and Cash EquivalentsCash and cash equivalents include cash held in demand deposit and money market accounts, certificates of deposit and all highly liquid debt instruments with original maturities of three months or less. Property and Equipment Property and EquipmentProperty and equipment are recorded at historical cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally three to five years. Depreciation is recorded in operating expenses in the consolidated statements of operations. Leasehold improvements and assets acquired through finance leases are amortized over the shorter of their estimated useful life or the lease term, and amortization is recorded in operating expenses in the consolidated statements of operations. Construction-in-process includes machinery and equipment and is stated at cost and not depreciated. Depreciation on construction-in-process commences when the assets are ready for their intended use and placed into service. Fair Value of Financial Instruments Fair Value of Financial Instruments The Company measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels: â—Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets. Â â— Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. Â â— Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement. Due to their short-term nature, the carrying values of cash equivalents, accounts payable and accrued expenses, approximate fair value. Leases LeasesThe Companyâ€™s right-of-use assets consist of leased assets recognized in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) No. 842, Leases, which requires lessees to recognize a lease liability and a corresponding lease asset for virtually all lease contracts. Right-of-use assets represent the Companyâ€™s right to use an underlying asset for the lease term and the lease liability represents the Companyâ€™s obligation to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the consolidated balance sheets and are expensed on a straight-line basis over the lease term in the consolidated statement of operations and comprehensive loss. The Company determines the lease term by agreement with the lessor. In cases where the lease does not provide an implicit interest rate, the Company uses the Companyâ€™s incremental borrowing rate based on the information available at commencement date in determining the present value of future payments.Â Stock-Based Compensation Stock-Based CompensationThe Company periodically issues stock options, restricted stock units and stock awards to employees and non-employees. The Company accounts for such awards based on FASB ASC Topic 718, whereby the value of the award is measured on the date of grant and recognized as compensation expense on a straight-line basis over the requisite service period, usually the vesting period. With respect to performance-based awards, the Company assesses the probability of achieving the requisite performance criteria before recognizing compensation expense. The fair value of the Companyâ€™s stock options is estimated using the Black-Scholes-Merton Option Pricing (Black Scholes) model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the options, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes model. The assumptions used in the Black-Scholes model could materially affect compensation expense recorded in future periods. Per-Share Amounts Per-Share AmountsBasic net loss per share is computed by dividing loss for the period by the weighted-average number of shares of common stock outstanding (WASO) during the period. In addition, the Company includes the number of shares of common stock issuable under pre-funded warrants as outstanding for purposes of the WASO calculation. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period. Potentially dilutive common shares consist of incremental shares of common stock issuable upon the exercise of stock options and exercise of warrants.The following table sets forth securities outstanding which were excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive (in thousands). Â Â Six Months Ended September 30,Â Â Â 2024Â Â 2023Â Options to purchase common stockÂ Â 4,531Â Â Â 2,913Â Unvested restricted stock unitsÂ Â 146Â Â Â 229Â Common stock purchase warrantsÂ Â 10,430Â Â Â 11,892Â TotalÂ Â 15,107Â Â Â 15,034Â Reclassifications ReclassificationsCertain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations or cash flows. Comprehensive Loss Comprehensive LossComprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may include certain changes in equity that are excluded from net loss. For the three and six months ended September 30, 2024 and 2023, the Companyâ€™s comprehensive loss was the same as its net loss. Recently Issued Accounting Pronouncements Recently Issued Accounting PronouncementsIn November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires disclosure of incremental segment information on an annual and interim basis. ASU No. 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and it requires retrospective application to all prior periods presented in the financial statements. The Company is currently evaluating the impact that this ASU will have on the presentation of its consolidated financial statements.In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which expands disclosures in an entityâ€™s income tax rate reconciliation table and disclosures regarding cash taxes paid both in the U.S. and foreign jurisdictions. The update

will be effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact that this ASU will have on the presentation of its consolidated financial statements.In November 2024, the FASB issued ASU No. 2024-03, Income Statement â€" Reporting Comprehensive Income â€" Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The new standard requires disclosures about specific types of expenses included in the expense captions presented on the face of the income statement as well as disclosures about selling expenses. The standard is effective for the Company for annual periods beginning April 1, 2027 and interim periods beginning April 1, 2028, with early adoption permitted. The standard may be applied either prospectively to financial statements issued for reporting periods after the effective date or retrospectively to any or all prior periods presented in the financial statements. The Company is evaluating the impact that this ASU will have on the presentation of its consolidated financial statements.Â X - DefinitionDisclosure of accounting policy for risks and uncertainties. + ReferencesNo definition available. + Details Name: modd_RisksAndUncertaintiesPolicyTextBlock Namespace Prefix: modd_ Data Type: dtr:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1 + Details Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for comprehensive income. + ReferencesNo definition available. + Details Name: us-gaap_ComprehensiveIncomePolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for credit risk. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 825 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1 + Details Name: us-gaap_ConcentrationRiskCreditRisk Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 + Details Name: us-gaap_EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for determining the fair value of financial instruments. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 825 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1 + Details Name: us-gaap_FairValueOfFinancialInstrumentsPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for leasing arrangement entered into by lessee. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1 + Details Name: us-gaap_LesseeLeasesPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 205 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483504/205-10-50-1 + Details Name: us-gaap_PriorPeriodReclassificationAdjustmentDescription Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1 + Details Name: us-gaap_ResearchAndDevelopmentExpensePolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for segment reporting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 36 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29 + Details Name: us-gaap_SegmentReportingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.C.Q3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.1.Q5) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.3.Q2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.2.Q6) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 40 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205-40/tableOfContent + Details Name: us-gaap_SubstantialDoubtAboutGoingConcernTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R18.htm IDEA: XBRL DOCUMENT v3.24.3 The Company and Summary of Significant Accounting Policies (Tables) 6 Months Ended Sep. 30, 2024 The Company and Summary of Significant Accounting Policies [Abstract] Â Schedule of Diluted Net Loss Per Share The following table sets forth securities outstanding which were excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive (in thousands). Â Â Six Months Ended September 30,Â Â Â 2024Â Â 2023Â Options to purchase common stockÂ Â 4,531Â Â Â 2,913Â Unvested restricted stock unitsÂ Â 146Â Â Â 229Â Common stock purchase warrantsÂ Â 10,430Â Â Â 11,892Â TotalÂ Â 15,107Â Â Â 15,034Â X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Consolidated Balance Sheet Detail (Tables) 6 Months Ended Sep. 30, 2024 Consolidated Balance Sheet Detail [Abstract] Â Schedule of Property and Equipment, Net Â Â SeptemberÂ 30, 2024Â Â March 31, 2024Â Â Â Â (in thousands)Â Property and equipment, netÂ Â Â Â Â Â Machinery and equipmentÂ $4,540Â Â $3,209Â Computer equipment and softwareÂ Â 66Â Â Â 66Â Construction-in-processÂ Â 74Â Â Â 283Â Leasehold improvementsÂ Â 33Â Â Â 33Â Office equipmentÂ Â 46Â Â Â 63Â Â Â Â 4,759Â Â Â 3,654Â Less:Â Â accumulated depreciation and amortizationÂ Â (1,118)Â Â (679) TotalÂ $3,641Â Â $2,975Â Schedule of Accrued Expenses Â Â SeptemberÂ 30, 2024Â Â March 31, 2024Â Â Â (in thousands)Â Accrued expensesÂ Â Â Â Â Â Accrued wages and employee benefitsÂ $265Â Â $243Â OtherÂ Â 80Â Â Â 37Â TotalÂ $345Â Â $280Â X - ReferencesNo definition available. + Details Name: us-gaap_BalanceSheetRelatedDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -

Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accrued liabilities. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Leases (Tables) 6 Months Ended Sep. 30, 2024 Leases [Abstract] Â Schedule of Future Minimum Payments Under the Facility Operating Lease Future minimum payments under the facility operating lease, as of September 30, 2024, are listed in the table below (in thousands). Annual Fiscal YearsÂ Â Â 2025Â $228Â 2026Â Â 470Â 2027Â Â 405Â Total future lease paymentsÂ $1,103Â Less:Â Imputed interestÂ Â (94) Present value of lease liabilityÂ $1,009Â X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholdersâ€™ Equity (Tables) 6 Months Ended Sep. 30, 2024 Stockholdersâ€™ Equity [Abstract] Â Schedule of Warrants Outstanding As of September 30, 2024, the Company had the following common stock purchase warrants outstanding (share amounts in thousands): Â Â Number of SharesÂ Â Exercise PriceÂ Â ExpirationÂ Balance as of March 31, 2024Â Â 12,521Â Â Â Â Â Â Â Â Â Warrants exercisedÂ Â (55)Â $1.22Â Â Â May 2028Â Balance as of June 30, 2024Â Â 12,466Â Â Â Â Â Â Â Â Â Warrants exercisedÂ Â (252)Â $0.01Â Â Â â€”Â Warrants exercisedÂ Â (649)Â $1.22Â Â Â May 2028Â Warrants exercisedÂ Â (39)Â $1.32Â Â Â May 2027Â Balance as of September 30, 2024Â Â 11,526Â Â Â Â Â Â Â Â Â As of March 31, 2024, the Company had the following warrants outstanding (share amounts in thousands): TypeÂ Number of SharesÂ Â Exercise PriceÂ Â ExpirationÂ Common stockÂ Â 1,348Â Â $0.01Â Â Â â€”Â Common stockÂ Â 4,421Â Â Â 1.22Â Â Â May 2028Â Common stockÂ Â 535Â Â Â 1.32Â Â Â May 2027Â Common stockÂ Â 768Â Â Â 6.00Â Â Â JanuaryÂ 2027Â -Â FebruaryÂ 2027Â Common stockÂ Â 4,011Â Â Â 6.60Â Â Â February 2027Â Common stockÂ Â 1,438Â Â $6.60Â Â Â November 2027Â TotalÂ Â 12,521Â Â Â Â Â Â Â Â Â X - DefinitionTabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1 + Details Name: us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 32 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation (Tables) 6 Months Ended Sep. 30, 2024 Stock-Based Compensation [Abstract] Â Schedule of Assumptions were used in the Fair-Value Method The following assumptions were used in the fair-value method calculations: Â Â Three Months Ended September 30,Â Â SixÂ MonthsÂ Ended September 30,Â Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Risk-free interest ratesÂ Â 3.4%Â -Â 4.1%Â Â Â 4.4%Â -Â 4.6%Â Â Â 3.5%Â -Â 4.4%Â Â Â 3.5%Â -Â 4.6%Â VolatilityÂ Â 114% - 117%Â Â Â 127%Â Â 114% - 123%Â Â Â 82.6% - 152.2%Â Expected life (years)Â Â 5.0 â€“ 5.7Â Â Â 5.0 â€“ 5.7Â Â Â 5.0 â€“ 5.7Â Â Â 5.0 â€“ 6.2Â Schedule of Activity in the Shares The following table summarizes the activity in the shares available for grant under the Plan during the six months ended September 30, 2024: Â Â Â Â Â Options OutstandingÂ Â Â Â Â Â Â Â Â WeightedÂ Â Â SharesÂ Â Â Â Â AverageÂ Â Â AvailableÂ Â Number ofÂ Â ExerciseÂ Â Â for GrantÂ Â SharesÂ Â PricesÂ Balance at March 31, 2024Â Â 3,648,651Â Â Â 3,689,341Â Â $Â Â Â Â Â Â Â Â Â Â Â 3.70Â Share awardsÂ Â (3,875)Â Â â€”Â Â Â 1.56Â Options grantedÂ Â (682,375)Â Â 682,375Â Â Â 1.52Â Options exercisedÂ Â â€”Â Â Â (7,530)Â Â 1.08Â Options cancelled and returned to the PlanÂ Â 42,230Â Â Â (42,230)Â Â 2.62Â Balance at June 30, 2024Â Â 3,004,631Â Â Â 4,321,956Â Â $3.36Â Share awardsÂ Â (3,875)Â Â â€”Â Â Â 2.28Â Options grantedÂ Â (483,673)Â Â 483,673Â Â Â 1.81Â Options cancelled and returned to the PlanÂ Â 274,901Â Â Â (274,901)Â Â 1.51Â Balance at September 30, 2024Â Â 2,791,984Â Â Â 4,530,728Â Â $3.33Â Â Schedule of RSU Activity under the Plan A summary of restricted stock unit (RSU) activity under the Plan is presented below. Â Â Â Â Â Weighted AverageÂ Â Â Number of SharesÂ Â Grant-Date Fair ValueÂ Non-vested shares at March 31, 2024Â Â 187,499Â Â $Â Â 0.91Â VestedÂ Â (20,832)Â $0.91Â Non-vested shares at June 30, 2024Â Â 166,667Â Â $0.91Â VestedÂ Â (20,833)Â $0.91Â Non-vested shares at September 30, 2024Â Â 145,834Â Â $0.91Â Schedule of Outstanding and Exercisable Options The following table summarizes the range of outstanding and exercisable options as of September 30, 2024: Â Â Options Outstanding Â Â Options Exercisable Â Range of Exercise Price Â Number Outstanding Â Â Weighted Average Remaining Contractual Life (in Years) Â Â Weighted Average Exercise Price Â Â Number Exercisable Â Â Weighted Average Exercise Price Â Â Aggregate Intrinsic value Â $0.93 - $2.28 Â Â 3,098,454 Â Â Â 8.41 Â Â $ 1.57 Â Â 2,640,918 Â Â $ 1.55 Â Â $ 1,839,613 Â $3.95 - $7.51 Â Â 933,145 Â Â Â 6.69 Â Â $ 5.30 Â Â Â 836,533 Â Â $ 5.42 Â Â Â â€” Â $8.61 - $17.70 Â Â 499,129 Â Â Â 6.73 Â Â $ 10.56 Â Â Â 490,036 Â Â $ 10.56 Â Â Â â€” Â $0.93 - $17.70 Â Â 4,530,728 Â Â Â 7.87 Â Â $ 3.33 Â Â Â 3,967,487 Â Â $ 3.48 Â Â $Â 1,839,613 Â X - DefinitionTabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (k) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1 + Details Name: us-gaap_ScheduleOfAssumptionsUsedTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock options and stock appreciation rights that were outstanding at the beginning and end of the year, exercisable at the end of the year, and the number of stock options and stock appreciation rights that were granted, exercised or converted, forfeited, and expired during the year. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 33 R23.htm IDEA: XBRL DOCUMENT v3.24.3 The Company and Summary of Significant Accounting Policies (Details) 6 Months Ended Sep. 30, 2024 USD ($) segment The Company and Summary of Significant Accounting Policies [Line Items] Â Business segment (in segment) | segment 1 FDIC insured amount (in Dollars) | $ $ 250,000 Minimum [Member] Â The Company and Summary of Significant Accounting Policies [Line Items] Â Estimated useful lives 3 years Maximum [Member] Â The Company and Summary of Significant Accounting Policies [Line Items] Â Estimated useful lives 5 years X - DefinitionThe amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation. + ReferencesNo definition available. + Details Name: us-gaap_CashFDICInsuredAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4 + Details Name: us-gaap_ChangeInAccountingEstimateLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfOperatingSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionUseful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. + ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentUsefulLife Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 34 R24.htm IDEA: XBRL DOCUMENT v3.24.3 The Company and Summary of Significant Accounting Policies (Details) - Schedule of Diluted Net Loss Per Share - shares shares in Thousands 6 Months Ended Sep. 30, 2024 Sep. 30, 2023 Schedule of Diluted Net Loss Per Share [Line Items] Â Â Anti-dilutive total 15,107 15,034 Options to purchase common stock [Member] Â Â Schedule of Diluted Net Loss Per Share [Line Items] Â Â Anti-dilutive total 4,531 2,913 Unvested restricted stock units [Member] Â Â Schedule of Diluted Net Loss Per Share [Line Items] Â Â Anti-dilutive total 146 229 Common stock purchase warrants [Member] Â Â Schedule of Diluted Net Loss Per Share [Line Items] Â Â Anti-dilutive total 10,430 11,892 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap_EarningsPerShareDilutedLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=modd_UnvestedRestrictedStockUnitsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 35 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Consolidated Balance Sheet Detail (Details) - Schedule of Property and Equipment, Net - USD ($) $ in Thousands Sep. 30, 2024 Mar. 31, 2024 Property and equipment, net Â Â Property and equipment, gross $ 4,759 $ 3,654 Less: accumulated depreciation and amortization (1,118) (679) Total 3,641 2,975 Machinery and equipment [Member] Â Â Property and equipment, net Â Â Property and equipment, gross 4,540 3,209 Computer equipment and software [Member] Â Â Property and equipment, net Â Â Property and equipment, gross 66 66 Construction-in-process [Member] Â Â Property and equipment, net Â Â Property and equipment, gross 74 283 Leasehold improvements [Member] Â Â Property and equipment, net Â Â Property and equipment, gross 33 33 Office equipment [Member] Â Â Property and equipment, net Â Â Property and equipment, gross $ 46 $ 63 X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated

depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentNetAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 36 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Consolidated Balance Sheet Detail (Details) - Schedule of Accrued Expenses - USD ($) $ in Thousands Sep. 30, 2024 Mar. 31, 2024 Accrued expenses Â Â Accrued wages and employee benefits $ 265 $ 243 Other 80 37 Total $ 345 $ 280 X - ReferencesNo definition available. + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedEmployeeBenefitsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 37 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Leases (Details) - USD ($) 3 Months Ended 6 Months Ended Feb. 01, 2023 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Leases [Line Items] Â Â Â Â Â Rent expense $ 36,000 $ 113,000 $ 113,000 $ 225,000 $ 225,000 Annual rent increases percentage 4.00% Â Â Â Â Discount rate Â 8.00% Â 8.00% Â Obtained a right-of-use asset Â Â Â $ 1,560,000 Â Cash paid Â Â Â $ 225,000 $ 257,000 Thornmint Road, San Diego, CA [Member] Â Â Â Â Â Leases [Line Items] Â Â Â Â Â Lease term Â 48 months Â 48 months Â X - DefinitionRepresent the percentage of annual rent increases. + ReferencesNo definition available. + Details Name: modd_PercentageOfAnnualRentIncreases Namespace Prefix: modd_ Data Type: dtr:percentItemType Balance Type: na Period Type: instant X - DefinitionDiscount rate used by lessee to determine present value of operating lease payments. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseDiscountRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionTerm of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseTermOfContract Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_LoansAndLeasesReceivableDisclosureLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionCash payments to lessor's for use of assets under operating leases. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_PaymentsForRent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase in right-of-use asset obtained in exchange for operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_LeaseContractualTermAxis=modd_ThornmintRoadSanDiegoCAMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 38 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Leases (Details) - Schedule of Future Minimum Payments Under the Facility Operating Lease $ in Thousands Sep. 30, 2024 USD ($) Schedule of Future Minimum Payments Under the Facility Operating Lease [Abstract] Â 2025 $ 228 2026 470 2027 405 Total future lease payments 1,103 Less: Imputed interest (94) Present value of lease liability $ 1,009 X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 39 R29.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholdersâ€™ Equity (Details) - USD ($) $ / shares in Units, shares in Thousands 3 Months Ended 6 Months Ended 12 Months Ended Nov. 30, 2023 Sep. 30, 2024 Sep. 30, 2024 Sep. 30, 2023 Mar. 31, 2024 Stockholdersâ€™ Equity [Line Items] Â Â Â Â Â Compensation services equal percentage 3.00% Â Â Â Â Shares sold (in Shares) Â 824,514 824,514 Â Â Net proceeds Â $ 1,933,000 $ 1,933,000 Â Â Legal fees Â Â 82,000 Â Â Exercise price of the pre-funded warrants (in Dollars per share) Â $ 0.01 Â $ 0.01 Â Common stock fair value Â Â $ 51,000 $ 1,400 Â Warrant [Member] Â Â Â Â Â Stockholdersâ€™ Equity [Line Items] Â Â Â Â Â Aggregate proceeds Â Â Â Â $ 142,000 Common Stock [Member] Â Â Â Â Â Stockholdersâ€™ Equity [Line Items] Â Â Â Â Â Issuance of common stock shares (in Shares) Â 825 Â Â Â Common Stock [Member] | Warrant [Member] Â Â Â Â Â Stockholdersâ€™ Equity [Line Items] Â Â Â Â Â Issuance of common stock shares (in Shares) Â Â 30,000 1,429 Â X - DefinitionThe price per of exercise price of the pre-funded warrants. + ReferencesNo definition available. + Details Name: modd_ExercisePriceOfThePrefundedWarrants Namespace Prefix: modd_ Data Type: dtr:perShareItemType Balance Type: na Period Type: duration X - DefinitionCompensation services equal. + ReferencesNo definition available. + Details Name: modd_compensationServicesEqual Namespace Prefix: modd_ Data Type: dtr:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of addition (reduction) to the amount at which an instrument classified in shareholders' equity could be incurred (settled) in a current transaction between willing parties. + ReferencesNo definition available. + Details Name: us-gaap_EquityFairValueAdjustment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(6)) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_LegalFees Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination. + ReferencesReference 1:

http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromDebtNetOfIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromWarrantExercises Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 40 R30.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholdersâ€™ Equity (Details) - Schedule of Warrants Outstanding - Warrant [Member] - $ / shares shares in Thousands 3 Months Ended 12 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Schedule of Warrants Outstanding [Line Items] Â Â Â Number of Shares, balance 11,526 12,466 12,521 Number of Shares, Common stock 11,526 12,466 12,521 Number of Shares, Warrants exercised Â (55) Â Exercise Price, Warrants exercised (in Dollars per share) Â $ 1.22 Â Expiration Dates, Warrants exercised Â May 2028 Â Common stock [Member] Â Â Â Schedule of Warrants Outstanding [Line Items] Â Â Â Number of Shares, balance Â Â 1,348 Number of Shares, Common stock Â Â 1,348 Exercise Price, Common stock (in Dollars per share) Â Â $ 0.01 Expiration Dates, Common stock Â Â Common stock [Member] Â Â Â Schedule of Warrants Outstanding [Line Items] Â Â Â Number of Shares, balance Â Â 4,421 Number of Shares, Common stock Â Â 4,421 Exercise Price, Common stock (in Dollars per share) Â Â $ 1.22 Expiration Dates, Common stock Â Â May 2028 Common stock [Member] Â Â Â Schedule of Warrants Outstanding [Line Items] Â Â Â Number of Shares, balance Â Â 535 Number of Shares, Common stock Â Â 535 Exercise Price, Common stock (in Dollars per share) Â Â $ 1.32 Expiration Dates, Common stock Â Â May 2027 Common stock [Member] Â Â Â Schedule of Warrants Outstanding [Line Items] Â Â Â Number of Shares, balance Â Â 768 Number of Shares, Common stock Â Â 768 Exercise Price, Common stock (in Dollars per share) Â Â $ 6 Expiration Dates, Common stock Â Â JanuaryÂ 2027Â -Â FebruaryÂ 2027 Common stock [Member] Â Â Â Schedule of Warrants Outstanding [Line Items] Â Â Â Number of Shares, balance Â Â 4,011 Number of Shares, Common stock Â Â 4,011 Exercise Price, Common stock (in Dollars per share) Â Â $ 6.6 Expiration Dates, Common stock Â Â February 2027 Common stock [Member] Â Â Â Schedule of Warrants Outstanding [Line Items] Â Â Â Number of Shares, balance Â Â 1,438 Number of Shares, Common stock Â Â 1,438 Exercise Price, Common stock (in Dollars per share) Â Â $ 6.6 Expiration Dates, Common stock Â Â November 2027 Warrants exercised [Member] Â Â Â Schedule of Warrants Outstanding [Line Items] Â Â Â Number of Shares, Warrants exercised (252) Â Â Exercise Price, Warrants exercised (in Dollars per share) $ 0.01 Â Â Expiration Dates, Warrants exercised Â Â Warrants exercised [Member] Â Â Â Schedule of Warrants Outstanding [Line Items] Â Â Â Number of Shares, Warrants exercised (649) Â Â Exercise Price, Warrants exercised (in Dollars per share) $ 1.22 Â Â Expiration Dates, Warrants exercised May 2028 Â Â Warrants exercised [Member] Â Â Â Schedule of Warrants Outstanding [Line Items] Â Â Â Number of Shares, Warrants exercised (39) Â Â Exercise Price, Warrants exercised (in Dollars per share) $ 1.32 Â Â Expiration Dates, Warrants exercised May 2027 Â Â X - DefinitionExpiration common stock. + ReferencesNo definition available. + Details Name: modd_ExpirationCommonStock Namespace Prefix: modd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExpiration dates warrants exercised. + ReferencesNo definition available. + Details Name: modd_ExpirationDatesWarrantsExercisedinDollarsPerShare Namespace Prefix: modd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares warrants exercised. + ReferencesNo definition available. + Details Name: modd_NumberOfSharesWarrantsExercised Namespace Prefix: modd_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=modd_CommonStockOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=modd_CommonStockTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=modd_CommonStockThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=modd_CommonStockFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=modd_CommonStockFiveMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=modd_WarrantOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=modd_WarrantTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=modd_WarrantThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 41 R31.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation (Details) - USD ($) 3 Months Ended 6 Months Ended Aug. 31, 2024 Jan. 31, 2024 Oct. 31, 2023 Oct. 31, 2017 Sep. 30, 2024 Jun. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Feb. 28, 2024 Jan. 31, 2023 Aug. 31, 2021 Jan. 31, 2020 Stock-Based Compensation [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Contractual term Â Â Â Â Â Â Â 10 years Â Â Â Â Unamortized compensation cost (in Dollars) Â Â Â Â $ 1,763,000 Â Â $ 1,763,000 Â Â Â Â Â Weighted average period Â Â Â Â Â Â 1 year 9 months 18 days Â Â Â Â Â Total number of options granted Â Â Â Â 7,530 Â Â Â Â Â Â Â Options granted Â 625,326 Â Â Â Â Â Â Â Â Â Â Â Options cancelled 242,307 Â Â Â Â Â Â Â Â Â Â Â Options granted 339,298 Â Â Â Â Â Â Â Â Â Â Â Weighted-average grant date fair value of options granted (in Dollars per share) Â Â Â Â $ 1.81 $ 1.52 Â Â Â Â Â Â Â Option exercised Â Â Â Â Â Â Â 7,530 Â Â Â Â Â Shares issued Â Â Â Â Â Â Â 7,750 12,640 Â Â Â Â Stock-based compensation (in Dollars) Â Â Â Â $ 9,000 Â $ 7,000 Â Â Â Â Â Â Expense over a period Â Â Â Â Â Â Â Â 1 year 9 months Â Â Â Â Â Milestone Bonus Program [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Stock-Based Compensation [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Total number of options granted Â Â 909,533 Â Â Â Â Â Â Â Â Â Â Stock-Based Compensation [Member] Â Â Â Â Â Â Â Â Â Â Â Â Stock-Based Compensation [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Weighted-average grant date fair value of options granted (in Dollars per share) Â Â Â Â $ 1.51 Â $ 1.02 $ 1.41 $ 1 Â Â Â Â Restricted Stock Units (RSUs) [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Stock-Based Compensation [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Unamortized compensation cost (in Dollars) Â Â Â Â $ 94,000 Â Â $ 94,000 Â Â Â Â Â Total intrinsic value (in Dollars) Â Â Â Â $ 328,000 Â Â 328,000 Â Â Â Â Â Non-employee Directors [Member] Â Â Â Â Â Â Â Â Â Â Â Â Stock-Based Compensation [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Shares issued Â Â Â Â 3,875 Â 6,265 Â Â Â Â Â Â Stock-based compensation (in Dollars) Â Â Â Â Â Â Â $ 15,000 $ 13,000 Â Â Â Â 2017 Equity Incentive Plan [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Stock-Based Compensation [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Shares approved under equity incentive plan Â Â Â 1,000,000 Â Â Â Â Â Â Â Â Â Number of shares reserved Â Â Â Â Â Â Â Â 3,000,000 2,000,000 1,333,334 333,334 X - DefinitionThe shares of options cancelled. + ReferencesNo definition available. + Details Name: modd_NetOfForfeituresOptionsCancelled Namespace Prefix: modd_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe shares of options granted. + ReferencesNo definition available. + Details Name: modd_NetOfForfeituresOptionsGranted Namespace Prefix: modd_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: modd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: modd_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesNo definition available. + Details Name: modd_StockIssuedDuringPeriodSharesStockOptionExercised Namespace Prefix: modd_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of unamortized loan commitment, origination, and other costs (fees) on financing receivable recognized as adjustment to yield. Excludes financing receivable covered under loss sharing agreement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481598/310-20-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 3 -SubTopic 20 -Topic 310 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481569/310-20-50-3 + Details Name: us-gaap_FinancingReceivableUnamortizedLoanFeeCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionIntrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of options vested. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares of stock issued attributable to transactions classified as other. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodSharesOther Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -

Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=modd_MilestoneBonusProgramMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=modd_NonemployeeDirectorsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=modd_TwoThousandAndSeventeenEquityIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 42 R32.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation (Details) - Schedule of Assumptions were used in the Fair-Value Method 3 Months Ended 6 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Schedule of Assumptions were used in the Fair-Value Method [Line Items] Â Â Â Â Volatility Â 127.00% Â Â Minimum [Member] Â Â Â Â Schedule of Assumptions were used in the Fair-Value Method [Line Items] Â Â Â Â Risk-free interest rates 3.40% 4.40% 3.50% 3.50% Volatility 114.00% Â 114.00% 82.60% Expected life (years) 5 years 5 years 5 years 5 years Maximum [Member] Â Â Â Â Schedule of Assumptions were used in the Fair-Value Method [Line Items] Â Â Â Â Risk-free interest rates 4.10% 4.60% 4.40% 4.60% Volatility 117.00% Â 123.00% 152.20% Expected life (years) 5 years 8 months 12 days 5 years 8 months 12 days 5 years 8 months 12 days 6 years 2 months 12 days X - DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 43 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation (Details) - Schedule of Activity in the Shares - $ / shares 3 Months Ended 6 Months Ended Sep. 30, 2024 Jun. 30, 2024 Sep. 30, 2024 Schedule of Activity in the Shares [Line Items] Â Â Â Shares Available for Grant, Beginning Balance 3,004,631 3,648,651 3,648,651 Number of Shares, Beginning Balance 4,321,956 3,689,341 3,689,341 Weighted Average Exercise Price, Beginning Balance (in Dollars per share) $ 3.36 $ 3.7 $ 3.7 Shares Available for Grant, Share awards (3,875) (3,875) Â Number of Shares, Share awards Â Weighted Average Exercise Price, Share awards (in Dollars per share) $ 2.28 $ 1.56 Â Shares Available for Grant, Options granted (483,673) (682,375) Â Number of Shares, Options granted 483,673 682,375 Â Weighted Average Exercise Price, Options granted (in Dollars per share) $ 1.81 $ 1.52 Â Shares Available for Grant, Options exercised Â Â Number of Shares, Options exercised Â (7,530) Â Weighted Average Exercise Price, Options exercised (in Dollars per share) Â $ 1.08 Â Shares Available for Grant, Options cancelled and returned to the Plan 274,901 42,230 Â Number of Shares, Options cancelled and returned to the Plan (274,901) (42,230) Â Weighted Average Exercise Price, Options cancelled and returned to the Plan (in Dollars per share) $ 1.51 $ 2.62 Â Shares Available for Grant, Ending Balance 2,791,984 3,004,631 2,791,984 Number of Shares, Ending Balance 4,530,728 4,321,956 4,530,728 Weighted Average Exercise Price, Ending Balance (in Dollars per share) $ 3.33 $ 3.36 $ 3.33 X - DefinitionShares available for grant, options granted. + ReferencesNo definition available. + Details Name: modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant Namespace Prefix: modd_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionOptions cancelled and returned to the plan, shares available for grant. + ReferencesNo definition available. + Details Name: modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledAndReturnedToThePlanSharesAvailableForGrant Namespace Prefix: modd_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionShares Available for Grant options exercised. + ReferencesNo definition available. + Details Name: modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareAwardsSharesAvailableForExercisedInShareAwards Namespace Prefix: modd_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionRepresent the share for share based compensation arrangement by share based payment award share awards shares available for grant in share awards. + ReferencesNo definition available. + Details Name: modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareAwardsSharesAvailableForGrantInShareAwards Namespace Prefix: modd_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: modd_ShareBasedCompensationArrangementByShareBasedPaymentShareAwardInPeriodGross Namespace Prefix: modd_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe amount of share awards in share based arrangement by share awards. + ReferencesNo definition available. + Details Name: modd_ShareBasedCompensationsArrangementsByShareBasedPaymentShareAwardsInPeriodWeightedAverageExercisePrice Namespace Prefix: modd_ Data Type: dtr:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-

gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 44 R34.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation (Details) - Schedule of RSU Activity under the Plan - Restricted Stock Units (RSUs) [Member] - $ / shares shares in Thousands 3 Months Ended Sep. 30, 2024 Jun. 30, 2024 Schedule of RSU Activity Under the Plan [Line Items] Â Â Number of Shares, Beginning Balance 166,667 187,499 Weighted Average Grant-Date Fair Value, Beginning Balance $ 0.91 $ 0.91 Number of Shares, Vested (20,833) (20,832) Weighted Average Grant-Date Fair Value, Vested $ 0.91 $ 0.91 Number of Shares, Ending Balance 145,834 166,667 Weighted Average Grant-Date Fair Value, Ending Balance $ 0.91 $ 0.91 X - ReferencesNo definition available. + Details Name: modd_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsVestedNumberOfShares Namespace Prefix: modd_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of equity instruments other than options outstanding, including both vested and non-vested instruments. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 45 R35.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation (Details) - Schedule of Outstanding and Exercisable Options 6 Months Ended Sep. 30, 2024 USD ($) $ / shares shares $0.93 - $2.28 [Member] Â Schedule of Outstanding and Exercisable Options [Line Items] Â Number Outstanding (in Shares) | shares 3,098,454 Weighted Average Remaining Contractual Life (in Years) 8 years 4 months 28 days Weighted Average Exercise Price $ 1.57 Number Exercisable (in Shares) | shares 2,640,918 Weighted Average Exercise Price $ 1.55 Aggregate Intrinsic value (in Dollars) | $ $ 1,839,613 $3.95 - $7.51 [Member] Â Schedule of Outstanding and Exercisable Options [Line Items] Â Number Outstanding (in Shares) | shares 933,145 Weighted Average Remaining Contractual Life (in Years) 6 years 8 months 8 days Weighted Average Exercise Price $ 5.3 Number Exercisable (in Shares) | shares 836,533 Weighted Average Exercise Price $ 5.42 Aggregate Intrinsic value (in Dollars) | $ $8.61 - $17.70 [Member] Â Schedule of Outstanding and Exercisable Options [Line Items] Â Number Outstanding (in Shares) | shares 499,129 Weighted Average Remaining Contractual Life (in Years) 6 years 8 months 23 days Weighted Average Exercise Price $ 10.56 Number Exercisable (in Shares) | shares 490,036 Weighted Average Exercise Price $ 10.56 Aggregate Intrinsic value (in Dollars) | $ $0.93 - $17.70 [Member] Â Schedule of Outstanding and Exercisable Options [Line Items] Â Number Outstanding (in Shares) | shares 4,530,728 Weighted Average Remaining Contractual Life (in Years) 7 years 10 months 13 days Weighted Average Exercise Price $ 3.33 Number Exercisable (in Shares) | shares 3,967,487 Weighted Average Exercise Price $ 3.48 Aggregate Intrinsic value (in Dollars) | $ $ 1,839,613 Minimum [Member] | $0.93 - $2.28 [Member] Â Schedule of Outstanding and Exercisable Options [Line Items] Â Range of Exercise Price $ 0.93 Minimum [Member] | $3.95 - $7.51 [Member] Â Schedule of Outstanding and Exercisable Options [Line Items] Â Range of Exercise Price 3.95 Minimum [Member] | $8.61 - $17.70 [Member] Â Schedule of Outstanding and Exercisable Options [Line Items] Â Range of Exercise Price 8.61 Minimum [Member] | $0.93 - $17.70 [Member] Â Schedule of Outstanding and Exercisable Options [Line Items] Â Range of Exercise Price 0.93 Maximum [Member] | $0.93 - $2.28 [Member] Â Schedule of Outstanding and Exercisable Options [Line Items] Â Range of Exercise Price 2.28 Maximum [Member] | $3.95 - $7.51 [Member] Â Schedule of Outstanding and Exercisable Options [Line Items] Â Range of Exercise Price 7.51 Maximum [Member] | $8.61 - $17.70 [Member] Â Schedule of Outstanding and Exercisable Options [Line Items] Â Range of Exercise Price 17.7 Maximum [Member] | $0.93 - $17.70 [Member] Â Schedule of Outstanding and Exercisable Options [Line Items] Â Range of Exercise Price $ 17.7 X - DefinitionAgreed-upon price for the exchange of the underlying asset relating to the share-based payment award. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher

FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -
Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -
Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-
2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -
URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section
50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -
SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24:
http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI
https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -
Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -
SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference
27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI
https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -
Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X -
DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. +
ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -
Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period
Type: instant X - DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and
currently exercisable under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -
Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-
types:perShareItemType Balance Type: na Period Type: instant X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. +
ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI
https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested
options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)
(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period
Type: instant X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1:
http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI
https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -
Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-
types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for
example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -
Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-
gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type:
xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-
gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=modd_zeroPointNineThreeToTwoPointTwoEightMember Namespace Prefix: Data Type: na
Balance Type: Period Type: X - Details Name: us-
gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=modd_ThreePointNineFiveToSevenPointFiveOneMember Namespace Prefix: Data Type: na
Balance Type: Period Type: X - Details Name: us-
gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=modd_EightPointSixOneToSeventeenPointSevenZeroMember Namespace Prefix: Data
Type: na Balance Type: Period Type: X - Details Name: us-
gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=modd_ZeroPointNineThreeToSeventeenPointSevenZeroMember Namespace Prefix: Data
Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name:
srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 46 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies
(Details) $ in Thousands Sep. 30, 2024 USD ($) Commitments and Contingencies [Line Items] Â Purchase obligations $ 990,000 Device Integration Agreement [Member] Â Commitments and
Contingencies [Line Items] Â Purchase obligations $ 400,000 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable
information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_OtherCommitmentsLineItems Namespace
Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionMinimum amount of purchase arrangement in which the entity has agreed to expend funds
to procure goods or services from a supplier. + ReferencesNo definition available. + Details Name: us-gaap_PurchaseObligation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType
Balance Type: credit Period Type: instant X - Details Name: us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=modd_DeviceIntegrationAgreementMember Namespace Prefix:
Data Type: na Balance Type: Period Type: XML 47 R37.htm IDEA: XBRL DOCUMENT v3.24.3 Related Party Transactions (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended
Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Related Party Transactions [Line Items] Â Â Â Â Company paid amount $ 28,954 $ 43,365 $ 100,625 $ 63,754 X - DefinitionLine
items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. +
ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI
https://asc.fasb.org/1943274/2147481990/310-10-45-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section
S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 3:
http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(ii)) -Publisher
FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards
Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-
gaap_RelatedPartyTransactionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense for salary and
wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service
sold. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph
(SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_SalariesAndWages Namespace Prefix: us-gaap_ Data Type:
xbrli:monetaryItemType Balance Type: debit Period Type: duration EXCEL 48 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 (+6 ;ED'04UB@0 +$ 0
9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y
#OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " "U@&Y9_:O)Y^X K @ $0 &1O8U!R;W!S+V-O&ULS9+! M3L,P#(9?!>7NFD'AZC+96BG(2$Q"
<0M2KPMHFFBQ*C=V].&K1."!^ 8^_G MSY);'83V$9^C#QC)8KH;7=,1@M(? MZHA05]4#."1E%"F8@458$RV1@L=49&/%[S1"SY\QB[#C ;LT&%/"7C)@UI]Y+7+6R? M2/4:IU_)"CH'7+/KY-=F\
[C?,EE7]:K@O."K?%W$W;>V(/] MQ\970=G"K[N07U!+ P04 " "U@&Y9F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?2N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-(9)-
NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y
\FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',
<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-
!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=
[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?
8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-
L,+$CN'MB[\!4$L#!!0 (M +6 ;EEX@#@^1P8 .$B 8 >&PO=V]R:W-H965T&UL MM9IK<^(V%(;_BH9BH9V.\(V%%(;=@RUVW4"##%%%#)RS0A;,AN9]OI!\46X%G;HI(,R;_O MD6ULLB,+RN
OB6_GM5X=71X976T9_RY6E$KT&H6QN&ZLI%Q_:K6$MZ(1$9=L M36.XLV \(A).^;(EUIP2/PV*PA:VK&XK(D'<&%ZEUV9\>,42&08QG7$DDB@B M_.V&AFQ[W; ;NPM/P7(EU876\&I-EG1.Y9?
UC,-9JU#Q@XC&(F QXG1QW1C9 MGURGJP+2)[X&="OVCI&R\L+8=W4R\:\;EBH1#:DGE02!?QOJTC!42E".?W/1 M1O%.%;A_O%._2\V#F1P%.(.*)P'X!\"[*HW.'F DQK-2I;: M&A-)AE>
<;1%73X.:.DCK)HT&-T<CB7'.X&$">'+MM0CII(K BGXJHE05/= M:7EY_$T6CROBN^B!Q7(ET&WL4_]]? O*4A0([PIT@XV"<[J^1(YU@;"%VYKR
MN.;P*=M<(MO1A;\KCE/4CY/J.15Z8^8ET&HEFL19GU%M[^][> I-)(W$/[HJ MRR3;>DG5,3^)-?'H=0-ZGJ!\0QO#7WZRN]:O.K]G$GOGOEVX;YO42_?/;VNJ M,2YT]LY3DB:Y27&/4B?:Z
MA;WND1GC!,;:M+E6^S-K+4@HM :-82<:[!4&>\9"W<8RD&_0'2%WV1R U,"' MW(1S*US:1:<,IU%8\R)%ON%Q;ZQ1"-(H)\F\2XD2YTC4!\]5\H1*G'57,2L4,43E%&.-/]&EY8QJ'>?T+A
>"=$W2CBZ@XOZ MZ=4L!A8[.HOFL%,][E&#_;\\YDFM=FF6^XRU'HU!IWK$I4=LG/J+D>;XB3]7 M/-/,?RZU]_Y+\K&-:+'S_T27@9 PFT@T)9&VOQX0>G@_96I]U M)!=$I!MYI;Z]FV--2'%
KMFTG*:C;\MU4)-= M8I-MIIW=H)3[S5@^B)=I>BLF6[/B-^TZWS5'G>@3E]2$S:"3^YRO:!A"2XW6 M)-8.O =D*MG7'>JO1*8L)EP]L9,Z_V9=:8L;A+/HR #(GXFJ/5;
M!SSAIZP4Z*=8TGF3"+@MM(WU@$[5&ML<=JJ]DHWP46QT&U&^5)WQ-U"0 M*V.[-0M6M]LZF B73(3;QT"PRV()JVW%^8+%,0T/HC ^$^/DM5 ',>&2F/!1 MQ#3R?5 7%[L#E-;!8ZR=
<0Y(*CRTT/.*\3@*U,#.B*]U7@=*X1*E\%$H53AW MU1DPQ3/;QEK79KDYB=$X@,%/:[4.BL(E1>&C**JP6O#3C+--$'OZ+)LUW9'6 M:!WLA$MVPF;8^='HC D)#/57L*Y$Q .*
VSCGM9I'?"$2WC"@V-&K]F*03^] M@^5 QO_B\.AU)AC*:Z$.M')*M'+,3)3VV1&GI#*]!P0^]#O]C]K?)NJ *J>$ M*L<,0__-[/[R9B>@YD"$,OPMDXP\O']&<>@F'VM#Z-BL!E46P]I]+YGU',U@H M?
B5A0M'/EY9EHS7P^%S]^*FM@CK@RRGARS%_17KFQ$^7>F_1"PNUSLT"#X_C ML=97'3CEE#CEF-EGETMT^^JM2+RDE5\6#PA-1_/Q2/L3HSGP5(/7 &5ZW-OL?6WB8"
MM:Q)]U8(Y*F/1]E^@N)JL7]CE.Y::)6/9YL_'HA:%0D4T@6$6I<]>#W/]E-D M)Y*MTRT)+TQ*%J6'*TI\RM4#<'_!F-R=J!<4NUJ&_P%02P,$% @ M8!N M6=<<25 A!0 %Q0 !@
!X;"]W;W)KB8J"2J))4T^_4C95>R+4I. MT'RQ2>GN]-]R1O.DT.>.>.T.1C"P,D)*T;32?WL6DPGO%(9*^SFC&'T]& M:/3KP0V[RGSP)E3.2G)/YU3=EM="SYS&2LIR6DC&"R#H\F1TBC[.L&L4:HF_
M&7V46V-@7+GC_+N97*8G(V@0T8PFRI@@^N^!SFB6&4L:QX^-T5'S3:.X/?YE M_7/MO';FCD@ZX]D_+%6KDU$T BE=DBI3-_SQ"]TXY!M["<]D_0L>-[)P!))* M*IYOE#6"G!7K?_)S$X@M!>3U*."-
GZN@KM1J"/GK)'5;IT31:83P1^!,-+: MFAG4L:FUM3>L,,LX5T*_95I/36>\2/6BT!3HD>092XG2DS.2D2*A8&X,2W $ M;N?GX/W;#^ M8 58K'@E29'*B:,T!F/)23;?.UM_#_=\;T[++^'#",< 0>Q;U
MV;#ZGT1H=613=[3GC?NX<1_7]MP^]V]O;BZ^+L#I?'ZQF-O<6>M[=GUSR#[* MDB3T9*1/D:3B@8ZF[]Z@ 'ZR.?=*QG9<=1M7W2'KTQF1*Z 7#21F0']4[(%D MM%#615R;"FI3)A,\3-
TH=B?.P[8W7:$8N[@1VD'I-2B]0937@I:$I8#^+,VV ME#5BKE94V&"N;?E;""TC[(KXP6^':3?@/0'02Z^+4ZOP.&]XW<_C<)@#U]7 M* [BT XP: &!Z*H\
[Q03W7TS%*7.O.J,2BHLN$,.A#'L2N#$)N#\2H@1@]8ZW[USCJ?#,*P_W8 M=860&\&>18X;9/&SG9Y=7EXO+""C!^S03V2L9V_$6PY2HXN!:G2<(K MG;% 29[(74:M] ,
[L?;A_GI8A"+8D[G0%I6B0_!$1=O<986'NF?-_?A=85P M!'O@M52'!NEE.E]QH8X4%3G(J*Y\0,;('VR48 ZN[,K%*&> M9(%:SD+/(:U#L>RR$8K\SO[L2F$<]IV?EK30,&O->)XS99AJ3?NZ(E6LN*=%
MHJ,)WG_EBH+P@Q7VH&%[7@+6ZO/W#>TZWS(A"@>S^7SQ;?;'EV]7YQ,BP:IEA=\RVI$#ISSA5/OH_!6W@, M(=)97@!=HU9T#/PQA!#(%1&F)*R43F7L/YKJ:H$$7%# I3=ZM2\5*2:4'>M]8
MXS:(Y"4;Y?<-[4:K97TT2++U*=',^;V^H$(3V8'T"KC=V0UC'R<5C+_!^"=D# MJ"LR4YOIEDW1_(Z*IF^K!74KEJR:7FRL>WI9TKHISYZLH8\MS+>?6"PR/6D% MMU4#/E UI"DS5P8D Z:U.-(-
;$)*IDAF[?KU@VQH"'ZPA MJKS*ZB8\I4N6,&LUC+L5PE'H0XSW85KD C_&<0_.K;YYN)A8L\G+DA;NU@I! MC/;[(8L40GY?&8_;F@(_IZ;8XC]P^O7\I1YT6UY+M6^1LI7[SM:MC;DRTP?J
MGA52%Q)+K0>/0QT"L;Z%6D\4+^N+G#NN%,_KX8J2E HCH-\ON6;(S<3<#35W M@=/_5!+ P04 " "U@&Y9$E O' ,# "L"@ & 'AL+W=OV[*>.9$X[*M:D*1[(P@F]<,L7B_\LB%8@S15"
[F4X4SMV&)>0J9YC(C"N9C MY]*[F'C4 LJ(;QQ6>F-(,4)N=A5! (B8RD8WI8P 2L^KX59,Z MS9X6N#E>L]^4YM','=,PD>([CTTR=H8.B6'."F%NY>HCU(9ZEB^20I=7LJIC
MJ4.B0AN9UF!4D/*LNK.'.A$; "_8 ?!K@/]<0+<&=$NCE;+2UC4S+!PIN2+* M1B.;'92Y*='HAF?V-4MN0;%V2W!K4$)WSWQNO3#VW& M_Q/95AJZ31JZ^]C#*385*(45@948W9^1G"FR9*(
'^BPSC#T<;_)#P M;-'F>B_I$:Y?S[/E>M"X'NQU/9%IBM^05[34X%DM=2AJ2_RP$3\\0ORS^FGX MI%4\2I]VU,&P+;WGC=[SX_7N;JCS)R*Z07?P6&I+E!_T@W:E'OWW,Z;;':SW0
M"S7E(<5M82V2W8VCA#W'X7]UP3--!,P11SL#)%#5T:B:&)F7IXL[:?"L4@X3 M/$Z"L@@'X?"ZE64_L@:4YH(9_ 5!+ P04 " "U@&Y9_1J@P;<$!S%0 M& 'AL+W=OG0D^:#) MGO'O(J94HMDDDTL]
BG(MABZI?"X>N;JS&Y'6 =VD+?AW@7]K"H XHT>V*O1RX!9%D-N%LC[A6*S=] M48Y^&:W&M\/W*KGY-5)R:#%8=BMT=>" MEXNT,V'6R1BPJE 28Z^Q6PK2!Z)C^A#ZWYB2]5=
MW:B]JKLVK[KFGNF:A[ZP7,8"A:J+$1_Z(\?]]L3;:IB:L7(/8S5W>PV7M+A# MGO,1N8[K _UYN#S<@W#^7^OA?VZ]-1A>,W&\TL\[XU?/B7R#Z&&NA9Q"8XTVQQ3;/P2F:M1/A-(OP^]]F3
M9Z[4K,Q=I58'=T'4U^F\0@L:M.#M M3+Y05RZV=IV/%BOM+N=* MK3(&&3\QN]>CYGC C(N2N#F.V30Z2,\DUY>B?4(MOFLCH6:)XV)X2?RW,QX_D<
MWS]@X/E"GRB6AU9'^^HX\@OAFR07**5KU91S-U)]Y=4)7W4C65$>8;TP*5E6 M7L:41)1K@?I]S9@\W.@&FG/6V;]02P,$% @ M8!N6<^#GGY+"0 STL M !@ !X;"]W;)K M+IKZ-
>";Y[SX4NZ2I/*^[;-#>3O95=73V]FL7.^2?5R^R9^2@_J?;5[LXTI] M+!YGY5.1Q)NFT3Z;,=^?S_9Q>IC3'*DL/R.NJO\PN[MYBA^3AZ3Z]/2Q4)]F9Y5-ND\.99H?O"+9WD[> M!6\C&=8-FHC_ILES>?
&[5Q_*YSS_4G_XL+F=^/6(DBQ95[5$K'Y\3>Z3+*N5 MU#C^;D4GYS[KAI>_OZC_WAR\.IC/<9G58V_WK/;:P_\=';'LLKW;6,U.@GUZ./V,O[5&7#0(>$\#UC9@G08L M[&G VP:\VZ!O2)M(,8.2-
G8Z],,6X55_'=39$_>T4=K=3J7QKWF];* MK_10)\I#5:C_356[ZNX^/VS4M"<;3_U6YEFZB2OUX:%2/U0^5*67]6G?/UE MEV>;I"A_^6G!@O
W+_K[F%;_>*\^'>+C)E5M7GM3[]/#RGOU\VOO9R\]\]>'_M M\F,9'S;ES:Q2(ZW[FZW;4;T_C8KUCFJ_5UG4] NTOL=;O]NH :DLC#/O8YQN MIA\.WGW\E%9Q!FBM!K36Z^/^F#6FK))MNDDXK0"3"1?
[*K;YG:I[.D\7.D\4: M'=&C\S[.XL[)\>+*^R,NWG@\-5C/N.0P(2)>E>:-K0-\(K-9?[X+@*9R%X$+ M+`!S".)$L%"ZXCX@H72^1*)CH8M#V M=6IG>G&0X+*UM-\X2/AA?_I'\L(3=
M*H&X(:8&)A2%Z.H;S%R;SO]^8^J7H-$MR (E/J:G!9;@&L<#ET08'; M#7*/,\NHXV@D\(9MEG_8C3%T%N"[#6L>:W0%F71:U9P'\& MB/*#G'5Q<]+%[OY*;2>?2IW6EB<%H(6?O4F
MH;.@&[4-^V>3-SAE/^U.V?(&GO#*!,5>\LY5;B-A72L0^ 5TI/EZ[V]%6?<% M4VN4&[L./#D@!+Q>%?=WK(A/K0/(HW,5]5KOE')ROLPCR.,$5K'AJ,BO*2#J M8#J0C.PY)(W=3^%GP$(IKB,E
M;HJ6CA(U?:6"[+*KH$IT&CZ98S'RT!E#,S1BLM/ZOK9"T=P+H"_"Q:Y)H2^ MKQ9$4GXJHJB$5 MN,;<#.6]8V5D2!1/;6A/8X[.[G7Q3)!UCT!(EG\XP4+/X=!12P/&C[H#Y;!G1Z MQ-9V
(XF1E8N+&#AKLKGM[X"_DCR_C&&58R'ZXO4Q6L)=Y7]_Q*FDNL(RH2"^>L M7K#)9OC+40"\Q6V%DEZF;'J&PQG-$&C7$ ^&=FGL3DA+IJ+/:@.T+9<:37 M%;U]]AVV-CG;DUNTW9@EB6:5
M#X21J@P5>EZ&LGJO_?/-?P5*62W^BYFWNAKNMMN>1[?_KO!8C6U&X.D.>X2BK M+[:5[C1W,?I7?:W\V4_-_:Q.DG_5-Z2^ 5.S4?U39?2&H,?5\"RRW>WG>G6_B#TT6@2J=!4MQT&'O_-H[/W.C8Y+J\GMB-:
MAB0-+UBFH:6_*8[A 1"O9=Z$H2-&8*:&W(/_"'2%=%7&&GD26A8D7W.U;I' MD>YQ]8^8,#DW0=W$X<(N=\?'/D:;>'*@,#E\V(MY#-:Q)R)7*>)%LK]MO M&>*6GH%@[3BWXP_F,MN]O:
MAH:Z)U$D]:^L6-S#OXH[^,(^U3PS]T ;C1(!L$P &@ !X;"]?< MVZ;Q,XGQ?E06-PC!S=S[MWJ$W6)ZHU69NWRR#>G'QTY=@+4QB2LCP);S\<@ MIT\'!B6IF>$S*R$!%QO3$Z(,'?0R99G0BRJ
T4<[X'B#H:T=/2MJE!,TL&C4!&A[M7_IV&FD1E('_[?:[0,V]1(N@BE%$EGE1E%F.\/VA@*YLDO)\$$;F>U=Y%ZP MHNDE Y6P!TMR;[T2G1[0T@D!E[1^9>9!8P(YX%*:#[&%OPR 2TGNSC^X&:#@
MWD#B'/7PI?,RV2'\L2VKZ)ERS97HK+OA@#HYEO.3)/6?.>KL/]Y:XX]=G#'< M?D;RH0A#I!_&KNB8R)%F1JH\[6 (=:G-B$K]4<.BCT@EDYS8,27LA7/4W&- M&G?=>P2_>:E4'D17X+Y,?,V.\
M+E8@;=.D4DXL3F9#=CRAN"]55;SI"D%,%M9[C:YZ:?UX(FQUJ(8BT%S(5H8R M3_@PL/Q/TOGW.2P3"+(6)"'9/=XF=PZ+]9+/FGT-G[&]E/#%#8!"F/4O#2 M/:E4Y(MSD29,#YT,K]X3?FGI00AL
MN2:=(EJ;C+BS!-,77DKG)$4OD'W\(B[2BS'8&VF,K+9B#;1L2P7R+U5)"C MG\>'\L-*;L!J^2[Y;#9"5BXA59*P40;CL?<^Q(?4T5!A-YWE1O#NKH09I M;(-+:3J]#BJYC]19V+U[,V5Y4
M@=9KA+Y#B^-GZ#6\\05+'I\X&KW_23/F'IE1L7/AYYW1B,1)5#BA6^\$JT- M)/M&!>;M0X2L*7S:YHW=%QK""W_5G'SB\FHB*$%P[;J\YN.K]CXN&-?1 MIV$/3+3=,1!A_Z=/<;]\>>=&[!Z4
M_[5IP(B?@BFZ]=$3T'#&V@/1>CB'^SF<0#^]$@Z3\ISX>F'8V-LYUPS4NE=2M M!+!0(4 Q0 (+6 ;EF2,8-/ P 7P, !0 M !X;"]S='-[>DD_Y8=]88B^^-:-C:E#<\H2KZ_H7! MO\^GVG0N/Y-4%!
M.?,J#1(9@).$\.P@FH2F$L"?!QE-/A!N"8T8&9EN"#DR@OFS=FB3J_ M!P:3)N/-H%@(Z9NKZ+Z9FCFEU:B=[>S3\W?_4=E]34DS!QNL#T"G9]:N3-;1\TL[N &"4UQ1[#_:ENGT;*:0_7U98'
MWLT"@HG.*O!!=EIY?^\VEU%+@O^*V7\#B3RV_P%D%EE6U<&PT%A24M@'Z]'T[(@3
MTZNP*@)3]X*M?U^DP$2HU2_D3TS5ATOQ,%>]2&\=C4UF,DC=X?8N5/2RX;MK%*\6 M>%(QU(I$_/L?J@N[*X?-3$'"MR1 M7T]):"7^.(T[YOGU0OFN%;WPTO>HC@@3QI2\A2H#-BR7Y\>"]U9DO(&_A
M/.=K(E_$[&>$1<4H(/T0J#*?=1<3R#N[,K3;IM&I4:_&KXSV6YRIS.PN_=SS__ MQTQS/BYC:<;]Z2]I[_W78D#T@QV)]9-BHM>O73$3,#A?1[*@@?(AIB?._]4%XTV*_6 MZ;%T:UN_LP?0>T3!
B4/$'33H&LQ=W;2R@P%%FYZ#>39;S4#R@D9>_ M81_8U/NN(<0R%N0X+1,]QYN^D#+\4 MFBVQ4>G9F?SH+X,72*)R6.9MJ%.=YNV2#:$*JUHS=%@R9=77\J95^R!ON6L
>"1,?G\H;3MG:/=6;#%I0+#4G4^D0*G76$!EZZ/ M(;FPM7?TOKX*N@TMX*[=SAL5*2\O,S&"T(\=$@'"4J$F*V')=#7PM6;#YSO$; M]:&?(#!RZ"?9!)*#]N5,V3U-+(/NSZL5#W+)8.O-M@A
M$&+/^\6-^#[Z!28%MX'E8]DT+H(7?'$12I;=#KU9H>JX5_=*!^0U\S*!N)R? MHVV4PW%S*(>G!+YOL-\TQ6CE'/:SG=]$7/I82_;YTVPM.[4X9;.=R"5NS+2, MOBO0NP;B4)PU<#;8G.1X/\U
MW!8N?)K=3@32FDB>CK:EB(WSDRQ+&"\Z;BGJ M)ZG>7;'YD%-]VYS:5Y]D)N2T$"Y-QR&L3*Y*'!H5=\X*HH1@<4^[]H!\ M1O@:J%5'=OQ=&IK^B^%HI9P>UC1EO%SKH1!E2W,G1$2/:^T:_;3H
M)Z@D)%]$EX%XG5M\3=H]J)&.KRE8D*MW&.=S&[!Q/*$M1'E,%HX7M'/)G4%7QCN;, M0OY?\TMN"!/2M)G6S8[\/QT@D%$6I*D1_5H/C$=[L%'W$[6MA-/FZ)%QM0P[PO_P)%_-3!QI^F%5=/?(#%="
MV1\%[XAJQ"WQN%:+U\!3C/Z,DT0.W=/+@[Z,2\F!$@&-QW>>O9H;QZO[=LKO/ M6+JX[;M'3&OHOBB8OI!V<_ M-&V2B<9[*,O5'5+44J!H:*4P?,J0W+!6TE6Z0T
MC/BZSL:FAUZ1#0?&O41_9&K#:]&S-IA'$M(9K^XO*D-[GJ!#?%\%K)>DT6 M:X*2.\VD6OX<7[,<$E=G/Q2,NDUM^&N31<&?[WI/X<#/9%^OB!^%X:J%DIT M&/&/:D.JJ%J<+2_P,L[!ZYIHL\.$
M_@(O3<*?\WC>&J.]J&F%#$T^A@ W_N^J@13J1J4*D';EDRW2>NM;MX*AN58. M4$;X%4+V']/?KM+&LUY#J[#,_76@#A)%&+.=-2'*])-
M@=E#(D;1^L1G^@S39D'U9K8+LWEQ:H))_P04YL/Q2)8R,%$2M_R1Q,O0;BY/-ZO M\IRJH,'R%G[],TD5G8^U4')S^<]$JZ@:SDXK6,-E\T_N
MJ.N6;=!_Q;=]FP/LL;Z0+J/R*];F*0J%#!4&+^&=FZLE_ MH/A0MH^M4%RH$_SHJY>_]4J1ET!SMG,\.MB/%UG'[6S M1?HQ^1*$)"Z/XH2RB;T0K6H&
M,J)^'*U04:C,8J)R;S+(51E&N@@VC4ZBZ*#/2(VW"/AEKF$HG";IZ71#[T4! M.7GH/AHRPF$RUVQT8_T[BG5X%24V%)KL0-\(!#!;9^IW2;P/.,IY<A$&ARA-1_
[-.]L;(OIV;C9,_6EFDX(PP,S]0)QG\NL-,)DS[6#3B?Q+\HB'S[U&DD@$$JJY M4\%D,4MO52O>WHL)W!/&I[M[$.=H43OK][;.=BE'2Y$FA2M.V#6%Q=!X7L
MS!F5"SW#N'N3JSP#Y6?.F@\;:CIP,;P+&.$56!T;4AS)@)O"F!Q9P0#S[Z:^W MG'O>C[>!(6T7AQ;HOR@#5T.UZ-^@/0T@-_!DM*J2>)E+*_]U'SD<)]1!"K,5O
M&8+U6#;S;I6=ZC9RO9LU^2P]!<8>JQWW+C!1>CN8?L!)!_!U>]UBD+>G#U]=3 M+^OKKI%)W-*[*<,^FH!4%7@N34D61J<&(=9I7TUW!DP;G[Q"SO>QA!="C\)K
MJJ?-J0Y@H'G*^'9_\UB5>'(@8+?->,Q4&%HH0^E6JC.#A3D-@ER7\-;1I M&:(XNK(4&*$*]\X(Z^1(HG8A&+DOA>P:4ZC/QJPWM:JV3/>!S6VP1;5O#X40 M*(T,FWA@T"?'M9K8T
M%OXN^ N[>OS-#.6>S3ZN/3AW"&O>UX+D32H-!_DLJBU,(*=P<+O7Z^FK? MR+NNLD^2>,TEQPB/ETH@CTX(I^<5+'$E4 MS#X[6J!YB>1P&C@^E+W4^\23@LI6R3< BAR2C, &1)[:ZMYZ_WWP</$\K
M&AL:[J"V!BY,B'Y>DUS'@J1%Y&Z!Q!2P%F]QDB#$'"4.=!+.,#L%)C7 /O M;%VH)MF,0O!QQ9;6/?
MAVQ.(3@1]3YN-D'MNTPGIS,RV)F'XMD-7G<_TDXR4D(9IH&N-@K.T@$? MJU5QS?@"SLAS%'%)<>EZOHA.V?K#GG=I< M"#%W1EKF_0#S\PY[.#'(/QU<Q*% MX_C0L[8H9(5-;!1)1,H?-@;^IYY2B @
M)P8YQ$?ZSQ+8XS0IN8S8"IZ8GUT<;W^MT<%-R?V^1Z]6X^GIH@[V.+V;JUN! M9O4?D)Y/CWC7G;K1UNV5LO)#8 KP@=?%\-@(4J&^[T?\5-CZLA]%]30B(M"(O<_#ETCEV1*-WXAB%(&0BIUX:#N
[G9BPS; M0H[]P0'@60RH+Y@\'4N5I&+-S2ZV=W$B4^X<>IEN&H]%2*HX:+LN'ONM:W! M0>.1&N?V>S(=83VL5$9Y*OAL3P;K^W;5P\$&Y&G9GE4B2T5SP>%"&,<CG;
\SV8%[8VD7>%ZTM/D?#<9H&[A^3>I*U"IP5.3A\5W"1T];>48+N.BHBP)%)1/8BL_^NU[Y7HG+>S<4(@/,M>.P/Q#</5WI.B3[-?N2$I

K*!RQ7AIVY8-V+PPH(FTIUM;%.:#LN7/*>"B/01!'@2-%S M0@\[8!?H+ B8 $[H*Y R25*M8A*S31?(TF ,XE3W1*.2#F;3\"ZQ0Z#ZQ8[M#JM;- D$. I<7;?8-79?
W7)%58_D'*5:1*5FFJ^9(L"AXF2XERH<5B2VS0NO M[B-58 Q:3L49@5WZ6VE)U%>$]F5N6&O$8#AB]-LVM&? [.J?V1F+=^^:L:1J
M$96::;W&'(9CSM6[7KBN0_(R&Y@Z9+NBZBM"^S(=O+C=@K,*R=X7LXF" ;M? M^%"<$YE2+:)2,Z=!PQ/#XS'< P; MS3'X)P7-E*.H5(SS=%I7$IE]RUV45VJ\T556_10&^F<1J4 M. Y*&$OC35V,
(A):<1O/%"1;SY4,AIEF:;#A5]V@ :MZ/@)L. V"U_ZW10" MP";T_7GW!@T0M_"#OB5.X ML'0KA:>J%E&IF>9K M+!$XEF#7!+RIZX,EI&HK4K5(V*PT7?K+G@U9H0E&C'Y2['([$DYG^TDQ+KJ)
M;*/!(ECZW2?%@+!I*'W6.?,C(&Z^[+N("$T:XJHGQ88=L/F "QX"^PSX)QS MB?1),2HUT_R+%U]P2'&I6UHI]"(B;%Z!ZA8@#*Q;@+C^ND5H)A#C[GRXUBW" M+K1[ZA9\ ,XI1_IB"I6::;
[F"H%SA=M^+"[F0!K"KOQY=S^6JK,([\PT3C.& MP!GC^OU889?_#%HG25]((56+J-1,[S7I")QTQN['MC+&]Q=EVWX60CKFDSU MM@G86U\J:O80.'M[Z7D?5<")Q M.!ET9_"E4[NN7S#@=@
^#N>73DG9A$K-G .-,)+@ 3+0^RMNBH#7>6E32G?C ME:JO".W+=%#CD"2X\3*8R38;@8E,"D:D:A&5FCD-&HPD#D8NMPUP*9?QQM MS(Y'*X7N^0 QT)X/$;N^0!Q_7L^4J.,''>
[Q'7/1]H@T[/G@P_ >6DC91DJ MM9/YLXOO0JJ_ZNJ/N'A,#Z67)5LE[[\)E5O%Z=NC3A^J_*GY>J3/>57E^^;7 M71*K:TT=H/Y_F^?5RX?Z&Y?.W^%U]W]02P,$% @ M8!N60L:3>"=!0 M[ZVUWM
M?FM=;+EXDDM*%7I.XE1>MI9*K"23724+$RQ6-^?:RY;;V#^[98JGT M@\[P8D46=$K5X^I.P%VGL!*QA*:2\10).K]LC=SS,?:U0B;Q@]&M/%@C[KO?6;S+GP9D9D73, MXY\L4LO+UJ"%
(CHGZUC=\^T7NG,H QCR6&:_:+N3=5HH7$O%DYTR($A8FE_) M\RX0!PI@QZR =PJXJM!M4/!V"E[F:(XL<^L3461X(?@6"2T-UO0BBTVF#=ZP M5*=QJ@3\RT!/#<<\C2 I-
$*PDCQF$5%P,U5P@6PIB?@(9:BAR5?2Y)&\J*C)FVWPEW**YR%+@!10]]XZE: M2G0-:*)C_0YX5+B%]VY=8:O!*5V=(<_YB+"#NP8\X[>K>Q8X7A%E+[/G-45Y M-/V";KY^_SE%-_??OZ'O=]?
WHX?)[6)M=34]1RJUVS55WAYW)% M0GK9@A*65&QH:_CW7V[/^P_ *6;\W+*/H72BS?YXI#6PIY&K*8HG2'5S_5 MZU!7P%J7"6QTZ*&"*)8N\B;$%*/RW.29?
\KTG()%PH]E_VP(2T7P/1]7L5H'49U_?,. <%SH$]J$L"F4) Q4CGBX746!Z# MVIMQ%5Q=Q'7-V(("6V!O6$N2+@ <['8B)87RT(&,&9FQN'F_!Z?<[RMU*K@PRKN.;L^4>L+AKA?N5 M0FTBH6>6-
I^WH5/E,(THW3J" :["- CU&@K3Q25,;(4Y"D.^ULUV15[(#/IL M5IYA*-:T#+41,Z[!:7N^7P5=EW*]?@/HDKM=*S/N:D&70IQ%>5\%+T:@7AVH
M(;I&J5X#TI)DW==9]E6F,J+NUO'T/;>V=PUBO>Z@VX"[9&'73L/5\6AR^^-Z M^H;QR#TIP9[*VG$02HIU[1Q[MQ;ADNA6 Q/W2NC4J9>L0.BO-5OI(<48@SJ%
MMEW'J8Y/)K&^VU30)=6Z=JZM[3B6;JA\RXZK$ZH1MD&L&7;)O.[@MS;1V M=#M^PX:S,OIO;[@363L.0DGQKI5"@>)X2&D$$XC@"2*J#>S6AF_Y)\BI)'&^ M$:6>_#[J&=@8CZ#>< -<2^(?
4#FR?026+(Y?8_%#%^DS%2&##@Y^P12;P'B8 MN8=6N])#6R($2T%SEH+'K[<>7)\2<-"O M?ID8I"S(RV$"VX<)C9REH<@FB?<1S5VDKG= :I'?
2MTOW88X0UJ)Q8&J9[G54\L.@=G=PD5B^Q(4Z)L M3L[/NXJGQ;'I*#LLK#R_%G:28_B_U&!&1$PO@Z!Y/.61^ B?QX,[]1 M?)6=$,ZX4CS)EDM*(BJT /P_YUSM;_0+BD/FX?]02P,$% @ M8!N6>U;
M :AD%0 '#D !@ !X;"]W;W)KOF%*V4E(529.2?$ML5\F2G:.SL:PU[9,ZM;4/0V!(3@QB& R@2W[]]M<] M PPD2E%J]T4B@;ET]_3EZ^[AFVM7?_=K8QIULRDK_W9OW33;GYX]_G:;+2?
MN*VIZ,W2U1O=T-=Z];;2M]MZ]X6>7];LWKFU*6YG+ M6OEVL]'U[7M3NNNW>[.]^."+7:T;/'CV[LU6K\S<--^VES5]>]:M4MB-J;QU ME:K-\NW>R>RG]\<8SP/^96YC7OOJZ-.G6;K:YNE:X*-9?#
M46ZIYG95V:7-==6HDSQW;=78:J4N76ES:_R;9PWMCU6>Y6&O][+7X0-[O5"? M7-6LO?I0%:88SG]&='?$'T;BWQ\^NN#<;"?J:#I2A]/#XT?6.^J$<<3K'?V_ M"T/]]\G"-S7IV/_LDHML>
[Q[6]C=3WZK<_-VCPS+F_K*[+W[\8?9B^G/CS!U MW#%U_-CJ[[[^XX,Z_?SI\N3BW^KDXDS-OWWZ=/+EW^KS1S4__^7B_./YZOKYV\77\XM?
U.7G7\]/SS_,=W'R^%X7G[]^4#/UXP^O#F>SG]73MLYV M;$V:4K2EKM4G4Y#0RY$ZK_*)VF_Z$SI0U]HK6^6NWKI:-Z;(;*4NS)4N-#U6 MG_/&+4RM9J]?
OU(M:5RM,+O2&Z/>&UKZ5_W=J"\F)U\&!Q&V2'5@K0M5.3*W MQM16EVK1>F+8>T4^L>9)7BUKMR']FQXJJ$2I]'9;NQN+.>5M=CB=O537:U,I MVY
'^J.UM2F4+DOH%,BQWK=X0MI&+M,W] %ZY=>:- &#_JO5OJVU%_)&2JLS M4^IK>JTBY_!N^W'Z6M'"MO',2H0ZVE_TM%Q;:Y, MU9J1VLA8&UZ:-O2=G4MMULO<(QK-
3&T9E6]D_:IC'YNG*E6]V" M#]()XLV;#*.5+MR65[2!%JL7IB'ADFE_-\VV),,#E[5K5VL>$24#&G25DM%< MN_%6UXW:ZB9?,S4C%K&M; ,-H;,OVKP9\3J?/I^=S499HK/*&_/=@\8E::2& M'$@7R-
F435!/\B&%&;OETBNB\MJ0YN3.B[0@W-++NBZ1/UGOBP1(I=WN(<0 OY/J,W-!8/0 Z=?JW,#=F)-14I!JN?K1J1#]0N MPXYY;;>BA+6QFT5;>P.AC" '60RK%_IVW+@Q_<.Z(MQ[$J7-,!;OKDG-!PP4
MIJ3C(T\>U%2.GB1\ZZHBB^(CWH-42*7@PPZG/_N66&!N/#\AK\:*VV^6T_"5 MH[6).SD*0DU1N\1\@E;TM+*/5PO7B,(UMUN3S51J-KFA(RLR6D#E)0X4:M2X>':L=03FV/QX85;3 M:.4#&B?
J5TM&4)#E9)CWBX-FG3I:L:X&#JYPQ!'Q3-"KKL47 MK4P%[X^3]VNU)%C+9YH[TK 8&6AY*'_EL?G<@G1Q$[F)9S6(,_P*6Q;)"J7S M-)\YK2%;N'4B]8($;Y)UK+P'E45$/"U)7T#&7WX&KIWD)PW
M@1L G-9DXD_;^CY=\53I/[D.PP:W;)N6? Y(EEE,+T4V$1-[@21X@N^FV\N+ M\[XRY.^BL^X#1A9J9"Y(J-( ]& M -T@F;O*B#[I98Q(!:AD =(WVGQI*S)%;.UA7) >+5='*,/.1A=D:W?5O"/)
M$A@C<1:&65Z1E V4==LN"$PCK$5TO;3UACV%'!V!G28B"L0RPMX%^^K=)'F) MWT6GJ,P8]BW4)RA!=C0;!==#YTN'!L3R-V2KGB9;5DG/)!=0HN(!XK.$^,*Q M%R+E*ML"]D1AN?
B=TD%YS<>Q0<(9=$TLBXZ0P!$V;2AZ0E_.@1@89D1CV<4' M8:!*_ P)^ND:4P+VX2!5NPW'\HB$1'6C9@#S49AK #.;!'MY35X$Y]:-RX!? M: DZQ,(L$$3)K] [0Y 8H;3=LEY
18+WN>/>@)0)QBT,L#R%YC:$$LC0M_ % M.V@BS-X 3P4_A.I'QB&7*"!* DWA[!"C61P+V.9RB92PXG$]EI*@M^R?C!(* MPK;=(H3_V"1$9A2D,R#8P3Q]P)47H@&:Y_,(*$IAAFL-
G]I]$/1V/WTUC.+LX M(:P>3#D (X+&?[0ZOXU.OYL9FUM)[+@8'3E>.U9# MR:M0:(!221ZYZU5/@V 54ZU9V5T=L@<.=DG %%4C\LE7#)R#8E<258R-;K?U M4I#;$#!?
F$XCV'.T\$%ENE5V/WA#%@^&9,FI$'Z#!B!O32C8&&2\@AIHUY;3 M3X$_Q"_G^^S!!&R#$(12E^TMQP;+B7E$5)VZJ3UR&UCW/!0JA@YL ##+QIA MD'+QL(GZ@&>U@?
T&P*H'ZXA#\7!&C>FRM[^*#6E@X\7Y=-DS#6F,L4T)A9*@ M) 32_DC8L?@^XJ*YT5"+45R'PN'S?@>U8P>H>MR"P^?S@TGV]6_RD'J@$/#] MG>@4XQ&Y8C*+V[&
[KD)X)B!/F$]IEU.DR&A+)IM;.CB_,^%1^[^L!/BU3BM M;,M@202ZVC(XF2#TX?2YQ%@Y@P\W4DS"P6P(Y'%>-_]P>H!U=,T*P0*WF^2P M!:[!L3RF'.$HE#0@!+(-E.N8DR.6%EDT,L((=>A,@E"?@
4;#K89ADS4J> C M(EJ:&M$3%:3HE-NP3ZGP1A)NUE0^HYUK/W:(.(7DO#LA9&1Y+B3=.Z:)@WCT MO$C^HI@I$ZP*MH/*?NW:LA#/K*-B_T[XL,L&LUVA\ GB1$8J[@OP2K*@3DJP
MV0UJ5LCA.;6JVDXAX$+13E&SZ?@_:?72%#TES-2YZ+/;DO\7R$IQ7*]B7>B. M+6:];?U-'XJ^$%=B4V"]SS4RSS;FJI*1AJ@"N*&DFA%0/^& PCC OFCC*$# M&@9 "DMM:YJ^2[X]05OG;:Q^
<7SZ:;I,2.HKL@0\YAH;"BNN<+'TAUR+]*(MK$=[<=4XT=L;.AENP4BHZ"LPL8O"_@JI1^3+L@UPS$ B'-0OKBR)B(1_2;9- MEV]E#T<,X!&,@GL6%!/@G[T4=\\;_6!3F+#'DG*:+"T02:SVRUG3PE
& [3 M@9OKC35@&)\HG12="'N8CAJN$% FL=G*0;$8-"&IO GB@:X3(1$L(Z.A]#+8 M3FD%;MJP5.]XN&K+2=>*3>>!.4V?F<<@_W="4JPS!BH#I,=279TK%#FEZ%&T M=<3-
G5OOCJH_(^A!']B=Y^-L0AV7:QIY39[CX@8EW\?HYLJ56W:IG?#:.EL M: 5]@USA)&_$>XC"Y>S2"@O4&B,!=NK.9J*^,(F,7.=FQ2>8UH1"?B,PL3)] M4\>'P41#UH)MO T@DU^0? ;E&%;A-
$W"W@F8/4O [-VJ%,OU(>B;I>F22HJ# M$RE:5DUO!:?TF"#X%^N_JX^=IMO*-W6;% NVY*ZYJ%%RP?=WTM1!8T*@\G#I M7):NL73PBP >&W$*W%\@W[0V);O]PFR$#?9J':H;%N1P30
:P7TD*)*KLI#, M\6(/KP.E1Y$^4D6)8)FDX(%G$EF?.^U"1LCL+21>2W< @7O!?CK[: HN_YV% MG<^K6"HX31MM'_."?JT6X@,J#%8=]KV4_]Q^'PZFDZG$W7A5&CI]D!F0WEL
M5UC8X9RRZ!J)#F^AQZBXQA+O3H81;TIB9L**(.;[K2L$V>! D]0NZ #G3CP# MMC2")T#D@TO.(,"5[S)W=F 174G2@<,@-D(A:1\&KR])W)R55DS+6 MY0<)_ZAK@3#RY-X57X7 DH-Q?
"#HCGA'\KW*3M @\9L;(XCUW7PV7E(,TQ= M.R)NT_G"*P> Q1H%,Y=29-<_2827A6C7Y\:Q#[?NJQ=AXBB4DN\FS>PI&5[0 M0GT18UC*Z8L_;,!YQ'))GE/>9H5I:BM]1*Y&$W_F)@ 8]K*4/!4FL!\&].
[J M%#:'-_SA TGV"LDBC>G>L%F:Y$WT*GQ9W>-%L4/A7IZC%28899MJ4JN<$1 PQ%_E*1_S)48_I74L/TDNTM%1S*" MVKT65'0V VB0 ((!ZIRH7]'/@-XHNT'3-X$-$9#DL?872K=BTN2H,%627G(E
M=-+HSG>L4T)2H]@EO-IZERR67*S":%Z+32#8D2RXB^?L_\PSQ54H&:=&8UN- MB6^VZJ#M #W*=C L4 M?'.D5XN@G;JXC1C;*)PG MMC4(U%UQ;2W)C+J*DWM,F1JFJ+].QZXMR9?@S6V\86
=C/7/L*JMR'"XRH3A MH<.,^B69OL&"4DD,E*0+ATX[[&)1.UUD);"3_RG[\8?7+UZ^_IDTF+YGLV0+ M]O'=-F*3S\.G\+5[>2JTX[RD6]-2+4%?TEC_V3.>';"S?)7AT?CB(+<\[8WC-1IVG&ECH-20EA
M-2@:H!WL!80HN:%"F1^Y% (LN3ACO&DK&]1;ON-J6R$7>C;;TMV:> ."?&3W M9)A4=(@IT+XM(@HF*$_&NB"_UU6T)U[V5 MZF^QA7Q[5>O@^)-ST7Z8R0;EP%Q]!Q$LI
$1HF+&B)8@D(G>.LAQ1"ZP[:P- MMR+2M/LWG'S--X/8'.@Y%P))*T)B+4(8WC2!/O'EC4:N)2UB*NN6F5PYZ!/] M2%6R,B5?EN]"$A#%M8]. %)^N<^^'-0P?NRJB0VT)"/II,@@DO2> MOW\3PG
M:&+\^!.A-]KHLUSNNR2EPKA]'J3"H .^)%C&I(^S^I 4#>HWM2EYKY -C9< MDEQFPUV46A+'KK[5YPK)0T$NRU"[%&V7VP=2V2HL+L]5!6.-'7J2 AHYO]A4 MST1R]\K? W$(HZ%7D7#&431
H1T30EH1;[BBVR!5K%V'F:4H#,5X/'I^-%.'H]>SH^P;WY SW#G?%4MGQR_4 MX>'K[#1=H%NV4\C9='1\-%6SV>C5Z\/LJ\,ASIZ/9M.7^#<].L8=\9)\20<- M?-F*KO[1\N MY >M#PK5E;%W-U&
<7$+,N(5>A)"WDL+%#Z9)JS* E/6%,QFU48.W\/C%I73U& MKT!1UE'48_ZAKD>%GJ#MQLQ(XB2(^@G](!H''=UYE6](K3CP:[$7Y?%#"[[@ MZ1,BOG!/D+S+N?SP(?TM3>TJA]MKDE"2:[Y
[2'<#PX$,)(+/YHXF7\#3N6W MX^G+41;+_5^Z)L6^ +[#5].#GW 9KJ]FD*GM:!2<)2U@(N",J'TR :]'V;FT M+KZB=1'W?GF\:^]^Y-T]4Z:/']WS>#P]ZO:]K]].]$?O'6#Y??#7[2]0H-A=
(L:>IT\O+YGB17\0M1SK]_6[BF M<1O^N#::S! #Z/W24= +7[!!]X/(=_\+4$L#!!0 (+6 ;EEB%T'4-0, M .(& 8 >&PO=V]R:W-H965T&ULG57;;MLX$'W75PS4 M19$;G2U[*2V =\6#9 ;:G?
[4.P#+8TMHA*IDE2<[-?O4'*4[,+UH@L($FCO53?=8YHX*DLA!Z[N3'5E>?I-,>2Z0M9H:"9K50E,V2JG:,E"LVE (7;L3L-KF:QC6\"_N"XUV_&8#O92/G=&M?9 MV/4M(2PP-1:!T>
<1YU@4%HAH_#A@NEU)F_AV_(+^>],[];)A&N>R^,HSDX_= MH0L9;EE=F,]R_PD/_?0M7BH+W;QAW\;&?1?26AM9'I*)0 MQS%\X3@+3P*NL+J R.]!Z(?Q";RHZSEJ*+_VS-\FVZT471B_CS6?
HL>'T>W MM^A*5RS%L4O71*-Z1'?R_EV0^!]/<(\[[O$I],G_FYU?W.]F*Z7"YA-;Z9W M\R6L/BV7:U@LU]/KFV.$3T(>)WQWOUY""._?#<,@^ C_6=:A33)8;E!U.P6W M3*4Y1$%K.F=
<@,EEK9G(]+GSH$A9E'D&,@%_U+RBNVYZ(- XMRS-B:7ZUR3\ M!G&O'_OTC7JA?^G,95G5AFJ^AM@$+;=FSQ1"DM#CV/TVJFYDX ,7'RHE4]0: M!C&$P\BY0;K5N2PRX"5-
/:+%T1!%]#CWVRVGT_&*'Q-DY,2]0?^22"3]F/*U MOB)Y2>NR+IHSE2$M9,I9JSM$B)52&?Y7ZS@+>D$PA',X2P:7<.ZLI6%%TU(2 M!_0->Y>#_J^OYS1-54W%\8D$6Z/N"L25]TN9%D5\AD1-
BAPRZE)JI;T[3NF M5DU.U88^1(-73G$S2\YC9]=[HSLEJEVCKAI260O32E#G[01\VNK6:WBK_M3; MC@L-!6XIU;\8D%ZJ5E%;P\BJ4;&--*2)S3"GGQ J&T#S6RG-BV$+=+^UR=]0 M2P,$% @
M8!N67/T&CQ0! >@D !@ !X;"]W;W)K=7#!@G2 !9O.ABQ98$R(Z-&G!:PW);%$4?EN1(M7(3DLKM+2_K[SBPE66X4 7F1N-PY9\[<=CE>*?W-Y(@6UF51F8F?6UM?!H%) MJL86L\%&#
M:5UG^V=P1\25^;@&3B21*EOO+C/)G[(@K# U#*#H+\7O,&B8"*2\>^6T]^[M9.#A\X[]SL5.L23"X(TJ_I29S2?^R(<,%Z(I[)-:_8+;> ;,EZK"N%]8M;81 M&:>-L:K<@DE!*:OV7ZRW>3@ C,(? .
(M(':Z6T=.Y1=AQ72LU0HT6Q,;/[A0 M'9K$R8J+,K>:=B7A[/0!*20S#BQQ\9L@W>*N6US\ ]P0OJK*Y@9NJPRSM_B M-.R%Q#LAU_%)PCG67>B%'8C#N'^"K[B<#@[]GB;&::O_/L1A;BOYQ
M"IZ'2U.+%"<^-;Q!_8+^],.[:!A>G1#8WPOLGV*?/MS.YK?S8ZI.XW[][?D6 M>O#AW2B.HBMH:> Y5[JB_K#PI$36@;FHX(O$I>K S8QV$?JC\Y)+!@5G!BSJ
M$E)5TH"EF,$=)KJAJ82HXU$%>AT050:6<*UYK=6+S"BA= [0%LA*6BD*-Q'@ M>(L-#2GY5PLXZPT[81A2*Y,[454-&;H]6:6ZK0M9B9I(UY(F"PG;?]^%>YK2 M+)-
N7*WRV#N%),NFW*D0&])K3<^%U*SZ+.8!BZ2E"PN$YS42W;_$A+ M)4@*N12<;!)%4ZR=E-=L.%%=N&LLR]P58E>" \A"I$[L*]9S6.HA5V@:;8ME M0M:[^:8=HBRDX222-
F:Q@HN7\#4!']T[U1A*AOG4]69M#]U16>CO+Q3:<)<. MX SB>,2/0^A?A/QP ?UPX#TK3O^BE?ZV=P@3=:*PYSV@,9=P7]9-JX(F HV% MCY_[\,E[Y(&G!G@118,<1$NR+XQC"CY+9Q35
TV6MPVV*S M .\[,DGSP)WQO^K%\<#5CAOB+!Y;Q0'?_ M%=123ZP"UW2ODX@3CMD7"NIY4OS&)U"=I(;W-->+/.N@> M.XF#@_NP1+UTM[X!-
]+MU;A_N_^PF+7WZ:MY^U7R5>@E'1Y4L05!P^[%P&]G M;[>PJG:W:Z(LW=7N,:>/(]1L0/L+I>QNP0[VGUO3_P!02P,$% @ M8!N M62/F!Y;_!0 TPX !D !X;"]W;W)K&ULE5=M
M;]LX#/Z>7T%DNT,+9(E?DC3K2X"VZ[#MNK6W=C<<#O=!L9E8J&UYDMPT__Y(MV7'C+.EP7]K((A^2#RE2.ETJ_6 21 M/69J;LVYB;7$\&)@HP4R8OBHPIYVY MTIFPM-
2+@2DTBM@I9>D@\+SQ(!,R[TY/W;=;/3U5I4UECK<:3)EE0J\N,%7+ MLZ[?77_X*A>)Y0^#Z6DA%GB']EMQJVDU:%!BF6%NI,I!X_RL>^X?7PQ9W@G\ M)7%I-
GX#1S)3ZH$7'^.SKL<.88J1901!_Q[Q$M.4@P4RTP8O%3I=QG;Y*P[Z4*,_1=/-0\;"A-OCT)0*P3.[\J0_*=L&)ZJM42-$L3&O]PH3IM6\%EJ$-58%Q56L =K M#)]5;A,#5WF,
<5M_0'XUS@5KYRZ"%P'OL.A#Z/4@\(+A"WAA$VSH\,+_'2S\ M'+Z%/ M[^YO+O_X<'/][NKK7>/TG]\^WO^]R].7L;['_C/H M9;Z CSE\48^8S5!S*L(>V 3A4F6%R%> N46-,0DE%I&&9R"AIF"
<$PI:I6SU0>U0U'6Z3V"NT6FB1M1Q=Q[24:!/::S\ M7Z9PI.&I9YSC M*2XHEW/$74"3@%'Z[!L;=QT.;DL=43ZP\UUH+7(JC'.GNRMBV\IA[-9SE=*P M9@I;,14U+#E;P]*4-Y9\9-$#QP2(3)6\):D
$E4:VC6'Q_"E=-V#G+AZ0AU) M0KEZ*J2NDGHA4I%'R*>%)#X+L@.A7[D(?M ;!3XTL6 -$,/!: 2'\!K\?A"0 MUHKE)UM@G\H"=6, HLS<6OTK4K,9V7$W._*O 7V;G<+ *_%PXGVS2U)(:](:6K
MS4Y+8!2.MCAI;1^-)S#N>QY\$GE)%\5*Y V\QYE^7F^9]'R?E,;>2U)^;QBR MZTYN0"G0O MHG35<9/:W1S6%Q!M^KNNKH.-AT:&>N&>4\P9=9;JS=%\;5YLY]5#Y5F\>NX1
M_0M)$R[%.:EZ_:-1%W3UA*H65A7NV3)3EAY![F="KT[4+$#[L$&FG?L M]#]02P,$% @ M8!N64LI,K8G"P -QX !D !X;"]W;W)K&ULK5E;;^,V%G[7KR#<9)$!%,>Z6+;G$B"99';;Q4R"<:;%
M8K$/M$3;W)%$EY+BI+]^OT-*LGQ+FW8?$E,4S^&Y?N>0>K]6^GNQ%*)D3UF: M%Q]ZR[)-2+BV*E!4\,499>^(-!=)%QF?WWY7E5E*G-QKUE191G7S]L//:_73'R5BV5)$Q>7[U=\(::B_+:Z
MUWBZ:+DD,A-Y(57.M)A_Z%UY;Z]#6F\6_"S%NNB,&6DR4^H[/?R8?.@-2""1 MBK@D#AP_C^*C2%-B!#%^K7GVVBV)L#MNN'\RND.7&2_$1Y7^(I-R^:$W[K%$ MS'F5EE_5^A^BUF=
(_&*5%N8_6]NU0=1C<564*JN)(4$F<_O+GVH[= C&@R,$ M?DW@&[GM1D;*&U[RR_=:K9FFU>!& Z.JH89P,B>G3$N-MQ)TY>6T5/'W\VOH
ME;"/*H.O"T[F>G]1@CNMN8AK3M>6DW^$4\0^J[Q<%NPV3T2R37\!J5K1_$:T M:_]%AE.QZK-@X#)_X(L(]WG^]O MOTRO'GZ\^W)(SI %HJ8 >-YPJZJ!7*
(GCTCI[,CI\QC0%F!361NA,ZKC!3#EO7F!S=CLV<6 M!($;!*'9QG.;)TOE$ME*&,1)GW=%"QRB^21FNID)K1$I*GG^;)PT>E=8=9!5$D4H- D?#@&*N\ %;RO"R 8,]L)MA"XTDD#F&$?R28BEC:-
-0&PE;/4,@9?N\IE*Z%-^8(5SFXGW.R4"(:A.RLBR% M0)$HY (O=FC[["@BW3[16-@%C=*-M1HF=;2PA9][@_%EP.$WHK,^N3&(!9$MAPJ=!6AN*5N-N>Z)VT+9-
MH.:JTO$2;F:3P<0=!L$19'.=]5+&2VBM!=JDV7]A)R(GOU(.V-BM5JH.N'@I MQ:, >):&D] ENK!NM*-CJ%4I=J.FSDCPK4ABX(6TN$8H:45'#N]"%Z+CD%J1
M/W0#/VK4.LN%D0ABS(4L*\S!4AW=&D-9SZS((V1ND.R9V#51W55[#R5;/Y), MM +>-8)OT/^(W'[HN\%@] ?D=H[)7:[58;FMIC&Y(:7:AN#NVC^1" P1GU1QZ3=I]=0_%98XF^9 9@F#B M^I-
Q:P9#V\IS9RFV/5A'IW,\.G?=9!1=V4A]A:X4DC<@M1A5JWLX>ITZQ#O1 M^["E2:-['5'(E7F5IO2[@4'#_J\IX>PI8079 S/C%Y8 P=B<2\T>>5I1%CB[MB]8!9#V0\\HCA'0%&EN'6;L1ML7\JE!?
=O$[8.[H;>HV"WG;L-WN-G!=QJ^ MY5*CBOTYSE;SN4IQ^J,@X>A&LJ984"!5A?4$;41&.+=&R$2Y!,['/(VKU%2> MXJWS8 3I'C-V!)G" MW7CI&,I&+MR/DJB^_G<^(DL(/3MG8)RYX&/I] M_]2Y;>I?
N>"G9FJ]88-^X.V.Q_V1Z]ZCOJ^-7,;1:T-%'$2V/=3K21Y1U* MV\R4\8JT^(W<8V LY>A*IC$:3_ A=K;R9RH1:0,"MC'#^T*BWY-S"3;69P9: MP)O/4EDL6[^:KJ,CE0'$-4[C#AT ZH1X;"UJXT8?
=I7)!R"P-#UNDWTW7*(1 M>*#>N$*U^I<4*:IZA4:8?27_FAU7E1%KTT5]ZT_[!C"-/#> MS59E]4$Z_%JA=:[KSJ:S,>]JNEIA=%P _4>9((/8LQ$."WX36AEUT,ZD9,29 MB#ERPNGB-T
:V/UH2@[*1L.E:>[P4AD#Y65=!%?\N;.JR2Y%YP+!J4F?5U3= M:GQL.H(X5A4UYZ1=IP0ZMG(],Q7'E=Y-Z-+PLWR-PH4A<6 M_@@7V?VQA;7GSJDDJ703AW\ SMXZ=7%B=U6)D,OIJ.#\4N.L,
[7;7MGHX1CF&@58UXS0NWNOD=\? MA>YDX+&S9D F&'I=#0[4)]\=32#\.(0:L)L[\L=6C0")V>W833INS$U7AY"J M6 (-"VIR9&&"Q5K_R!7%Z\+8Y)2VL$RYO'U^V(BRS=5YF6L 6'N5%)T*OG50
M(.^"8.2.AO8,Y_F(_/9>P-EO)/YLXW!H6QM4M"9R_6AX\#8"E,HT7;G*SYO[MA\[MPP9C=OLY!=@ 2K9KM\^Z*\13GWUZ77OE[.M"1URCC'%L?06QM5-S[*TM M5]20V:36WG'WQ!NV1^H3S]
[5;)O$^7\YXJ*[^P+/]G(/MH7G0IE_8V %-^] MSC'W,^SLZ_3;F[;..#M51*+04[&SUR7TY:&_J0H;\#=X?WX#J9POB)SZ6- 4 MJSW]\8C-YQ,@!J#_L1S?K;+S_R!.PY\@%]?Y#5-
J1Z4>1&T>@@I^!W.!UP MG!<.01C69*9 EZKD=+*!Z?)"QNW1@L%N-NR;:LF/W ,U74G7<8$_)G_9'N#E M*Z+#DA[@.0F)I=.Y4C(B_HG+HN-W0T"0^G+H#S0O[27DEI4@3@W$AJ;MK8]8
M[RT[T)FT<[<=3E^;[9I6Q'8>38_2A.UFL/OB:K'08D%MZ0G<'^"@<4*5E^KV M9.R&PY"-^Z8U09$<,8/=[L0;VXDA_2!X)F[D!7!P?S(D!B,Z"4Z"P$5HX7@1 M4= /^ZAWXR
R%UCT&/IMJ3\9]R./"+T1^A^&+'$]?P+*$2WU!NAX,#EP!T'4 M/K>TC=0U;5N=1_WQJ"G1@3N)D'WU1#C>$IN" TII =[/E2J;!]J@_59\^3]02P,$% @ M8!N M64GU=0'G P R @ !D
!X;"]W;W)K&ULC5;= M;]LV$'_W7W%0@3X%EJVX;I#8!NPLP_*0*0-JC3;<"P!THZ66PH4B,I.^Y?OSO2 M=EW$\?9B\^/N=[_[X)TF&V.?78WHX:51VDV3VOOV.DU=46,C7-^TJ.FF,K81
MGK9VE;K6HBB#4J/2;# 8IXV0.IE-PMFCG4U,YY74^&C!=4TC[':!RFRFR3#9 M'WR1J]KS03J;M&*%2_1?VT=+N_2 4LH&M9-&@\5JFLR'UXL1RP>!WR5NW-$: MV)/W)?
39,"$4&'A&4'0WQIO42D&(AK_[#"3@TE6/%[OT7\-OI,ON7!X M:]0?LO3U-+E*H,1*=,I_,9O?<.?/!\8KC'+A%S91-ALE4'3.FV:G3 P:J>._ M>-G%X4CA:O"&0K93R
+O:"BP_$5X,9M8LP'+TH3&B^!JT"9R4G-2EM[2K20] M/[O7A6D0GL0+NDGJ"9'/TV*GO8C:V1O:8W@PVM<.[G2)Y<_Z*3$YT,GV=!;9 M6< EMGVX'%Q -LA&9_ N#^Y=!KS+_^$>_#7/G;=4!W^?
\C0"C4X#\=NX=JTH M<)I0\3NT:TQF[]\-QX.;,S1'!YJC<^BS^T^WGQ_NX&G^Y]WR%+?SVI\^/]W! M&-Z_N\J&PQLX!H.G&N'6-*W06RI6CY9JB$)!=8O68@E>O(!P#KT#HDB*7
M2GI),ESL)70MO1U/**6L2 =UP5?H-XCQO)):Z$(*!]5C;$IP#J0')&8P!?1XWO M(A'I6:\Q%LF?9U1;HB$T:.-YX1D>& A:8X.]75Q.H6XD";-FCM3ZA)+?L>SW
M%B$CNWR(M9!JYTMLSL$'BJ:A:PL5%;JQ[H*ZA:;V&O*2HY*XYJ#^!U?)GF&) MEM+*D"&UH&E([-GVWF!;=8K0]IPO8BD0N6PP'',9';;9)05VRQZ[+O\62LM0_0EZ7P&NEV^#WV^0#M'K M?
&ULJ'JR'>A0_Z,GE%/Z]DWPXE7T.- _(DB'^]>S#80[S9%G,[T<-5:< M4(N*3)=,M*,06T\S.Q!IC9,Q!*=Z67HT71JTJS!#'12FTSX.FL/I84S/XW3Z M(1YG_(.P*TF!55B1ZJ#_\4,"-L[-N/&F#;,J-
YXF7UC6]*F!E@7HOC+&[S=L MX/#Q,OL74$L#!!0 (+6 ;EE\1%YM?P4 / , 9 >&PO=V]R:W-H M965TO7'Q*7:^N^^IPHB.?"E/ZJ MFX=0?>SWO#P=M^(779'5_&;P]N M?
&GK8'1)#T[XNBBDVUR3L>NK[GEW^^&+7N:!/_3'EY5VU(X6EQU)^\/V[X7=/:MYX%1S*W]BN_W&97W0$3(D,J,(+$OQ5- MR1@& HUO#69WYY(-V\];])]B[(AE+CU-K?
E#9R&_ZK[OBHP6LC;ABUW_0DT\ M;QA/6>/C7[%.>T?PJ&H?;-$8X[W09?HOGQL=6@;O!]\Q&P\@[.8HL/\L@ MQY?.KH7CW4#CAQAJM 8Y77)2'H/#JH9=&$]M4>@ E8,7LLS$U)9!ETLJE29_
MV0]PP1O[JH&[3G##[\"]%7< R+VX*3/*#NW[H+;C-]SRNQZ>!'RDJB\>=D[H-#I?QU+/2$/#J.S-WST5=2T547[>')K:@[M?OWJ_.W@TPG>HQWOT2GT\?3^[N[VZ>YF]O0H)K//8GH_>[J=_7PSF]
[>/!XC M>QIN=O]T(]Z)UZ_>#\//XF3Z.)7'?12E6RYDDX#<\E&C&D=MF.>'":$T][IQ@A"GM]XTE9'WP'N%9I&2^V:D!Z>5.T<]D0J2KD:WS$0A321\ES.#<5%\D$7\72$0D8 MZ8;)L+"'0-6T@6.
<.%L(5@ACIY:X3HRDI5@A#E&OLH[H.@HUG<94DG$N->1 M":.=B874IG;1;46.SPVAR 4<$'"\HA+[L OJM?+;>-ZF-C+:&M$JI=V+YE#) M.IRK)OTQ"%4;Z7;*G#4BL *
(Q=09G<5TT;,L*H.78^[,KLI;W-H*5-*';42R M5-3K/-8L]8OVL!U[NOYWSB%& 2C6Q=UT11:VGI8ICD"E<9;$9,> MFZ.5P*V7F-F8]R@&$@YY%ECF.F%%,XUZ#]8!?
6:%+#CE7JR!R&>'A(LF*/0@,*)Y>AG=$$I8R=5-%V2O.Y%%%E-#1OLQ0D!'[G&Z8OF!%SE]&&]\KZZU-]@M4#%I8]*.U47 M4 G%@=%250;N>18 F)NG7:L[UXC4"E;ZH.-
W(1A*FYH5XY%_&K]S@!^];:6@9]Q1,QTP=;@+!*1W]CF6BMF('SY\ M&)P-!@,>P^(SJ<2(Z_"0C=?+DF<\+G4K]!&B#K1T+S1-QX3DJ;_27$EPAW8I M8S_]J*2CAEF!JN2&T*@ACBU#!5(OT
J+ZVQ2WBTIF[*?1*)'Q&L\U(PR>"8 MBPRZ3]*^KAOZXCC]?ZLS&D1U!$:S:_IY0[)1?T^V@V+&71SU3IA8QVXT_=8M MM""WC'=MGPZ;="'=?=U=YR?I%KO?GGX+W$FWU"4?
U0N8#GKOWG2%2_?K]!)L M%>^TPBXJZJJ#R:9)-8FL6L["WS[CAV@W(E% M:JN^)+8S_-_)I[Q>"O4BRX1#>SJJM$3KS1&W@>!3DNLF;X1$AOZD@M5,T-3 M501:*F29:B 87YQ$OZ]
[.!M7<&WSAN]=D8;"0; M(5[LY%,V\4(K""M,C24P>KWB'*O*@DC&GP>F=]K2.IZ/C_2/+G:*9<,TSD7U M*\],.?%&'F28L[8R2[']&0_QW%I>*BKMGK#M;&,R3EMM1'UP)@4U;[HWVQWR
M<.8P"M]PB X.D=/=;>14/C+#IF,EMJ"L-='LP(7JO$D<;^Q/61E%7SGYF>D2 M*V8P@P539@]KQ1K-7+[T.##$MU9!>F#-.E;T!FL(GT5C2@U/38;9]_X!Z3J) MBX[B9M%5X KE#<2A#U$8#:
[PXE.PL>/%_SA8^#W9:*-H]L>EN#OLX#+6ULV] MEBS%B4>%H5&]HC?]*X_#!^NB!Z<1 ^NT:?+IU^2]=,C+)+E^C=8+Y/G53)? M?_KRO+JD]#KK^H *1@VC0ODR),!>U M9,W><>X>=

]WF+:VO,@@YRDJ#5P#:P!K68D]_NAX X^MXDWAUDRIR*#NC@[: MHP/TXTVW[_'O$RRS@]@_YX!D/',+G=K>02V34HD=IZ)%"N'](/;CX:U#O(]& M_D^W
Y\:BI;H6D*U]V%;\K0$WJ15FZ%V1%84"@LB0$$'Q4!FASGC"EY9U:+V M@6FJ?X.*RI(TRU;IUAH:T?N8K&:0K.:P%I*G<-L M2P4R4B!1<9%]EQ[-=_\N.;T?D@.7D],/0W\8';(SC/V[_R,[O;/LP'_-SJ6B
M"LY:8(VJ<(U>0RK:QG3=\+1ZNDN2KH7^;=Y=1)^9*C@IJ# GU_#F[M8#U37W M;F*$= UU(PRU9SRZ$.4[L!J<;=OH74$L#!!0 (+6 ;EGF MYV%^L@((4) 9 >&PO=V]R:W-H965T"#"*A%+#\K.
6LDP)R6/\J36-QJ0B;H\WZA/MN_3E&7.XI=GO-!;) MP+@V4 P+7&;BD:[OH/:GH_0BFG']B]85MM,Q4%1R0?.:+$^0IZ3ZXM?Z'K8(M]GL$IR8X^P3O'8);$]QC"5Y-\(XE=&I"YU@?
_)K@'VNA6Q.Z.EC5[>K0C+# M8<#H&C&%EFIJH..KV3(B*5&9.!=,[J:2)\(9?D,KCF; =%:3"- HY5%&>*!$)1V,20]S" MGQSF^P?XIO2Y<=S9.#YT#@K.H;A"KO4%.9;CM9SG]C#]6TD.TD?'6W=;Z./C
MK;?1)__G^_3#A]\)A=ODH*OUW(_D8%NJ57)>NYQZN_N\P!$,#/DXUDB]=DBW=(/?PAR_,]B6@.Z/P[Y?RB M+4,J"5]+J&*\"B^]7LD9;G2IW%L?VOVQW;(^D3U& MU1+\DZ\:E ?,EBGA*(.%-
&5==65U8U71KR:"%KKF/%,A*Y@>)K)/ J8 OV6 M-O%\?*)_=;6;6@Y8P8-@ORC11>Q]\!"!#-=,[T3S#;IZ9I:7"J;<%35M[.2C MA])::5%VR<:@I+R]XY?N',X2#.=R0M@EA,Z[W!>ZA&:!+

TX80>*:DQNU1U"YU>AMKO9JDJG$+LF0]#@3R"E[Q_-YX'GP:4I[WR M=(B>[&H&:!P<9O?CK?%S0KGG_6'$F3NNJ!"J:BY;EM%
MO]HWVE7;7_Z&MUWZ$: @*($P Y3H !D !X M;"]W;W)K&ULK5M;<]NXDG[GKT!YMJ;L*MF69"=. M,DFJ'"(A"1.2$)#D+[,KS]?=P,D:-.*D[,OB242C49?
MOKY!+Z]M_=5MC&G435E4[M7>IFFV+XZ/7;HQI79'=FLJ/%G9NM0-/M;K8[>M MCESJN]UR_YNX_UZY>V;8J\,A]KY=JRU/7M&U/8ZU=[L[WP
MQ:=\O6GHB^/7+[=Z;1:F^;+]6./3<4#X_#++4S%[;X(\^:S:N]9WLJ,RO=%LTG>_W?QA_H"=%+;>'X7W4M[YY- M]U3:NL:6?C$X*/-
*_MZYO5YFMJV:O)JK3[:(D]SXR9J>2L?;M5^^/+@Y7&# M[6C1<>I)OQ'2\P=(/U4?;-5LG'I7928;KC\&FQVO\\#KF_E.@@NS/5(GTXF: M3^>G.^B==&
<_87HG#]#[O#'JPI9;7=TJ765J(9:I[$HM\G65K_)45XT:$9'Z MW_.E:VJ8U/^-R46V/1W?EOSLA=OJU+S:@R,Y4U^9O=<__S1[.OUEQZ%.NT.= M[J+^^M?
\KS;/\D:.]]+;%_8*C5U-<;J3F+CK'8[)/=V4+%(,PM!5;:!&=>U MJ9KB5FWTE8$O7YFJQ;/&)FM3F5HW1J7:;=0*&$%?J]1>F5H!>O",R)L;H) S
M[@B*P48J;YRB/[;DV1/51+MN-#^B+;.(0F$=UK-,*K/6! 71GDE>*:/3C;HU MNE99:X0)UT2T\$IJJ\JCR77>;)@-OX6MP%Q\>F(Y;?QIR'I:D^!O)G>?+\ K
MGP+_0\Q&+PO\W39M;9AE6<7\ EE%3*O:EM'NBL[=='OQQGEU95Q#G!/M#'(O M[!:0VK#F4EN6IDYS7>1_,PTR?#K2MK99"]X?.-!&-_P:<:IK"
(V(1<3YLRBV MX+]U!N#*R5]8[$&9D&%1)(%AX3=%9'%F0LLF=")-NP!@)W0V>E^1\32M+F!- ME8%:L*PS(A=YK;@[%YOA$YUKEC5[F!8SW2-
4Z=UC3PI.Q &* Q;9+L+^$ MC&.;^OFG9_/9V2\N\4MCG0J3:W:"U#L!V09D;BLC]J17C1'U9L0E"Q"?L/DJ
MKW1%&E#@H3$D/9"#TG/G6I,=J4O$K0R^=M?,.Y9R8"O$F1D^\AI2-F2LVW8) MI,+).^A:Y74Y(5,0U6UMW8!#I@F^'8"-F,L>8,F1;9 N@Z'RP6C?
3'T@(TA. M9H++$](OE.;PY#MDJQXG6S9)QRQG9$39 \PG$?.9912"<15M1OX$:,S^1&B5 MQZR.DH*WMS7Q+*C0J98V;9#;D+U *WA& M01]D7;MENR
3\>AS!]YJ0LU*+0U$BH.XMM:$QRQ#UQ(6C/!TO3%@IPXX1*ED M K:8 W#B>?*ZJ]83$<>2?'.UHGA;\7OZ2N<%(R.C0[[JOYE$'/AM.R)VM6*7
M(*F:NA3=D/TPGU!12G&$Z4($D> '\-=IH8=N@A_7F14M)-U7;)-.D%]>EGBU M;!VBJW,3OX1(Z)+?9_,WZ">ZC'C?/H=1<6
M>.K>E4&)>-49OM7I;0#]7KK$@$MBDX3H2G*;%1(>6P].\ U#A492G'G5$E[' M 4=D\N'WMV]G(=Y,Z(6M8=DV)MU4MK!K@'G!T0J9V5<4*5&
<<9/N,"$2X%NV M,W:W L>Q(3IRO+9LABFS2UD<&57*LAE[U/,@N8JI-FSL5MX3+(@#II@:V =6
M#,!!,90$$V.G&_=>!+E2WY+5!HM@Y&@)@XIXJ^1^\"99/!B2$7^!PA1^O07H MKP,.2H1=LB<&%X,=3)?
^X+P9A2]&,$X!F1%*1H[4CH3U29>P/MF9L+[1+N?P M\I&X]^@ZEJK^)EQ[\@=C*J+8([,.\0P(L")(-[,[Q!KQVI=_0=ZD4@">,= MP&] 1Z#-$2PV(D4?
6'=&J3C$,G&V,\;((8\ARBKAD&G'#&+_#)Y"Q/R=_U@AP$I-,S@?C1^<4E*/!HX&!] IMW^^*[&>K?<5 &]09 MPP8CD$^+ 882=FAQGZ-M
1YI#L6Y$"N_5+S!@G9V:O\?Y^% M]VFD?VWAX=/#N)@61LJ6 MQ)$@;I=Q>%4HZ2M)\C@PKE,NTUA:P!:@4A:2+NC$"_4166G#83^A5X[4A61J
M8%IZ50$3,Q@ZJBQ&MXJ>D/2]I;*.1FGO4B)I(=)W)X0$GF?+O&G&EPE [-07 MY"^&&1^"32'ODG:WL6V128S0P;#_1*;:U:7)6%!^A#BI-
A;XHD1/ZK%.2N2S M)4("=DVER*O:SB (0JE)IF;3P_\!]<)D/2=\J$NQ9[M%))+D&1F%7O/6DPXP M@B\FO6]])X92MT]!Q8,4?Y^6HC0BF[95P3F/F
*=!N4]YV+]@@,D%)2V (\2 M3F*H+T0YRTKG-9:/R;=G:&N=+]BDGF#MQH4ZYW)=NR-45,'9\&)N,[9 BF-4 M!<(BDC[O#%3#0I??0#/<:9-
0L2!@*9<(VJ%9QGA%15 X5\X^P#G)O?H&R ME$22B$C9;[K*+WDX8E!F1&\1/$L^Y1-1.=+1CF3A:9)_E%*T#6[[P-KFKY/ M$1*-
[PF+/A\/7/H"ATAU73]ZIVL!96T=JH@NM 1SB71$MM@G%]:Q21':\V+J M*0UT,A-P(Q-OQY2GSZ3<@))0A<*0,*6H*!OJ'(Z3QM!,#'ZE&$URRF'#]&(
M=NITL\M^SSK[/=MI?9_XD%P)+,R:A#9FP=]+8]"G\S6GI.Z5Z>I.U!WKT)Y+ M6A(^/?6)/S^ E@8M,G;FN'3=)8%GG02>?8/[J$1YVY;SKL,^[PS[?
R2*WQ:NF1Y8+$$:1]REW7\<.O)/:>#=^UQ;J?0=0 M>>6:NHTZ7EM$>N[,(1(@_?X3 !/G#;[>&Y).A71-I'U(I9RUE'A"+U!8VYB"
M,X;,E")K#HA=03#L*M/@D!R9>F+L_[9*?$>"B3U,A[!JDZ\W@:N_X,Q1'\F? M&7KM&P!C236UIW(R"^JZ5N0+&3X-#8(Y'\ I"Y G%$\KA*+E(2)]KUW6-
!.6=LQ!%8Z(*"7D.$KN:(DBHOR8^ M/Q'2=Q=%GE)S;TJ,3G;7V_27,+SC<- MI"/H%T[\>.9N(XKC+2?*(-0W!H?
MT;ZARGB2AJHDJMB+VR0S39UST[S@"0_. M9VY*LZQ>F.+S/CC^Q<>$VYFT8![MAN#"4:(.O_Q#MJYHM9),VZ\/TA+=4\8 MM4ST).0M,38F=S&-
&IP(Q[>AS1E #M8-'V%Q4DCGKGF_A.H<@D H2@Q5>NHQ MUDO?L\YAI*S7QO?
[);NKC4E\Z0"$*;XE\WDO_E..7VLR>!#IP&C\EBQ=UQ>IMI,3YXD!&"8V=._N,S(P M'>+
<#'G>]:A^2!$L3'W/8*@H<$(9)57#3>_0""%7$SU1#3Y0FI5NXMB>W)CG M/N3UQE2167CKU-EM**5S'E5(S=XZF?
1O"^1W6<(C#,H2\M3L=,G^KLMLYZV3 MU^\UMON7+EHN[/K$\+('BU'__(^I#M.];LZPD6Z*N@J+^X(RQB]Q3!V_N\FA M>63RMSZ11;%
(F/:WIYI7<&EN<]/KHB\>Y0 A#1&4H8KG)";,0A>/7=969TE! M98)[D?S\T_.G9\]_@6_A;J_FC-@\QYSX##@E)07<2QNO_>_M/?.$L>W(S@GH) M2[)-
F19ZAV>"\7&0XIBSQ9=&PFRDMXFH/@8&M"$)PG/&PT-FM**P:B8^Q:IK[AGQ M>I>$JBA*"29]#;/5MQTCW,0P?7-D$M<0$4\[\:"_)C;
[QCTQ!OM1E_^1.V$2 M.L;&;35'4[LZ9(@3L_/%(PF' T47FR@L0!U_CW?0>WR)[N2AC*,Y6.;4&XO_ M4(^=+]XQBYX"[4&S[9 M1=2%&A7WCY$:P*ITS
A7J*]+=X><9-<(DQPC)PE4A4P\E4!*3]HJ]P @G_4U MBXBFZ.6VL+A"0<[JL]VB8#F;/9LD MUS1=D!*[1W^&$%I,\=@[718N*(5VY+K6/FA'=J+=L-'GW8?
6ZCO9W%)FQ#ZC M2;A40RYM0J3U4ION=9#:S4]QU%",-KB63? M?-./[XG4=AEZ;':5R/VTO@\:N(HHJQ0A#@QH5%AT1[3@'2G[Q]?%#6,L&-C
MBX&5))!.G-4%EMX@*?EZN$B15AIW^ &9-S;ZG=<@%<^I5%;[_)+R+QV@G,E, M$9HKW&[TU?Z@O5V;@O?R9?[ABBH2GH30Q<5:&C3="*
(O@J,O)>M<^?&26+M< M59/A0Y9?4=3-.$\%HZ!2"I7'OMR#.C :J/."K\6L@PYM6_0J6N^\8"F- M"''-
Y:CQ\R++'8*XTYO14K[[[!GUG$<\C,CCXPB%9$@AM(.I=TNW>'W+YYN2 M"9<=S0W=9I+9W "3_+RH?QIDYQ'.%H6]9H:9(&
<1$",PNK_<&)\O$42ZIJN, MYL;/MSO7%@OL&M[9PY+6KBOA0(2O3UR'%ACELX>=J/<9!6SKP(
[.$H6^6W"\UK\7,0$.K*=0SY//EI0X>S*93<_HO^G)Z3ZWOX;3>E2<#]OV=TL=/PV@)5[_0E?!MB)YOV$;;9[,$9H M59L-_70*A_X5=CLJW>\EHH9?
L3_4QDO&]Y?Y2A&7D7*K-^%KXW(O$UJAJ_W2 M>43J'A,[S,33XE#LN$Y2CJ.^B)VZ/W! MQ8_H(@L?
1CH!4B(^XH8%WB.O';VF/^160MJU((ARNC3RXPW7,['+#OKAXVSW M]/$3W]0!9E_RKPD&/V2J;67I=OO#C9__)]H43'^C-B1)JQ<0%P:Y7[OX0F48
M/SVO""+N+WC4V X\A _&UTZ0L,O 6WCV;@^22Y ME(L"G^FB0-C[['1L[_[-NWO&AS[=N>?IX?2DVW,1NIR*C6?V2R2%H0/Z!>&U M=SZ?!1MZO:
[Y1TZ H)BK_46[;$20\^DAGV?X-KGK/3X\83=FD\?1+P]+4Z_Y M]Y5\EZ)JY$>(W;?=;SC/Y9>+_>OR] /NE[3'+@P*RR='IVA+J[E-Y7R 9SS
M[QB7MFELR7]NC 9,T MXOK)(4_P'VJ#[9>OK?P-02P,$% @ M8!N67<2 M1EL/ P AP8 !D !X;"]W;W)K&ULK57;CM,P M$'WO5XR"A$
JF^M>:2OM+B"0N%3;!1X0#ZXS::QU[& [F^7O&3O=T)5*GWAI M?)DY<\CKKM;FS-:*#AT8J.X]JY]J]+.+:\QH;9(]VBHIM*FX8YVII-;%N# MK
Q.C8RS)#F)&R94M)B%LZ59S'3GI%"X-&"[IF'F]Q5*W<^C-'H\N!&;VOF# M>#%KV097Z+ZV2T.[>$0I18/*"JW 8#6/+M.+J\+;!X-O GN[LP:O9*WUG=]\
M*.=1X@FA1.X\ J///5ZCE!Z(:/S:8D9C2.^XNWY$?Q>TDY8ULWBMY7=1NGH> MG4508L4ZZ6YT_QZW>HX]'M?2AE_H!]O3) +>6:>;K3,Q:
(0:ONQAFX<=A[-_ M.61;ARSP'@(%EF^88XN9T3T8;TUH?A&D!F\B)Y1_E)4S="O(SRUN:X1KW;1, M_0:F2E@-CP.Z@I78*%$)SI2#2\YUIYQ0&UAJ*;A
"R]NV5JB?3F+'1'Q<#'? M!KT:@F;_"'H"G[1RM86WJL3RJ7], D85V:.*J^P@X K;(\B3*61)5AS R\>L MY $O__]9^7&YMLY0L?WI*\/B"J M&$45A]
7*VKHLI/H5;P1LG-8PF=J^X_:6EBB@57-#.YC?1!W/VN?P4I+ZGF? M'>1+ZWE0' UM9WA-@\$3;"@4 M]2R_@V)ZG*>03<_3?/)5W:/U7"D]S@CNEX-
5IP3E)"U.(,O.)]>["-LSXPA MUF263(L\@32=GIUGDUOMF(3T>)HFI_Z3Y 7LJY)X9S@T:#9A!%H(E3O,B?%T MG+*7PW#Y:SZ,Z$_,; 2)EEB1:W)T>AR!&
<;>L'&Z#:-FK1T-KK"LZ9\"C3>@ M^TIK][CQ <;_GL4?4$L#!!0 (+6 ;EGMJ2*',P, &8' 9 >&PO M=V]R:W-H965T+*$6J)!4G_?4[4K:<#JXQ# ,$\>WNN>?
N>,?Y3NE/ MID:T\-P(:19!;6U[$X:FJ+%AYDJU*.FD4KIAEI9Z&YI6(RN]4B/".(KRL&%< M!LNYWWO4R[GJK. 2'S68KFF8?EFA4+M%,
D.&Q_XMK9N(US.6[;%-=K?VD=- MJW! *7F#TG E06.U"&XG-ZO,R7N!WSGNS*LY.$\V2GURBY_+11 Y0BBPL Z! MT?"$=RB$ R(:G_>8P6#2*;Z>']#?
>=_)EPTS>*?$'[RT]2*8!5!BQ3IA/ZC= M3[CWQQ,LE##^#[M>-LT"*#IC5;-7)@8-E_W(GO=Q>*4PB[ZA$.\58L^[-^19 MOF66+>=:[4
[:4)S$^^JUR9R7+JDK*VF4TYZ=GFGI%&"E\QB"2LFF"P0UOXZ MO$7+N("+CVPCT%S.0TOVG%98[+%7/7;\#>P<'I2TM8%[66+YM7Y(/ >R\8'L
M*CX+N,;V"I)H#'$4IV?PDL'YQ.,E_]GY/V\WQFJZ.G^=#MS3<^C+-95GV0D$5<&CIB+5]@68+.'^<\=;
M*AL[AE_0GJ)]%O@T;8J\Q6:#>@@_/#!=U)!,^N7H@DNPM>H,<3"7HZ\HX9&2 M1#MZ8$5-1O4_#N%
[2,=9&M&8C./H>G2GFK:S9/,HXA2,JNR.:80\IV_DDFAU MYXO\#9=O6JT*- :F*<2S9/0>J69K)4K@#1T]H<,QD"3TC7ZM*DXI/^*G!)F,
MTO$TNR82>9:2OC$WU#R*KNF$OR@E4EP*SOJN0H18H[3E7_J-B\EX,IG!)5SD MTVNX''U4E@GO4IY.:(S'U],,SER ;+@ V;^^
+=%H3NB=O],S=J@.97ULVC_ M4]8//'#/8]C848,W?;J;5J@71-B@Q(I3*B@F>>;^*27$UF1M%D$R/48N]:>T
M>2IJX:O>UZ#>^@YOH%"=M'T;'':'1^2V[YU'\?X%(M^V7!H06)%J=#6ED.F^ MJ_<+JUK?23?*4E_VTYH>0M1.@,XKI>QAX0P,3^OR;U!+ P04 "
"U@&Y9 MU!D)9+L" #H!0 &0 'AL+W=OV_W]F!M),8 M7^([^^ZYYXE]-@8^^36B 0OA=)N&*V)RJLX=MD:"^':ID3-)TMC"T'LVE7L
M2HLB#TF%BM,D.8L+(74T&H2]F1T-3$5*:IQ9<%51"/LZ064VPZ@3[3;NY6I- M?B,>#4JQPCG28SFS[,4-
2BX+U$X:#1:7PVCMU'8#7C=PPI_C1>.+#^"W_LTUA"]_1"^,:Y<*3(<1OSR'=IG MC$8?/W3.DD\'"/8:@KU#Z*,Y-UI>*02SA&E%E46XDUH650$S\^>=:
MH#7"5&1227J%;R5:05*O("C0>\\\<8Y]))^Z\$0!RYKZH',&_$CZ)QVDF[K%IV[
M@INBK&H6A*R9X/BR!R>MF=>O"9Z%JL(]U"!*BD6MU:,DR27LN^[X7?<5:%=A MQCC(3*6I;L1FMQECX[I[W\+K&7@G[$IJQ^67G)JTS_L1V'JNU
Z9,O3RPA!/ MAF"N>12C]0%\OC2&=HXOT SWT5]02P,$% @ M8!N6;?=UU N P D0< M !D !X;"]W;W)K&ULE55-;]LX$+WOKQBBR(! MO-:G%3>Q#
<39%&V!=H,ZNST4>Z"EL26$(E62BN-_WR%E*[:A>K$7FT.^>?-F M-$-.-E(]Z0+1P$O%A9YZA3'UM>_KK,"*Z:&L4=#)2JJ*&3+5VM>U0I8[IXK[
M41"D?L5*X,=\BY)2(9/W:<7A?2.AZN]^SO7>Z4)IO)/\6YF;8NJ-/3:_<*FQ<:Q!UFCC:QVSJ2@*D7[SUYV=3AP& >_<(AV M#I'3W09R*O]DALTF2FY
632QV85+U7F3N%+8C[(PBDY+\C.SA9'94R%YCDJ_ M?3..PJL;N/_1E&8+%X]LR5%?3GQ#@2SY%C?NSO MD\!.9;17.8_.$BZP'D(<#"
*HN0,7]QE'3N^^/]G_?UVJ8VB9OFW+^^6-NFG MM0-TK6N6X=2C"=&HGM&;O7T3IL'-&=%))SHYQSY;T$#F#4>0*_C&E&+":/BK M,=HPD9=BW:?
W+&._WEMM U#%#59+5+_MRSX 4R#E("K9:#K5E]?PI;%QK8C[M%U1922SW+W6IF!OC.>-,9.3L9'YF% ?BL)4(83081>%K=7!'D,/%: 27\#N$
MPR@BKZW%CT_(/C4"NRZS7$F:]G)%H\B1!<,@!-<_T4TO,$W>]43M0\9[8-P! MKT[D=9_D0&-(^:;PN*WQ/\IV=_AUPD&&^R.>V([W* WC M^Q;HFS?
_X)JL4*W=8Z"I<:D+VQNSV^W>F]OVFGV%MX\5]=VZ%!HXKL@U&%Z- M/%#M] :1M;NTEU*0U>X6Q;T9J*R #I?26GVA@W0O<*SGU!+ P04 " "U
M@&Y9B;)\NX(% !$#@ &0 'AL+W=O@+9!W*8/BWU@;-H6(HE>DHK3_?H= M4K+BM*J;[HM$4C-GSG N%,^W4MWIM1 &'LJBTA%TA%_8S]>BY-
J7&U'A MEZ54)32DJG#*?D[#*Q M\D[@)A=;O3<&Z8FME'=V\L?B8AA80J(05V8:[G]7;3^1!9O+@OMGK!M9*-L M"/-:&UFVRLB@S*OFS1_:?=A32(,?*-
!6@3K>C2''\@TW?'*NY!:4E48T.W"N M.FTDEUF8R,W)^=WJ)?BW@M2PQUIJ[[1I]XK>%T"?G8X-FK/!X MWD)>-I#T!Y
QO)>566MX6RW$XJG^&.EU'.F.XR4]"#@3&Q]8X $-:'@ CW4^ M,X?'?M7GOZ:WVBA,E+_[O&Y PWY06SQG>L/GXF*(U:&%NA?#R': <
M=I3#0^B3&1;CHBX$R"5,-5;0QA+6L!5*0&T=R2LP:P'O>*Y.;WA1"W@OS%HN M^CPY:*O?DT^(O90%UG!>K8 ?HK"T%.X=A=)1@#DOYG7A]EB?
#3ZME1!/<@0P MPD:4MT*Y,,_RAR>?!S;N-O@,NM'@.M=WITN+E%<&*6@#BANA@?GA,9Q"Z)-C M?+3C^!C7HV8<[HWCX\&-M,R*W'P%0IPX(/#V
M88.-!;D7^5+ Z*O@2I] Y ?P\D5*"7F%X^27YK%/X4"J1%VJ1,]/%=OSK&=M M:&9KCCO5EQ(',9^3$L:VB[:WY_]B'*P]_FA_8.?:V0=^S_/"R>.I BO%*P,U
M1EHYI:N"5["HE4.U2I@.99,.HB=;;$J<#3ZVV?BQ-MKP:H'*@R^N)6/^-&[# M]%XH/&@&T\[\A]K!X$Z]?1!JGFLQL(Q^7'*D-4>7#+SG:KX&
M1AK;P+PX3+TX(G:49AX+"1QABB5!8QCXEJN%AA'STB2"DR;@]!40/XH[XFX7 MT+E1G%*/.;G=".5H)R=:HHL.9I1X$0M0GOA!VLG-
+=NB0#G<#3P^3:TJG!CY MN,TQ>A<$H1P61&3?@^]3!:B79$@^#=$-W#'>^]WN.2MNTIKM.T:=T7]X,&_G?KQ8BM'"NYUQ$M*['2K;%QK65
M[.FKT--7N[5]_ZYWYG:-M.F;NPZ[RZG'P;X&'@!B[MY MI[MCW>IVO27QTV378)B7Q5@:[4*8/J'=EXWCO3_[4JB5N[]@48M4(L437P$SSR57-

G:29&;MP]X58:O'6XX1JO>4)9 M ?R^E-+L)M9 =W&<_ =02P,$% @ M8!N6&ULQ59M:]LP$/XKAU=&"Z-VG+>V2PQ- MTK'"
J%9MP]E'Q3[G(CJQ9/DI(7]^$ERXF:0NE ZF@^QWNZYYSF==!ILI+K7 M*T0##YP)/0Q6QA078:C3%7*B3V6!PL[D4G%B;%1\CD9ABT@MW
#5VNC!L(DT%!ECA'2_:2960V#LP RS$G)S(W03MZQB#>&L2>=^7(LYP0 M0Y*!DAM0;K5%IM3/)]Q7"6/*"B$<@(H-YM3L@HULIE10 M7G*XFR)?
H#JX-8;_2AMJKUF9 J3$O&3![M9^M#+)MQVO"(-FD:&)W7C,Z;X\O)@(C0BOC%@K>KK!H_=*A:WG-U:V5YM: M;Y0-+P!UGT^'<*]V , #T. 9
>&PO=V]R:W-H965T.&Y_8+M-FPXT7)=W!!O27&R2,X[\&U&G/-(ZG M\R/Z'S9Y3.:>*EB)_!^6ZFSI7#HDA2VM0II MU]]%'EHR@B,9-\$@X ;*"Q)ZOY+
"Z*>>%8O=P\'P@G;NPDM7O@LY6,VAFYG3Q0934+_3+9/C8*Y'_:K]K*-[W(POB]\ M#\I<$J:N)4O,M)9KQ9E6@Z(=1'[M)8T$UB%AWI(P?PO1SL?
D8R2P#A^^]]@9 M>&/(MD'I5-)H>B;;'J,@F/?+UC_I7?S!"%>GI;4MN .0A> OM-J>,Q;%ZPZ?J]:+0.]=OCYE_.0_.%.R> M-.(%R)U]GRAB>^>Z#6UWVS?
0M>W\S_9OS-O(-OB/,/7#ZH[*'<,6(XJ%%:=O]>Z'Q\6"G&;[O0!H#_+X50A\7YH#VQ1C_#U!+ P04 M" "U@&Y959/[A.H# #%$P &0
'AL+W=OKZGA>Y&:&YLYQ7YQ[Y7QI0I[VF M;CS>?T9_4XE78IZ(@!5+_Z")W"V MUEOQ"HW06KDH*5- ;(,>N?(2E]\0R1/TRY>2%FIVY6OT3K6.T*?
U/7KYXA5Z M@6B./NY8*529F+M2<=97=N.&WUW-S[_ ;PW%#0J\U\CW_'"@?65N?R!.A M=E>-5#M]KJGMJ]
MVZ=GS@O'H7=BS_.BP/3:,V:):DVT+K:S*,-BN61N\8R-&T8E7S35]IEUVP,97=)6U M)"^K_#JB^:C@+%9O*Z-)S9!73]7_D2%P%R)P8-
6FQDQRM79+:'WM72S!YEQR MO4W/ \8D/+7I>8T_#2[XM LAV)Q"WH+Z+MJQ-$$T4Q[=@V;Z+S8U(EX]59;0 M^OJ[R(,CJS:UFG=LH?6U=XD'&X/%?
[#IY/RU'IS:U%C39]IE%&P.*>\W&ZJ^ M5;\ODIJQKIXC2VA]Y5WFP3.K_K0:=&RA]3^_NZ3C&]/$]?YL\'I?HJ=O^X&: MZ-2?
[M$:BU[@>B!\2W.!4MBH)N]FHMS-ZS6C^D"RHEIV>6)2LJS:W0%)@.L" M]?^&,?E\H%=RVI6[Y3]02P,$% @ M8!N68$W$CMM @ 208 !D !X
M;"]W;W)K&ULK55=3]LP%/TK5H8FD#:2)FE!+(T$ M91-[F(8H;,]NC-OOW'MJ6Q&WZ:U'0+:S /]:W"E3^PY*P"
MH9D41$&Q]"YG%ZNYC7C0GULE&RD>[^)XOO< * @Z9L0P4AQVL@'-+ MA#+^])S><*4%CN=[]F_..WK94 TKR7^SW)1+[]PC.12TX>9.MC?
0^W$",\FU M^R5M'QMX)&NTD54/1@45$]U(G_H\C "S^!U V /"?P5$/2!R1CMESM8U-31- ME&R)LM'(9BC/B&?R1H?4=YP(+(@EUFF&@1]?
<(7I4'C_D;TP&PUF MHT/L@]D6:U@3_'X$JIK+9P"R 0$%,Y/^.]*%([6=8Y>&BWGB[\:V)F+B:(AY MH38>U,8'U?
XT):@I/1UL/KKK/'@EYVU(=#:M9CZHF1]42.SW^J-!MD\67OF5"$PX%HH+3,R117>/J%D;6KO8WTF G<=,2>STH M&X#GA91FO[#M9/CW2/\"4$L#!!0 (
+6 ;EE),KQ]Q , '(4 9 M>&PO=V]R:W-H965T5Z%I#C= M$?J=;0 X>BF+BLVL#>?UK6VS= ,E9@-20R6>K @M,1>W=&VSF@+.E*@L;,]Q M
KO$>66%4]7V2,,IV?(BK^"1(K8M2TS_N8>"[&:6:[TV/.7K#9<-=CBM\1H6 MP+_6CU3-Y%"6A'R7-Y^RF>7(M'D$!*9<(+'Z>80Y%
(4FB'W^W4*O+*87[UZ_T1 U>#&:)&>\%OR)[#Y".Z"1Y*6D8.HOVC6Q_HV%TBWCI&S%H@=E7C6_^*4MQ)[';XA
M\%J!=RP8O2'P6X%_;H9A*QB>FV'4"D;G9@A:0:!JWQ1+53K"'(=32G:(RFA! MDQ?*+J46!ACO3[0Z&TQKFYPWNO@[CTM,('E #GN%?(< MS^\;CUZ^@'J
?$?)ASWRZ'QY7_;XY[(G_SO[02W][D7Q%<_7ORC?/HMV](E# MR?[JZ=1] QGV0^0T>O@$%4?P(A8J!GU^-NI J>4J]1SZ@>,X4_MYWZC3*-?U3*B\\+B
MTS#/&YV$)?\9=E"045>0D;8@=U6UQ858-$5=\BJES6M? TU%BUAK^XK4$%UG MKRO.P!D>%4F;]]*WV20L-@E+#,$.S
LZ\P*M>5'.4K(5SE',>YW2RB^=GH)> MVR='+[W)E/%9*1-#*0\L&'<6C+46?%F*C40%&<*(REW=-5E=;QD@S!CP/DNT MN$LM,0F+3,+B\>G<-Y(SZ?
&L9BCI@7>3SKN)UKLY9AM4X[QO[W:OE5[JDTE8 M9!(63\Y;?'K"1N,W%Y^;SH ;K0&_;PBMQ"Z?HR>"LRNTP!6* MH%P"
[=UW:;F7NF,2%IF$Q29AB2'8@=.N\^/#RS&QH6XIAIPU2HN,TF*CM,04 M[=#=O<]J5_N?K-Q%'&C9:ZI6?+&I^JX,)ZA4W]6]%IKL2?P3/4E,]:0QS-X[
M$BF!KM7A%4-J=]A\]':MW0'9G3H6.FJ?N[>1V],>RP,U=03S]^+YBA#^>B,3=,>,X;]0 M2P,$% @ M8!N63Z^+@VC @ UP8 !D
!X;"]W;W)K&ULK57=3]LP$/]73AF:F:#1(FG[2M9'X$!H2:!6%[6':@]M<&PO' MSNQ+"__];"=$W1K*RUX2V_']/NR[RV2K])/)$
F>HS1<2="XF@;GG?'%R.WW M&[YSW)J=,3@G"Z6>W.0FG0:1$X0"E^00F'UM\!*%<$!6QN\:,V@H7>#N^!7] MVGNW7A;,X*42/WA*V308!9#BBI6"
[M7V*]9^^@YOJ83Q3]C6>Z, EJ4AE=?! M5D'.9?5FS_4Y[3$\1L!<1T0>]T5D5=YQ8@E$ZVVH-UNB^8&WJJ/MN*X=)"!EX ME"EJH
SAFBVYX/0"WPK4C+A<@\>$(^ 2'C)5&B93,PG)JG6/\RLX/OKT-TQHS3:.X\9Q['&[;^'^'WL_SQ>&M$VJ7VW6 M*@F]=@FNT,:F8$NH!FU4551_AZHWC-
JI^@U5_SVJ81M5?Y\JZK=3#1JJ MP4&J!T5,P*K*#>%ONZ@SHTW!8$]!IQ-UVR4,&PG#@Q)NT9@QW.1%29C:0B*T M>4)M[,,]]I.S7COYJ"$?'22?
N9R4!!LF2E\FU1D(SA:^%MIDC/:2JQ-%9__H M"'?ZE&OY=TRON306?V7#HM.AM:&K-EI-2!6^=2T4V4;HAYG]\Z!V&^SWE5+T M.G'=L/F7)7\ 4$L#!!0 (
+6 ;ED8&%I4[P0 %,B 9 >&PO=V]R M:W-H965T_=BNB]IH3_OJ()6X\L;&U._(CG"ZE/V./ADLSIA,K[MY1U7);NF3..49B)F&>)T-
K(N\46(!UI0U/@GIFNQ@> MT81&4B.(^EK1:YHDFJ3Z\51!K;I-+=P]WM##XN+5Q3P00:]9\C.>RL7(&EAH M2F2I958]2"-L_*;/%<#L2/ WBL"
MMQ*X^X+N*X).)>@<*O J@7=HE[J5H+LOZ+TBZ%6"7C'VY6 5(^T32<9#SM:(MZ]J*I@*NPJU&N XTW?61'+U:ZQT#B_E<4/.6Q_(U. M?"I)G(A3]
7=3WQT\O$4?40V$@O"J4!QANZS6(K/.R?^7K!NR(^XK'>F@6Y;)A4!!-J73%KUOUO?>TH=F/78- %N-:CVT[F9HKUPC M\3M;G:&.\QFYCMMI&Q"S?
$*7M=QK&X_DP>'R]LZ'YKEMX0K.6YKO3&6G?HV M[12\SO&WZ:]OJBZZD305_[9T]*H$>^U@';@OQ))$=&2IR"PH7U%K_.D#[CE? MVRR#A/F0L
2%@+!&E9[M=6>B3Z^9JE:-@4I%AX-CR,57.A33A*TI#RBF51+ M7IO3)1<[!5@OJ:NQ<^:HNW>U:Z&Q]6,MA(0%D+ 0"-:PL%M;V#5:."D7!*'F
M*SI1RT)9/FWSS @Z=G:6L.Z._P/7ZV*O>0?XAU4+(+L6 L$:=O1J.WI&.[ZK M#>J2LXC2UH7YRJ@^UH,2UML97'S>Z3B.LV?"@?4"R,Z%0+"&"_W:A;
[1A6]T MKB+8C-)6#XS:8SV A/G]EMGRTB;()D,@6,.F06W3P&A3*S6F%A0-6/4PH/8 M#,F%+M OLUQO#-&:
<$XR*8K(YK,D(5SHA:GND9"TGQ06@!*"RM:,YPW=E=-V[;I$FQ\1-^LB,5\-0=BT/0(*,T'I06@M!"*
MUO1WFR/!WKL%8L@TPS4HS0>E!:"T$(K6='R;4L'FG,J-$#G)RB>2:'>_6V7? MW\BSF.E'N]Z60NGN/8. -AF TD(H6M/,;4(&FS,RK>$9_8<.VCJ#IFM
:3XH M+0"EA5"TIN7;[_NOUO$!DT.@=)\4%H 2@NA:$W'MXDD;,XD_6G$!LT:@=+\ MBK8;_W7J=C]9T5)-;6_/]](54%TK;;)W_@M/*9\7;RT(94">R?
*_V_IL_6;$ M9?$^P-YY'U\$Y?L-6TSYNL4MX?,X$RBA,X5TSOKJ GGY!D-9D&Q9_./^P*1D M:7&XH$3-?%U!_3YC3&X*NH'Z/9+Q_U!+ P04 " "U@&Y9OB,
[XJP' #9 M2@ &0 'AL+W=O"VC_)W;. F] M+'^9W(W3=2*]91D4!F,ZF4S'H>='H_EIN>TJF9_&FRSP(WF5D'03AE[R>"Z# M^.%LY(R>-
GSV[U99L6$\/UU[=_):9O^LKY+\U;BF+/U01JD?1R21MV>CM\Z) MX,=%0+G'O[Y\2!O/29'*31Q_+UY\6)Z-)L6(9" 768'P\H=[>2&#H"#EX_BA
MH*/ZF$5@_D3_7V9?)[,C9?*BSCXXB^SU=EH-B)+>>MM@NQS_/"'5 GQ@K>(M@[3\2Q[4OI,166S2+ Y5<#Z"T(^J1^^G$J(1D'/: Z@*H-L!K"/ 50'N5@
] M[@A@*H"5RE2IE#H(+_/FITG\0))B[YQ6/"G%+*/S]/VH^+]?9TG^KI_'9?/K M+%Y\7\7!4B;IB]]FU#EZ0][[]V/C9(WDI9.;Y0?J*')#K_'Q;;@))XEORQ4L2
M+\I2\ME MI^,L3Z 8QGBA!GM>#99V#-8EEW&4K5+R+EK*94N\@.,="@#&N7*U?/1)OG,* M$J_E^I"XD]>$3BAK&= %'/YQ$X'A @Z_])(\W&D+-
[)QZY/!+7EN5S9]_^6O M?^81Y$,FP_1;V[^OPK-V?#&%G:1K;R'/1ODM)!M$E8H7J**2?M^[CB<3D_']TUM M6O:B;+JUEVC;BU.GWLO(AM?
9<,ML+N(PS*?PM)A*VE+B@U)JV:LEI;:].E.: MUBE-+5.JSW[Y4R8+/VV=;R1#FB(=%2+= 2*]$XI0:X2 M?R';)"(O\^E=Q$'@)2E9YX*6D_ZK-N7
0]DJ5\%FS7/BD-(MZ9".:$@WJZ6; M]4BW]A.O7.?D17KX^052;56"AWCI/1959-8V=R(-PY#NN);N&!Q7=.735FO.$5%3Z*M7*HBV]%
M:U;HR>&D8]'FZ&6U Z^K=\MJ[^D% JU%PJ2)Y] (-(WI!;T#K^@'UUB88RT? M)DU@T4P-M8-PIGLNLZAF I4FL&BFMMIX.+#SL"NSJ-
8"E284K5E!&.LRKXYV M%PZ\=G]&F45U%J@TH6@#1=(^PH&-!%:91?49J#2A:)U&V/R&4SL("JZBGU%F M8:"M2*@TT9-
LNP\VE=/^@,+^8'!AA3G6@J%Z RR:J:'V$)3NM[!25$N!2A-8 M-%-;;3TH;#VL"BO,LM81U6 H6K-F<)=W3'S:7U#;[^U[)SY4?X%*$W3WUX!N
MC;1WH+!W0"JK\%&LA4-U%HIFEE6WJZQJQT#A'QV>4591+0(J3?0DJ\KJ$31M M:3]
83\PO*RB>@%4FL"BF1IJST!G>RZKJ!8"E2:P:*:VVFI0V&K8E5540X%* M$XK6+!E'TXXO/%WM)UQXB6U?5F&@=5\!JI]0M&$::>?@PLX!J:S"1[$6#M57
M*-JT(=RT0S9M%ESX!P?[F@H#K15"=0<]R7[THHV7/%;Q17&MGAU4#^_E36*^ M#34(-3J$8,LPN/;"'&MA<9N!]M$-Y&I?X;
(]MUFAV@Q4FL"BF=IJ/^+:=BN(ZCKMP;5N=>F=(5->!2A/N;M,4()(V&*Y=J]-S MJR^J_4"E"44[;E;?
PZ[ZJUV%:]OHU'MVH=H(5)KH2?:IPO896U<;!Q>IV0GF M6*N&:AJP:&:KK787;,_]3@S5;*#2!!;-U%:[$H;8[P2SK'5$]1ZLI=^)N1VN MC6G[P;#
[G6"@M4BH]H.U]#MUBZ0=!/LE_4[P4:R50_47BC:HN++&5038[4XP MT%HC5)_0D^RG^+XL?WW%E6EGP&!GT-*O#I58F&:M':HWP**92FH/P?;\
<%3G@4H36#136^U0N*U#&?:9Y[M>X&#*CKXWB!3PB:_WV\2L'UW:%V]J5@:<:C 4N5+R M0ZWUV\JE_!HIE*:K_"]^Q7.*I?0:4)+)JIK?8K?#]^ MA;?
X%7>GGJ#:%2R:J92V*_P7VA6^:U>,GD2E'ZI=P:*9^FF[PO=C5WJP[9V) M2C]4@X)%J_0;-
^[Y$\KDKKQW4DH6\2;*JOO7U%OK^S.]+>]*M+7]W#FYJ.ZR MI#'539\NO>3.CU(2R-L<.3D\RC^M274?I>I%%J_+.PO=Q%D6A^73E?26,BEV MR-
^_C>/LZ45Q@/IN5O/_%!+ P04 " "U@&Y90UQ\HV$* 1BP &0 M 'AL+W=O;ZY' ZSY1.-_.PBV="X^,ECDD9^7GR;KH?9 M)J7^JBJ*PJ$D")-AY ?
Q8'%5/7:7+JZ2;1X&,;U+2;:-(C]]O:%A\G(]$?[M![X$ZZ>\?&"XN-KX:WI/\Z^;N[3X;GA05D%$XRQ(8I+2Q^O!9_'2D^6RH%KB
MWP%]R8Z^)N6F/"3)M_(;? S>IN$?P2K_.EZ,!N0%7WTMV'^)7DQ:+U!X]);)F%6_4U> MZF6% 5ENLSR)ZN)B#:(@WOWK?Z__(XX*Q-$;!5)=
('4MD.L"N6O!J"X8=2T8 MUP7CTX+Q&P63NF#2=81I73#M6C"K"V8G!=);!?.Z8-YU!%'8[SFA<\EA9W?> MV^)^=XN=][>XW^%BYSTN[G>Y6.WSX>
[PK8Y]Q<_]Q56:O)"T7+[PRB^J$ZBJ M+P[Y("[/]?L\+7X:%'7YXCY/EM\^W11GRXK<)E'10C*_.@D_*#3W@S#[2#Z1 MK_<*^?#+QZMA7HQ8U@V7M:
[M=.D-729N$N=/&5'C%5VUU)O\^@FG?EALZ6%S MI?WFWDA<\/-V?4%D\566'W/+%7[Y;\O\4"ZWE*N=R\5IV\[@
ME]_335$NO+GR^CO;OHVYY4;WT=NVW?RQE;=^;'2;7Z[1APLBS=XE^V+2- M[G8_:,66#XI92T;39SI8_/,?XD3X5]N)BL04)*8B,0V)Z4C,0&
(F$K.0F(W$'"3F M(C$/A#$-971H*".>OK@M?L>GQ:1_ZX@<04)*8B,0V)Z4C, M0&(F_^ 2!?)*_31K:Q3(U;"1F(/$7"3F@3"F48P/C6+,W9=?8S]*TCSX;S'S
M6![//)9)EI,/04R4) R+G=WV5.6&:_=M(4A,06(J$M-VV*3"RLM&SPMQ.I$% MH9A'/A]W!^2@!A(S.VZ!A1S41F(.$G.1F ?"F%XP.?2"";<7_%%=Q2L:@?],
M4W]-R8:F0=)VC>&"_4]\9>YW2RB=T5)-;6_/Z4CL2T)))CjA1B5)A>H;@@%5$3%EHEER2T)RFDNBPM.KIKD+=1A-EO41qV<=pf8&Q=H;@YIH2IG0q8KCXs8Y-8WdZ.8I;-1iEHT=;$]C?7:5G8!T8;0O%#.@#I%G>YQ8UV:4RE:2'H$2'3N0;?8@+ZW3-!EqBA4U7%R$PT
MYB(Q#X0Q+6)V:!$$S:HOX[?V6P 7ZMH39V>$]D<:R-&$/< 4YIHK$-"2F(S$# MB9E(S$)B-A)SD)B+Q#P0QC2%^:$IS#LUA:4?+VD8MK>%^=F9+
(TD69BR9_(M M=Z2^

A61-+9< 1C5=ICP'2@ M]M-?Q)WD"-K:7D4!KHU51^V^5@1L$FO*U'?Q+LV.A82]2A;#\)=33W"5X7>8 MVW>1I$4UN6R>GD5!N!7>E57")"Z@3EPD
9LIB5V-Y50XEH9.YOFV--HXUW]L MCCG'%2#+,/ILD0BJ(/(9G[40WT#$XEF8PV)'5
MZOUIAO5>KU8;@KM]SVE]ZBI!1'YMT(_K3!G.S>$C>)NW!1X9)7MUGDHFB?4@ MZJA-TT Z_(B:($8;$$.@,PZ 89#B\$&M/?^DF$YU](M(
:SR9*V3GZE]H:IN M5:.)S^Z(!Z9>\&I!Z7'OK5Z85!J5N)R\;K3==N=\KP+>@/@4_AN#T(WU\'G MN,ZQ9O@YJ?Y\$(#N*_Z\!KL5$B/:F5LW;FG#G:\+-
V40,89AFC4O=.'6==C1 MR:K&-P,!-.H+^'#HZNR;Z\S51YA+C8R7NX7+M^,7)I9[M]$&$T#/D":_H%&U%"+>V[M APPD!.^',<#/A8ZNG4.6C.::Q5S?
X_AS-$%/4WV]_GD/MGG'Q(*WA*FL5I+ MJ6< 9 H0X#D F004LXQ(5]'?,9=C#/'U(@R.2FZ^2D@#!:CGY1XHEE+SMJQ@ MM0B?^+>Z(_6)YO9J-
&4FIT<(&Y=PAR^89G0CHD0U^M4GB; I0-271DMK&\8\EOR+VH!S-@Z]57:XRQFOANN$0']"UVE M3"5O]B"H(,)EY=G/O=E=7&*^9=%Q3W:GMB*:2
-335]9^;G,6^:G8@=O%[RK M1KIAQP9XOFN(R!+"U&A3]QF9[:A1+B+S72_"&@$&#C85%AW:AX2%"S4+O"KJ
M.HZUV*ONMGE$-4.9TQNS+IU/N.LN#O/LYO9.?F\RK0[H223#P-=H8/8-+U3) M2YZY9&,\(FE@PG]1#W(/T%\SP= =;M+BCVPDN7?#I]0 >[8,V=3)*!(
MXD&:]V(#"P')KDB ;"8?10(D\&@4"2A'8^D;C:]D]%:9 '\U C1(QZD1H$*+ M8TOR!QC#-(BP8KG:AG&((<'YYKA/$259,\K]L)+L??!+J*]\ @KW[=# MF9\7#
((C,;'I&+3?G)C"XYA=Z8;&M/&ALNGH&,AG\D6@RY,Z^RG MWM(1H,MX/G^]H(K'%3W2P)6KA:F=K"Q0W.@?QZE2[%I-XL'>THK$&_34H^\Z
M2.)33/!4X-%4BWJ4W M5JNQ8HLZXHC81NSE;%%;!S6CZ9VG,N6)CAE++7QV'XHCT][RR/+Y59K'19*N M88C+\VOK'K9!M]I** .3I1KZ$K500TH,HH=:
<8.+EYP($XM-DL;;$,GX2;"Z M#>)I"!^2LXE<;*H& 3P*H&& C /E0*_U:*5;:DE3&@AP?/L?<$>9:S7%8C@L MN0ND41DH)_CS5@\5 MG_I)#;],03GWFG=_
M:.LE'$Y*$F<'=YA /A(%/IK839HP((K;?!F<:(/S7MC4GMACJK-QOMU%R3.$
M17\A'$!EWF2J5D'+Z0#;KVBT53@XFS<(=U$@T'$//MR*>CH[F\6XJ,1*;@K'
M'R,%$7T.BN];1FU/CNW6%D2.;,%>G5=KTVN7V4^C4:_4T=VJKJ=)C"9W05B+ M+PE2!O<9T@PF\>H6/B(X(*R*[2_1CTB:Q4=:H1U_24 Y$4
S@6JJ.JVOF(Q< MB+Z=#J;[;JO05HAS:ONN(\GXCSL;ZUW&FNFUY.,:WWB58:O8O#&W:+'%#O>A M[
GG/@2D1J;@59)#@QYAQ2'G9H&/(C]2L!^AL*./#,>DND:3;1!;S>^C\"&0 M57$NOP3UIY[S&UJ@\] OVJ!CAT@0E=7!FX6?J!0\BYG.<,)K,HCJLNKM\ENE
M(A'&;%,]SPE&!MOFGAUCM+E-*UI"N,IP"$=1=ZH*F).D$I$Q-#:FK*Y5#?/] MBLFVQ#U<2A2X/6:D+Z9NRQWZ\?BZ[7 WP8TL$N_6]2LB2A?

KEELGE_/&E%)G METSGKP,S4BF2+;Q,LHP&H"'U(MXC3;)0*9$X^1ZNDQ32[Q;!$XY80_R5I*LP M#M+G60ZWN#+'$A6ZH%X8*>=X95!|
M3]8F95]8M4"YF%<-?D D\MAH<)]YUA)L;<3*FEFM:('A6X?+2ZZ]K("0?K!N M%0?2)\$=NDG9:%)U2=5FP"ROKJH/GR5_#S*_-*_&JK_^BB9]%3V?
P#;P7!.O M8(N."_F7)N8B'5&HV-0&]_)+GP:;%M@\# OVYC("G-J#]@)F=8R[W60W9/-
M%_.]PIGOKV"49^5O2"X\R8.W6M)D08U/*),^')HL_AT.7HT.K(0E9O&6$W4 MN+UF63O*%-[G5Q !6'85)+T+] Q*>"S2E2 A7]6*D4S@\SI6;T]E7)(AQ556
M5-WED9&"F%Z/L\)=-U^O(0Y]0/"*(C\]TLQQ*7!&'IRPS3)GE;>SG!*3UI/T M8HN"E@AIC4;'$OU-F/V2(9CN<(W>/ AC+
(9QTEIXM"5C2$;HT$KT<>KO*^S MPQ;I]-'BV.S;*DW)B.P\&G%*>8Y%.Q#NA6L!EF^\;XV@(N0;G4!L=1)EIFN6
M"5),YC*L61,FC6!Q03DR<53,)4%VA6#?-8,TB,EIVR0!HHE $+: MVQM7E"*^G0>(U%.8&81-,;/0"ESL/*">2-1>PUN&L_[6>?2S0=Y(XY]O$)2+
M+S!ZA!_1-C:2IM4F<%@YPN$-L& M$29:7PQ034X->WAZPA1C]J&DAQ5KAI#@V)_%CVL1T3/X58:DI&E(\OKH*O>F
MLO9)$.+'K8MN3@.G+OK;=T("#W:9,_=@@\Z20HE-ERGO4'CZSS#UHX@6+^') MF5C?1NHW6Y*CK*U?C?6&?-6F6H30PX)#-;OVQF6+Y
;B#8<1>DKS.@9ID>"L M,71J'\,57+U_OB/--*KKM\A&")M%AKEAF/5:^,6]5B,VE6;0&/HS*2I;KHK# M<[]&"X,P_H9Y"NO%QZ,9#H%2KDEP,-
*Y\K/\#;;)=1+&^3480O)ELDBJC"CR M!_(3_DQ^*>,O !D \%1%L,TB8;+)Z%_)SX!\/H)0'./M^X32PPVA6*KHO+H MX=[2R^L33'"%EK,6F;M'V$>:,9&5;;-
YP=B_%Y\U@U"E(7\|()3@KN@-A:O3 M,W$@=.*VV=ECG7H[;N#5KK? JNN'1L]7OV:M.1<]3I8&I7+RLQ5Y?N(JW9CXYAR'S@?Y;^C$WYG0B2S @3-
S:BDK]\S5I5K!L50IY_]#F%L,S]^4!PZ_5Z>N MW1NGKE&/%/H]]EMC"0<=Z 5,MZ^[U+3N)V^Q @TPL $,G.?@?_?$$)YX'SSA MS]U'*\>0N/A"?
X7^>XZAEM\TOXILL+C$%_T]_A>9R;?33'^WK3O*%%%.RY2P MVKIHY&6P4*[UXA_ X9)OQ$3+'E*P212.3%SS==W&235/]3IF(4N0\8=)^MC M-
!*0H;YI)=T7CT0:B'#I(F6+KVB6F/'M@F1!YOH.VWOR%Q4SSSNQ[?E2*@ U]H" !4 !M;V1D+3(P,C0P.3,P7W!R92YX;6SM/6ESXS:R
MW_=7>.=|>:^V"N.S(Q3R=N2K\19C^4GR7-D:RM%DY"$#$5]>,C6 /H'\)}!(MD2 !L$&0LJOV\-@2NM'=:#3Z_/F?CPO[8(4\'IO.+R]>_G#\X@ YIFMA9_;+
MB[OQX6!\=G7UXI__>W#PMY__?GAX\"MRD&<$R#]X7Q^/GFX.7[G]Z0_QP?W$W.#EX=OWH3?^5O/]O8^7IO^.B X.WX MO[S(0'J\]^P?
7&]V].KX^/51^L$7\]2=_>]2_R'W^X77TZ9,'AF-2 #[^R8]^>>V:1A!1LA:O ^8GZ+\.TX\=
MTE\=OGQU^/KE#X^^]2*FV\'!SYYKHQ&:'D28_Q2LE^B7%SY>+&V*4/2[N8>F MO[Q8N)9U2"EX?/+ZF"[Q7_0W?WI_GKF.[]K8HK0_-6RZE?$#%
5WZ;G25 MVP3Y4F@;W@)9V#3(B;EXQ'IY!%SH2/UR/YY:WC("9HH&GV8+COK]MH*U?D MJ"W0."_+PBX1NCOKA6C#
(/S>$[(,7=MBRB*BV\A#M83LL@KUWLMC'+%4A'& MX#0^_SYI>T^-"+N9A&"(PB&DSFBVM-PUH9CC$DR<8&": M;N@$1__?
$B1,C,2%6P:&&AYDC]8Y"@QL@YW49#DHOEPCHG3%29U\#8YZX\ U MO^:.B?A)*RY!\8-#[Y3LV:(2AAP_NO;D4"PN ZFZ8K4X,1XEN)K]+N3!6"QP
M0'6T3\XED6MZ (G1)7/$]J:"L.((V?3@D5N1Z&MJ[1DFY90XPLR% &_8HEH[M74<_B9^ABJ7@!$)"3T^,>
[N=&R&!!"E,U:I<#3=#]_ZD%>1A$D:FW2M6+\I*#!6QJ.? M[[RWX9]S>>L/5D$V2N!W9ZEAEXC?)FK@7I]F0]U6=PYE@3<-.OA+HM]W7K"
M]@8%ZQ.X43#%\1^8/,W=U9"%\1'=#?XBV%6W)=%?(*V)<^&:$]_6:(24RH3?] MECA)!1 SL#!6@]#"]P95#HV];YQE%;TDN5/*!Z)?7!)L$)_KMQI&=W)
[18X#(MW;>-31'@MFOF/F/3P)CKI5^TC7MD__(B]]GAK'\C1$)(B M_,MA;!#,,G_@Y9$W/#-%AOQ8D(=\,#+YQ-$RBH<=FG-L6^FWTYZ[D&-BX-92
MR_7('?++BV,:D2:[F2+R=^LZ)C03YPC5@-P]*/JD+ -IM(?^E]Y@*\.F&G:$ M"&+83$)! \?*_R+S26!&-|-%IT!4'H.L!#0DMTY)N?70TL"IHX#@.20O "^W
M]4$2YCYNOEQDV%FWO,XPK,Y,2?NB&Z@FP/F9C6L MQ(SN."JKZ)4P\PV [I17G4IT9C\LFY0 "1]^;*HA99APC8U[ZM7'2/&3I)0
M'].\E572#LDFD#E7LI/1OC35UQBHR3,]!9/2Z!D[62W+N[#'H!/5#2P6 M=P+//P85,,UVK860.L5SRM(UR#UP0(8Y6?3>:A[L' M*XZCS+,!X
W(D*D;US';/(\9>/WB* ?]X)X2#0^ENM.HU4R5/H)Z7Q>9(.2@ MD,P,ZPBO@*37+I5]8532#NP:E O(]8;QE87AF(#Z^&:LHAN48TTR3!'#BQ",
M4L;@PQ(%"%I=:/4BO!.)*!(((]*4H=PBI>G =91PK+*_WP(EPJT@9K0X9RXH4 M U$1!K:NG#-CB$YY [V!Z89 M+L(H0>D<3;&)H>\]/#H]TIX\Y(.+*P%9-
,HMF9X=S3(*-7CT ;SJ,X\<8A\K MYV M,-VO#!%NUM,,ZM48)1L>[68;]D]"++1^R/+@.2>Q\@5 2#?T(G!69$"E ME69*'P5,H/KUI-
QKCY>F<.^(YIR/"VT&83!W/?P=64HY7@"F.5 !P^@B"77' MHLKPN_+]L!7V)H#ZZ*ZIHAO4@P2*GYG*K!:8FH6V+YS-45"G-R[COFCI(N:!
MV%/=S$5,P#RXIAQ7? %70=+]?FG,8,:-*_(:1XE*6"FY,YE0>FKUIL.)HME1K.E>;5%&FE-0UU1(A&-DP+Z\[1"MEN5/^1(D>ZJB"I37*42O*
M^2!')>+48BGM633[=DI[$:UDM7\ M2!#B7@EQH$H1&_$JOB!H!S=5W,I T*I 9.["+'4:'*_F[**UQC$RT&S*K*Q3 M%8IP)TL,O;D86_FX)+N)LR)#(C>)
!'[_!1-70]EFO->/)*-$:S)>\5;7Y'=-M^C1SF7R3(&5'(D<00[X:XUH-ICV1&Z7,TEM3L$$YN5U.B:TP!4\$8D'1[080 MEH$20NGVNMZ@0-E5G%^[1]S:
(0I8%H@DC]*4L=17K\B9P 33%_.)32GDMG\@R5/\1V4QM@ M@TJ,-6UM[C1IF?DC5L;"4EB;B]C*CE@IS\]H)!<'"AKE('Q"]+-0E("7K=R0U ML$I>&5-
70#,X4@RH*5,),!I&XMI?(PZY%('M!(V>J:J=`U]P:G+R"]$J4L4K^;4.$*"X9. \].JHK6CP] M^(E_?>EZ8^2ML F>+2<&NRL%5?
5GDI^<-^KN2%7'-5I&TSGL6\$YM^OYU**IHX9;,&ORHM&FQ"P MP>_!]5TI")K:(A5^G$W^XG+B.JE*=#Y<>O9%\8($47GXP ECH=XSR-DNC,G
M6A$\E-H.UOT0N=9XF$JJEO9J3Z#@1G@5=R. M6\W&)!#HBF^Z@NL[UY0PB;466SP=.T->^NOM$ G>%L%^+L*]E=!>AHR4$EKW6W?MO& W4A
)B5GZ)W9!@:OR1*#K=F&;$M: M!!FBO8.61^?XG[X_\EN:7NO[99]'T4C1S-#@@C)U+6@;82-;MM6U"!I3'W=
M)1/%#=QZ;&E@.LLMPB7[\T2V$.TLWI!RJ>%"0G<['XAS5RU,?+R0L&1.8AER MT(SZ>B15T"Z^T3SQ$2U_=Z]FM4LBL?]]@8\7.H<:E9 AI4
D\"FBT.52_'#W1)U(M$%QO;C^_]U";SUSSHUB!=(@0'6X,+*1\7#DKY.N,K50AL!^QE4H2@RD-J1%Y MQCI-4S&_A=A#!'4BNL&:9D(%Y'30^/@R.
[8%:EH>/V"].D/^U.0&Z0G06=>C M0WS'VO3#7LB$_")UU=OAGX)F,M=)W;U0AL!_W1B6)P=J"RXU6=4V$K*A=?6G6 M/?
1U40M/MW]3_I3D!Z[6TE5K+D8Y?]D3OQ6F;X!I/N,J&;XE*&P/RT;\CMY* M2EJQL*#LWYG.T5!K%PC^O6F[S;MIY0ER7X3.4)-:DHE$B3I?ZEPK@R;/E9&
MQ (UL)FDK))'2OX7F4_&I0F[[I6+1],.K6BPF#DWG!D:$:OH8CI%X!9BR\CW MS+ILFI5@PU!:E^,NB64W;JG;$+$F/1(8/;%:EQSP4HW&LO-
4%%2F%$2B[4)) MZ8[R;N^3.:()DX:S-AQK'"X6AK=VIV,\<_"4?-@)DB@DK55U;6QF;#"0-O#% MY56E5;,!R4Z;]&:&D^07;FMJR#_H] !_,+W-<.C9=4=
(IV%I=]#ET318I0/F-%V>&H .;YV5S.K]S@UQ&K M-]<,NWEVR=4"TUM 6:%QU.23<,AISURC2"GTEDH/44M 338 :3\X(C!;N#ZYX&CZG0) M
M=I'4K)PN[$.1%" [<24'D@DWOWUO"'"]<0SR&UL1FW\]QZ#>S<,?G4)!*)]3>0YZMSBW(U]T41"EN)T%-K7FX21MO977(Z5#&=
M$ZAN#2K&O_@L_P NBZ*'3EG86UQK%$F/>+ED >X!(]6,T MHZ;N'"'UI5Z1V#B4?S%XI83XJ;JVC'!$:DOW31*5SM$*V&]7R)5U%\C8*F U;
M#U%W5RDA-G.1$*SH2=I10*Y!)_!B3ROVOYX1^#B@/X%[!=B0^G1Z*RFF9?H9 M!4V]#W?4@J/CMFGR?:529C37X5I(I[N&CU-\](
;8R:;FTL=1CNYZ4IO4CZ8 MO3J+?%0$&V0F67%67ABOEMG<8'MU1_(34]>DLQ332P-[T6BFX30IC3+L*X?L M+%QL9128YWPP^W3 .:D(-
NI,/B,MS]U2>Z:K((6)]Y44 YQ:!I?+,DRSMJ\B MXP^O$-5 ;DZQ# ;=-\H:T1=L@)F42%P8GD-V1RL'(^S5'O(Z:/UA=2W=P*9]
M21IFV/4V.\ALP >C;6(G)OVT9F:#7 #31!\OIS.XM1M,%\,Q+E)]9&'YD0E M$?439]6TX=_D!MLK0YV?F W&E$&_'O([,MS'?*CB3*VI5K>"X/OEPX0IVZ#
M$6AM!^\EBEXGM 4O<#9;GX/[YAP1\I*WW8"L:V$]I(;?&)FA%_4/B7LR((OV MF:&D#F-^#:>[AH6RT!,\@GUZI]G@3U]RM*OK6FL.\G-E:
[W#KG6_9^^K6'E(_M"5B4U$2=%UK,1P>F!35=!UBO^FU0P2Q 6]@.>^I+F%5817VM9-[TWO]@!/26 M72L].#(8Z'0_R14\UI*T/PG#Q?+4NL/S]*JA-
YJRO)8W[40Z]*)).NKZ:DCC MH;O5E5"]M#RU^_(2*"^@KCUW3I>..F.K^'ZXB+R[/FT2VI816 E5[Q!CX:)H M;F*"MO)HHG5+MQ@=HCC(YR<-8M6:-@
(:>U:T4!0Y#F@>Y18;A"Y\6)\S18+C>SH6-[ICO2UQQ?S7:G6HTG MQT&H$@S5)FI""7=Z3IWTR+I! 1UQO?&_TVW!.%BV1"\56ZL,O+-N1<#,48;
MQC"R-.QZ-L4#G[L+ T!E\M> T!_O5 MG^-ZD

>Y[Z5M5/\6DC\J MFFWSP8*F_W7+"D]PTJJ&>9^_@"9TRHH>-03I!FRCB:GE"ZMR#G$_U*
(LA"6RW#U4)Q\0KV=0 M/T^N)^3K"MPW/!!U3Z84/-9<^;I9@NIS\[$W1+ZLQ%_" U$SOP4. 5]J=H:6
M>?>'#,L^& 1U!WDYQ:/DT50%2:_]+\FA2M)!>3ADJTZ)K>FIY2<+BN[GL"0W
MF433.H&W__GW9W,9/GYQ?CRQOK];S;ZLG;OS\.'7=]])NW^]^NMNLO;M M=ROS^['']>W 4C-
'OW]^]_OKXTKP.CO^XO'PU_M?1ZO'T[,OQRAI[QM?WKX,? M;__E]/90_#[\/)H?7LRF4W-
Q?'OW\Q/P5_V[ )]N1X_O+O^\(^3R;?_AQ?'*]_/'GS9OSY[N+3 MV=O?/OY^?+?_.;V\AMZ@S[//X9??
_O'^I-S-[Q=!J.;:7!^OGQS].7XZG1T M_WH>_C8^>?G5=8WYER_WRX]CLJ^WJ_O?
_A&>++WPW>.UXWY[.[W]_MN;RY?3X2(\L7^['[X_>AVN+H?^YS^LKT=_77XR M?QV=B*&#?
AR@O;!@KZ;F#XI=0^G4L=5E[1*I0>5 MCY*PU5EP[/[5<_W6/"
(QL*X^CFM\7W4D!':!R[30"!=A7(Z+MOFAY&<;)6W) M!@O:JCL>]\W<#G1A;+1$UR-E2K
M.4B781!ZZ -V\")&0$HM'ULNN&@Y4#8A&26Y :T-3G9I*/*BF" MD,-!MTVB6D38Q(?SR3;E^BL
M3^$0LUSB907;]=4GC G1HFS!N)LH3?EU':J9%%2B5,/26II8?R;SY?N51-/' MS1U\E-
27E,/0VLB%1X9SM"9[:JHX=$B@4AL(2,9[^FVRX7)GQVR]"M'20OZ^2ZBILM*KRH"W T
M.ULDK^DBN6!Z2S2QH2-DE%S0)0 Z<^98@EMB*.<(!-+4BASU1=*P5%7YW\[Z
MNH<,B%"]2!SYBWV%O'M76MUE4!&SJ$J_J+NVG8<)Y3O6<<]G,!$SKDJ_V#/: M%VTLB)
[$4K07M+,87^V!_F%M&JIH45KU7+JA)\>!S#<[\<+@)']VPV EA[+$ MQRM)\<]\LU?$SVPX(?
Y;/>7U92:V@C<&&TZOWA@5Y)*_0AJ_,9Y.I\=:<:WO MTR@132_:MQVC@)B\7A<*?
B6N7:B'<1ZU3'"E#064!:?7>.(+M=6R-D<_>8%? M(@^[UH63*])3PN4_C[7P>:\X36D(5U
QN6+1^29V$>W'C:S\=-D:N'+-AA? MB\.>2$,]K;4T<;IX7&(O(F?&]N4R\?B;))XO&;"7#N-*-^%?. M;71[?
T*4%,@:$.O5F*&5;N76E1S37"3"\Q5=-!B)FAFQNX#\E 8;2TJ)\3>1\,.T0<4 MS%U+479H!OHG
IU.^;UR)@7HDAFCHJL+6]CE@[+/46!@VV]&X^HM*H#;9(AM MG09F*=#"R6OKRJM'2(?
9U/A<4,6E1"9;GV_F>\&?(\HM7F\W^4)&,LB_ME*1 M7TL+8]7I"E)S2(8]?+K:;+(
M*\FWLV,]#K(($>,1EO2Y]3I)^OR.H0M:]T>M0IHW&G,O, MVVS]&N 5.7:1P14'=U2Y$A-(D9\DAB3K-
JQ829F+L(9.(.Y %@QPXS(A6DC, M:@]_1U;4HRXS9YOV-?9S89'HM=*N.[QDII=A/7R+N(.9,J?%M??)F-
W;"+' M\+ +Y 8L7U>7@PE(-Z0/>P;1,@R4XT6RVIWCD_L(3S&R^$OEZOC!7%O/&ZU6
M]C:T9A.%41[73[E2K>?

[Z!?)YZH,5H2JE&R7KO(FN\0*0UZ3,]I+\E4RR:KSAKD@P$S^MQ43=%ULV7^6-N5)YU2RM M74]B
\+Z62F#RX&\B0&@HZ5W&?TV^LEGW#Y73N8S?'Z"MI#IH%L:4H3;8ZJ. MRG>9W6V13G-@2V8%
DHE"UXGG4[\&ORK3.G0CR%7DCPH#'9 M;UNU)6["Y)O(K'O-#5.K-M27;U5?D]=<@(8M[%'#4M
@XI#8G@O^^ P=OT MM;@I1.N*&X"!T/ZKZG;YFXCPB:[9E!&1KGP_1-9YZ&%G%I^[> ,9"K*]V 'Z
MX0HCL/(LMVKH!-7+9U^$&^(Z 6S0T:ZKQG5B0S$>PGOE$,D)(V=69RL# M15#N9,Q46YV*M3%
[1$50&P:(]F^3PBQ(CH2[?I?(Z\5[?F]:J17\C]$^\TY=_GP!!;#W25*5\4?"
M]&@S6BI]\.+=,B)E/=;4HOO:IT/0/>KJ&?[4IBG7'0^_H.7^+/-2O):O["UZ M\;MU(_";8MV1>7##_?
DN4"0O\G7&C)!O.[&OC X@_YL$]:BK*R%"31!,+@:6 M 3HH RH9#.-
>5J(9"Y_O4(B:$!$R/H!M]^+G0!DC4"8J^ (1,T[1TSCAYRG- M8Q)3]VH&,3V/87H>P_0\ANEY#)..-
&^N7+;3=3&;34%JA0H,.YZ@(7S]*.6F MAD[-WY'GWKK8"6Z(Y3M15[(T2G3)'?
G[E.%&4(#9L.B'RE0FA;WL'^:MZV M10%X5FA7"Y>
[]ZA[..2E0R]$H^3'9LFF[H!+2+LVMC$R,_\5:R$SGE&B(4 MX)1G;C;OCL &)!PAE*4=?
^YF4Q@-7D]GO9ATOR!*78C=$L*N<"MG/8<#1;-P(F7Y:M%70#C,I*V;"&/[\\OS]]
M!4R>M=>Q+:97W+(CY M?EW/66 G&+F&-3:<\M80 -!H[*I:$+G^(-ZT *HQ:@7M$6-
UKRRJ2>GCJ*U3;V?1RFI .>1@C\I;N[MNN8W4$->%FBEI=+L%GDFI=L,#:
<#QR':EB)SY9A>M"NNJZ1N#:U7M1R3:LFB M.
[>T3!/0/='7^(@\PUO0JSEP>JL%%:C5/#'ALBWE^OW3W*3A],ZG!2@H&-X3 MV\"AS1TO'LW($T.42!
[]:VS<8QL':V!!:())GV_>1AS0F1:91RJ]=("E@@&D MUTJ!13BX5$#EK?%HM>?#;+8>@]?
AP"G&4@@TSR3LV-:G(7 M"]>))$K)1*OB^II[G8A2OH1 $L=E,_M =M#&SE7RR:"YZ\'0BVQE!6J/#4>3
M)TA U@KP+4L+%=^3.QOZ\YGJGIQ4394[!LL
MQU#JV6'09MP1WOEQ2%>^'U+_U(0<&I^\H0C>T*\0$=!:?7^UW)6C)GB063@Q MT43(\B_)7L_1?
7"#@N&4(FHX)CIS?7 O'P? ?K"9AW*:YYA>HYEA7Z+="!Q M("==MQ^LRM!!4PPF5PD^G-*!X
0XG:=K)28)7Y249YVNWX)NE$C:^ TI,41Z?9'6CK8I1 M O90412FK 8&/+0+:!37-FK9\O",8I?
F@O#KGY]1A60'>X.)3M_2U_AA8X@0 M*M\8"Q5C4W)+=[#S-M/IEZ>)KM!VBH62J,#.XEI?
I64B6,8.AK=?J(#CP9W, MW= W'&O@6)N.\^DD3YI\BE>(A2IZ1!=5+<1RR*X.'5T]#FF_18F.* NPRO'
MPBMLA88-U+ZF?-U.SFHJ[5C#H$O;A2BEJ'S"P7R$[&@/_APO)^X%D:=@S:_? M1)E7
U&+TJN57B8KZ^@GGP%RXSIHL;3=-4+GV$,F^80OH/\JOJ[#1..B<-66 M-0<8HFZ#$_)!!299?
NU^Z#4&72!"L&K:@OJL%I+;'3B64NM."8I:;<320R'4
MUU.**TT22SY@&_D!T3.GKA/ZMYX[\XS2GE@,M5KU?;V).TQF5&Y9ZTP,JG&R M@L$R\6'\V
Q('>4:%Y$T!V9'1*X\; ;(BK"\!U.SO4>LBY0WZEG)'/88,*
M_F5RVL^,)0X,.T:7Z!'DK9!UZ7J781!Z*,W3@.L7"] M@-**EBM?HBC]$%CH^.$^#8D2X
.LF:3H1R!3D[C;/W-P&".?'9HX=4@%"6BZ?K$[)PB3.U./T'L5Y](MNBLSK$A1]1)[S_4Z$H)-D +@ZQE]5-
AV,\YN%]%:= H[KDUHY:]BE"!SZE_55')>A? PF*N)9%<#W',9 M$2%]*AS:!N8,
[.COR"JGR\4C_1'ZFN,$^G1B@+Q<2,5%5SZ%M+F8)H/[@1=& M=VXD_Y.YX227[& V\]",D" _'CGC-
NO*JP%B*T]% VH5E_2P0/0@:#>T6;M] M<6]R.\5YNO;V-$)AW:+YYGR!](Y06;I,DR)P5'%-
:Y3H1LA^D,,WGUXZ/R:! M.-B%N&EHK:B<60RVN"U03TW^$F?>M61?/Y&<9X 4CA=42W4F'-U-
"F0$D>H< M;B[K+$(./7,>39]*<;UX-.V0:K%KUYD1);/8_DE%I;(P?"UVG^"!S=70BE.X
M_9'W4LBJ*8^6P$"GZ2)]@*1EI'G5X3FB[1R)V8]F7DPK\A*(K!^!(IG:1?0Z MQQOQI9Y
P+.K^J'**DP!F"'RC736\-[&LXB"BE12!H!NMUJM45:F7;($@NSA
MJO+=$95=TY>8%ZPSO4AK'QURE4[EL!0],FK!"=<]UA"+_TW!M9!D4AQC;57/
MBEIP>]\I7IFCYYF/O9#&8XL$$9'=?-E=G3CILZ;'!M%JY%XES\9/Q@P^:6=W M>9UV,.^QWND^O4.?
SEQ+$00?F3_,W-61A7 ,Q'+-R/EW=.:NMF;RSN43#,Q+3%?;6]D=6QA#,Q+3)?;6]D=6QA#,R+3%?;6]D
M=6QA&UL4$L! A0#% @ M8!N62AM[2M:*0 $XX" !4 (! M\,X &UO9&0M,C R-# Y,S!?9&5F+GAM;%!+
0(4 Q0 (+6 ;EG-*IPU MK& &/&UL4$L%!@) D XML 56 ea0220455-10q_modular_htm.xml IDEA:
XBRL DOCUMENT 0001074871 2024-04-01 2024-09-30 0001074871 2024-11-13 0001074871 2024-
09-30 0001074871 2024-03-31 0001074871 2024-07-01 2024-09-30 0001074871 2023-07-01 2023-
09-30 0001074871 2023-04-01 2023-09-30 0001074871 us-gaap:CommonStockMember 2024-03-31
0001074871 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001074871 us-
gaap:RetainedEarningsMember 2024-03-31 0001074871 us-gaap:CommonStockMember 2024-04-
01 2024-06-30 0001074871 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30
0001074871 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001074871 2024-04-01
2024-06-30 0001074871 us-gaap:CommonStockMember 2024-06-30 0001074871 us-
gaap:AdditionalPaidInCapitalMember 2024-06-30 0001074871 us-gaap:RetainedEarningsMember
2024-06-30 0001074871 2024-06-30 0001074871 us-gaap:CommonStockMember 2024-07-01 2024-
09-30 0001074871 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001074871
us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001074871 us-
gaap:CommonStockMember 2024-09-30 0001074871 us-gaap:AdditionalPaidInCapitalMember
2024-09-30 0001074871 us-gaap:RetainedEarningsMember 2024-09-30 0001074871 us-
gaap:CommonStockMember 2023-03-31 0001074871 us-gaap:AdditionalPaidInCapitalMember
2023-03-31 0001074871 us-gaap:RetainedEarningsMember 2023-03-31 0001074871 2023-03-31
0001074871 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001074871 us-
gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001074871 us-
gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001074871 2023-04-01 2023-06-30
0001074871 us-gaap:CommonStockMember 2023-06-30 0001074871 us-
gaap:AdditionalPaidInCapitalMember 2023-06-30 0001074871 us-gaap:RetainedEarningsMember
2023-06-30 0001074871 2023-06-30 0001074871 us-gaap:CommonStockMember 2023-07-01 2023-
09-30 0001074871 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001074871

us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001074871 us-gaap:CommonStockMember 2023-09-30 0001074871 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001074871 us-gaap:RetainedEarningsMember 2023-09-30 0001074871 2023-09-30 0001074871 srt:MinimumMember 2024-09-30 0001074871 srt:MaximumMember 2024-09-30 0001074871 us-gaap:StockOptionMember 2024-04-01 2024-09-30 0001074871 us-gaap:StockOptionMember 2023-04-01 2023-09-30 0001074871 modd:UnvestedRestrictedStockUnitsMember 2024-04-01 2024-09-30 0001074871 modd:UnvestedRestrictedStockUnitsMember 2023-04-01 2023-09-30 0001074871 us-gaap:WarrantMember 2024-04-01 2024-09-30 0001074871 us-gaap:WarrantMember 2023-04-01 2023-09-30 0001074871 us-gaap:MachineryAndEquipmentMember 2024-09-30 0001074871 us-gaap:MachineryAndEquipmentMember 2024-03-31 0001074871 us-gaap:ComputerEquipmentMember 2024-09-30 0001074871 us-gaap:ComputerEquipmentMember 2024-03-31 0001074871 us-gaap:ConstructionInProgressMember 2024-09-30 0001074871 us-gaap:ConstructionInProgressMember 2024-03-31 0001074871 us-gaap:LeaseholdImprovementsMember 2024-09-30 0001074871 us-gaap:LeaseholdImprovementsMember 2024-03-31 0001074871 us-gaap:OfficeEquipmentMember 2024-09-30 0001074871 us-gaap:OfficeEquipmentMember 2024-03-31 0001074871 modd:ThornmintRoadSanDiegoCAMember 2024-09-30 0001074871 2023-02-01 2023-02-01 0001074871 2023-02-01 0001074871 2023-11-30 2023-11-30 0001074871 us-gaap:WarrantMember 2023-04-01 2024-03-31 0001074871 us-gaap:WarrantMember us-gaap:CommonStockMember 2024-04-01 2024-09-30 0001074871 us-gaap:WarrantMember us-gaap:CommonStockMember 2023-04-01 2023-09-30 0001074871 us-gaap:WarrantMember 2024-03-31 0001074871 us-gaap:WarrantMember 2024-04-01 2024-06-30 0001074871 us-gaap:WarrantMember 2024-06-30 0001074871 us-gaap:WarrantMember modd:WarrantOneMember 2024-07-01 2024-09-30 0001074871 us-gaap:WarrantMember modd:WarrantTwoMember 2024-07-01 2024-09-30 0001074871 us-gaap:WarrantMember modd:WarrantThreeMember 2024-07-01 2024-09-30 0001074871 us-gaap:WarrantMember 2024-09-30 0001074871 us-gaap:WarrantMember us-gaap:CommonStockMember 2024-03-31 0001074871 us-gaap:WarrantMember us-gaap:CommonStockMember 2023-04-01 2024-03-31 0001074871 us-gaap:WarrantMember modd:CommonStockOneMember 2024-03-31 0001074871 us-gaap:WarrantMember modd:CommonStockOneMember 2023-04-01 2024-03-31 0001074871 us-gaap:WarrantMember modd:CommonStockTwoMember 2024-03-31 0001074871 us-gaap:WarrantMember modd:CommonStockTwoMember 2023-04-01 2024-03-31 0001074871 us-gaap:WarrantMember modd:CommonStockThreeMember 2024-03-31 0001074871 us-gaap:WarrantMember modd:CommonStockThreeMember 2023-04-01 2024-03-31 0001074871 us-gaap:WarrantMember modd:CommonStockFourMember 2024-03-31 0001074871 us-gaap:WarrantMember modd:CommonStockFourMember 2023-04-01 2024-03-31 0001074871 us-gaap:WarrantMember modd:CommonStockFiveMember 2024-03-31 0001074871 us-gaap:WarrantMember modd:CommonStockFiveMember 2023-04-01 2024-03-31 0001074871 modd:TwoThousandAndSeventeenEquityIncentivePlanMember 2017-10-31 2017-10-31 0001074871 modd:TwoThousandAndSeventeenEquityIncentivePlanMember 2020-01-31 0001074871 modd:TwoThousandAndSeventeenEquityIncentivePlanMember 2021-08-31 0001074871 modd:TwoThousandAndSeventeenEquityIncentivePlanMember 2023-01-31 0001074871 modd:TwoThousandAndSeventeenEquityIncentivePlanMember 2024-02-28 0001074871 modd:MilestoneBonusProgramMember 2023-10-31 2023-10-31 0001074871 2024-01-31 2024-01-31 0001074871 2024-08-31 2024-08-31 0001074871 us-gaap:StockCompensationPlanMember 2024-04-01 2024-09-30 0001074871 us-gaap:StockCompensationPlanMember 2023-04-01 2023-09-30 0001074871 us-gaap:StockCompensationPlanMember 2024-07-01 2024-09-30 0001074871 us-gaap:StockCompensationPlanMember 2023-07-01 2023-09-30 0001074871 modd:NonemployeeDirectorsMember 2024-07-01 2024-09-30 0001074871 modd:NonemployeeDirectorsMember 2023-07-01 2023-09-30 0001074871 modd:NonemployeeDirectorsMember 2024-04-01 2024-09-30 0001074871 modd:NonemployeeDirectorsMember 2023-04-01 2023-09-30 0001074871 us-gaap:RestrictedStockUnitsRSUMember 2024-09-30 0001074871 srt:MinimumMember 2024-07-01 2024-09-30 0001074871 srt:MaximumMember 2024-07-01 2024-09-30 0001074871 srt:MinimumMember 2023-07-01 2023-09-30 0001074871 srt:MaximumMember 2023-07-01 2023-09-30 0001074871 srt:MinimumMember 2024-04-01 2024-09-30 0001074871 srt:MaximumMember 2024-04-01 2024-09-30 0001074871 srt:MinimumMember 2023-04-01 2023-09-30 0001074871 srt:MaximumMember 2023-04-01 2023-09-30 0001074871 us-gaap:RestrictedStockUnitsRSUMember 2024-03-31 0001074871 us-gaap:RestrictedStockUnitsRSUMember 2024-04-01 2024-06-30 0001074871 us-gaap:RestrictedStockUnitsRSUMember 2024-06-30 0001074871 us-gaap:RestrictedStockUnitsRSUMember 2024-07-01 2024-09-30 0001074871 srt:MinimumMember modd:zeroPointNineThreeToTwoPointTwoEightMember 2024-09-30 0001074871 srt:MaximumMember modd:zeroPointNineThreeToTwoPointTwoEightMember 2024-09-30 0001074871 modd:zeroPointNineThreeToTwoPointTwoEightMember 2024-09-30 0001074871 modd:zeroPointNineThreeToTwoPointTwoEightMember 2024-04-01 2024-09-30 0001074871

srt:MinimumMember modd:ThreePointNineFiveToSevenPointFiveOneMember 2024-09-30 0001074871 srt:MaximumMember modd:ThreePointNineFiveToSevenPointFiveOneMember 2024-09-30 0001074871 modd:ThreePointNineFiveToSevenPointFiveOneMember 2024-09-30 0001074871 modd:ThreePointNineFiveToSevenPointFiveOneMember 2024-04-01 2024-09-30 0001074871 srt:MinimumMember modd:EightPointSixOneToSeventeenPointSevenZeroMember 2024-09-30 0001074871 srt:MaximumMember modd:EightPointSixOneToSeventeenPointSevenZeroMember 2024-09-30 0001074871 modd:EightPointSixOneToSeventeenPointSevenZeroMember 2024-09-30 0001074871 modd:EightPointSixOneToSeventeenPointSevenZeroMember 2024-04-01 2024-09-30 0001074871 srt:MinimumMember modd:ZeroPointNineThreeToSeventeenPointSevenZeroMember 2024-09-30 0001074871 srt:MaximumMember modd:ZeroPointNineThreeToSeventeenPointSevenZeroMember 2024-09-30 0001074871 modd:ZeroPointNineThreeToSeventeenPointSevenZeroMember 2024-09-30 0001074871 modd:ZeroPointNineThreeToSeventeenPointSevenZeroMember 2024-04-01 2024-09-30 0001074871 modd:DeviceIntegrationAgreementMember 2024-09-30 shares iso4217:USD iso4217:USD shares modd:segment pure 10-Q true 2024-09-30 false 000-49671 MODULAR MEDICAL, INC. NV 87-0620495 10740 Thornmint Road San Diego CA 92127 (858) 800-3500 Common Stock Par Value $.001 per Share MODD NASDAQ Yes No Non-accelerated Filer true false false 34571939 3893000 9232000 283000 465000 4176000 9697000 3641000 2975000 954000 1135000 8771000 13807000 501000 802000 345000 280000 398000 373000 1244000 1455000 611000 817000 1855000 2272000 0.001 0.001 5000000 5000000 0.001 0.001 100000000 100000000 34370000 34370000 32464000 32464000 34000 32000 81904000 77432000 -75022000 -65929000 6916000 11535000 8771000 13807000 3702000 3159000 6907000 5927000 1294000 1031000 2309000 2014000 4996000 4190000 9216000 7941000 -4996000 -4190000 -9216000 -7941000 42000 9000 125000 23000 -4954000 -4181000 -9091000 -7918000 2000 2000 2000 2000 -4956000 -4183000 -9093000 -7920000 -0.14 -0.14 -0.19 -0.19 -0.27 -0.27 -0.4 -0.4 34338000 34338000 22445000 22445000 34114000 34114000 19786000 19786000 32464000 32000 77432000 -65929000 11535000 10000 15000 15000 55000 68000 68000 32000 6000 6000 529000 529000 -4137000 -4137000 32561000 32000 78050000 -70066000 8016000 20000 35000 35000 939000 1000 844000 845000 825000 1000 1922000 1923000 25000 9000 9000 1044000 1044000 -4956000 -4956000 34370000 34000 81904000 -75022000 6916000 10949000 11000 53524000 -48459000 5076000 10139000 10000 9723000 9733000 7000 6000 6000 478000 478000 -3737000 -3737000 21095000 21000 63731000 -52196000 11556000 2000 1000 1000 27000 7000 7000 557000 557000 -4183000 -4183000 21124000 21000 64296000 -56379000 7938000 -9093000 -7920000 1588000 1048000 456000 153000 26000 11000 -64000 -105000 182000 168000 -355000 137000 -182000 -186000 -7314000 -6484000 1003000 718000 -1003000 -718000 1923000 1055000 9733000 2978000 9733000 -5339000 2531000 9232000 3799000 3893000 6330000 NOTE 1 – THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES   Modular Medical, Inc. (the Company) was incorporated in Nevada in October 1998 under the name Bear Lake Recreation, Inc. The Company had no material business operations from 2002 until approximately 2017 when it acquired all of the issued and outstanding shares of Quasuras, Inc., a Delaware corporation (Quasuras), and changed its name from Bear Lake Recreation, Inc. to Modular Medical, Inc.   The Company is a pre-revenue, medical device company focused on the design, development and eventual commercialization of innovative insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. Through the creation of an innovative two-part patch pump, its initial product, the MODD1, the Company seeks to fundamentally alter the trade-offs between cost and complexity and access to the higher standards of care requiring considerable motivation that presently available insulin pumps provide. By simplifying and streamlining the user experience from introduction, prescription, reimbursement, training and day-to-day use, the Company seeks to expand the wearable insulin delivery device market beyond the highly motivated “super users” and expand the category into the mass market. The product seeks to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets. In January 2024, the Company submitted a 510(k) premarket notification to the United States Food and Drug Administration (FDA) for the MODD1, and, in September 2024, the Company received FDA clearance to market and sell its MODD1 pump in the United States.   Liquidity and Going Concern   The Company does not currently have revenues to generate cash flows to cover operating expenses. Since its inception, the Company has incurred operating losses and negative cash flows in each year due to costs incurred in connection with its operations. The Company expects to continue to incur operating losses for the foreseeable future and incur cash

outflows from operations as it continues to invest in the development and commercialization of its products. The Company expects that its research and development and general and administrative expenses will continue to increase, and, as a result, it will eventually need to generate significant revenue to achieve profitability. When considered with its current operating plan, these conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that these financial statements are issued. In addition, the Company's independent registered public accounting firm, in its report on the consolidated financial statements as of and for the year ended March 31, 2024, expressed substantial doubt about the Company's ability to continue as a going concern. These condensed consolidated financial statements do not include any adjustments that might result from this uncertainty. Implementation of the Company's plans and its ability to continue as a going concern will depend upon the Company's ability to raise additional capital, through the sale of additional equity or debt securities, to support its future operations. There can be no assurance that such additional capital, whether in the form of debt or equity financing, will be sufficient or available and, if available, that such capital will be offered on terms and conditions acceptable to the Company. The Company's operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital expenditures. The Company's future capital requirements and the adequacy of its available funds will depend on many factors, including the Company's ability to successfully commercialize its MODD1 product, competing technological and market developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement its product offering. If the Company is unable to secure additional capital, it may be required to curtail its product commercialization and research and development initiatives and take additional measures to reduce costs in order to conserve its cash. Basis of Presentation   The Company's fiscal year ends on March 31 of each calendar year. Each reference to a fiscal year in these notes to the condensed consolidated financial statements refers to the fiscal year ended March 31 of the calendar year indicated (for example, fiscal 2025 refers to the fiscal year ending March 31, 2025). The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Quasuras. All significant intercompany transactions and balances have been eliminated in consolidation.   The accompanying condensed consolidated financial statements are unaudited and have been prepared in accordance with generally accepted accounting principles in the United States (GAAP) and with the rules and regulations of the United States Security and Exchange Commission (SEC) regarding interim financial reporting. The condensed consolidated balance sheet as of March 31, 2024 has been derived from the audited consolidated financial statements at that date. Certain information and disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted in accordance with these rules and regulations of the SEC. The information in this report should be read in conjunction with the Company's consolidated financial statements and notes thereto included in its most recent annual report on Form 10-K filed with the SEC.   In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company's financial position, results of operations and cash flows for the interim periods presented. The operating results for the six months ended September 30, 2024 are not necessarily indicative of the results that may be expected for the year ending March 31, 2025 or for any other future period.   Use of Estimates   The preparation of the accompanying condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of revenues and expenses during the reporting period. Estimates may include those pertaining to accruals, stock-based compensation and income taxes. Actual results could differ from those estimates.   Reportable Segment   The Company operates in one business segment and uses one measurement of profitability for its business. <p style="font:

10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Research and Development   The Company expenses research and development expenditures as incurred.   Concentration of Credit Risk   Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash held in demand deposit accounts. The Company maintains a portion of its cash in demand deposit accounts at high credit quality financial institutions within the United States, which are insured by the Federal Deposit Insurance Corporation (FDIC) up to limits of approximately $250,000. No reserve has been made in the financial statements for any possible loss due to financial institution failure. Risks and Uncertainties   The Company is subject to risks from, among other things, competition associated with the industry in general, other risks associated with financing, liquidity requirements, rapidly changing customer requirements, limited operating history, pandemics, wars and acts of terrorism and the volatility of public markets. The Company may be unable to access the capital markets, and additional capital may only be available to the Company on terms that could be significantly detrimental to its existing stockholders and to its business.   Cash and Cash Equivalents   Cash and cash equivalents include cash held in demand deposit and money market accounts, certificates of deposit and all highly liquid debt instruments with original maturities of three months or less.   Property and Equipment   Property and equipment are recorded at historical cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally three to five years. Depreciation is recorded in operating expenses in the consolidated statements of operations. Leasehold improvements and assets acquired through finance leases are amortized over the shorter of their estimated useful life or the lease term, and amortization is recorded in operating expenses in the consolidated statements of operations. Construction-in-process includes machinery and equipment and is stated at cost and not depreciated. Depreciation on construction-in-process commences when the assets are ready for their intended use and placed into service.   Fair Value of Financial Instruments   The Company measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"> ●</td><td style="text-align: justify">Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.</td> </tr></table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 0.25in">●</td> <td style="text-align: justify"> Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.</td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"> <tr

style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 0.25in">●</td> <td style="text-align: justify">Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.</td></tr> </table>   Due to their short-term nature, the carrying values of cash equivalents, accounts payable and accrued expenses, approximate fair value.   Leases   The Company's right-of-use assets consist of leased assets recognized in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) No. 842, Leases, which requires lessees to recognize a lease liability and a corresponding lease asset for virtually all lease contracts. Right-of-use assets represent the Company's right to use an underlying asset for the lease term and the lease liability represents the Company's obligation to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the consolidated balance sheets and are expensed on a straight-line basis over the lease term in the consolidated statement of operations and comprehensive loss. The Company determines the lease term by agreement with the lessor. In cases where the lease does not provide an implicit interest rate, the Company uses the Company's incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. Stock-Based Compensation   The Company periodically issues stock options, restricted stock units and stock awards to employees and non-employees. The Company accounts for such awards based on FASB ASC Topic 718, whereby the value of the award is measured on the date of grant and recognized as compensation expense on a straight-line basis over the requisite service period, usually the vesting period. With respect to performance-based awards, the Company assesses the probability of achieving the requisite performance criteria before recognizing compensation expense. The fair value of the Company's stock options is estimated using the Black-Scholes-Merton Option Pricing (Black Scholes) model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the options, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes model. The assumptions used in the Black-Scholes model could materially affect compensation expense recorded in future periods.   Per-Share Amounts   Basic net loss per share is computed by dividing loss for the period by the weighted-average number of shares of common stock outstanding (WASO) during the period. In addition, the Company includes the number of shares of common stock issuable under pre-funded warrants as outstanding for purposes of the WASO calculation. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period. Potentially dilutive common shares consist of incremental shares of common stock issuable upon the exercise of stock options and exercise of warrants.   The following table sets forth securities outstanding which were excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive (in thousands).   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"> Six Months Ended
  September 30, </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Options to purchase

common stock</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">4,531</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2,913</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Unvested restricted stock units</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">146</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">229</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Common stock purchase warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,430</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,892</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt; text-indent: -8.65pt; padding-left: 17.3pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">15,107</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">15,034</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   Reclassifications   Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations or cash flows.   Comprehensive Loss   Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may include certain changes in equity that are excluded from net loss. For the three and six months ended September 30, 2024 and 2023, the Company's comprehensive loss was the same as its net loss.   Recently Issued Accounting Pronouncements   In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires disclosure of incremental segment information on an annual and interim basis. ASU No. 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and it requires retrospective application to all prior periods presented in the financial statements. The Company is currently evaluating the impact that this ASU will have on the presentation of its consolidated financial statements.   In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which expands disclosures in an entity's income tax rate reconciliation table and disclosures regarding cash taxes paid both in the U.S. and foreign jurisdictions. The update will be effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact that this ASU will have on the presentation of its consolidated financial statements.   In November 2024, the FASB issued ASU No. 2024-03, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The new standard requires disclosures about specific types of expenses included in the expense captions presented on the face of the income statement as well as disclosures about selling expenses. The standard is effective for the Company for annual periods beginning April 1, 2027 and interim periods beginning April 1, 2028, with early adoption permitted. The standard may be applied either prospectively to financial statements issued for reporting periods after the effective date or retrospectively to any or all prior periods presented in the financial statements. The Company is evaluating the impact that this ASU will have on the presentation of its consolidated financial statements. Liquidity and Going Concern <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:

justify">The Company does not currently have revenues to generate cash flows to cover operating expenses. Since its inception, the Company has incurred operating losses and negative cash flows in each year due to costs incurred in connection with its operations. The Company expects to continue to incur operating losses for the foreseeable future and incur cash outflows from operations as it continues to invest in the development and commercialization of its products. The Company expects that its research and development and general and administrative expenses will continue to increase, and, as a result, it will eventually need to generate significant revenue to achieve profitability. When considered with its current operating plan, these conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that these financial statements are issued. In addition, the Company's independent registered public accounting firm, in its report on the consolidated financial statements as of and for the year ended March 31, 2024, expressed substantial doubt about the Company's ability to continue as a going concern. These condensed consolidated financial statements do not include any adjustments that might result from this uncertainty. Implementation of the Company's plans and its ability to continue as a going concern will depend upon the Company's ability to raise additional capital, through the sale of additional equity or debt securities, to support its future operations. There can be no assurance that such additional capital, whether in the form of debt or equity financing, will be sufficient or available and, if available, that such capital will be offered on terms and conditions acceptable to the Company. The Company's operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital expenditures. The Company's future capital requirements and the adequacy of its available funds will depend on many factors, including the Company's ability to successfully commercialize its MODD1 product, competing technological and market developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement its product offering. If the Company is unable to secure additional capital, it may be required to curtail its product commercialization and research and development initiatives and take additional measures to reduce costs in order to conserve its cash.   Basis of Presentation The Company's fiscal year ends on March 31 of each calendar year. Each reference to a fiscal year in these notes to the condensed consolidated financial statements refers to the fiscal year ended March 31 of the calendar year indicated (for example, fiscal 2025 refers to the fiscal year ending March 31, 2025). The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Quasuras. All significant intercompany transactions and balances have been eliminated in consolidation. The accompanying condensed consolidated financial statements are unaudited and have been prepared in accordance with generally accepted accounting principles in the United States (GAAP) and with the rules and regulations of the United States Security and Exchange Commission (SEC) regarding interim financial reporting. The condensed consolidated balance sheet as of March 31, 2024 has been derived from the audited consolidated financial statements at that date. Certain information and disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted in accordance with these rules and regulations of the SEC. The information in this report should be read in conjunction with the Company's consolidated financial statements and notes thereto included in its most recent annual report on Form 10-K filed with the SEC. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company's financial position, results of operations and cash flows for the interim periods presented. The operating results for the six months ended September 30, 2024 are not necessarily indicative of the results that may be expected for the year ending March 31, 2025 or for any other future period. Use of Estimates The preparation of the accompanying condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of revenues and expenses during the reporting period. Estimates may include those pertaining to accruals, stock-based compensation and income taxes. Actual results could differ from those estimates. Reportable Segment The Company operates in one business segment and uses one measurement of profitability for its business. 1 Research and Development The Company expenses research and development expenditures as incurred. <p

style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash held in demand deposit accounts. The Company maintains a portion of its cash in demand deposit accounts at high credit quality financial institutions within the United States, which are insured by the Federal Deposit Insurance Corporation (FDIC) up to limits of approximately $250,000. No reserve has been made in the financial statements for any possible loss due to financial institution failure. 250000 Risks and Uncertainties The Company is subject to risks from, among other things, competition associated with the industry in general, other risks associated with financing, liquidity requirements, rapidly changing customer requirements, limited operating history, pandemics, wars and acts of terrorism and the volatility of public markets. The Company may be unable to access the capital markets, and additional capital may only be available to the Company on terms that could be significantly detrimental to its existing stockholders and to its business. Cash and Cash Equivalents Cash and cash equivalents include cash held in demand deposit and money market accounts, certificates of deposit and all highly liquid debt instruments with original maturities of three months or less. Property and Equipment Property and equipment are recorded at historical cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally three to five years. Depreciation is recorded in operating expenses in the consolidated statements of operations. Leasehold improvements and assets acquired through finance leases are amortized over the shorter of their estimated useful life or the lease term, and amortization is recorded in operating expenses in the consolidated statements of operations. Construction-in-process includes machinery and equipment and is stated at cost and not depreciated. Depreciation on construction-in-process commences when the assets are ready for their intended use and placed into service. P3Y P5Y Fair Value of Financial Instruments The Company measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.</td> </tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 0.25in">●</td> <td style="text-align: justify">Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. </td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 0.25in">●</td> <td style="text-align: justify">Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.</td></tr> </table> Due to their short-term nature, the carrying values of cash equivalents, accounts payable and accrued expenses, approximate fair value. Leases The Company's right-of-use assets consist of leased assets recognized in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) No. 842, Leases, which requires lessees to recognize a lease liability and a corresponding lease asset for virtually all lease contracts. Right-of-use assets represent the Company's right to use an underlying asset for the lease term and the lease liability represents the Company's obligation to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at

inception are not recorded on the consolidated balance sheets and are expensed on a straight-line basis over the lease term in the consolidated statement of operations and comprehensive loss. The Company determines the lease term by agreement with the lessor. In cases where the lease does not provide an implicit interest rate, the Company uses the Company's incremental borrowing rate based on the information available at commencement date in determining the present value of future payments.   Stock-Based Compensation The Company periodically issues stock options, restricted stock units and stock awards to employees and non-employees. The Company accounts for such awards based on FASB ASC Topic 718, whereby the value of the award is measured on the date of grant and recognized as compensation expense on a straight-line basis over the requisite service period, usually the vesting period. With respect to performance-based awards, the Company assesses the probability of achieving the requisite performance criteria before recognizing compensation expense. The fair value of the Company's stock options is estimated using the Black-Scholes-Merton Option Pricing (Black Scholes) model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the options, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes model. The assumptions used in the Black-Scholes model could materially affect compensation expense recorded in future periods. Per-Share Amounts Basic net loss per share is computed by dividing loss for the period by the weighted-average number of shares of common stock outstanding (WASO) during the period. In addition, the Company includes the number of shares of common stock issuable under pre-funded warrants as outstanding for purposes of the WASO calculation. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period. Potentially dilutive common shares consist of incremental shares of common stock issuable upon the exercise of stock options and exercise of warrants. The following table sets forth securities outstanding which were excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive (in thousands). <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"> Six Months Ended
  September 30, </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Options to purchase common stock</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">4,531</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2,913</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Unvested restricted stock units</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">146</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td> <td style="text-align: right">229</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Common stock purchase warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,430</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,892</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt; text-indent: -8.65pt; padding-left: 17.3pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">15,107</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">15,034</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The following table sets forth securities outstanding which were excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive (in thousands).<table cellpadding="0" cellspacing="0" style="border-collapse: collapse;

width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"> Six Months Ended
  September 30, </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Options to purchase common stock</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">4,531</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2,913</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Unvested restricted stock units</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">146</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td> <td style="text-align: right">229</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Common stock purchase warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,430</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,892</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt; text-indent: -8.65pt; padding-left: 17.3pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">15,107</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">15,034</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 4531000 2913000 146000 229000 10430000 11892000 15107000 15034000 Reclassifications Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations or cash flows. Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may include certain changes in equity that are excluded from net loss. For the three and six months ended September 30, 2024 and 2023, the Company’s comprehensive loss was the same as its net loss. Recently Issued Accounting Pronouncements In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires disclosure of incremental segment information on an annual and interim basis. ASU No. 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and it requires retrospective application to all prior periods presented in the financial statements. The Company is currently evaluating the impact that this ASU will have on the presentation of its consolidated financial statements. In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which expands disclosures in an entity’s income tax rate reconciliation table and disclosures regarding cash taxes paid both in the U.S. and foreign jurisdictions. The update will be effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact that this ASU will have on the presentation of its consolidated financial statements. In November 2024, the FASB issued ASU No. 2024-03, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The new standard requires disclosures about specific types of expenses included in the expense captions presented on the face of the income statement as well as disclosures about selling expenses. The standard is effective for the Company for annual periods beginning April 1, 2027 and interim periods beginning April 1, 2028, with early adoption permitted. The standard may be applied either prospectively to financial

statements issued for reporting periods after the effective date or retrospectively to any or all prior periods presented in the financial statements. The Company is evaluating the impact that this ASU will have on the presentation of its consolidated financial statements. NOTE 2 – CONSOLIDATED BALANCE SHEET DETAIL   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"> September 30,
  2024 </td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"> March 31,
   2024 </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">(in thousands)</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Property and equipment, net</td> <td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Machinery and equipment</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,540</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,209</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Computer equipment and software</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">66</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">66</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Construction-in-process</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">74</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">283</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Leasehold improvements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">33</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">33</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Office equipment</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">46</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">63</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,759</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,654</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation and amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,118</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(679</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt; padding-left: 9pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,641</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,975</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"> September 30,
  2024 </td><td style="padding-bottom: 1.5pt"> </td><td

style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"> March 31,
  2024 </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">(in thousands)</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Accrued expenses</td><td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Accrued wages and employee benefits</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">265</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">243</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">80</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">37</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; padding-left: 9pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">345</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">280</td><td style="padding-bottom: 2.5pt; text-align: left"> </td> </tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"> September 30,
  2024 </td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"> March 31,
  2024 </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">(in thousands)</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Property and equipment, net</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Machinery and equipment</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,540</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,209</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Computer equipment and software</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">66</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">66</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Construction-in-process</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">74</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">283</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Leasehold improvements</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">33</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">33</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Office equipment</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">46</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">63</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,759</td><td style="text-align:

left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,654</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation and amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,118</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(679</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt; padding-left: 9pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,641</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,975</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 4540000 3209000 66000 66000 74000 283000 33000 33000 46000 63000 4759000 3654000 1118000 679000 3641000 2975000 <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"> September 30,
  2024 </td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"> March 31,
  2024 </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">(in thousands)</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Accrued expenses</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Accrued wages and employee benefits</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">265</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">243</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">80</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">37</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; padding-left: 9pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">345</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">280</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 265000 243000 80000 37000 345000 280000 NOTE 3 - LEASES   Thornmint Road, San Diego, CA   The 48-month lease term commenced February 1, 2023, and the lease provides for an initial base monthly rent of $36,000 with annual rent increases of approximately 4%. In addition to the minimum lease payments, the Company is responsible for property taxes, insurance and certain other operating costs. A discount rate of 8%, which approximated the Company’s incremental borrowing rate, was used to measure the lease asset and liability. The Company obtained a right-of-use asset of approximately $1,560,000 in exchange for its obligations under the operating lease.   Future minimum payments under the facility operating lease, as of September 30, 2024, are listed in the table below (in thousands).   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times,

Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Annual Fiscal Years</td> <td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">2025</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">228</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">470</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">2027</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">405</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Total future lease payments</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,103</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(94</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Present value of lease liability</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,009</td><td style="padding-bottom: 2.5pt; text-align: left"> </td> </tr> </table>   Cash paid for amounts included in the measurement of lease liabilities was approximately $225,000 and $257,000 for the six months ended September 30, 2024 and 2023, respectively. Rent expense was approximately $225,000 for each of the six month periods ended September 30, 2024 and 2023, respectively and $113,000 for each of the three month periods ended September 30, 2024 and 2023.</p> P48M 36000 0.04 0.08 1560000 Future minimum payments under the facility operating lease, as of September 30, 2024, are listed in the table below (in thousands).<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Annual Fiscal Years</td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">2025</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">228</td><td style="width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">470</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">2027</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">405</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Total future lease payments</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,103</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(94</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Present value of lease liability</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,009</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 228000 470000 405000 1103000 94000 1009000 225000 257000 225000 225000 113000 113000 NOTE 4 – STOCKHOLDERS' EQUITY   ATM Offering   In November 2023, the Company entered into a Sales Agreement (the ATM Agreement) with Leerink Partners LLC (Leerink) under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock through an "at the market offering" program under which Leerink will act as sales agent or principal. The ATM Agreement provides that Leerink will be entitled to compensation for its services equal to 3.0% of the gross proceeds from sales of any shares of common stock under the ATM Agreement. The Company has no obligation to sell any shares under the ATM Agreement and may, at any time, suspend solicitation and offers under the ATM Agreement. During the three and six months ended September 30, 2024, under the ATM Agreement, the Company sold 824,514 shares of common

stock for proceeds of approximately $1,933,000, which was net of commissions and legal fees of approximately $82,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Common Stock Purchase Warrants</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2024, the Company had the following common stock purchase warrants outstanding (share amounts in thousands):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of
 Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise
 Price</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Expiration</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 58%">Balance as of March 31, 2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">12,521</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: center"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Warrants exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(55</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">1.22</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: center">May 2028</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance as of June 30, 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,466</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Warrants exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(252</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td> <td style="text-align: right">0.01</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: center">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrants exercised</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">(649</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1.22</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td> <td style="text-align: center">May 2028</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Warrants exercised</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(39</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1.32</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: center">May 2027</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Balance as of September 30, 2024</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">11,526</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: center"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="margin:

0"> As of March 31, 2024, the Company had the following warrants outstanding (share amounts in thousands):   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Type</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">Number of
 Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">Exercise
 Price</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Expiration</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 58%; text-align: left">Common stock</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1,348</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.01</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: center"> </td> <td style="width: 15%; text-align: center">— </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,421</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.22</td><td style="text-align: left"> </td> <td> </td> <td style="text-align: center"> </td><td style="text-align: center">May 2028</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">535</td><td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.32</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td style="text-align: center">May 2027</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">768</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td style="text-align: center">January 2027 - February 2027</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,011</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td> <td style="text-align: right">6.60</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td style="text-align: center">February 2027</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Common stock</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,438</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td> <td style="padding-bottom: 1.5pt; text-align: right">6.60</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center">November 2027</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; padding-left: 0.125in">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">12,521</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 2.5pt; text-align: center"> </td> <td style="padding-bottom: 4pt; text-align: center"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   The outstanding pre-funded warrants with an exercise price of $0.01 per share were included in the weighted average shares outstanding calculation for each of the three and six month periods ended September 30, 2024 and 2023. At March 31, 2024, the Company had a receivable from its transfer agent for approximately $142,000 for the proceeds from warrants exercised prior to March 31, 2024. The receivable was recorded in the prepaid and other line in the consolidated balance sheet at March 31, 2024 and was collected during the three months ended

June 30, 2024.   Other   During the six months ended September 30, 2024 and 2023, the Company issued 30,000 and 1,429 shares of common stock with fair values of approximately $51,000 and $1,400, respectively to service providers.</p> 0.03 824514000 824514000 1933000 1933000 82000 As of September 30, 2024, the Company had the following common stock purchase warrants outstanding (share amounts in thousands):<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of
 Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise
 Price</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Expiration</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 58%">Balance as of March 31, 2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">12,521</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: center"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Warrants exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(55</td><td style="padding-bottom: 1.5pt; text-align: left">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">1.22</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: center">May 2028</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance as of June 30, 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,466</td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Warrants exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(252</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.01</td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: center">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrants exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(649</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1.22</td><td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: center">May 2028</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Warrants exercised</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(39</td><td style="text-align: left">) </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1.32</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: center">May 2027</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Balance as of September 30, 2024</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">11,526</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: center"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td>

</tr> </table>As of March 31, 2024, the Company had the following warrants outstanding (share amounts in thousands):<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Type</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">Number of
 Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">Exercise
 Price</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Expiration</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 58%; text-align: left">Common stock</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1,348</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.01</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: center"> </td><td style="width: 15%; text-align: center">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,421</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1.22</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td style="text-align: center">May 2028</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">535</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.32</td><td style="text-align: left"> </td> <td> </td> <td style="text-align: center"> </td><td style="text-align: center">May 2027</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">768</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td> <td style="text-align: right">6.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td style="text-align: center">January 2027 - February 2027</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,011</td><td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">6.60</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td style="text-align: center">February 2027</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Common stock</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,438</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">6.60</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center">November 2027</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; padding-left: 0.125in">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">12,521</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 2.5pt; text-align: center"> </td><td style="padding-bottom: 4pt; text-align: center"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td> </tr> </table> 12521000 -55000 1.22 May 2028 12466000 -252000 0.01 -649000 1.22 May 2028 -39000 1.32 May 2027 11526000 1348000 0.01 4421000 1.22 May 2028 535000 1.32 May 2027 768000 6 January 2027 - February 2027 4011000 6.6 February 2027 1438000 6.6 November 2027 12521000 0.01 0.01 142000 30000000 1429000 51000 1400 NOTE 5 - STOCK-BASED COMPENSATION   Amended 2017 Equity Incentive Plan   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align:

justify">In October 2017, the Board approved the 2017 Equity Incentive Plan (the Plan), as amended, with 1,000,000 shares of common stock reserved for issuance. In January 2020 and August 2021, the Board approved increases in the number of shares reserved for issuance by 333,334 and 1,333,334 shares, respectively. In January 2023 and February 2024, the Company's stockholders approved increases in the number of shares reserved for issuance under the Plan by an additional 2,000,000 and 3,000,000 shares, respectively. Under the Plan, eligible employees, directors and consultants may be granted a broad range of awards, including stock options, stock appreciation rights, restricted stock, performance-based awards and restricted stock units. The Plan is administered by the Board or, in the alternative, a committee designated by the Board.   Stock-Based Compensation Expense   Stock options granted by the Company generally vest over 36 months and have a 10-year term. As of September 30, 2024, the unamortized compensation cost related to stock options was approximately $1,763,000 and is expected to be recognized as expense over a weighted-average period of approximately 1.8 years.   In October 2023, under its Two-Part FDA Submission and Clearance Milestone Bonus Program (the Bonus Program), the Company granted stock options to purchase 909,533 shares of common stock, which were subject to vesting based upon the achievement of certain performance milestones by the Company and continued service by the optionees. In January 2024, options to purchase 625,326 shares (net of forfeitures), which were granted under part one of the Bonus Program, vested upon the Company's submission to the FDA. In August 2024, options to purchase 242,307 shares (net of forfeitures), which were granted under part two of the Bonus Program, were canceled, as the Company did not receive clearance from the FDA for its MODD1 product by August 1, 2024. In August 2024, the Company granted new options to purchase 339,298 shares (the Clearance Options), which were subject to vesting based upon the Company's receipt of clearance from the FDA for its MODD1 product by December 31, 2024 and continued service by the optionees. The Clearance options vested in full in September 2024 upon the Company's receipt of clearance from the FDA for its MODD1 product.   The weighted-average grant date fair value of options granted was $1.41 and $1.00 per share for the six months ended September 30, 2024 and 2023, respectively, and $1.51 and $1.02 for the three months ended September 30, 2024 and 2023, respectively. The following assumptions were used in the fair-value method calculations: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"> Three Months Ended September 30, </td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Six Months Ended
 September 30,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rates</td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="text-align: center">3.4% - 4.1% </td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="text-align: center">4.4% - 4.6%</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td

style="text-align: center">3.5% - 4.4%</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="text-align: center">3.5% - 4.6%</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; width: 52%">Volatility</td><td style="text-align: center; width: 1%"> </td> <td style="width: 1%; text-align: center"> </td><td style="width: 9%; text-align: center">114% - 117%</td><td style="width: 1%; text-align: center"> </td><td style="text-align: center; width: 1%"> </td> <td style="width: 1%; text-align: center"> </td><td style="width: 9%; text-align: center">127%</td><td style="width: 1%; text-align: center"></td><td style="text-align: center; width: 1%"> </td> <td style="width: 1%; text-align: center"> </td><td style="width: 9%; text-align: center">114% - 123%</td><td style="width: 1%; text-align: center"> </td><td style="text-align: center; width: 1%"> </td> <td style="width: 1%; text-align: center"> </td><td style="white-space: nowrap; width: 9%; text-align: center">82.6% - 152.2%</td><td style="width: 1%; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected life (years)</td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="text-align: center">5.0 - 5.7</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="text-align: center">5.0 – 5.7</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="text-align: center">5.0 – 5.7</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="text-align: center">5.0 – 6.2</td><td style="text-align: center"> </td></tr> </table>   The fair values of options at the grant date were estimated utilizing the Black-Scholes valuation model, which includes simplified methods to establish the fair term of options, as well as average volatility. The risk-free interest rate was derived from the Daily Treasury Yield Curve Rates, as published by the U.S. Department of the Treasury as of the grant date for terms equal to the expected terms of the options. A dividend yield of zero was applied because the Company has never paid dividends and has no intention to pay dividends in the foreseeable future. The Company accounts for forfeitures as they occur.   The following table summarizes the activity in the shares available for grant under the Plan during the six months ended September 30, 2024:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: right"> </td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td> <td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Available</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">for Grant</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom:

Black 1.5pt solid; font-weight: bold; text-align: center">Prices</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Balance at March 31, 2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">3,648,651</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">3,689,341</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3.70</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in">Share awards</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,875</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.56</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Options granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(682,375</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">682,375</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.52</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Options exercised</td><td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(7,530</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1.08</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">42,230</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(42,230</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">2.62</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Balance at June 30, 2024</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,004,631</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,321,956</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3.36</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in">Share awards</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,875</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td> <td style="text-align: right">— </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.28</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Options granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(483,673</td><td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">483,673</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.81</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; padding-left: 0.125in; text-align: left">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">274,901</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(274,901</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="padding-bottom: 1.5pt; text-align: right">1.51</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Balance at September 30, 2024</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">2,791,984</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">4,530,728</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td

style="padding-bottom: 4pt; text-align: right">3.33</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> A stock option was exercised on a cashless basis for 7,530 shares of common stock during the six months ended September 30, 2024. There were no stock options exercised during the six months ended September 30, 2023. During the six months ended September 30, 2024 and 2023, the Company awarded 7,750 and 12,640 shares, respectively, and for the three months ended September 30, 2024 and 2023, the Company awarded 3,875 and 6,265 shares, respectively, to its non-employee directors under the Company's outside director compensation plan. For the six months ended September 30, 2024 and 2023, the Company recorded stock-based compensation expense for these share awards of approximately $15,000 and $13,000, respectively, and for the three months ended September 30, 2024 and 2023, the Company recorded stock-based compensation expense for these share awards of approximately $9,000 and $7,000, respectively. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of restricted stock unit (RSU) activity under the Plan is presented below.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted
 Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of
 Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Grant-Date
 Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Non-vested shares at March 31, 2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">187,499</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"> 0.91</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; padding-left: 9pt">Vested</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(20,832</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td> <td style="padding-bottom: 1.5pt; text-align: right">0.91</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in">Non-vested shares at June 30, 2024</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">166,667</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.91</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(20,833</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">0.91</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Non-vested shares at September 30, 2024</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">145,834</td><td style="padding-bottom: 4pt; text-align: left"> </td> <td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td> <td style="padding-bottom: 4pt; text-align: right">0.91</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>   The total intrinsic value of RSUs outstanding as of September 30, 2024 was approximately $328,000. The unamortized compensation cost at September 30, 2024 was approximately $94,000 related to RSUs and is expected to be recognized as expense over a period of approximately 1.75 years.   The following table summarizes the range of outstanding and exercisable options as of September 30, 2024:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align:

center">Options Outstanding</td> <td> </td> <td> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center">Options Exercisable</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid">Range of Exercise Price</td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Number
 Outstanding </td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"> Weighted
 Average
 Remaining
 Contractual
 Life
 (in Years) </td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"> Weighted
 Average
 Exercise
 Price</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Number
 Exercisable </td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"> Weighted
 Average
 Exercise
 Price</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Aggregate
 Intrinsic
 value</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">$0.93 - $2.28</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 7%; text-align: right">3,098,454</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 7%; text-align: right"> 8.41</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 7%; text-align: right">1.57</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 7%; text-align: right">2,640,918</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 7%; text-align: right">1.55</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 7%; text-align: right">1,839,613</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; "> <td>$3.95 - $7.51</td> <td> </td> <td> </td> <td style="text-align: right">933,145</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6.69</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">5.30</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">836,533</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">5.42</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$8.61 - $17.70</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">499,129</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6.73</td> <td> </td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</td> <td style="text-align: right">10.56</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">490,036</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right"><span

style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.56</td>
<td> </td> <td> </td> <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1.5pt solid; padding-bottom: 1pt; text-align: right">—
</td> <td> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">$0.93 - $17.70</td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double"> </td> <td style="border-bottom: Black 4pt double; text-align: right">4,530,728</td> <td
style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: right">7.87</td> <td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt"><span
style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</td> <td
style="padding-bottom: 4pt; text-align: right">3.33</td> <td style="padding-bottom: 4pt"> </td> <td
style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double"> </td> <td
style="border-bottom: Black 4pt double; text-align: right">3,967,487</td> <td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt"><span
style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</td> <td
style="padding-bottom: 4pt; text-align: right">3.48</td> <td style="padding-bottom: 4pt"> </td> <td
style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double"><span
style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$ </td> <td
style="border-bottom: Black 4pt double; text-align: right">1,839,613</td> <td style="padding-bottom: 4pt"> </td></tr> </table>   The intrinsic value per share is calculated as the excess of the closing price of the common stock on the Company’s principal trading market over the exercise price of the option. 1000000 333334 1333334 2000000 3000000 P10Y 1763000 P1Y9M18D 909533 625326 242307 339298 1.41 1 1.51 1.02 The following assumptions were used in the fair-value method calculations:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td
style="padding-bottom: 1.5pt; text-align: center"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"> Three Months Ended September 30, </td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Six Months Ended
 September 30,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td
style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td>
<td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td
style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rates</td><td
style="text-align: center"> </td> <td style="text-align: center"> </td><td style="text-align: center">3.4% - 4.1% </td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td
style="text-align: center"> </td><td style="text-align: center">4.4% - 4.6%</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td
style="text-align: center">3.5% - 4.4%</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="text-align: center"><span
style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5% - 4.6%</td><td

style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; width: 52%">Volatility</td><td style="text-align: center; width: 1%"> </td> <td style="width: 1%; text-align: center"> </td><td style="width: 9%; text-align: center">114% - 117%</td><td style="width: 1%; text-align: center"> </td><td style="text-align: center; width: 1%"> </td> <td style="width: 1%; text-align: center"> </td><td style="width: 9%; text-align: center">127%</td><td style="width: 1%; text-align: center"></td><td style="text-align: center; width: 1%"> </td> <td style="width: 1%; text-align: center"> </td><td style="width: 9%; text-align: center">114% - 123%</td><td style="width: 1%; text-align: center"> </td><td style="text-align: center; width: 1%"> </td> <td style="width: 1%; text-align: center"> </td><td style="white-space: nowrap; width: 9%; text-align: center">82.6% - 152.2%</td> <td style="width: 1%; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected life (years)</td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="text-align: center">5.0 - 5.7</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="text-align: center">5.0 – 5.7</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="text-align: center">5.0 – 5.7</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="text-align: center">5.0 – 6.2</td><td style="text-align: center"> </td></tr> </table> 0.034 0.041 0.044 0.046 0.035 0.044 0.035 0.046 1.14 1.17 1.27 1.14 1.23 0.826 1.522 P5Y P5Y8M12D P5Y P5Y8M12D P5Y P5Y8M12D P5Y P6Y2M12D The following table summarizes the activity in the shares available for grant under the Plan during the six months ended September 30, 2024:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: right"> </td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Available</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number of</td> <td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">for Grant</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Prices</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Balance at March 31, 2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">3,648,651</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right">3,689,341</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3.70</td><td style="width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in">Share awards</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,875</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> — </td><td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.56</td><td

style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Options granted</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">(682,375</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">682,375</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.52</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Options exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> — </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(7,530</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.08</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">42,230</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(42,230</td> <td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">2.62</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Balance at June 30, 2024</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,004,631</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,321,956</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3.36</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in">Share awards</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,875</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">— </div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.28</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Options granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(483,673</td><td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">483,673</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.81</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; padding-left: 0.125in; text-align: left">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">274,901</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(274,901</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="padding-bottom: 1.5pt; text-align: right">1.51</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Balance at September 30, 2024</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">2,791,984</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">4,530,728</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">3.33</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 3648651 3689341 3.7 -3875 1.56 -682375 682375 1.52 7530 1.08 42230 42230 2.62 3004631 4321956 3.36 -3875 2.28 -483673 483673 1.81 274901 274901 1.51 2791984 4530728 3.33 7530 7750 12640 3875 6265 15000 13000 9000 7000 A summary of restricted stock unit (RSU) activity under the Plan is presented below.<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted
 Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of
 Shares</td><td style="padding-bottom: 1.5pt; font-

weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Grant-Date
 Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Non-vested shares at March 31, 2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">187,499</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"> 0.91</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; padding-left: 9pt">Vested</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(20,832</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">0.91</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in">Non-vested shares at June 30, 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">166,667</td><td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.91</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(20,833</td><td style="padding-bottom: 1.5pt; text-align: left">) </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">0.91</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Non-vested shares at September 30, 2024</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">145,834</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">0.91</td><td style="padding-bottom: 4pt; text-align: left"> </td> </tr> </table> 187499000 0.91 20832000 0.91 166667000 0.91 20833000 0.91 145834000 0.91 328000 94000 P1Y9M The following table summarizes the range of outstanding and exercisable options as of September 30, 2024:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"> Options Outstanding</td> <td> </td> <td> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center">Options Exercisable</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid">Range of Exercise Price</td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"> Number
 Outstanding</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted
 Average
 Remaining
 Contractual
 Life
 (in Years)</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted
 Average
 Exercise
 Price </td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"> Number
 Exercisable</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted
 Average
 Exercise
 Price </td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"> Aggregate
 Intrinsic
 value</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">$0.93 - $2.28</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 7%; text-align: right"> 3,098,454</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 7%; text-align: right">8.41</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</td> <td style="width: 7%; text-align: right"><span style="font-family: Times

New Roman, Times, Serif; font-size: 10pt">1.57</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 7%; text-align: right">
2,640,918</td>
<td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><span
style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</td> <td
style="width: 7%; text-align: right">
1.55</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td
style="width: 1%">
$</td> <td style="width: 7%; text-align: right">
1,839,613</td> <td style="width: 1%"> </td>
</tr> <tr style="vertical-align: bottom; "> <td>$3.95 - $7.51</td> <td> </td> <td> </td> <td style="text-align: right">
933,145</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">
6.69</td>
<td> </td> <td> </td> <td>$</td> <td style="text-align: right">
5.30</td> <td> </td> <td> </td> <td> </td> <td
style="text-align: right">
836,533</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">
5.42</td> <td> </td>
<td> </td> <td> </td> <td style="text-align: right">
—</td> <td> </td></tr> <tr
style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$8.61 - $17.70</td> <td> </td> <td
style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">
499,129</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">
6.73</td>
<td> </td> <td> </td> <td>$</td> <td style="text-align: right">
10.56</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">
490,036</td>
<td> </td> <td> </td> <td>$</td> <td style="text-align: right">
10.56</td> <td> </td> <td> </td> <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1pt; text-align: right">
—</td> <td> </td></tr> <tr
style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">
$0.93 - $17.70</td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double"> </td> <td style="border-bottom: Black 4pt double; text-align: right">
4,530,728</td> <td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: right">
7.87</td> <td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt">
$</td> <td style="padding-bottom: 4pt; text-align: right">
3.33</td> <td
style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double"> </td> <td style="border-bottom: Black 4pt double; text-align: right">
3,967,487</td>
<td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt"> </td> <td
style="padding-bottom: 4pt">
$</td> <td style="padding-bottom: 4pt; text-align: right">
3.48</td> <td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double">
$ </td> <td
style="border-bottom: Black 4pt double; text-align: right">
1,839,613</td> <td style="padding-bottom: 4pt"> </td></tr> </table> 0.93 2.28 3098454 P8Y4M28D 1.57 2640918 1.55 1839613 3.95 7.51 933145 P6Y8M8D 5.3 836533 5.42 8.61 17.7 499129 P6Y8M23D 10.56 490036 10.56 0.93 17.7 4530728 P7Y10M13D 3.33 3967487 3.48 1839613 NOTE 6 – INCOME TAXES <p style="font:

10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> The Company determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the Company’s assets and liabilities using tax rates in effect for the year in which the Company expects the differences to affect taxable income. A valuation allowance is established for any deferred tax assets for which it is more likely than not that all or a portion of the deferred tax assets will not be realized. Based on the available information and other factors, management believes it is more likely than not that its federal and state net deferred tax assets will not be fully realized, and the Company has recorded a full valuation allowance.   The Company files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations. All tax returns for fiscal 2016 to fiscal 2023 may be subject to examination by the U.S. federal and state tax authorities. As of September 30, 2024, the Company has not recorded any liability for unrecognized tax benefits related to uncertain tax positions. NOTE 7 – COMMITMENTS AND CONTINGENCIES   Litigations, Claims and Assessments   In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements.   Indemnification   In the ordinary course of business, the Company enters into contractual arrangements under which it may agree to indemnify the counterparties from any losses incurred relating to breach of representations and warranties, failure to perform certain covenants, or claims and losses arising from certain events as outlined within the particular contract, which may include, for example, losses arising from litigation or claims relating to past performance. Such indemnification clauses may not be subject to maximum loss clauses. The Company has also entered into indemnification agreements with its officers and directors. No amounts were reflected in the Company’s consolidated financial statements for the three and six months ended September 30, 2024 and 2023 related to these indemnifications. The Company has not estimated the maximum potential amount of indemnification liability under these agreements due to the limited history of prior claims and the unique facts and circumstances applicable to each particular agreement. To date, the Company has not made any payments related to these indemnification agreements.   Purchase Obligations   The Company’s primary purchase obligations include purchase orders for machinery and equipment. At September 30, 2024, the Company had outstanding purchase orders for machinery and equipment and related expenditures of approximately $990,000.   In December 2023, the Company signed a device integration agreement with a provider of connected-care and remote monitoring diabetes technology solutions. As of September 30, 2024, the Company had a remaining obligation under the device integration agreement of approximately $400,000 over three years for technology license fees. 990000000 400000000 NOTE 8 – RELATED PARTY TRANSACTIONS   A family member of one of the Company’s executive officers is an employee of the Company. During the three months ended September 30, 2024 and 2023, the Company paid the family member approximately $43,365 and $28,954, respectively, which includes the aggregate grant date fair values, as determined pursuant to FASB ASC Topic 718, of stock options granted during each period. During the six months ended September 30, 2024 and 2023, the Company paid the family member approximately $100,625 and $63,754, respectively, which includes the aggregate grant date fair values, as determined pursuant to FASB ASC Topic 718, of stock options granted during each period. 43365000 28954000 100625000 63754000 false false false false false --03-31 Q2 2025 0001074871

TY7+$\6L;Y85.DCWY*6U]E8._"GV?DT U M!:JI4$VKM=GQ"P47,_'D=8[6I<;2R34(Z)J94,V":C94IC]04J*9"-0VJZ5#-@&IFK?$OH5K0,6VHYD U M%ZIY*(UM$4TL4^2&M!;WY9P@(T&6;=_H#])E13H)H*U32HID,U ZJ9M<;T MA^GXK#^<+R5*D]')8C9TU1RHYD(U#Z6Q)WX3GQ3Y$;==(/NA"F0SL:CW$E%\ MMW=#0&H*5%.AFE9KQZ&B^7DF"CJFT3+F]&Q,$SJF!=5LJ.9 -1>J>2B-[0=- M2E+DQR35[V4+H"1YIBGQ.

<$HOM/[_(=F(J&:"M4TJ*9#-0.JF>\<:2 M @U60C4'JKE0S4-I;]ITI4B/_KF!B'-\B2FY":)MQFY2Y-UZD?D3Y>6D:G6 M]W?QR=
[M!)JTA&HJ5-.@F@[5#*AF0C4+JME0S8%J+E3S4!K;6IKDI;A+;<'? M/RI"$YA038%J*E33H)H.U0RH9D(U"ZK94,V!:BY4\U :VU^:V*;(SVW^C6@W
M7^S=69":(I[G0N?"?"S+[%-_%3JJ!M5TJ&9 -1.J65#-AFH.5'.AFH?2V)[1 MI#I%?JSS[3D)[_D.,KYV"]44J*9"-0VJZ5#-@&HF5+.@F@W5'*CF0C4/I;&?
M.-4D0R7AYSS?D9#9MUNHID U%:II4$V':@94,Z&:!=5LJ.9 -1>J>2B-[2]- MJE3Z_Z=*^:O0NQ5!4Z50385JFM2:%SU-E4+'-%K'%$XRJF;K4J.3-;/JI9B/
MSSB)>4!7WH%J+E3S4!I[GDO->Z'!4*BF0C4-JNE0S8!J)E2SH)H-U1RHYD(U#Z6Q#:8)D$H_Z8,] M)6BP%*HI4$V%:AI4TZ&: =5,J&9!-1NJ.5#-
A6H>2F/[2Y-3E;BYMQ_\^#X^ MWKO)(#4%JJE03:LU)JPZ.D^K0@@05.H MID(U33H/P=]$Q^5 MNL1'_\8[\/EN[WX C9!"-16J:5!-AVH&5#-
KC4E@C%LN=;0L=GZ7$QNZ;@Y4 MTICTN3>13%G_.=0P9FN.$:@I44Z&: M!M5TJ&9 -1.J65#-AFH.5'.AFH?2V/XB-?V%'S6MKV/XFTV:/!<]9ANO:$KH
M;CH3'*8SFV(ZT]IEH'E3J*9 -54^_T!-4:C^L!-O#3JL#M4,J&9"-0NJV5#- M@6HN5/-0&MM CFX1S_\L4N_P[OMLUTKJ05HOBO*MWNT">V=X[*WAL?
>&Q]X< M'GMW>.SMX;'WA\?>(/[\TU#EME\!3LN"4MN";LN"HES^&;$+>FU#L\OM3M]A M]D1IKOBYO[B*:+JFMS0,,[),MG%>/LDX>K0X41_+M\M??
I8&P[/'-?'2$%L> M-\5+JWI\V/"+JXV_IJZ?KH,X(R%]+(82+J;%RJ;E^]7VW^3)YGI0S'8>DCQ/ MHNK+)^H7TXUR@>+GCTF2[[\I!WA)TF_5YBS^!U!+
P04 " "U@&Y9$42G MM_<# #M%0 &0 'AL+W=O8YS3GW&6\H>>0P@T'.:9'QBQ$+DUZ;)ES&DF/=H#IE\LZ(LQ4(. MV=KD.0,<%:
T,1W+\LP4D\SPQ\7<+?/'=",2DL$M0WR3IIB]3"&AVXEA&Z\3 M=V0="S5A^N,P);OO>, ME"L/E#ZJP;=H8EAJ1Y# 4B@*+'^>8
9)HICD/OZO2(W:I@+N/[^R?RFE.+5"SJM"4Z>3< %Y#[G6 M)^183K]E/[/SX6Z;.W]F/;S8>D,,MSXN;L'G'N.[^"2@G]\E%_HF(.7_M1V+ MTG"_W;#*E]
<\QTN8&#(A]4];3'22!3K)0DUDC>CUZ^CUN]C] M>YK(CSLAXJ4M)W8MP:@)+.M@DU5JR??[CG#L?FTKZQ.DZ$FLH:R@UK90:>R M3K))UFH
MB:P1O6$=O6'G1W1'^./5B@'(* D9,2X0PP)X6SA*)MO>RR]6SW+[S00S:U_6 M/U@6'&$;-)>%)YAGIX6W'JBS3(:C-C%&CM &PH9UM[?Z9
MM[K+$'X^68:Z*=Z:R;2R!5K90EULS6#LW:SLOU6,*LNZ8JB3+=#*%NIB:\;0 MV<70T5:2*JK?BHU]D*N/K?,.BM*Q=8>)^#1?
T_G=7<_NO(R<*$P5^+!,# ^] MU7H5:S>JKK9-2=S?);%[*JDCT8H+;L5MH,B_-): ML/11!?JHPA-47D7E=%*543#WVE9*%L3]6S=F[PI.G('\U/[M>F:WS
>JEUFTRW;T92-TCMF:R)R7MA96^Q' B:%\VS!RH$38O' M&' $3"V0[U>4BM>!,E!W>/U?4$L#!!0 (+6 ;EGXY,TS\ 0 *H9 9 M >&PO=V]R:W-
H965TV:]I&TZ3;L33YN'3A^T(-O, G(DV=[\^PK!@@&M;!/G91?!O4;GQ*UAM>W##G MTRU:XR7F?V\?J&B9-4J<9#AG"@H/)(R%/1 M^!#/#*L8$4YQQ
L()/[M\3U.TP))C.-+!6K4?1:)Q]H0(H[F4TH.@!;1 JVXD&+* M;$$_R8MY7W(JGB8BC\^7G$1/-PNA7 SN22:6$T-R0MZ$F*,D96_!#5B*U1;O
M4@S("MP5$Y7PKR#) =]@L-P@BID(^A&8@,G&U.1B9 6^&56C6)2C@*^,P@$? M2.YUZ?_OLNU MZ>'@WEMLG'J2'8GGO(9W>O[^_4/D@ \<9^P_U?
R5';CJ#HK-Z99M481GAMA] M&*9[;,Q_^L'VK9]5XET3++P26$M8MQ;6U:'/*_'N]J)2T*,06&S$X%>*896L);PGX8LM>C]W+,OU'7MJ[H\54\3Y;N!
[G;CP=%R+ MIU?S]+0_]QECY@6RZ=D?"8[KS<:UX'VQ/,[[/IQCA],'+?+[G1:!)A!5GP1E1/2-(440:V0AFY\;U5:5!V M'1R/>>1T!2B#)JV@<8>\/J9%?
%P3'P]>OO(90 =$8^6&/N[-Q8T3C+T.L;.B M0NTH!Y9P4&L07+BT3S'7XJE'"U2[X)5PP@$X)]6;U.I-OJUTCL6\H&HFO:J!
M(QAT%E<_R!YU]Y90._Z!ZMA6XZZLP17VU[8P6@RLBZ;2]2PJ]%;]N('CCYV. M%*I /X!.K]3TXQVJQY';M"^LMG-4L/OO$:4(_3BU!MHQ#M4 -AK
;ZN9CB07 ME$W5<[LD@JZ94$9YL*N2EL50E1K+:FN-VUF5@ROAU*OFJI9U")IRM[[6L-JR M-H;5UCO6UPM0+Z86]6(Q^S;U9NPY5G<%7JG3ME2-
Y[7UIO?L.JV5NZ12M7U? M+*BGJ&@KZ.IYI3[;>C8NV];;[',J.BK<=9H**5$> XKYCN:BP8G\K?H@S+=2 M3+^WGN#8G5B]C:\?YT+87W=:'D-U:DRYK7?
EKY?H0'44)EPMCR)0J<_W\.MV M8]AMO6,_NRY/RW5)P0:JEV9/PGX4'/F]5^OWL.QVX]EMO6G7%>+[/#[QH[X" M;Q?;Q)X$;E>+?J#R<",\ [%]B-?
8;ZBWW_U2.LT/]JVT*]Y-X][/#U6@ZG@C M/ .QS:^QTU!OIT^60ION!! MLL')5AZ5/Q+.228O-QC%F!8!XOF*$/[2*#JH/_,_P=02P,$% @ M8!N
M60USF]PW P R@D !D !X;"]W;W)K&ULK5;; M;MLX$/V5@;I8M$ 3R9*O65M [&YV6S1%$&_2AZ(/C#2VB$BD2U)V^_<=4K;6
M('BZ1F#L\YXF7&&ZD>=89HX'N1"SWQ,F-6%[ZODPP+IL_E"@6]64A5 M,$-=M?3U2B%+75*1^V$0]/V"
<>'%8S=VH^*Q+$W.!=XHT&51,/5CBKG<3+R. MMQNXY!=QSW.B] M-E@E#U(^VL[[=.
(%EA#FF!B+P.BQQAGFN04B&M^VF%X]I4W<;^_0KYQVTO+ M-,YD_IFG)IMX0P]27+ R-[=R\R]N]?0L7B)S[?YALXT-/$A*;62Q328&!1?5 MDWW?
^K"70#CM">$V(3Q,Z!Y)B+8)D1-:,7.RWC'#XK&2&U VFM!LPWGCLDD-
M%_8KSHVBMYSR3#PW,GD\FY(1*4(D4%)D.XR9F@R%O41O'$$)I#ACO!C8;7E$5(7ZZQ>$#UE0+_ M !]TQA3JW8,+^"^3I68BU6/?D#;+T$^V.J:5CO"
(C@BNI3"9AK^)4MK,]\F3 MVIAP9\PT?!)PCJMSB(*W$ 9AMX7/[.GT#Z4XEMZ@$]7?*7)XT3$ZQS[!7?,3 M?/E(B?#>8*&_MKE8S=)MG\4>&1=ZQ1*
<>'0F:%1K].(_7W7ZP5]M%KP06,.0 M;FU(]RGT^%-IEY*U8^[6SUN8XI(+P<42IHRL2+!-?P7:N%RCHC,2_E%,F#/:N A7C"NX9WF) MSU12337X_&)H
;U84U]^)L>T[EV8D$,?UVSW=XPZA[0;0EK[H & MX5%->/0B7I^6,7J.YR>"*@G^WK58H%JZ:D%#(DMAJHN@'JT+DDMW#Q^,3ZE0
MJ>J*_V&J*N>:*=JJ&G)<$&1P/B!?554Y5!TC5^[R?9"&KG+7S*C80F4#Z/U" M2K/KV GJ\BW^"5!+ P04 " "U@&Y9V(O$234& "Q* &0 'AL+W=O
M).ESC&0RX85 M:-8@1E<,Q3XP-FT+U<63Y"0%]N-'2HHHP]*Q+5_R(;Z)AX>'+]_'E#E\B9/O
MZ4+*#+V&091>]199MOS0[Z>3A0Q%:L5+&:E/9G$2BDR]3.;]=)E(,DJ#$7RXT8&\WGCTYXM,O]$? M#9=B+LBA/ MK9.B,9R$FF0PCU\"QO91#H2"J/?
\N@O:I/W;#^_"WZ[_G@U6"> M1"IOX^"K/\T65SVWAZ9R)E9!]AB__"'+ 7$=;Q(':?X?O937VCTT6:59'):- M50:A'Q6/XK4L1*T!:VM R@8DS[OH*,_R3F1B-
$SB%Y3HJU4T_20?:MY:)>=' M>E;&6:(^]56[;#3.XLGW]S=J7%-T&X=JLE.1E^O=GD"_O:F;IL-^IC+3\?N3,HN;(@O2DH6#
M[N,H6Z3HMV@JI^OM^VI$U;#(V[!N"!AP+)<6HO8OB-B$H2_C._3NXA)=H#Y* M%R*1:?D]$2K M*\)];2TX5M>535Z()8Q$7?[F7X))-_FDH
QM&K[T.Z%!-Y MU5/+*Y7)L^R-?OX)._:O0):LRI+ET6E;/?:;0?3MDPJ /F8R3!O'PDXP%EZ- MA8,5_W.E2[PVC'=^A,;YC%ZB_QKGMDB[",SSP-JOGD?
4]ES&V;#_W)"14V7D M@!E]S=>^6D'7SS)17H8>I39$G=FMTG6BK&E9%W[,)X387AS6E@VQBU#29R/9\G6D=@Q0"(^4PTX2#[V^:Q&"'P-
BI=MG;31..U-5E#):(>U[3["J[<,Q MM"(PK0XQ36]S/7%J#TC+CHP:,%%X*W0\U]S2T:!T36R_V2;>:IO4 (G"0.K@ M"V7$NB]0J^U;'348HC =#G#-
,O+:/17/&3"WY4X K=U8.SI5Z"95J,7:]&:@ M0F&H'.::9?"=M][4@(7"8+E7F@]7866'.H/=;T>"L3L:"S4DHLY9?9)V8-/V MX1A
41A0CR*:YV/90:2;^R$]:2UB,."A\'ZH20P[WYJ!8W>MGJ$,],)!^]:/X,C=MX[=>P4=^J8 M 1F#0;:/'.BF'-2TV5[]KT4;M=^"8)Q!V-A!&Z?X[8<9YC%^7FV<
H/,8)#! M&[)]M.%L:J,=',R@B\'HNA>OW;]%P+&[EL] CYUWM\5.P4%F.,C@W=8^:O V MU:!GJUD-W+"+P^QJ4L/.7R/@V%U_%S;0X_BL:N"GP"
W&.3PKFP/-921UM2@ M9ZM%#09='$97DQIV_QH!!^]:/\,Y?MY##_PDIQYJQQ[@W=X^_O(P=WX>;)!#?W:*;)0
M)O/\K%R*)O$JRHH#9=6[U7F\Z^(4FKF\.,QW+Y*YKTH8R)EJ:EL#I<>D.!]7 MO,CB97XF[2G.LCC,GRZDF,I$7Z ^G\5Q]O9"=U"=4AS]#U!+ P04 " "U
M@&Y9<21,R4D" @!@ &0 'AL+W=OTC:Y1^-!6)4^"2S,-*FOK21B:H@)!S4#5('%EH[2@ M%DU=AJ;60-<^2/ PCJ(T%)3)(,_\W$+GF=I:SB0L-#%;
(:A^O@:NFFDP# X3 M=ZRLK)L(\ZRF)2S!WM<+C5;8H:R9 &F8DD3#9AI<#2?7J?/W#C\8-.9H3%PF M*Z4>G7&SG@:1$P0<"NL0*'YV,
/.'1#*^+W'##I*%W@\/J!_\;EC+BMJ8*;X M3[:VU33X%) U;.B6VSO5?(5]/HG#*Q0W_DV:UC=) E)LC55B'XP*!)/MES[M MZW 4$,/F@IP1)LGW2FT-
>IDLM,CM$,)BSW/= M\L0O\"RA'I!1]('$43PF]\LY.3^[^!LF1.F=_KC3'WO@=!_O[=,(T^GU ^ZI2/3J'GBZTN*CQ/1*TX
M*ZD[H[UU;5%2C^*NV"Z_O(SPR<)=#_NX8Q^?9)_#CA58&FFAU)Z<7)4:P%62 M/-R"6('N+=E)V%>6+.E$)V^XVE_V>STG\T>1SV;'1Y=>-<[;ZDN
MF32$PP8#H\%'S%6W_:@UK*I]#U@IBQW%#RMLX:"= ZYOE+('P[65[J>0_P%0 M2P,$% @ M8!N6>O;IZN5 @ TP< !D
!X;"]W;W)K&ULK55M3]LP$/XK5H8FD#:2)FE@71N)-D5#&E)%8?LP[8-)KHV% M7S+;;>'?SW;2K$"HV,:7Q#[?\YR?\^ENN!R3I4 &MTSRM7(*
[6N!KZO\A(8 M5L>B FY.%D(RK,U6+GU52<"% S'JAT&0^ P3[J5#9YO)="A6FA(.,XG4BC$L M'\9 Q6;D];RMX8HL2VT-?CJL\!+FH&^JF30[OV4I" .NB.!
(PF+DG?4&T]CZ M.X=O!#9J9XVLDELA[NSFHAAY@;T04,BU9<#FMX8)4&J)S#5^-9Q>&]("=]=;
M]G.GW6BYQ0HF@GXGA2Y'WJF'"EC@%=578O,%&CU]RY<+JMP7;6K?)/10OE): ML 9L;L (K__XOLG##L#P= /"!A ^!<0O *(&$+TV0MP XM=&Z#<
)]VOM;O$ M95CC="C%!DGK;=CLPF7?H4V^"+=U,M?2G!*#T^D54*RA0#,L]0.ZEI@K[)Y0 MH<,,-"94':&/Z&:>H<.#(W2 "$?7I5@IS LU]+6Y@B7R\R;"
MZU*A*2^@Z,!G^_')'KQOI+?ZPZW^<;B7< [5,8J"#R@,PKCC/I/7PZ,N.?\7 M??K/T1\E(VJ+(7)\T=\7PX^OQA==:&#J9]>SU\1Q-
[%M=@-5X1Q&GNEF"N0: MO/3]NUX2?.[*^5N296])-GTCLD>O$[>O$^]C3R>"59@_H J3 F$F5EQWO41- MDC@2.R76:7CZJ6^J:[V;XN=>
<10E_<=>V7.OGID_X1.WZ7.W)#K9"5G+]7>Z M% .Y=.-!H=P*J6NTM;83Z,PUWB?V<6\PZ778,S.QZ@'SA[X>=Y=8+HFI8@H+ M$RHX/C%-5-8CI-
YH4;D>>2NTZ;AN69JI"](ZF/.%$'J[L0':.9[^!E!+ P04 M " "U@&Y9&I%9F40# #*% #0 'AL+W-T>6QE+M[_G!?Z]EW@[FWN_$+"UR2T"MZ'
MB>_3QJ2[!TGO4<:$>]O"=O2YT7&\&C&_IH)'83<;7G)&U1+#.LR&?:S M0JZK)2(N8)1ISH)G*@9D1 4?*PZLC.9<+%VX X%)(0H5:%.F)E4;(M6+@]NN
M!Q5O@.L>F"0"]$8[! 7&/9+JC53\LYT[& ;? 4%=?MQ M61J'4T67[-E--I M(:GUL&+4#2,[84(\P./](]O27F0;>V9W3#9-8ZAN.AG7 ?U--:>]*7O])MV@
MY,^%_CPWTY&V#X7-[A7+^,+V%UEC %-OX^JT+,7RD^!3F3,W^8,3#OMTQ0MF MA>(O)AN4RL0$F"+!,U.:3S8COQ0M']E"K\IID>&>.R?
H^>^N\Y1)IJC8-&UJ M_YA7^70FP_HDM''_PO3:<7.B-KFX3-F"I:.Z MJZ9CVPQ,PV2M+R#L(G?V\B,8QV%^!# L#^8 XS@6EN=_FD\/G8_#,&\]+])#
M.3V4XU@^9&0_6!X_)S&7?Z9)$D5QC*WH:.1U,,+6+8[AQZ^&>0,&E@_/]A3$D5)XD< \SN((@R!IQ%', ?@ M 4.BR+X'=]Y'X>H]%:[_>SG\#5!+ P04 "
"U@&Y9EXJ[', 3 @ M"P %]R96QS+RYR96QSG9*Y;L,P#$$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(% MBD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$$%)6X
4BV)8]ISI%"KM0L M'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO M8R*T>EOH^7%H5
J.W&,EC'%BM/XU@LD/['X 4$L#!!0 (+6 ;EFC[V0? M:0, "(9 / >&PO=V]R:V)O;VLN>&ULQ9E;;]HP%(#_BI6G35H7H7D@"] MJ%1JRRZ5J@T5F-)@5*-;
>PZ@@NS'5KZZV;T0>G[MN5+WY%%P:4+;PRMKU29J:<@6"FJ]J#=)=62@MJ'5%O4S-6@.MS K "I[FO=XP
M%93)Y.QTU]9$IV%!62@M4])5^HI;!@_FWW5?)!MFV)QQ9K>CI#GGD!#!)!/L M":I1TDN(6:F'GTJS)R4MY=-2*\Y'2=9>N 5M6?FJ>NHA9W1NFAI+YS?
4@8R2 M8<\UN&#:V.:.IGWJ&#?@;FY+M57?&;>@Q]3"#ZWJ-9-+WXQ[BS1XC28.NV,; MQ!/]/V%4BP4K8:S*6H"T;1PU<
\HS8JM34(D%3!*+M4&M'\?]X"KJGTWZZ"" M2.D3YB[HJZK!BXDB*Y &*N+.C.*L(>_R +) ((N] M0$X]COMI -E'(/M[A.Q$Q86\!FK !"S'",MQ7):I5>7]
M2O$*M+DCW_[4SE]AHNYAF;KW 6P'%[0=&,*U9)J;0C[4))%5FUA!"8M;((FOC2AKFQJT/8.7ZF)QK M%\DE-
)T?,F+2R");X[PL5=U\@F3B$K/_"K^0^;8M;,/I5H9I(XOL#51NG6E" MAHDCBVP.5&]=3,PI662IM((CG]Q*A(/Y',ZI,9_D'^&3%ZY[$Q*32AY9*N])
M[QDTQ$07*)$]@P^8<,J:8Z;)(YL&Q^R'F)AN\OBK%&1<=Z*)"2>/OTY!,#O1 MQ)R31W;.+OWX&3_CW:&-22:/+)F77.2 3%VS5W)5[!@$JI?[A'&U9>4EQ-
-_*'=:N@/_$Q_47-^Z>I^RVM%J]T6_^[OB;._ M4$L#!!0 (+6 ;EF9/J*$? $)86 : >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/-V$UNPC 0AN&K1#X
SLSP6P&K;MA67" *AB#RI]A5X?:- MPB)\41?=(,\JLJ.,W]6CR-LO5V;AVM2^N+8^N5=E[7>F"*']L-;GA:LR/VM: M5_=OSDU79:%?
=A?;9ODMNSC+:;JTW>L,L]^^SDR.C];]9V)S/E]S]]GDWY6K MPQ^#[4_3W7SA7##),>LN+NR,O9?CMK?#@V;]9),<3CO3'4YD;.P@AB".'R00 M)/&#YA
TCQ^T@*!%_* E!"WC!ZT@:!4_: U!Z_A!&PC:Q ^B%&5,%21-L%:@ M-2'7I,!K0K!)@=B$9),"LPG1)@5J$[)-"MPFA)L4R$U(-RFPFQ!O4J WH]ZL
M0&]&O5F!WCSYV5:@-Z/>K$!O1KU9@=Z,>K,"O1GU9@5Z,^K-"O1FU)L5Z,VH M-RO06U!O4:"WH-
ZB0&]!O46!WC*Y+%&@MZ#>HD!O0;U%@=Z">HL"O07UEG?J M[<.C=-'[L>:[Q_'=2'?IOW7C\L'QN3M@9<+9P#;W_!5!+ P04 " "U@&Y9 MJF<489@!
+%P $P %M#;VYT96YT7U1Y<&5S72YX;6S-F,UNPC 0A%\E M A418[NE/P(N;:\MA[Z FVQ(1!);MJ'P]>7G7,C2W=\CD M?
6O(19NZ:MPT+KPWCXRYM*!:N40;:L).KFVM?'BU"V94NE0+8F(T&K-4-YX:
M/_2M1CR;/%.N5I6/7C;ALRMU,XTM52Z.GG:%K=@8I*\^'[73SB@[TSM<[Z>VRVX>CG7+]7?\<9'_0MS M") <$B3'#4B.6Y <8Y <=R
Y[D%R/(#DX".4("A$Y2A(Y2A,Y2A0Y2A4Y2A8 MY2A[9=DUJ5S<&?=?_ 9U]02P$"% ,4 M " "U@&Y9!T%-8H$ "Q $ @ $ 9&]C4')O M<',O87!P+GAM;%!+
0(4 Q0 (+6 ;EG]J\GG[@ "L" 1 M " :\ !D;V-0&UL4$L! A0#% @ M8!N67B .#Y'!@ X2(!@ ("! M#0@ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @
MM8!N6?T:H,&W! &PO=V]R:W-H965T&UL4$L! A0#% @ M8!N62/F!Y;_!0 TPX !D ("! MYD@ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @
M8!N67Q$7FU_!0 \ P !D ("!F%X 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M8!N6>VI(H&PO=V]R M:W-H965T&UL M4$L! A0#% @
M8!N68FR?+N"!0 1 X !D ("!T(T M 'AL+W=O&PO=V]R:W-H965T , #T. 9 M " @9^6 !X;"]W;W)K&UL4$L! A0#% @ MM8!N6563^X3J P Q1, !D ("!3IH
'AL+W=O&UL4$L! A0#% @ M8!N63Z^+@VC @ MUP8 !D ("!#J4 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M8!N64-&PO=V]R:W-H
M965T&UL4$L! M A0#% @ M8!N60USF]PW P R@D !D ("!WL@ 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M8!N M6>O;IZN5 @ TP< !D ("!.-4
'AL+W=O&PO&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 M" "U@&Y9JF<489@! +%P $P @ &FX0 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08

+0 M #(, !OXP ! end XML 49 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent) {a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 50 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 52 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 133 204 1 false 34 0 false 5 false false R1.htm 995100 - Document - Cover Sheet http://xbrl.sec.gov/dei/role/document/Cover Cover Cover 1 false false R2.htm 995301 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 995302 - Statement - Condensed Consolidated Balance Sheets (Parentheticals) Sheet http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet_Parentheticals Condensed Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 995303 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 995304 - Statement - Condensed Consolidated Statements of Stockholders??? Equity (Unaudited) Sheet http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3 Condensed Consolidated Statements of Stockholders??? Equity (Unaudited) Statements 5 false false R6.htm 995305 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.modularmedicalinc.com/role/ConsolidatedCashFlow Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 995306 - Disclosure - The Company and Summary of Significant Accounting Policies Sheet http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPolicies The Company and Summary of Significant Accounting Policies Notes 7 false false R8.htm 995307 - Disclosure - Consolidated Balance Sheet Detail Sheet http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetail Consolidated Balance Sheet Detail Notes 8 false false R9.htm 995308 - Disclosure - Leases Sheet http://www.modularmedicalinc.com/role/Leases Leases Notes 9 false false R10.htm 995309 - Disclosure - Stockholders??? Equity Sheet http://www.modularmedicalinc.com/role/StockholdersEquity Stockholders??? Equity Notes 10 false false R11.htm 995310 - Disclosure - Stock-Based Compensation Sheet http://www.modularmedicalinc.com/role/StockBasedCompensation Stock-Based Compensation Notes 11 false false R12.htm 995311 - Disclosure - Income Taxes Sheet http://www.modularmedicalinc.com/role/IncomeTaxes Income Taxes Notes 12 false false R13.htm 995312 - Disclosure - Commitments and Contingencies Sheet http://www.modularmedicalinc.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 13 false false R14.htm 995313 - Disclosure - Related Party Transactions Sheet http://www.modularmedicalinc.com/role/RelatedPartyTransactions Related Party Transactions Notes 14 false false R15.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 15 false false R16.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 16 false false R17.htm 996000 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) Policies http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPolicies 17 false false R18.htm 996001 - Disclosure - The Company and Summary of Significant Accounting Policies (Tables) Sheet http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesTables The Company and Summary of Significant Accounting Policies (Tables) Tables http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPolicies 18 false false R19.htm 996002 - Disclosure - Consolidated Balance Sheet Detail (Tables) Sheet http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetailTables Consolidated Balance Sheet Detail (Tables) Tables http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetail 19 false false R20.htm 996003 - Disclosure - Leases (Tables) Sheet http://www.modularmedicalinc.com/role/LeasesTables Leases (Tables) Tables http://www.modularmedicalinc.com/role/Leases 20 false false R21.htm 996004 - Disclosure - Stockholders??? Equity (Tables) Sheet http://www.modularmedicalinc.com/role/StockholdersEquityTables Stockholders??? Equity (Tables) Tables http://www.modularmedicalinc.com/role/StockholdersEquity 21 false false R22.htm 996005 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.modularmedicalinc.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.modularmedicalinc.com/role/StockBasedCompensation 22 false false R23.htm 996006 - Disclosure - The Company and Summary of Significant Accounting Policies (Details) Sheet http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesDetails The Company and Summary of Significant Accounting Policies (Details) Details http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesTables 23 false false R24.htm 996007 - Disclosure - The Company and Summary of Significant Accounting Policies (Details) - Schedule of Diluted Net Loss Per Share Sheet http://www.modularmedicalinc.com/role/ScheduleofDilutedNetLossPerShareTable The Company and Summary of Significant Accounting Policies (Details) - Schedule of Diluted Net Loss Per Share Details http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesTables 24 false false R25.htm 996008 - Disclosure - Consolidated Balance Sheet Detail (Details) - Schedule of Property and Equipment, Net Sheet http://www.modularmedicalinc.com/role/ScheduleofPropertyandEquipmentNetTable Consolidated Balance Sheet Detail (Details) - Schedule of Property and Equipment, Net Details http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetailTables 25 false false R26.htm 996009 - Disclosure - Consolidated Balance Sheet Detail (Details) - Schedule of Accrued Expenses Sheet http://www.modularmedicalinc.com/role/ScheduleofAccruedExpensesTable Consolidated Balance Sheet Detail (Details) - Schedule of Accrued Expenses Details http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetailTables 26 false false R27.htm 996010 - Disclosure - Leases (Details) Sheet http://www.modularmedicalinc.com/role/LeasesDetails Leases (Details) Details http://www.modularmedicalinc.com/role/LeasesTables 27 false false R28.htm 996011 - Disclosure - Leases (Details) - Schedule of Future Minimum Payments Under the Facility Operating Lease Sheet http://www.modularmedicalinc.com/role/ScheduleofFutureMinimumPaymentsUndertheFacilityOperatingLeaseTable Leases (Details) - Schedule of Future Minimum Payments Under the Facility Operating Lease Details http://www.modularmedicalinc.com/role/LeasesTables 28 false false R29.htm 996012 - Disclosure - Stockholders??? Equity (Details) Sheet http://www.modularmedicalinc.com/role/StockholdersEquityDetails Stockholders??? Equity (Details) Details http://www.modularmedicalinc.com/role/StockholdersEquityTables 29 false false R30.htm 996013 - Disclosure - Stockholders??? Equity (Details) - Schedule of Warrants Outstanding Sheet http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable Stockholders??? Equity (Details) - Schedule of Warrants Outstanding Details http://www.modularmedicalinc.com/role/StockholdersEquityTables 30 false false R31.htm 996014 - Disclosure - Stock-Based Compensation (Details) Sheet http://www.modularmedicalinc.com/role/StockBasedCompensationDetails Stock-Based Compensation (Details) Details http://www.modularmedicalinc.com/role/StockBasedCompensationTables 31 false false R32.htm 996015 - Disclosure - Stock-Based Compensation (Details) - Schedule of Assumptions were used in the Fair-Value Method Sheet http://www.modularmedicalinc.com/role/ScheduleofAssumptionswereusedintheFairValueMethodTable Stock-Based Compensation (Details) - Schedule of Assumptions were used in the Fair-Value Method Details http://www.modularmedicalinc.com/role/StockBasedCompensationTables 32 false false R33.htm 996016 - Disclosure - Stock-Based Compensation (Details) - Schedule of Activity in the Shares Sheet http://www.modularmedicalinc.com/role/ScheduleofActivityintheSharesTable Stock-Based Compensation (Details) - Schedule of Activity in the Shares Details http://www.modularmedicalinc.com/role/StockBasedCompensationTables 33 false false R34.htm 996017 - Disclosure - Stock-Based Compensation (Details) - Schedule of RSU Activity under the Plan Sheet http://www.modularmedicalinc.com/role/ScheduleofRSUActivityunderthePlanTable Stock-Based Compensation (Details) - Schedule of RSU Activity under the Plan Details http://www.modularmedicalinc.com/role/StockBasedCompensationTables 34 false false R35.htm 996018 - Disclosure -

Stock-Based Compensation (Details) - Schedule of Outstanding and Exercisable Options Sheet http://www.modularmedicalinc.com/role/ScheduleofOutstandingandExercisableOptionsTable Stock-Based Compensation (Details) - Schedule of Outstanding and Exercisable Options Details http://www.modularmedicalinc.com/role/StockBasedCompensationTables 35 false false R36.htm 996019 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.modularmedicalinc.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.modularmedicalinc.com/role/CommitmentsandContingencies 36 false false R37.htm 996020 - Disclosure - Related Party Transactions (Details) Sheet http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://www.modularmedicalinc.com/role/RelatedPartyTransactions 37 false false All Reports Book All Reports ea0220455-10q_modular.htm modd-20240930.xsd modd-20240930_cal.xml modd-20240930_def.xml modd-20240930_lab.xml modd-20240930_pre.xml http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 54 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea0220455-10q_modular.htm": { "nsprefix": "modd", "nsuri": "http://www.modularmedicalinc.com/20240930", "dts": { "inline": { "local": ["ea0220455-10q_modular.htm"] }, "schema": { "local": ["modd-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024_def.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024_lab.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024_pre.xsd", "https://xbrl.sec.gov/dei/2024/dei-sub-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/sic/2024/sic-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["modd-20240930_cal.xml"] }, "definitionLink": { "local": ["modd-20240930_def.xml"] }, "labelLink": { "local": ["modd-20240930_lab.xml"] }, "presentationLink": { "local": ["modd-20240930_pre.xml"] } }, "keyStandard": 183, "keyCustom": 21, "axisStandard": 12, "axisCustom": 0, "memberStandard": 14, "memberCustom": 18, "hidden": { "total": 58, "http://fasb.org/us-gaap/2024": 47, "http://www.modularmedicalinc.com/20240930": 6, "http://xbrl.sec.gov/dei/2024": 5 }, "contextCount": 133, "entityCount": 1, "segmentCount": 34, "elementCount": 549, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 472, "http://xbrl.sec.gov/dei/2024": 29, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://xbrl.sec.gov/dei/role/document/Cover", "longName": "995100 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c0", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["b", "p", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["b", "p", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet", "longName": "995301 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "unique": true } }, "R3": { "role": "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet_Parentheticals", "longName": "995302 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)", "shortName": "Condensed Consolidated Balance Sheets (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPershares", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPershares", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement", "longName": "995303 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c4", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c4", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3", "longName": "995304 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity (Unaudited)", "shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c24", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true }, "uniqueAnchor": { "contextRef": "c28", "name": "modd:IssuanceOfCommonStockAndWarrantsInEquityOfferingNet", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "unique": true } }, "R6": { "role": "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow", "longName": "995305 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "unique": true } }, "R7": { "role": "http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPolicies", "longName": "995306 - Disclosure - The Company and Summary of Significant Accounting Policies", "shortName": "The Company and Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetail", "longName": "995307 - Disclosure - Consolidated Balance Sheet Detail", "shortName": "Consolidated Balance Sheet Detail", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.modularmedicalinc.com/role/Leases", "longName": "995308 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.modularmedicalinc.com/role/StockholdersEquity", "longName": "995309 - Disclosure - Stockholders\u2019 Equity", "shortName": "Stockholders\u2019 Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.modularmedicalinc.com/role/StockBasedCompensation", "longName": "995310 - Disclosure - Stock-Based Compensation", "shortName": "Stock-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null,

"ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.modularmedicalinc.com/role/IncomeTaxes", "longName": "995311 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.modularmedicalinc.com/role/CommitmentsandContingencies", "longName": "995312 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.modularmedicalinc.com/role/RelatedPartyTransactions", "longName": "995313 - Disclosure - Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true } }, "R15": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c4", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true }, "uniqueAnchor": null }, "R16": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c4", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ecd:Rule10b51ArrTrmntdFlag", "ecd:NonRule10b51ArrAdoptedFlag", "ecd:NonRule10b51ArrTrmntdFlag", "p", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c4", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ecd:Rule10b51ArrTrmntdFlag", "ecd:NonRule10b51ArrAdoptedFlag", "ecd:NonRule10b51ArrTrmntdFlag", "p", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy", "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)", "shortName": "Accounting Policies, by Policy (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "17", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesTables", "longName": "996001 - Disclosure - The Company and Summary of Significant Accounting Policies (Tables)", "shortName": "The Company and Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "18", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetailTables", "longName": "996002 - Disclosure - Consolidated Balance Sheet Detail (Tables)", "shortName": "Consolidated Balance Sheet Detail (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "19", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.modularmedicalinc.com/role/LeasesTables", "longName": "996003 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.modularmedicalinc.com/role/StockholdersEquityTables", "longName": "996004 - Disclosure - Stockholders\u2019 Equity (Tables)", "shortName": "Stockholders\u2019 Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.modularmedicalinc.com/role/StockBasedCompensationTables", "longName": "996005 - Disclosure - Stock-Based Compensation (Tables)", "shortName": "Stock-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesDetails", "longName": "996006 - Disclosure - The Company and Summary of Significant Accounting Policies (Details)", "shortName": "The Company and Summary of Significant Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "23", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.modularmedicalinc.com/role/ScheduleofDilutedNetLossPerShareTable", "longName": "996007 - Disclosure - The Company and Summary of Significant Accounting Policies (Details) - Schedule of Diluted Net Loss Per Share", "shortName": "The Company and Summary of Significant Accounting Policies (Details) - Schedule of Diluted Net Loss Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef":

"ea0220455-10q_modular.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.modularmedicalinc.com/role/ScheduleofPropertyandEquipmentNetTable", "longName": "996008 - Disclosure - Consolidated Balance Sheet Detail (Details) - Schedule of Property and Equipment, Net", "shortName": "Consolidated Balance Sheet Detail (Details) - Schedule of Property and Equipment, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.modularmedicalinc.com/role/ScheduleofAccruedExpensesTable", "longName": "996009 - Disclosure - Consolidated Balance Sheet Detail (Details) - Schedule of Accrued Expenses", "shortName": "Consolidated Balance Sheet Detail (Details) - Schedule of Accrued Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:AccruedEmployeeBenefitsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:AccruedEmployeeBenefitsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.modularmedicalinc.com/role/LeasesDetails", "longName": "996010 - Disclosure - Leases (Details)", "shortName": "Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "c62", "name": "us-gaap:PaymentsForRent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c62", "name": "us-gaap:PaymentsForRent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.modularmedicalinc.com/role/ScheduleofFutureMinimumPaymentsUndertheFacilityOperatingLeaseTable", "longName": "996011 - Disclosure - Leases (Details) - Schedule of Future Minimum Payments Under the Facility Operating Lease", "shortName": "Leases (Details) - Schedule of Future Minimum Payments Under the Facility Operating Lease", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.modularmedicalinc.com/role/StockholdersEquityDetails", "longName": "996012 - Disclosure - Stockholders\u2019 Equity (Details)", "shortName": "Stockholders\u2019 Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "c64", "name": "modd:compensationServicesEqual", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c64", "name": "modd:compensationServicesEqual", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable", "longName": "996013 - Disclosure - Stockholders\u2019 Equity (Details) - Schedule of Warrants Outstanding", "shortName": "Stockholders\u2019 Equity (Details) - Schedule of Warrants Outstanding", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "c74", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true }, "uniqueAnchor": { "contextRef": "c69", "name": "modd:NumberOfSharesWarrantsExercised", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "unique": true } }, "R31": { "role": "http://www.modularmedicalinc.com/role/StockBasedCompensationDetails", "longName": "996014 - Disclosure - Stock-Based Compensation (Details)", "shortName": "Stock-Based Compensation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.modularmedicalinc.com/role/ScheduleofAssumptionswereusedintheFairValueMethodTable", "longName": "996015 - Disclosure - Stock-Based Compensation (Details) - Schedule of Assumptions were used in the Fair-Value Method", "shortName": "Stock-Based Compensation (Details) - Schedule of Assumptions were used in the Fair-Value Method", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "c5", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["td", "tr", "table", "ix:continuation", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c5", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["td", "tr", "table", "ix:continuation", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.modularmedicalinc.com/role/ScheduleofActivityintheSharesTable", "longName": "996016 - Disclosure - Stock-Based Compensation (Details) - Schedule of Activity in the Shares", "shortName": "Stock-Based Compensation (Details) - Schedule of Activity in the Shares", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c17", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "ix:continuation", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true }, "uniqueAnchor": { "contextRef": "c4", "name": "modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardShareAwardsSharesAvailableForGrantInShareAwards", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "ix:continuation", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "unique": true } }, "R34": { "role": "http://www.modularmedicalinc.com/role/ScheduleofRSUActivityunderthePlanTable", "longName": "996017 - Disclosure - Stock-Based Compensation (Details) - Schedule of RSU Activity under the Plan", "shortName": "Stock-Based Compensation (Details) - Schedule of RSU Activity under the Plan", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c114", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true }, "uniqueAnchor": { "contextRef": "c112", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "unique": true } }, "R35": { "role": "http://www.modularmedicalinc.com/role/ScheduleofOutstandingandExercisableOptionsTable", "longName": "996018 - Disclosure - Stock-Based Compensation (Details) - Schedule of Outstanding and Exercisable Options", "shortName": "Stock-Based Compensation (Details) - Schedule of Outstanding and Exercisable Options", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c118", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c118", "name": "us-

gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.modularmedicalinc.com/role/CommitmentsandContingenciesDetails", "longName": "996019 - Disclosure - Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:PurchaseObligation", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:PurchaseObligation", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails", "longName": "996020 - Disclosure - Related Party Transactions (Details)", "shortName": "Related Party Transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c4", "name": "us-gaap:SalariesAndWages", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c4", "name": "us-gaap:SalariesAndWages", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0220455-10q_modular.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "The Company and Summary of Significant Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofAccruedExpensesTable"], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses", "label": "Accounts Payable and Accrued Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r25", "r443"] }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedEmployeeBenefitsCurrent", "crdr": "credit", "calculation": { "http://www.modularmedicalinc.com/role/ScheduleofAccruedExpensesTable": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofAccruedExpensesTable"], "lang": { "en-us": { "role": { "terseLabel": "Accrued wages and employee benefits", "label": "Accrued Employee Benefits, Current", "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r27"] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "http://www.modularmedicalinc.com/role/ScheduleofAccruedExpensesTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet", "http://www.modularmedicalinc.com/role/ScheduleofAccruedExpensesTable"], "lang": { "en-us": { "role": { "totalLabel": "Total", "terseLabel": "Accrued expenses", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r27"] }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrentAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Accrued Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.modularmedicalinc.com/role/ScheduleofPropertyandEquipmentNetTable": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofPropertyandEquipmentNetTable"], "lang": { "en-us": { "role": { "negatedLabel": "Less: accumulated depreciation and amortization", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": ["r19", "r82", "r307"] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": ["r513"] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": ["r35", "r443", "r656"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-In Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r333", "r592", "r593", "r594", "r596", "r640", "r657"] }, "dei_AdditionalSecurities462b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AdditionalSecurities462b", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Additional Securities. 462(b)" } } }, "auth_ref": ["r569"] }, "dei_AdditionalSecurities462bFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AdditionalSecurities462bFileNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Additional Securities, 462(b), File Number" } } }, "auth_ref": ["r569"] }, "dei_AdditionalSecuritiesEffective413b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AdditionalSecuritiesEffective413b", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Additional Securities Effective, 413(b)" } } }, "auth_ref": ["r567"] }, "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AddressTypeDomain", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": ["r526"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": ["r526"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": ["r526"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": ["r526"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "crdr": "credit", "presentation": ["http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",

"presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": ["r560"] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r476", "r487", "r503", "r538"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": ["r479", "r490", "r506", "r541"] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": ["r561"] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": ["r526"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": ["r533"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": ["r480", "r491", "r507", "r533", "r542", "r546", "r554"] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": ["r552"] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation (in Dollars)", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r219", "r227"] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": ["r483"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofDilutedNetLossPerShareTable"], "lang": { "en-us": { "role": { "terseLabel": "Anti-dilutive total", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r123"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofDilutedNetLossPerShareTable"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r13"] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofDilutedNetLossPerShareTable"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r13"] }, "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": { "xbrltype": "dateOrAsapItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Approximate Date of Commencement of Proposed Sale to Public", "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings." } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "totalLabel": "TOTAL ASSETS", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r60", "r66", "r83", "r98", "r126", "r130", "r139", "r140", "r145", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r253", "r255", "r268", "r300", "r367", "r429", "r430", "r443", "r455", "r611", "r612", "r646"] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "totalLabel": "TOTAL CURRENT ASSETS", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r79", "r87", "r98", "r145", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r253", "r255", "r268", "r443", "r611", "r612", "r646"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "CURRENT ASSETS", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": ["r483"] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorFirmId", "presentation": ["http://xbrl.sec.gov/dei/role/document/AuditInformation"], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": ["r468", "r471", "r483"] }, "dei_AuditorLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLineItems", "lang": { "en-us": { "role": { "label": "Auditor [Line Items]" } } }, "auth_ref": [] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLocation", "presentation": ["http://xbrl.sec.gov/dei/role/document/AuditInformation"], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": ["r468", "r471", "r483"] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorName", "presentation": ["http://xbrl.sec.gov/dei/role/document/AuditInformation"], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": ["r468", "r471", "r483"] }, "dei_AuditorOpinionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorOpinionTextBlock", "presentation": ["http://xbrl.sec.gov/dei/role/document/AuditInformation"], "lang": { "en-us": { "role": { "label": "Auditor Opinion [Text Block]" } } }, "auth_ref": ["r565"] }, "dei_AuditorTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorTable", "presentation": ["http://xbrl.sec.gov/dei/role/document/AuditInformation"], "lang": { "en-us": { "role": { "label": "Auditor [Table]" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": ["r549"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": ["r550"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": ["r545"] },

"ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": ["r545"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": ["r545"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": ["r545"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": ["r545"] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": ["r545"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofRSUActivityunderthePlanTable", "http://www.modularmedicalinc.com/role/StockBasedCompensationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r190", "r191", "r192", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r214", "r215", "r216", "r217", "r218"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": ["r548"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r547"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": ["r546"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": ["r546"] }, "us-gaap_BalanceSheetRelatedDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetRelatedDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Consolidated Balance Sheet Detail [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": ["http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "dei_BusinessContactMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "BusinessContactMember", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Business Contact [Member]", "documentation": "Business contact for the entity" } } }, "auth_ref": ["r471", "r483"] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": ["http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": ["r12"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet", "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents at beginning of period", "periodEndLabel": "Cash and cash equivalents at end of period", "terseLabel": "Cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r11", "r44", "r96"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r0", "r44"] }, "us-gaap_CashFDICInsuredAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFDICInsuredAmount", "crdr": "debit", "presentation": ["http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "FDIC insured amount (in Dollars)", "label": "Cash, FDIC Insured Amount", "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation." } } }, "auth_ref": [] }, "us-gaap_ChangeInAccountingEstimateLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ChangeInAccountingEstimateLineItems", "presentation": ["http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "The Company and Summary of Significant Accounting Policies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r108"] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r524"] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": ["r521"] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": ["r519"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable"], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock,

redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": ["r76", "r84", "r85", "r86", "r98", "r117", "r118", "r120", "r122", "r128", "r129", "r145", "r155", "r157", "r158", "r159", "r162", "r163", "r165", "r166", "r169", "r172", "r179", "r268", "r324", "r325", "r326", "r327", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r355", "r376", "r399", "r414", "r415", "r416", "r417", "r418", "r578", "r590", "r597"] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": ["http://www.modularmedicalinc.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r84", "r85", "r86", "r128", "r165", "r166", "r167", "r169", "r172", "r177", "r179", "r324", "r325", "r326", "r327", "r433", "r578", "r590"] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable", "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": ["r20"] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": ["http://www.modularmedicalinc.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable"], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price, Common stock (in Dollars per share)", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r180"] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightLineItems", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable"], "lang": { "en-us": { "role": { "label": "Schedule of Warrants Outstanding [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable"], "lang": { "en-us": { "role": { "periodEndLabel": "Number of Shares, balance", "terseLabel": "Number of Shares, Common stock", "label": "Class of Warrant or Right, Outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightTable", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame." } } }, "auth_ref": ["r20"] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": ["r525"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": ["r525"] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies (Note 7)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r31", "r61", "r301", "r354"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://www.modularmedicalinc.com/role/CommitmentsandContingencies"], "lang": { "en-us": { "role": { "terseLabel": "COMMITMENTS AND CONTINGENCIES", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r52", "r149", "r150", "r420", "r608", "r610"] }, "modd_CommitmentsandContingenciesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.modularmedicalinc.com/20240930", "localname": "CommitmentsandContingenciesDetailsTable", "presentation": ["http://www.modularmedicalinc.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": ["http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of shares reserved", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": ["r34"] }, "modd_CommonStockFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modularmedicalinc.com/20240930", "localname": "CommonStockFiveMember", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable"], "lang": { "en-us": { "role": { "terseLabel": "Common stock [Member]", "label": "Common Stock Five Member" } } }, "auth_ref": [] }, "modd_CommonStockFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modularmedicalinc.com/20240930", "localname": "CommonStockFourMember", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable"], "lang": { "en-us": { "role": { "terseLabel": "Common stock [Member]", "label": "Common Stock Four Member" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable", "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3", "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "verboseLabel": "Common stock [Member]", "netLabel": "Common Stock [Member]", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r445", "r446", "r447", "r449", "r450", "r451", "r452", "r592", "r593", "r596", "r640", "r655", "r657"] }, "modd_CommonStockOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modularmedicalinc.com/20240930", "localname": "CommonStockOneMember", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable"], "lang": { "en-us": { "role": { "terseLabel": "Common stock [Member]", "label": "Common Stock One Member" } } }, "auth_ref": [] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet_Parentheticals"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in Dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r34"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet_Parentheticals"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r34", "r355"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet_Parentheticals"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r34"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet_Parentheticals"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r7", "r34", "r355", "r373", "r657", "r658"] }, "modd_CommonStockThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modularmedicalinc.com/20240930", "localname":

"CommonStockThreeMember", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable"], "lang": { "en-us": { "role": { "terseLabel": "Common stock [Member]", "label": "Common Stock Three Member" } } }, "auth_ref": [] }, "modd_CommonStockTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modularmedicalinc.com/20240930", "localname": "CommonStockTwoMember", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable"], "lang": { "en-us": { "role": { "terseLabel": "Common stock [Member]", "label": "Common Stock Two Member" } } }, "auth_ref": [] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Common Stock, $0.001 par value, 100,000 shares authorized; 34,370 and 32,464 shares issued and outstanding as of September 30, 2024 and March 31, 2024, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r34", "r303", "r443"] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": ["r530"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": ["r529"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": ["r531"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": ["r528"] }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "presentation": ["http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Comprehensive Loss", "label": "Comprehensive Income, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for comprehensive income." } } }, "auth_ref": [] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComputerEquipmentMember", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofPropertyandEquipmentNetTable"], "lang": { "en-us": { "role": { "terseLabel": "Computer equipment and software [Member]", "label": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": ["http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Concentration of Credit Risk", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": ["r23", "r70"] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConstructionInProgressMember", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofPropertyandEquipmentNetTable"], "lang": { "en-us": { "role": { "terseLabel": "Construction-in-process [Member]", "label": "Construction in Progress [Member]", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "dei_ContactPersonnelEmailAddress": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContactPersonnelEmailAddress", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Contact Personnel Email Address", "documentation": "Email address of contact personnel." } } }, "auth_ref": [] }, "dei_ContactPersonnelFaxNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContactPersonnelFaxNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Contact Personnel Fax Number", "documentation": "Fax Number of contact personnel." } } }, "auth_ref": ["r471"] }, "dei_ContactPersonnelName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContactPersonnelName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Contact Personnel Name", "documentation": "Name of contact personnel" } } }, "auth_ref": [] }, "dei_ContainedFileInformationFileDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContainedFileInformationFileDescription", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Contained File Information, File Description", "documentation": "The description of the contained file." } } }, "auth_ref": [] }, "dei_ContainedFileInformationFileName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContainedFileInformationFileName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Contained File Information, File Name", "documentation": "The name of the contained file." } } }, "auth_ref": [] }, "dei_ContainedFileInformationFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContainedFileInformationFileNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Contained File Information, File Number", "documentation": "The SEC Document Number of the contained file." } } }, "auth_ref": [] }, "dei_ContainedFileInformationFileType": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContainedFileInformationFileType", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Contained File Information, File Type", "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc.)." } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DelayedOrContinuousOffering": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DelayedOrContinuousOffering", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Delayed or Continuous Offering" } } }, "auth_ref": ["r495", "r496", "r510"] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAndAmortization", "crdr": "debit", "calculation": { "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization, Nonproduction", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": ["r4", "r18"] }, "modd_DeviceIntegrationAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modularmedicalinc.com/20240930", "localname": "DeviceIntegrationAgreementMember", "presentation": ["http://www.modularmedicalinc.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Device Integration Agreement [Member]", "label": "Device Integration Agreement Member" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://www.modularmedicalinc.com/role/StockBasedCompensation"], "lang": { "en-us": { "role": { "terseLabel": "STOCK-BASED COMPENSATION", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r186", "r189", "r220", "r221", "r222", "r435"] }, "dei_DividendOrInterestReinvestmentPlanOnly": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DividendOrInterestReinvestmentPlanOnly", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Dividend or Interest Reinvestment Plan Only" } } }, "auth_ref": ["r495", "r496", "r510"] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": ["r471"] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": ["r468", "r471", "r483"] }, "dei_DocumentCopyrightInformation": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentCopyrightInformation", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Copyright Information", "documentation": "The copyright information for the document." } } }, "auth_ref": [] }, "dei_DocumentCreationDate": {

"xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentCreationDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Creation Date", "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different." } } }, "auth_ref": [] }, "dei_DocumentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentDescription", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Description", "documentation": "The description of the document." } } }, "auth_ref": [] }, "dei_DocumentDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentDomain", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document [Domain]", "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards." } } }, "auth_ref": [] }, "dei_DocumentEffectiveDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentEffectiveDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Effective Date", "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases." } } }, "auth_ref": [] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": ["r468", "r471", "r483", "r534"] }, "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Financial Statement Restatement Recovery Analysis [Flag]", "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)." } } }, "auth_ref": ["r468", "r471", "r483", "r534"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationDocumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationDocumentAxis", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Information, Document [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTextBlock", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Information [Text Block]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Name", "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the <FILENAME> field of EDGAR filings, such as 'htm_25911.htm', 'exhibit1.htm', 'v105727_8k.txt'." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r469"] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": ["r457"] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": ["r471"] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": ["r471"] }, "dei_DocumentSubtitle": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentSubtitle", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Subtitle", "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth'." } } }, "auth_ref": [] }, "dei_DocumentSynopsis": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentSynopsis", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Synopsis", "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period'" } } }, "auth_ref": [] }, "dei_DocumentTitle": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTitle", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Title", "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report'." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r511"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentVersion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentVersion", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Document Version", "documentation": "The version identifier of the document." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": ["r460"] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": ["r523"] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Basic (in Dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or

unit outstanding during the reporting period." } } }, "auth_ref": ["r93", "r105", "r106", "r107", "r108", "r109", "r110", "r115", "r117", "r120", "r121", "r122", "r125", "r249", "r252", "r265", "r266", "r297", "r312", "r424"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in Dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r93", "r105", "r106", "r107", "r108", "r109", "r110", "r117", "r120", "r121", "r122", "r125", "r249", "r252", "r265", "r266", "r297", "r312", "r424"] }, "us-gaap_EarningsPerShareDilutedLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDilutedLineItems", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofDilutedNetLossPerShareTable"], "lang": { "en-us": { "role": { "label": "Schedule of Diluted Net Loss Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r117", "r118", "r120"] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": ["http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Per-Share Amounts", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": ["r13", "r14", "r124"] }, "dei_EffectiveAfter60Days486a": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveAfter60Days486a", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective after 60 Days, 486(a)" } } }, "auth_ref": ["r573"] }, "dei_EffectiveOnDate486a": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveOnDate486a", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective on Date, 486(a)" } } }, "auth_ref": ["r573"] }, "dei_EffectiveOnDate486b": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveOnDate486b", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective on Date, 486(b)" } } }, "auth_ref": ["r574"] }, "dei_EffectiveOnSetDate486a": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveOnSetDate486a", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective on Set Date, 486(a)" } } }, "auth_ref": ["r573"] }, "dei_EffectiveOnSetDate486b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveOnSetDate486b", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective on Set Date, 486(b)" } } }, "auth_ref": ["r574"] }, "dei_EffectiveUponFiling462e": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveUponFiling462e", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective Upon Filing, 462(e)" } } }, "auth_ref": ["r572"] }, "dei_EffectiveUponFiling486b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveUponFiling486b", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective upon Filing, 486(b)" } } }, "auth_ref": ["r574"] }, "dei_EffectiveWhenDeclaredSection8c": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EffectiveWhenDeclaredSection8c", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Effective when Declared, Section 8(c)" } } }, "auth_ref": ["r576"] }, "modd_EightPointSixOneToSeventeenPointSevenZeroMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modularmedicalinc.com/20240930", "localname": "EightPointSixOneToSeventeenPointSevenZeroMember", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofOutstandingandExercisableOptionsTable"], "lang": { "en-us": { "role": { "terseLabel": "$8.61 - $17.70 [Member]", "label": "Eight Point Six One To Seventeen Point Seven Zero Member" } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitiesTable", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entities [Table]", "documentation": "Container to assemble all relevant information about each entity associated with the document instance" } } }, "auth_ref": [] }, "dei_EntityAccountingStandard": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAccountingStandard", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Accounting Standard", "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'. This is distinct from the Document Accounting Standard element." } } }, "auth_ref": [] }, "dei_EntityAddressAddressDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressDescription", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Description", "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressesAddressTypeAxis", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityAddressesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressesLineItems", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Addresses [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityAddressesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressesTable", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Addresses [Table]", "documentation": "Container of address information for the entity" } } }, "auth_ref": ["r459"] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": ["r463"] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r459"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership

Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] },
"dei_EntityContactPersonnelLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityContactPersonnelLineItems", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity
Contact Personnel [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to
disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] },
"dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityCurrentReportingStatus", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity
Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13
or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file
such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's
current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": ["http://xbrl.sec.gov/dei/role/document/AuditInformation",
"http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the
entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are
corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical
segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": {
"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation":
"Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r459"] }, "dei_EntityExTransitionPeriod": { "xbrltype":
"booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an
emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting
standards." } } }, "auth_ref": ["r575"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityFileNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity File
Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence
number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] },
"dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory",
"presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation":
"Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these
categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing
containing the related disclosure." } } }, "auth_ref": ["r459"] }, "dei_EntityHomeCountryISOCode": { "xbrltype": "countryCodeItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityHomeCountryISOCode", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang":
{ "en-us": { "role": { "label": "Entity Home Country ISO Code", "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If
home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity Incorporation, State
Country Code' element." } } }, "auth_ref": [] }, "dei_EntityIncorporationDateOfIncorporation": { "xbrltype": "dateItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationDateOfIncorporation", "presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, Date of Incorporation",
"documentation": "Date when an entity was incorporated" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype":
"edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code",
"documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] },
"dei_EntityInformationFormerLegalOrRegisteredName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityInformationFormerLegalOrRegisteredName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-
us": { "role": { "label": "Entity Information, Former Legal or Registered Name", "documentation": "Former Legal or Registered Name of an entity" }
} }, "auth_ref": [] }, "dei_EntityInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityInformationLineItems", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity
Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose
reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] },
"dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityInteractiveDataCurrent", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity
Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File
required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files)." } } }, "auth_ref": ["r564"] }, "dei_EntityInvCompanyType": { "xbrltype": "invCompanyType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityInvCompanyType", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": {
"en-us": { "role": { "label": "Entity Inv Company Type", "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No
Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-
4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face
Amount Certificate Company), S-6 (UIT, Non-Insurance Product)." } } }, "auth_ref": ["r563"] }, "dei_EntityLegalForm": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityLegalForm", "presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Legal Form", "documentation": "The details of the
entity's legal form. Examples are partnership, limited liability company, trust, etc." } } }, "auth_ref": [] },
"dei_EntityListingDepositoryReceiptRatio": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityListingDepositoryReceiptRatio", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label":
"Entity Listing, Depository Receipt Ratio", "documentation": "The number of underlying shares represented by one American Depository Receipt
(ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2
ADR's then the value would be represented as '0.5'." } } }, "auth_ref": [] }, "dei_EntityListingDescription": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityListingDescription", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": {
"en-us": { "role": { "label": "Entity Listing, Description", "documentation": "Description of the kind of listing the entity has on the exchange, if
necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security." } } }, "auth_ref": [] },
"dei_EntityListingForeign": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingForeign",
"presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Listing, Foreign", "documentation":
"Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt." } } }, "auth_ref": [] },
"dei_EntityListingParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityListingParValuePerShare", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity
Listing, Par Value Per Share", "documentation": "The par value per share of security quoted in same currency as Trading currency. Example:
'0.01'." } } }, "auth_ref": [] }, "dei_EntityListingPrimary": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityListingPrimary", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Listing,
Primary", "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity." } } },
"auth_ref": [] }, "dei_EntityListingSecurityTradingCurrency": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityListingSecurityTradingCurrency", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label":
"Entity Listing, Security Trading Currency", "documentation": "The three character ISO 4217 code for the currency in which the security is quoted.
Example: 'USD'" } } }, "auth_ref": [] }, "dei_EntityListingsExchangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityListingsExchangeAxis", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label":
"Entity Listings, Exchange [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the
table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityListingsLineItems": { "xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingsLineItems", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"],
"lang": { "en-us": { "role": { "label": "Entity Listings [Line Items]", "documentation": "Line items represent financial concepts included in a table.
These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } },
"auth_ref": [] }, "dei_EntityListingsTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityListingsTable", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Listings
[Table]", "documentation": "Container for exchange listing information for an entity" } } }, "auth_ref": [] }, "dei_EntityNumberOfEmployees": {
"xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityNumberOfEmployees", "presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Number of Employees", "documentation": "Number of
persons employed by the Entity" } } }, "auth_ref": [] }, "dei_EntityPhoneFaxNumbersLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityPhoneFaxNumbersLineItems", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"],
"lang": { "en-us": { "role": { "label": "Entity Phone Fax Numbers [Line Items]", "documentation": "Line items represent financial concepts included
in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." }
} }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityPrimarySicNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Primary

SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": ["r483"] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r459"] }, "dei_EntityReportingCurrencyISOCode": { "xbrltype": "currencyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityReportingCurrencyISOCode", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Reporting Currency ISO Code", "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD'." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r459"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r459"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r459"] }, "dei_EntityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTextBlock", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity [Text Block]", "documentation": "Container to serve as parent of six Entity related Table concepts." } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": ["r566"] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": ["r517"] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": ["r559"] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": ["r559"] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": ["r559"] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable", "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3", "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r7", "r77", "r90", "r91", "r92", "r100", "r101", "r102", "r104", "r109", "r111", "r113", "r127", "r146", "r147", "r148", "r181", "r239", "r240", "r246", "r247", "r248", "r250", "r251", "r252", "r257", "r258", "r259", "r260", "r261", "r262", "r264", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r277", "r287", "r311", "r317", "r318", "r319", "r333", "r399"] }, "us-gaap_EquityFairValueAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityFairValueAdjustment", "crdr": "credit", "presentation": ["http://www.modularmedicalinc.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common stock fair value", "label": "Equity, Fair Value Adjustment", "documentation": "Amount of addition (reduction) to the amount at which an instrument classified in shareholders' equity could be incurred (settled) in a current transaction between willing parties." } } }, "auth_ref": [] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": ["r527"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": ["r476", "r487", "r503", "r538"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": ["r473", "r484", "r500", "r535"] }, "dei_ExchangeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ExchangeDomain", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Exchange [Domain]", "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383." } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": ["r533"] }, "modd_ExercisePriceOfThePrefundedWarrants": { "xbrltype": "perShareItemType", "nsuri": "http://www.modularmedicalinc.com/20240930", "localname": "ExercisePriceOfThePrefundedWarrants", "presentation": ["http://www.modularmedicalinc.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Exercise price of the pre-funded warrants (in Dollars per share)", "documentation": "The price per of exercise price of the pre-funded warrants.", "label": "Exercise Price Of The Prefunded Warrants" } } }, "auth_ref": [] }, "dei_ExhibitsOnly462d": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ExhibitsOnly462d", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Exhibits Only, 462(d)" } } }, "auth_ref": ["r571"] }, "dei_ExhibitsOnly462dFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ExhibitsOnly462dFileNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Exhibits Only, 462(d), File Number" } } }, "auth_ref": ["r571"] }, "modd_ExpirationCommonStock": { "xbrltype": "stringItemType", "nsuri": "http://www.modularmedicalinc.com/20240930", "localname": "ExpirationCommonStock", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable"], "lang": { "en-us": { "role": { "terseLabel": "Expiration Dates, Common stock", "documentation": "Expiration common stock.", "label": "Expiration Common Stock" } } }, "auth_ref": [] }, "modd_ExpirationDatesWarrantsExercisedinDollarsPerShare": { "xbrltype": "stringItemType", "nsuri": "http://www.modularmedicalinc.com/20240930", "localname": "ExpirationDatesWarrantsExercisedinDollarsPerShare", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable"], "lang": { "en-us": { "role": { "terseLabel": "Expiration Dates, Warrants exercised", "documentation": "Expiration dates warrants exercised.", "label": "Expiration Dates Warrants Exercisedin Dollars Per Share" } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": ["http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value of Financial Instruments", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": ["r6"] }, "us-gaap_FinancingReceivableUnamortizedLoanFeeCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivableUnamortizedLoanFeeCost", "crdr": "debit", "presentation": ["http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Unamortized compensation cost (in Dollars)", "label": "Financing Receivable, Unamortized Loan Cost (Fee)", "documentation": "Amount of unamortized loan commitment, origination, and other costs (fees) on financing receivable recognized as adjustment to yield. Excludes financing receivable covered under loss sharing agreement." } } }, "auth_ref": ["r144", "r577", "r606"] },

"ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r480", "r491", "r507", "r542"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r480", "r491", "r507", "r542"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r480", "r491", "r507", "r542"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": ["r480", "r491", "r507", "r542"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r480", "r491", "r507", "r542"] }, "dei_FormerAddressMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "FormerAddressMember", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Former Address [Member]", "documentation": "Former address for entity" } } }, "auth_ref": ["r470", "r494"] }, "dei_FormerFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "FormerFiscalYearEndDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Former Fiscal Year End Date", "documentation": "Former end date of previous fiscal years" } } }, "auth_ref": [] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": ["r522"] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r42", "r379"] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "IcfrAuditorAttestationFlag", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": ["r468", "r471", "r483"] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "totalLabel": "Loss before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r40", "r63", "r65", "r298", "r309", "r426", "r429", "r599", "r601", "r602", "r603", "r604"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Taxes [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": ["http://www.modularmedicalinc.com/role/IncomeTaxes"], "lang": { "en-us": { "role": { "terseLabel": "INCOME TAXES", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": ["r99", "r231", "r233", "r234", "r235", "r236", "r237", "r238", "r241", "r243", "r244", "r245", "r329", "r436"] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Provision for income taxes", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r67", "r75", "r112", "r113", "r126", "r131", "r140", "r232", "r233", "r242", "r314", "r436"] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued expenses", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": ["r3"] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Change in lease liability", "label": "Increase (Decrease) in Operating Lease Liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": ["r582", "r589"] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract", "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Changes in assets and liabilities:", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": ["r3"] }, "modd_IncreaseDecreaseLeaseRightofuseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.modularmedicalinc.com/20240930", "localname": "IncreaseDecreaseLeaseRightofuseAsset", "crdr": "debit", "calculation": { "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Lease right-of-use asset", "documentation": "Lease right-of-use asset.", "label": "Increase Decrease Lease Rightofuse Asset" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": ["r480", "r491", "r507", "r533", "r542", "r546", "r554"] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": ["r552"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": ["r472", "r558"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": ["r472", "r558"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri":

"http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not
Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": ["r472", "r558"] },
"dei_InvestmentCompanyActFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"InvestmentCompanyActFileNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label":
"Investment Company Act File Number" } } }, "auth_ref": ["r496", "r497", "r498", "r499"] }, "dei_InvestmentCompanyActRegistration": {
"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "InvestmentCompanyActRegistration", "presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Investment Company Act Registration" } } }, "auth_ref": [
"r512"] }, "dei_InvestmentCompanyRegistrationAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"InvestmentCompanyRegistrationAmendment", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": {
"label": "Investment Company Registration Amendment" } } }, "auth_ref": ["r512"] }, "dei_InvestmentCompanyRegistrationAmendmentNumber":
{ "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"InvestmentCompanyRegistrationAmendmentNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role":
{ "label": "Investment Company Registration Amendment Number" } } }, "auth_ref": ["r512"] },
"modd_IssuanceOfCommonStockAndWarrantsInEquityOfferingNet": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.modularmedicalinc.com/20240930", "localname": "IssuanceOfCommonStockAndWarrantsInEquityOfferingNet", "crdr": "credit",
"presentation": ["http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of
common stock and warrants in equity offering, net", "documentation": "Amount of issuance of common stock and warrants in equity offering, net.",
"label": "Issuance Of Common Stock And Warrants In Equity Offering Net" } } }, "auth_ref": [] },
"modd_IssuanceOfCommonStockAndWarrantsInEquityOfferingNetinShares": { "xbrltype": "sharesItemType", "nsuri":
"http://www.modularmedicalinc.com/20240930", "localname": "IssuanceOfCommonStockAndWarrantsInEquityOfferingNetinShares",
"presentation": ["http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of
common stock and warrants in equity offering, net (in Shares)", "documentation": "Number of Issuance of common stock and warrants in equity
offering, net.", "label": "Issuance Of Common Stock And Warrants In Equity Offering Netin Shares" } } }, "auth_ref": [] }, "us-
gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IssuanceOfStockAndWarrantsForServicesOrClaims", "crdr": "debit", "calculation": {
"http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": {
"terseLabel": "Shares for services", "label": "Issuance of Stock and Warrants for Services or Claims", "documentation": "Fair value of share-based
compensation granted to nonemployees as payment for services rendered or acknowledged claims." } } }, "auth_ref": ["r4"] }, "us-
gaap_LeaseContractualTermAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LeaseContractualTermAxis", "presentation": ["http://www.modularmedicalinc.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "label":
"Lease Contractual Term [Axis]", "documentation": "Information by contractual term of lease arrangement." } } }, "auth_ref": ["r286", "r581"] },
"us-gaap_LeaseContractualTermDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LeaseContractualTermDomain", "presentation": ["http://www.modularmedicalinc.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "label":
"Lease Contractual Term [Domain]", "documentation": "Contractual term of lease arrangement." } } }, "auth_ref": ["r286", "r581"] }, "us-
gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LeaseholdImprovementsMember", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofPropertyandEquipmentNetTable"],
"lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements [Member]", "label": "Leasehold Improvements [Member]", "documentation":
"Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": ["r51", "r285"] }, "us-gaap_LeasesAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" }
} }, "auth_ref": [] }, "modd_LeasesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.modularmedicalinc.com/20240930",
"localname": "LeasesDetailsTable", "presentation": ["http://www.modularmedicalinc.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "label":
"Leases (Details) [Table]" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "LegalEntityAxis", "presentation": ["http://xbrl.sec.gov/dei/role/document/AuditInformation",
"http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal
entities associated with a report." } } }, "auth_ref": [] }, "dei_LegalEntityIdentifier": { "xbrltype": "legalEntityIdentifierItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityIdentifier", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-
us": { "role": { "label": "Legal Entity Identifier", "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as
LEI." } } }, "auth_ref": ["r456"] }, "us-gaap_LegalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LegalFees", "crdr": "debit", "presentation": ["http://www.modularmedicalinc.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": {
"terseLabel": "Legal fees", "label": "Legal Fees", "documentation": "The amount of expense provided in the period for legal costs incurred on or
before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings." } } },
"auth_ref": ["r583"] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LesseeLeasesPolicyTextBlock", "presentation": ["http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"], "lang": {
"en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for
leasing arrangement entered into by lessee." } } }, "auth_ref": ["r281"] }, "us-gaap_LesseeOperatingLeaseDiscountRate": { "xbrltype":
"percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseDiscountRate", "presentation": [
"http://www.modularmedicalinc.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Discount rate", "label": "Lessee, Operating
Lease, Discount Rate", "documentation": "Discount rate used by lessee to determine present value of operating lease payments." } } }, "auth_ref": [
"r441"] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [
"http://www.modularmedicalinc.com/role/LeasesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Future Minimum Payments Under
the Facility Operating Lease", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular
disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows
to operating lease liability recognized in statement of financial position." } } }, "auth_ref": ["r644"] }, "us-
gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": {
"http://www.modularmedicalinc.com/role/ScheduleofFutureMinimumPaymentsUndertheFacilityOperatingLeaseTable": { "parentTag": null,
"weight": null, "order": null, "root": true } }, "presentation": [
"http://www.modularmedicalinc.com/role/ScheduleofFutureMinimumPaymentsUndertheFacilityOperatingLeaseTable"], "lang": { "en-us": { "role":
{ "totalLabel": "Total future lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's
undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": ["r284"] }, "us-
gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": {
"http://www.modularmedicalinc.com/role/ScheduleofFutureMinimumPaymentsUndertheFacilityOperatingLeaseTable": { "parentTag": "us-
gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.modularmedicalinc.com/role/ScheduleofFutureMinimumPaymentsUndertheFacilityOperatingLeaseTable"], "lang": { "en-us": { "role":
{ "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted
obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods
when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r284"] }, "us-
gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": {
"http://www.modularmedicalinc.com/role/ScheduleofFutureMinimumPaymentsUndertheFacilityOperatingLeaseTable": { "parentTag": "us-
gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.modularmedicalinc.com/role/ScheduleofFutureMinimumPaymentsUndertheFacilityOperatingLeaseTable"], "lang": { "en-us": { "role":
{ "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted
obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods
when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r284"] }, "us-
gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": {
"http://www.modularmedicalinc.com/role/ScheduleofFutureMinimumPaymentsUndertheFacilityOperatingLeaseTable": { "parentTag": "us-
gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.modularmedicalinc.com/role/ScheduleofFutureMinimumPaymentsUndertheFacilityOperatingLeaseTable"], "lang": { "en-us": { "role":
{ "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's
undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder
of current fiscal year." } } }, "auth_ref": ["r644"] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr":
"credit", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofFutureMinimumPaymentsUndertheFacilityOperatingLeaseTable"],

"lang": { "en-us": { "role": { "negatedLabel": "Less: Imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": ["r284"] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": ["http://www.modularmedicalinc.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Lease term", "label": "Lessee, Operating Lease, Term of Contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r643"] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": ["http://www.modularmedicalinc.com/role/Leases"], "lang": { "en-us": { "role": { "terseLabel": "LEASES", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": ["r276"] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r10", "r26", "r27", "r28", "r29", "r30", "r31", "r32", "r98", "r145", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r254", "r255", "r256", "r268", "r353", "r425", "r455", "r611", "r646", "r647"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r39", "r62", "r305", "r443", "r591", "r607", "r642"] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "totalLabel": "TOTAL CURRENT LIABILITIES", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r28", "r80", "r98", "r145", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r254", "r255", "r256", "r268", "r443", "r611", "r646", "r647"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "CURRENT LIABILITIES", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LoansAndLeasesReceivableDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoansAndLeasesReceivableDisclosureLineItems", "presentation": ["http://www.modularmedicalinc.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "label": "Leases [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_MachineryAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MachineryAndEquipmentMember", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofPropertyandEquipmentNetTable"], "lang": { "en-us": { "role": { "terseLabel": "Machinery and equipment [Member]", "label": "Machinery and Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofAssumptionswereusedintheFairValueMethodTable", "http://www.modularmedicalinc.com/role/ScheduleofOutstandingandExercisableOptionsTable", "http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Maximum [Member]", "label": "Maximum [Member]" } } }, "auth_ref": ["r151", "r152", "r153", "r154", "r184", "r228", "r267", "r295", "r315", "r316", "r322", "r345", "r346", "r406", "r407", "r408", "r409", "r410", "r421", "r422", "r432", "r433", "r434", "r437", "r438", "r439", "r440", "r444", "r613", "r648", "r649", "r650", "r651", "r652", "r653"] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": ["r525"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": ["r525"] }, "modd_MilestoneBonusProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modularmedicalinc.com/20240930", "localname": "MilestoneBonusProgramMember", "presentation": ["http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Milestone Bonus Program [Member]", "label": "Milestone Bonus Program Member" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofAssumptionswereusedintheFairValueMethodTable", "http://www.modularmedicalinc.com/role/ScheduleofOutstandingandExercisableOptionsTable", "http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Minimum [Member]", "label": "Minimum [Member]" } } }, "auth_ref": ["r151", "r152", "r153", "r154", "r184", "r228", "r267", "r295", "r315", "r316", "r322", "r345", "r346", "r406", "r407", "r408", "r409", "r410", "r421", "r422", "r432", "r433", "r434", "r437", "r438", "r439", "r444", "r613", "r648", "r649", "r650", "r651", "r652", "r653"] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": ["r545"] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": ["r553"] }, "dei_NameChangeEventDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NameChangeEventDateAxis", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Name Change Event Date [Axis]", "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them. The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type." } } }, "auth_ref": [] }, "dei_NameChangeEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NameChangeEventLineItems", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Name Change Event [Line Items]", "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table." } } }, "auth_ref": [] }, "dei_NameChangeEventTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NameChangeEventTable", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Name Change Event [Table]", "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period." } } }, "auth_ref": [] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": ["r526"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r95"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0,

"order": 2.0 } }, "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r95"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r44", "r45", "r46"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedCashFlow", "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement", "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "verboseLabel": "Net loss", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r41", "r46", "r64", "r78", "r88", "r89", "r92", "r98", "r103", "r105", "r106", "r107", "r108", "r109", "r112", "r113", "r119", "r145", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r249", "r252", "r266", "r268", "r310", "r375", "r397", "r398", "r453", "r611"] }, "modd_NetOfForfeituresOptionsCancelled": { "xbrltype": "sharesItemType", "nsuri": "http://www.modularmedicalinc.com/20240930", "localname": "NetOfForfeituresOptionsCancelled", "presentation": ["http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Options cancelled", "documentation": "The shares of options cancelled.", "label": "Net Of Forfeitures Options Cancelled" } } }, "auth_ref": [] }, "modd_NetOfForfeituresOptionsGranted": { "xbrltype": "sharesItemType", "nsuri": "http://www.modularmedicalinc.com/20240930", "localname": "NetOfForfeituresOptionsGranted", "presentation": ["http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Options granted", "documentation": "The shares of options granted.", "label": "Net Of Forfeitures Options Granted" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Recently Issued Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "dei_NewEffectiveDateForPreviousFiling": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NewEffectiveDateForPreviousFiling", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "New Effective Date for Previous Filing" } } }, "auth_ref": ["r496", "r497", "r498", "r499"] }, "dei_NoSubstantiveChanges462c": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoSubstantiveChanges462c", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "No Substantive Changes, 462(c)" } } }, "auth_ref": ["r570"] }, "dei_NoSubstantiveChanges462cFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoSubstantiveChanges462cFileNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "No Substantive Changes, 462(c), File Number" } } }, "auth_ref": ["r570"] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": ["r525"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": ["r480", "r491", "r507", "r533", "r542"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r516"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r515"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": ["r533"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r553"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r553"] }, "modd_NonemployeeDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modularmedicalinc.com/20240930", "localname": "NonemployeeDirectorsMember", "presentation": ["http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Non-employee Directors [Member]", "label": "Nonemployee Directors Member" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": ["http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Business segment (in segment)", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": ["r430", "r600"] }, "modd_NumberOfSharesWarrantsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.modularmedicalinc.com/20240930", "localname": "NumberOfSharesWarrantsExercised", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable"], "lang": { "en-us": { "role": { "terseLabel": "Number of Shares, Warrants exercised", "documentation": "Number of shares warrants exercised.", "label": "Number Of Shares Warrants Exercised" } } }, "auth_ref": [] }, "us-gaap_OfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OfficeEquipmentMember", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofPropertyandEquipmentNetTable"], "lang": { "en-us": { "role": { "terseLabel": "Office equipment [Member]", "label": "Office Equipment [Member]", "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine." } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri":

"http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": {
"http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } },
"presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r65", "r426", "r599", "r601", "r602", "r603", "r604"] }, "us-gaap_OperatingLeaseLiability": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [
"http://www.modularmedicalinc.com/role/ScheduleofFutureMinimumPaymentsUndertheFacilityOperatingLeaseTable"], "lang": { "en-us": { "role":
{ "terseLabel": "Present value of lease liability", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": ["r279"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": {
"http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } },
"presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Short-term lease liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r279"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": {
"http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } },
"presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Long-term lease liabilities", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r279"] }, "us-gaap_OperatingLeasePayments": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [
"http://www.modularmedicalinc.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash paid", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": ["r280", "r282"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": {
"http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } },
"presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Right of use asset, net", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r278"] }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "OperatingLeasesFutureMinimumPaymentsDueAbstract", "lang": { "en-us": { "role": { "label":
"Schedule of Future Minimum Payments Under the Facility Operating Lease [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "presentation": [
"http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPolicies"], "lang": { "en-us": { "role": { "terseLabel":
"THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles." } } }, "auth_ref": ["r47",
"r48", "r49", "r59"] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": {
"http://www.modularmedicalinc.com/role/ScheduleofAccruedExpensesTable": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0,
"order": 2.0 } }, "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofAccruedExpensesTable"], "lang": { "en-us": { "role": {
"terseLabel": "Other", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r27"] }, "dei_OtherAddressMember": { "xbrltype":
"domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherAddressMember", "presentation": [
"http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Other Address [Member]", "documentation": "Other address for entity" } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "OtherCommitmentsLineItems", "presentation": ["http://www.modularmedicalinc.com/role/CommitmentsandContingenciesDetails"],
"lang": { "en-us": { "role": { "label": "Commitments and Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_OtherIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherIncome", "crdr": "credit", "calculation": { "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } },
"presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Other income", "label": "Other Income", "documentation": "Amount of revenue and income classified as other." } } }, "auth_ref": ["r313", "r377", "r411",
"r412", "r413"] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": ["r525"] }, "dei_OtherReportingStandardItemNumber":
{ "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"OtherReportingStandardItemNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label":
"Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": ["r471"] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"],
"lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r478", "r489", "r505", "r540"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype":
"monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount",
"terseLabel": "Compensation Amount" } } }, "auth_ref": ["r481", "r492", "r508", "r543"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel":
"Name" } } }, "auth_ref": ["r481", "r492", "r508", "r543"] }, "dei_ParentEntityLegalName": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "ParentEntityLegalName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": {
"en-us": { "role": { "label": "Parent Entity Legal Name", "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": {
"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": {
"role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r514"] }, "us-gaap_PaymentsForRent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRent", "crdr":
"credit", "presentation": ["http://www.modularmedicalinc.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Rent expense",
"label": "Payments for Rent", "documentation": "Cash payments to lessor's for use of assets under operating leases." } } }, "auth_ref": ["r2"] },
"us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": {
"http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
"weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": {
"negatedLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r43"] },
"ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": ["r524"] },
"ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r524"] },
"ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r516"] }, "ecd_PeoMember": { "xbrltype":
"domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": ["r533"]
}, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [

"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": ["r526"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": ["r515"] }, "modd_PercentageOfAnnualRentIncreases": { "xbrltype": "percentItemType", "nsuri": "http://www.modularmedicalinc.com/20240930", "localname": "PercentageOfAnnualRentIncreases", "presentation": ["http://www.modularmedicalinc.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Annual rent increases percentage", "documentation": "Represent the percentage of annual rent increases.", "label": "Percentage Of Annual Rent Increases" } } }, "auth_ref": [] }, "dei_PhoneFaxNumberDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PhoneFaxNumberDescription", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Phone Fax Number Description", "documentation": "Description of Phone or Fax Number" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": ["http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": ["r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639"] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": ["http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": ["r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639"] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": ["r517"] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": ["r562"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": ["r516"] }, "dei_PostEffectiveAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PostEffectiveAmendment", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Post-Effective Amendment" } } }, "auth_ref": ["r457"] }, "dei_PostEffectiveAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PostEffectiveAmendmentNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Post-Effective Amendment Number", "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective." } } }, "auth_ref": ["r457"] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": ["r464"] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": ["r466"] }, "dei_PreEffectiveAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreEffectiveAmendment", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Pre-Effective Amendment" } } }, "auth_ref": ["r457"] }, "dei_PreEffectiveAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreEffectiveAmendmentNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Pre-Effective Amendment Number", "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective." } } }, "auth_ref": ["r457"] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet_Parentheticals"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in Dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r33", "r165"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet_Parentheticals"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r33", "r355"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet_Parentheticals"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued", "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r33", "r165"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet_Parentheticals"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r33", "r355", "r373", "r657", "r658"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock, $0.001 par value, 5,000 shares authorized, none issued and outstanding", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r33", "r302", "r443"] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r586"] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": ["http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Reclassifications", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": ["r584"] }, "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromDebtNetOfIssuanceCosts", "crdr": "debit", "presentation": ["http://www.modularmedicalinc.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds", "label": "Proceeds from Debt, Net of Issuance Costs", "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination." } } }, "auth_ref": ["r94"] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from at-the-market sales of stock, net", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": ["r1"] }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "calculation": { "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercise of common stock purchase warrants", "label": "Proceeds from Issuance of Warrants", "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)." } } }, "auth_ref": ["r1"] }, "us-

gaap_ProceedsFromOtherEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromOtherEquity", "crdr": "debit", "calculation": { "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of common stock and warrants, net", "label": "Proceeds from Other Equity", "documentation": "Amount of cash inflow from the issuance of equity classified as other." } } }, "auth_ref": ["r1"] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "presentation": ["http://www.modularmedicalinc.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate proceeds", "label": "Proceeds from Warrant Exercises", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": ["r588"] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofPropertyandEquipmentNetTable"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": ["r5", "r285"] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.modularmedicalinc.com/role/ScheduleofPropertyandEquipmentNetTable": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofPropertyandEquipmentNetTable"], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, gross", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r51", "r81", "r308"] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofPropertyandEquipmentNetTable"], "lang": { "en-us": { "role": { "label": "Schedule of Property and Equipment, Net [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r285"] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://www.modularmedicalinc.com/role/ScheduleofPropertyandEquipmentNetTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet", "http://www.modularmedicalinc.com/role/ScheduleofPropertyandEquipmentNetTable"], "lang": { "en-us": { "role": { "totalLabel": "Total", "terseLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r5", "r285", "r299", "r308", "r443"] }, "us-gaap_PropertyPlantAndEquipmentNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNetAbstract", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofPropertyandEquipmentNetTable"], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": ["http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Property and Equipment", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": ["r5", "r71", "r74", "r306"] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetailTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property and Equipment, Net", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": ["r5"] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofPropertyandEquipmentNetTable"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": ["r51", "r285"] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": ["http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Estimated useful lives", "label": "Property, Plant and Equipment, Useful Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseCommitmentExcludingLongtermCommitmentAxis", "presentation": ["http://www.modularmedicalinc.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Purchase Commitment, Excluding Long-Term Commitment [Axis]", "documentation": "Information by arrangement, in which the entity has agreed to expend funds to procure goods or services from one or more suppliers." } } }, "auth_ref": ["r31", "r61"] }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseCommitmentExcludingLongtermCommitmentDomain", "presentation": ["http://www.modularmedicalinc.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Purchase Commitment, Excluding Long-Term Commitment [Domain]", "documentation": "This item is intended to be populated, by the entity, with Members identifying each purchase commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate." } } }, "auth_ref": ["r31", "r61"] }, "us-gaap_PurchaseObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseObligation", "crdr": "credit", "presentation": ["http://www.modularmedicalinc.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Purchase obligations", "label": "Purchase Obligation", "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier." } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r514"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": ["r514"] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofAssumptionswereusedintheFairValueMethodTable", "http://www.modularmedicalinc.com/role/ScheduleofOutstandingandExercisableOptionsTable", "http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": ["r151", "r152", "r153", "r154", "r182", "r184", "r215", "r216", "r217", "r228", "r267", "r293", "r294", "r295", "r315", "r316", "r322", "r345", "r346", "r406", "r407", "r408", "r409", "r410", "r421", "r422", "r432", "r433", "r434", "r437", "r438", "r439", "r440", "r444", "r447", "r609", "r613", "r641", "r649", "r650", "r651", "r652", "r653"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofAssumptionswereusedintheFairValueMethodTable", "http://www.modularmedicalinc.com/role/ScheduleofOutstandingandExercisableOptionsTable", "http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": ["r151", "r152", "r153", "r154", "r182", "r184", "r215", "r216", "r217", "r228", "r267", "r293", "r294", "r295", "r315", "r316", "r322", "r345", "r346", "r406", "r407", "r408", "r409", "r410", "r421", "r422", "r432", "r433", "r434", "r437", "r438", "r439", "r440", "r444", "r447", "r609", "r613", "r641", "r649", "r650", "r651", "r652", "r653"] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": ["r473", "r484", "r500", "r535"] },

"dei_RegistrationStatementAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "RegistrationStatementAmendmentNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Registration Statement Amendment Number", "documentation": "Amendment number to registration statement under the Investment Company Act of 1940." } } }, "auth_ref": ["r457"] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": ["http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r143", "r380", "r381", "r384"] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "modd_RelatedPartyTransactionsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.modularmedicalinc.com/20240930", "localname": "RelatedPartyTransactionsDetailsTable", "presentation": ["http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Related Party Transactions (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": ["http://www.modularmedicalinc.com/role/RelatedPartyTransactions"], "lang": { "en-us": { "role": { "terseLabel": "RELATED PARTY TRANSACTIONS", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": ["r288", "r289", "r290", "r291", "r292", "r330", "r331", "r332", "r382", "r383", "r384", "r403", "r405"] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r230", "r423", "r429", "r654"] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": ["http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Research and Development", "label": "Research and Development Expense, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": ["r229"] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": ["r474", "r485", "r501", "r536"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": ["r475", "r486", "r502", "r537"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": ["r482", "r493", "r509", "r544"] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofRSUActivityunderthePlanTable", "http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Units (RSUs) [Member]", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r36", "r54", "r304", "r320", "r321", "r328", "r356", "r443"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r77", "r100", "r101", "r102", "r104", "r109", "r111", "r113", "r146", "r147", "r148", "r239", "r240", "r246", "r247", "r248", "r250", "r251", "r252", "r257", "r259", "r260", "r262", "r264", "r275", "r277", "r317", "r319", "r333", "r657"] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": ["http://www.modularmedicalinc.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Obtained a right-of-use asset", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": ["r283", "r442"] }, "modd_RisksAndUncertaintiesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.modularmedicalinc.com/20240930", "localname": "RisksAndUncertaintiesPolicyTextBlock", "presentation": ["http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Risks and Uncertainties", "documentation": "Disclosure of accounting policy for risks and uncertainties.", "label": "Risks And Uncertainties Policy Text Block" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r553"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r553"] }, "us-gaap_SalariesAndWages": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalariesAndWages", "crdr": "debit", "presentation": ["http://www.modularmedicalinc.com/role/RelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Company paid amount", "label": "Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold", "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold." } } }, "auth_ref": ["r587"] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": ["http://www.modularmedicalinc.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Shares sold (in Shares)", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofActivityintheSharesTable"], "auth_ref": ["r114", "r185", "r579", "r595"] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetailTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accrued Expenses", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "modd_ScheduleOfActivityInTheSharesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.modularmedicalinc.com/20240930", "localname": "ScheduleOfActivityInTheSharesAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Activity In The Shares Abstract" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofDilutedNetLossPerShareTable"], "lang": { "en-us": { "role": { "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": ["r13"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": ["http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Diluted Net Loss Per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of

Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r13"] }, "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAssumptionsUsedTableTextBlock", "presentation": ["http://www.modularmedicalinc.com/role/StockBasedCompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Assumptions were used in the Fair-Value Method", "label": "Defined Benefit Plan, Assumptions [Table Text Block]", "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate." } } }, "auth_ref": ["r183"] }, "modd_ScheduleOfAssumptionsWereUsedInTheFairValueMethodAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.modularmedicalinc.com/20240930", "localname": "ScheduleOfAssumptionsWereUsedInTheFairValueMethodAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Assumptions Were Used In The Fair Value Method Abstract" } } }, "auth_ref": [] }, "modd_ScheduleOfDilutedNetLossPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.modularmedicalinc.com/20240930", "localname": "ScheduleOfDilutedNetLossPerShareAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Diluted Net Loss Per Share Abstract" } } }, "auth_ref": [] }, "modd_ScheduleOfOutstandingAndExercisableOptionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.modularmedicalinc.com/20240930", "localname": "ScheduleOfOutstandingAndExercisableOptionsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Outstanding And Exercisable Options Abstract" } } }, "auth_ref": [] }, "modd_ScheduleOfPropertyAndEquipmentNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.modularmedicalinc.com/20240930", "localname": "ScheduleOfPropertyAndEquipmentNetAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Property And Equipment Net Abstract" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofPropertyandEquipmentNetTable"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": ["r5", "r285"] }, "modd_ScheduleOfRsuActivityUnderThePlanAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.modularmedicalinc.com/20240930", "localname": "ScheduleOfRsuActivityUnderThePlanAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Rsu Activity Under The Plan Abstract" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": ["http://www.modularmedicalinc.com/role/StockBasedCompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of RSU Activity under the Plan", "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": ["r55"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://www.modularmedicalinc.com/role/StockBasedCompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Activity in the Shares", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r8", "r9", "r55"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock", "presentation": ["http://www.modularmedicalinc.com/role/StockBasedCompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Outstanding and Exercisable Options", "label": "Share-Based Payment Arrangement, Option and Stock Appreciation Rights, Activity [Table Text Block]", "documentation": "Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock options and stock appreciation rights that were outstanding at the beginning and end of the year, exercisable at the end of the year, and the number of stock options and stock appreciation rights that were granted, exercised or converted, forfeited, and expired during the year." } } }, "auth_ref": ["r55"] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": ["http://www.modularmedicalinc.com/role/StockholdersEquityTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Warrants Outstanding", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": ["r20"] }, "modd_ScheduleOfWarrantsOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.modularmedicalinc.com/20240930", "localname": "ScheduleOfWarrantsOutstandingAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Warrants Outstanding Abstract" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r458"] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": ["r462"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r461"] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": ["r467"] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": ["http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Reportable Segment", "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": ["r132", "r133", "r134", "r135", "r136", "r137", "r138", "r141", "r142", "r427", "r428", "r431"] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.modularmedicalinc.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r3"] }, "us-gaap_ShareBasedCompensationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAbstract", "lang": { "en-us": { "role": { "label": "Stock-Based Compensation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": ["http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Contractual term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": ["r435"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDat { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFai "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofRSUActivityunderthePlanTable"], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted Average Grant-Date Fair Value, Beginning Balance", "periodEndLabel": "Weighted Average Grant-Date Fair Value, Ending Balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r202", "r203"] }, "us-

gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemain
{ "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingC
"presentation": ["http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Expense
over a period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options,
Outstanding, Weighted Average Remaining Contractual Terms", "documentation": "Weighted average remaining contractual term for equity-based
awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and
thirteen days." } } }, "auth_ref": ["r58"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGra
{ "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDat
"presentation": ["http://www.modularmedicalinc.com/role/ScheduleofRSUActivityunderthePlanTable"], "lang": { "en-us": { "role": { "terseLabel":
"Weighted Average Grant-Date Fair Value, Vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity
Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as
of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the
reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in
accordance with the terms of the arrangement." } } }, "auth_ref": ["r206"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "xbrltype": "perShareItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "presentation": [
"http://www.modularmedicalinc.com/role/ScheduleofOutstandingandExercisableOptionsTable"], "lang": { "en-us": { "role": { "terseLabel": "Range
of Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
"documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award." } } }, "auth_ref": [] },
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype":
"percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [
"http://www.modularmedicalinc.com/role/ScheduleofAssumptionswereusedintheFairValueMethodTable"], "lang": { "en-us": { "role": { "terseLabel":
"Volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
"documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be
defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of
the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in
the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": ["r215"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype":
"percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [
"http://www.modularmedicalinc.com/role/ScheduleofAssumptionswereusedintheFairValueMethodTable"], "lang": { "en-us": { "role": { "terseLabel":
"Risk-free interest rates", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free
Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [
"r217"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [
"http://www.modularmedicalinc.com/role/ScheduleofAssumptionswereusedintheFairValueMethodTable",
"http://www.modularmedicalinc.com/role/ScheduleofOutstandingandExercisableOptionsTable",
"http://www.modularmedicalinc.com/role/ScheduleofRSUActivityunderthePlanTable"], "lang": { "en-us": { "role": { "label": "Schedule of
Assumptions were used in the Fair-Value Method [Line Items]", "terseLabel": "Schedule of RSU Activity Under the Plan [Line Items]",
"verboseLabel": "Schedule of Outstanding and Exercisable Options [Line Items]", "documentation": "Line items represent financial concepts
included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to
the table." } } }, "auth_ref": ["r187", "r188", "r190", "r191", "r192", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203",
"r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r214", "r215", "r216", "r217", "r218"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "presentation": [
"http://www.modularmedicalinc.com/role/ScheduleofRSUActivityunderthePlanTable"], "lang": { "en-us": { "role": { "periodStartLabel": "Number of
Shares, Beginning Balance", "periodEndLabel": "Number of Shares, Ending Balance", "label": "Share-Based Compensation Arrangement by Share-
Based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "documentation": "Number of equity instruments other than
options outstanding, including both vested and non-vested instruments." } } }, "auth_ref": ["r56", "r57"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [
"http://www.modularmedicalinc.com/role/ScheduleofActivityintheSharesTable"], "lang": { "en-us": { "role": { "periodStartLabel": "Shares Available
for Grant, Beginning Balance", "periodEndLabel": "Shares Available for Grant, Ending Balance", "label": "Share-Based Compensation Arrangement
by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares
(or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the
number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or
other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref":
["r21"] }, "modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant": { "xbrltype":
"sharesItemType", "nsuri": "http://www.modularmedicalinc.com/20240930", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant", "presentation": [
"http://www.modularmedicalinc.com/role/ScheduleofActivityintheSharesTable"], "lang": { "en-us": { "role": { "terseLabel": "Shares Available for
Grant, Options granted", "documentation": "Shares available for grant, options granted.", "label": "Share Based Compensation Arrangement By
Share Based Payment Award Number Of Shares Granted Available For Grant" } } }, "auth_ref": [] },
"modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledAndReturnedToThePlanSharesAvailableForGrant": {
"xbrltype": "sharesItemType", "nsuri": "http://www.modularmedicalinc.com/20240930", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledAndReturnedToThePlanSharesAvailableForGrant",
"presentation": ["http://www.modularmedicalinc.com/role/ScheduleofActivityintheSharesTable"], "lang": { "en-us": { "role": { "terseLabel":
"Shares Available for Grant, Options cancelled and returned to the Plan", "documentation": "Options cancelled and returned to the plan, shares
available for grant.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled And Returned To The
Plan Shares Available For Grant" } } }, "auth_ref": [] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
"presentation": ["http://www.modularmedicalinc.com/role/ScheduleofOutstandingandExercisableOptionsTable"], "lang": { "en-us": { "role": {
"terseLabel": "Number Exercisable (in Shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options,
Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance
sheet date can be currently converted under the option plan." } } }, "auth_ref": ["r196"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [
"http://www.modularmedicalinc.com/role/ScheduleofOutstandingandExercisableOptionsTable"], "lang": { "en-us": { "role": { "terseLabel":
"Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable,
Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the
shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [
"r196"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [
"http://www.modularmedicalinc.com/role/ScheduleofActivityintheSharesTable"], "lang": { "en-us": { "role": { "negatedLabel": "Number of Shares,
Options cancelled and returned to the Plan", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options,
Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of
occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": ["r200"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",

"presentation": ["http://www.modularmedicalinc.com/role/ScheduleofActivityintheSharesTable"], "lang": { "en-us": { "role": { "terseLabel": "Number of Shares, Options granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r198"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofOutstandingandExercisableOptionsTable"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic value (in Dollars)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": ["r21"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofActivityintheSharesTable", "http://www.modularmedicalinc.com/role/ScheduleofOutstandingandExercisableOptionsTable"], "lang": { "en-us": { "role": { "periodStartLabel": "Number of Shares, Beginning Balance", "periodEndLabel": "Number of Shares, Ending Balance", "terseLabel": "Number Outstanding (in Shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r194", "r195"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofActivityintheSharesTable", "http://www.modularmedicalinc.com/role/ScheduleofOutstandingandExercisableOptionsTable"], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted Average Exercise Price, Beginning Balance (in Dollars per share)", "periodEndLabel": "Weighted Average Exercise Price, Ending Balance (in Dollars per share)", "terseLabel": "Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r194", "r195"] }, "modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareAwardsSharesAvailableForExercisedInShareAwards": { "xbrltype": "sharesItemType", "nsuri": "http://www.modularmedicalinc.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardShareAwardsSharesAvailableForExercisedInShareAwards", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofActivityintheSharesTable"], "lang": { "en-us": { "role": { "terseLabel": "Shares Available for Grant, Options exercised", "documentation": "Shares Available for Grant options exercised.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Share Awards Shares Available For Exercised In Share Awards" } } }, "auth_ref": [] }, "modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareAwardsSharesAvailableForGrantInShareAwards": { "xbrltype": "sharesItemType", "nsuri": "http://www.modularmedicalinc.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardShareAwardsSharesAvailableForGrantInShareAwards", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofActivityintheSharesTable"], "lang": { "en-us": { "role": { "terseLabel": "Shares Available for Grant, Share awards", "documentation": "Represent the share for share based compensation arrangement by share based payment award share awards shares available for grant in share awards.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Share Awards Shares Available For Grant In Share Awards" } } }, "auth_ref": [] }, "modd_ShareBasedCompensationArrangementByShareBasedPaymentShareAwardInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://www.modularmedicalinc.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentShareAwardInPeriodGross", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofActivityintheSharesTable"], "lang": { "en-us": { "role": { "terseLabel": "Number of Shares, Share awards", "label": "Share Based Compensation Arrangement By Share Based Payment Share Award In Period Gross" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://www.modularmedicalinc.com/role/StockBasedCompensationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r190", "r191", "r192", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r214", "r215", "r216", "r217", "r218"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofActivityintheSharesTable", "http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable"], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price, Warrants exercised (in Dollars per share)", "verboseLabel": "Weighted Average Exercise Price, Options exercised (in Dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": ["r199"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofActivityintheSharesTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price, Options cancelled and returned to the Plan (in Dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": ["r200"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofActivityintheSharesTable", "http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price, Options granted (in Dollars per share)", "verboseLabel": "Weighted-average grant date fair value of options granted (in Dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r198"] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": ["http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Stock-Based Compensation", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": ["r186", "r193", "r212", "r213", "r214", "r215", "r218", "r223", "r224", "r225", "r226"] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofOutstandingandExercisableOptionsTable"], "lang": { "en-us": { "role": { "label": "Exercise Price Range [Axis]", "documentation": "Information by range of option prices pertaining to options granted." } } }, "auth_ref": ["r22"] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofActivityintheSharesTable", "http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Activity in the Shares [Line Items]", "terseLabel": "Stock-Based Compensation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "modd_ShareBasedCompensationsArrangementsByShareBasedPaymentShareAwardsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.modularmedicalinc.com/20240930", "localname": "ShareBasedCompensationsArrangementsByShareBasedPaymentShareAwardsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofActivityintheSharesTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price, Share awards (in Dollars per share)", "documentation": "The amount of share awards in share based arrangement by share awards.", "label": "Share Based Compensations Arrangements By Share Based Payment Share Awards In Period Weighted Average Exercise Price" } } }, "auth_ref": [] }, "us-

gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding", "crdr": "debit", "presentation": ["http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Total intrinsic value (in Dollars)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding", "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofAssumptionswereusedintheFairValueMethodTable"], "lang": { "en-us": { "role": { "terseLabel": "Expected life (years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r214"] }, "modd_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsVestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.modularmedicalinc.com/20240930", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsVestedNumberOfShares", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofRSUActivityunderthePlanTable"], "lang": { "en-us": { "role": { "negatedLabel": "Number of Shares, Vested", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Vested Number Of Shares" } } }, "auth_ref": [] }, "modd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://www.modularmedicalinc.com/20240930", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingWeightedAverageRemainingContractualTerm2", "presentation": ["http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average period", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Option Outstanding Weighted Average Remaining Contractual Term2" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofOutstandingandExercisableOptionsTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Contractual Life (in Years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r58"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "presentation": ["http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Options granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares", "documentation": "Number of options vested." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": ["http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "periodStartLabel": "Balance (in Shares)", "periodEndLabel": "Balance (in Shares)", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": ["r465"] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable"], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": ["r76", "r84", "r85", "r86", "r98", "r117", "r118", "r120", "r122", "r128", "r129", "r145", "r155", "r157", "r158", "r159", "r162", "r163", "r165", "r166", "r169", "r172", "r179", "r268", "r324", "r325", "r326", "r327", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r355", "r376", "r399", "r414", "r415", "r416", "r417", "r418", "r578", "r590", "r597"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable", "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3", "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r7", "r34", "r37", "r38", "r77", "r90", "r91", "r92", "r100", "r101", "r102", "r104", "r109", "r111", "r113", "r127", "r146", "r147", "r148", "r181", "r239", "r240", "r246", "r247", "r248", "r250", "r251", "r252", "r257", "r258", "r259", "r260", "r261", "r262", "r264", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r277", "r287", "r311", "r317", "r318", "r319", "r333", "r399"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r100", "r101", "r102", "r127", "r277", "r296", "r323", "r344", "r347", "r348", "r349", "r350", "r351", "r352", "r355", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r368", "r369", "r370", "r371", "r372", "r374", "r378", "r379", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r399", "r448"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofActivityintheSharesTable"], "auth_ref": ["r114", "r185", "r579", "r580", "r595"] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r100", "r101", "r102", "r127", "r143", "r277", "r296", "r323", "r344", "r347", "r348", "r349", "r350", "r351", "r352", "r355", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r368", "r369", "r370", "r371", "r372", "r374", "r378", "r379", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r399", "r448"] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": ["r477", "r488", "r504", "r539"] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "modd_StockBasedCompensationDetailsScheduleofActivityintheSharesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.modularmedicalinc.com/20240930", "localname": "StockBasedCompensationDetailsScheduleofActivityintheSharesTable", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofActivityintheSharesTable"], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation (Details) - Schedule of Activity in the Shares [Table]" } } }, "auth_ref": [] }, "modd_StockBasedCompensationDetailsScheduleofAssumptionswereusedintheFairValueMethodTable": { "xbrltype": "stringItemType", "nsuri": "http://www.modularmedicalinc.com/20240930", "localname": "StockBasedCompensationDetailsScheduleofAssumptionswereusedintheFairValueMethodTable", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofAssumptionswereusedintheFairValueMethodTable"], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation (Details) - Schedule of Assumptions were used in the Fair-Value Method [Table]" } } }, "auth_ref": [] }, "modd_StockBasedCompensationDetailsScheduleofOutstandingandExercisableOptionsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.modularmedicalinc.com/20240930", "localname": "StockBasedCompensationDetailsScheduleofOutstandingandExercisableOptionsTable", "presentation": [

"http://www.modularmedicalinc.com/role/ScheduleofOutstandingandExercisableOptionsTable"], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation (Details) - Schedule of Outstanding and Exercisable Options [Table]" } } }, "auth_ref": [] },
"modd_StockBasedCompensationDetailsScheduleofRSUActivityunderthePlanTable": { "xbrltype": "stringItemType", "nsuri": "http://www.modularmedicalinc.com/20240930", "localname": "StockBasedCompensationDetailsScheduleofRSUActivityunderthePlanTable", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofRSUActivityunderthePlanTable"], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation (Details) - Schedule of RSU Activity under the Plan [Table]" } } }, "auth_ref": [] },
"modd_StockBasedCompensationDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.modularmedicalinc.com/20240930", "localname": "StockBasedCompensationDetailsTable", "presentation": ["http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_StockCompensationPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockCompensationPlanMember", "presentation": ["http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Stock-Based Compensation [Member]", "label": "Share-Based Payment Arrangement [Member]", "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares." } } }, "auth_ref": ["r598"] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan", "presentation": ["http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3", "http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Issuances under equity incentive plan (in Shares)", "verboseLabel": "Shares approved under equity incentive plan", "label": "Stock Issued During Period, Shares, Employee Benefit Plan", "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": ["http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Shares issued for services (in Shares)", "label": "Stock Issued During Period, Shares, Issued for Services", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3", "http://www.modularmedicalinc.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "At-the-market sales of stock, net (in Shares)", "verboseLabel": "Issuance of common stock shares (in Shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r7", "r33", "r34", "r54", "r324", "r399", "r415"] }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesOther", "presentation": ["http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Shares issued", "label": "Stock Issued During Period, Shares, Other", "documentation": "Number of shares of stock issued attributable to transactions classified as other." } } }, "auth_ref": [] }, "modd_StockIssuedDuringPeriodSharesStockOptionExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.modularmedicalinc.com/20240930", "localname": "StockIssuedDuringPeriodSharesStockOptionExercised", "presentation": ["http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Option exercised", "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Stock Issued During Period Shares Stock Option Exercised" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofActivityintheSharesTable", "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3", "http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Exercise of warrants (in Shares)", "negatedLabel": "Number of Shares, Options exercised", "verboseLabel": "Total number of options granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r7", "r33", "r34", "r54", "r199"] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueEmployeeBenefitPlan", "crdr": "credit", "presentation": ["http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Issuances under equity incentive plan", "label": "Stock Issued During Period, Value, Employee Benefit Plan", "documentation": "Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueIssuedForServices", "crdr": "credit", "presentation": ["http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Shares issued for services", "label": "Stock Issued During Period, Value, Issued for Services", "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": ["http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "At-the-market sales of stock, net", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": ["r7", "r33", "r34", "r54", "r333", "r399", "r415", "r454"] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": ["http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Exercise of warrants", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": ["r7", "r34", "r37", "r38", "r54"] }, "us-gaap_StockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockOptionMember", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofDilutedNetLossPerShareTable"], "lang": { "en-us": { "role": { "terseLabel": "Options to purchase common stock [Member]", "label": "Equity Option [Member]", "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)." } } }, "auth_ref": ["r447"] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet", "http://www.modularmedicalinc.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "totalLabel": "TOTAL STOCKHOLDERS\u2019 EQUITY", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r34", "r37", "r38", "r50", "r357", "r373", "r400", "r401", "r443", "r455", "r591", "r607", "r642", "r657"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity [Abstract]", "terseLabel": "STOCKHOLDERS\u2019 EQUITY" } } }, "auth_ref": [] }, "modd_StockholdersEquityDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.modularmedicalinc.com/20240930", "localname": "StockholdersEquityDetailsTable", "presentation": ["http://www.modularmedicalinc.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://www.modularmedicalinc.com/role/StockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "STOCKHOLDERS\u2019 EQUITY", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r53", "r97", "r164", "r166", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r178", "r181", "r263", "r402", "r404", "r419"] }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "presentation": ["http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Liquidity and Going Concern", "label": "Substantial Doubt about Going Concern [Text Block]", "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern." } } }, "auth_ref": ["r24"] }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "presentation": ["http://www.modularmedicalinc.com/role/ConsolidatedBalanceSheetDetail"], "lang": { "en-us": { "role": { "terseLabel": "CONSOLIDATED BALANCE SHEET DETAIL", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity." } } }, "auth_ref": ["r585"] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": {

"en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": ["r532"] },
"modd_TheCompanyandSummaryofSignificantAccountingPoliciesDetailsTable": { "xbrltype": "stringItemType", "nsuri":
"http://www.modularmedicalinc.com/20240930", "localname": "TheCompanyandSummaryofSignificantAccountingPoliciesDetailsTable",
"presentation": ["http://www.modularmedicalinc.com/role/TheCompanyandSummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": {
"role": { "label": "The Company and Summary of Significant Accounting Policies (Details) [Table]" } } }, "auth_ref": [] },
"modd_ThornmintRoadSanDiegoCAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modularmedicalinc.com/20240930",
"localname": "ThornmintRoadSanDiegoCAMember", "presentation": ["http://www.modularmedicalinc.com/role/LeasesDetails"], "lang": { "en-us":
{ "role": { "terseLabel": "Thornmint Road, San Diego, CA [Member]", "label": "Thornmint Road San Diego CAMember" } } }, "auth_ref": [] },
"modd_ThreePointNineFiveToSevenPointFiveOneMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.modularmedicalinc.com/20240930", "localname": "ThreePointNineFiveToSevenPointFiveOneMember", "presentation": [
"http://www.modularmedicalinc.com/role/ScheduleofOutstandingandExercisableOptionsTable"], "lang": { "en-us": { "role": { "terseLabel": "$3.95 -
$7.51 [Member]", "label": "Three Point Nine Five To Seven Point Five One Member" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": [
"http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Title and Position [Axis]" } } },
"auth_ref": ["r605", "r645"] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [
"http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Title and Position [Domain]" } }
}, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder
Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": ["r524"] },
"ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label":
"Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": ["r531"] },
"ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel":
"Trading Arrangement:" } } }, "auth_ref": ["r552"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"],
"lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } },
"auth_ref": ["r554"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"TradingSymbol", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Trading Symbol",
"documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date",
"terseLabel": "Adoption Date" } } }, "auth_ref": ["r555"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"],
"lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": ["r556"] },
"ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate",
"presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement
Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": ["r556"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"],
"lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r554"] },
"ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title",
"terseLabel": "Title" } } }, "auth_ref": ["r554"] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate
Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": ["r557"] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date",
"terseLabel": "Termination Date" } } }, "auth_ref": ["r555"] }, "modd_TwoThousandAndSeventeenEquityIncentivePlanMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.modularmedicalinc.com/20240930", "localname":
"TwoThousandAndSeventeenEquityIncentivePlanMember", "presentation": [
"http://www.modularmedicalinc.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "2017 Equity Incentive
Plan [Member]", "label": "Two Thousand And Seventeen Equity Incentive Plan Member" } } }, "auth_ref": [] },
"ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"UndrlygSecurityMktPriceChngPct", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label":
"Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": ["r551"] },
"modd_UnvestedRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modularmedicalinc.com/20240930",
"localname": "UnvestedRestrictedStockUnitsMember", "presentation": [
"http://www.modularmedicalinc.com/role/ScheduleofDilutedNetLossPerShareTable"], "lang": { "en-us": { "role": { "terseLabel": "Unvested
restricted stock units [Member]", "label": "Unvested Restricted Stock Units Member" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [
"http://www.modularmedicalinc.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use
of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial
statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r15", "r16", "r17", "r68", "r69", "r72", "r73"] },
"ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": {
"en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date
Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": ["r520"] }, "us-gaap_WarrantMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": [
"http://www.modularmedicalinc.com/role/ScheduleofDilutedNetLossPerShareTable",
"http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable",
"http://www.modularmedicalinc.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common stock purchase
warrants [Member]", "verboseLabel": "Warrant [Member]", "label": "Warrant [Member]", "documentation": "Security that gives the holder the
right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [
"r445", "r446", "r449", "r450", "r451", "r452"] }, "modd_WarrantOneMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.modularmedicalinc.com/20240930", "localname": "WarrantOneMember", "presentation": [
"http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable"], "lang": { "en-us": { "role": { "terseLabel": "Warrants exercised
[Member]", "label": "Warrant One Member" } } }, "auth_ref": [] }, "modd_WarrantThreeMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.modularmedicalinc.com/20240930", "localname": "WarrantThreeMember", "presentation": [
"http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable"], "lang": { "en-us": { "role": { "terseLabel": "Warrants exercised
[Member]", "label": "Warrant Three Member" } } }, "auth_ref": [] }, "modd_WarrantTwoMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.modularmedicalinc.com/20240930", "localname": "WarrantTwoMember", "presentation": [
"http://www.modularmedicalinc.com/role/ScheduleofWarrantsOutstandingTable"], "lang": { "en-us": { "role": { "terseLabel": "Warrants exercised
[Member]", "label": "Warrant Two Member" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [
"http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in Shares)", "label":
"Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding
that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." }
} }, "auth_ref": ["r116", "r122"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [
"http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Basic (in Shares)", "label":
"Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently
issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period
that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r115", "r122"] }, "us-
gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract", "presentation": [
"http://www.modularmedicalinc.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Shares used in computing
net loss per share", "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]" } } }, "auth_ref": [] },

"dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": ["r568"] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": ["r518"] }, "modd_ZeroPointNineThreeToSeventeenPointSevenZeroMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modularmedicalinc.com/20240930", "localname": "ZeroPointNineThreeToSeventeenPointSevenZeroMember", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofOutstandingandExercisableOptionsTable"], "lang": { "en-us": { "role": { "terseLabel": "$0.93 - $17.70 [Member]", "label": "Zero Point Nine Three To Seventeen Point Seven Zero Member" } } }, "auth_ref": [] }, "modd_compensationServicesEqual": { "xbrltype": "percentItemType", "nsuri": "http://www.modularmedicalinc.com/20240930", "localname": "compensationServicesEqual", "presentation": ["http://www.modularmedicalinc.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Compensation services equal percentage", "documentation": "Compensation services equal.", "label": "compensation Services Equal" } } }, "auth_ref": [] }, "modd_zeroPointNineThreeToTwoPointTwoEightMember": { "xbrltype": "domainItemType", "nsuri": "http://www.modularmedicalinc.com/20240930", "localname": "zeroPointNineThreeToTwoPointTwoEightMember", "presentation": ["http://www.modularmedicalinc.com/role/ScheduleofOutstandingandExercisableOptionsTable"], "lang": { "en-us": { "role": { "terseLabel": "$0.93 - $2.28 [Member]", "label": "zero Point Nine Three To Two Point Two Eight Member" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "40", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205-40/tableOfContent" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic":

"10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "250", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/250/tableOfContent" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(c)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" },

"r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r138": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "36", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher":

"FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740",

"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842",

"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r329": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, r374": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50",

"Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r425": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r426": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r427": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r428": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r429": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r430": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r431": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r432": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r433": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r434": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r435": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r436": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r437": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r438": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r439": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r440": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r441": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r442": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r443": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r444": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r445": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r447": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r451": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r452": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r453": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r454": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r455": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r456": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "Global LEI Foundation" }, "r457": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r458": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r459": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r461": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r463": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r464": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r465": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r466": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r467": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r468": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r469": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r470": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "249", "Section": "308", "Subsection": "a" }, "r471": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r472": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r473": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":

"Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r474": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r475": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r476": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r477": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r478": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r479": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r480": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r481": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r482": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r483": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r484": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r485": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r486": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r487": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r488": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r489": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r490": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r491": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r492": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r493": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r494": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 8-K", "Number": "249", "Section": "308" }, "r495": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form F-3" }, "r496": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-3" }, "r498": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-4" }, "r499": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-6" }, "r500": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r501": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r502": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r503": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r504": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r505": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r506": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r507": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r508": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r509": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r510": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form S-3" }, "r511": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Investment Company Act", "Number": "270" }, "r513": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r514": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r515": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r516": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r517": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r518": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r519": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r520": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r521": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r522": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r523": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r524": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r525": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r526": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r527": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r528": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r529": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r530": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r531": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r532": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r533": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r534": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r535": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r536": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r537": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r538": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r539": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r540": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r541": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r542": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r543": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r544": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r545": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection":

"x", "Paragraph": "1" }, "r546": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r547": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r548": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r549": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r550": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r551": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r552": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r553": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r554": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r555": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r556": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r557": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r558": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r559": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r560": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r561": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r562": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r563": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "313" }, "r564": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r565": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-X", "Number": "210", "Section": "2", "Subsection": "2" }, "r566": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r567": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "413", "Subsection": "b" }, "r568": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r569": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "b" }, "r570": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "c" }, "r571": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "d" }, "r572": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "e" }, "r573": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "486", "Subsection": "a" }, "r574": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "486", "Subsection": "b" }, "r575": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r576": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Section": "8", "Subsection": "c" }, "r577": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "20", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-3" }, "r578": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r579": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r580": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r581": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r582": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r583": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(6))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r584": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1" }, "r585": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/210/tableOfContent" }, "r586": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r587": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r588": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r589": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r590": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r591": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r592": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r593": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r594": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r595": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r596": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r597": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r598": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r599": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r600": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r601": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r602": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r603": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" },

"r604": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r605": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r606": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481598/310-20-45-1" }, "r607": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r608": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r609": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r610": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r611": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r612": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r613": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r614": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r615": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r616": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r617": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r618": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r619": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r620": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r621": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r622": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r623": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r624": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r625": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r626": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r627": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r628": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r629": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r630": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r631": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r632": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r633": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r634": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r635": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r636": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r637": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r638": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r639": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r640": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r641": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r642": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r643": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r644": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r645": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r646": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r647": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r648": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r649": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r650": {

"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r651": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r652": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r653": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r654": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r655": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r656": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r657": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r658": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } }

ZIP 55 0001213900-24-098418-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-24-098418-xbrl.zip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| .ECZ8X.ZU@,8-0"NV^QM.PE6H.."8MQQ4V23\:?:B"[MT'\VFCA?]K;'"@HG+G&\XA9 7@7477R3"8SU;97F3Q*NOZRW62/ M_I8BE^3,ELJ8W7Z?C\W9B?WIPY_8]? P)-.WR;-J/,$?#/+ZK,-??)Y/(^#A MA'"B)\M<&AJRB&E](?]Y=G9Q<7D90[&*>V4)$?4NR6-&L_Z5)2FY^BK0[PJ0 M>7!,0-.=:I&_]I,E)7\Z;;4D#!.0AV>X)78Y,1*9JG%A(CW@=%M$ "#/ 'P M_?;\/-?CY;;S1[AS$OK#D-C776$N,5T(5@B[:T$'4NK ,[:F_K&F8W&ZP+0% MZC3(]?793Z4H7!F8->A0S$^=/%. Q!P3.%Z?*?/QH%)@>>1I7[43Z1)Y5F\4O M-*+.9O A!C=1R_ACJ:.. :K%F(H'8$U/S5#0&<2CE4+9".@H+MI0 <&/,5I) M-/@4A#H^NK#HA#(1+\F$1?OMV@FL!\1!["(4(!OL;Z!--^KG/*O.RM[)JQK> M)8O!L"^+,WQJ$-70R(G,SS@&$H//Q_^"$^#S[%'X$NY"K(-Q7KLV% <"A6H[M9- BFOINGQY M8TX1)2XM:#;L&-U M@0&D':Q*LK(JWZ_'@=3^])'Y"\@=6(&DY+4 2#^!>N%> VTJYLUQ^&1OYP: MD+1*9K L)>H$#$Y1NH$D9^'E$/E7 D!L1GY@SX$QX2V6*_<(5EZHQGL#[T)8 M#BX0/,(3 5W[U7EV/SZM/5#*]J;1J6ZP?!;F7D2/A]SZNFF'[&/IJ_O8S@&#U_KA.;;$?H5-3L]NYY<\U>WK:,(A M7B[:5HM9R79TUQ"0 MXYD>- O%ZDF3;Z/QI#@7V@F]+6S>H'5;M>AMSIU-B>L54S1%*%]%"+CF,UM)" M.9#<]7]CRY_QU4/ ZF_,#/VYS-+IEOL1_?LKUWJ-7>OZ=%631(V9ZH,) MU- RES>]6>"W/-H](&H7K&=\U>\>7O^KP:J0" TYD(@N]Z#836H9J3'1UAA(5 M4V[@X1H6=FFJI=D$D[X4_% *;A:-S'Z&.]KCQ1- *=.+ M>"+;=JWC9S 4\A).#PCF*)DTV%S\\E'M#U, 5Q7' F4M4K5JT+= M4*7J5;'F4J5:-;3@<;["%_]84F."0/3/QLJD^1+2GV(013B8-X&-VUX;%'U]^:8 L_#^1;LO,'ENQ'+X\%RV6(J]$;#=)7 MU4AK8]7O:D(_WX"?U?\A2R)XL3_*2]6WFMM^L/%W>/%]V\7]WP'?DGE!P;X MX^C;]066Y9W=WCQ>W#P^%'/:TOK":B1HZ:]G&UA/XQ.YU6[(2K\A=SJ?ZD+T M.!HN@G;PG^MR?:NGX%>5/%NHU/RG^G^@=]6'=Z/[1\'/S*6OGU5N97OOW"),-V4(2;Z=S@^[MEIDXH4'P"'-Q.IW!=*: M,SH%S+1.);FC&X+:P#:FB*^F]^=M;^JWM[\I_IF]);OA%0,P2(7P;4B^.F9_"Q?FL5_RF)S-G[39UAFQ\"EC4%0N'&DM<]('S?L=R#[ZHU>19_E]Q[M\$A1/QM%M3=25$#L "G=+B@OM+*)FX3BP#*4T9*MOXGX.]\Z=W9ZU$="A+?V M9R47NI./=%V<+O12[^6.K.^U8ZY-U=^($VT&%NE*<< M*:]*E- >-27EGJQL,+F?FJR_Q5NEKDXC+C;3:1]*J$FGU, CO@-7JF&0#C46I M];F02N=(*KF8>/*>3+Q^??A=-=0G1@)>?=FY;D^6O'$+"I*1H<[>;9W)(Y]R MD+1X$!F?N:?VR)I@;UX=\P_*^#:,&L7"0/^,/,_1VI M:V;:2XPJJF-SZ8A:!'*OV[_G0S*](\GD0C+M_9",U&+:D&.9,YN1RYUE3JB& M%'*DASW20RI7LQ1V-? N^YMO'OUS3 ZI71_^, (]&A[4&4\O$PXU MOTKR2!]EHH\]F0]2ISX\IU.569,_%EB/1PW=M(YT45*ZV)>-T*T/O^L&!7DQ MI2 F E;DD1[*1 ^=/=%#KS[D;1FO#&_8T)$2RD0)W3U10K\^O'A[UL=Z3DYL M:7 D@ H%/*1!??@ GZE.,I>!W H#*%1W5OYTWX29Y.BK63"'_1=\@2C9^LK; M!E4LT3R_FM@ P%Q0?24X[^@+N39?J<66^X%3=$ MEXN "ONO?.K?'V)3HJQMY5)IX8.Q@:;L!VC?^3!+\IU/LVR .CLYY0VZ8R59 M[KEXX>3* (,ZSN;150X/OTK<)A>>]HKJ/9:#^1+G^&Y/V5Y+[XP^)#&M4FU2, M+%I16(OSUV"7V"O% E)\T4S[2MQEO3L"+]QH]2PB^K/KSA;W9OB54:@*I2@Q MZN:YONRG0#[YZHDBMQ_QUNI!A&4^$T4*0B.7PZ\K]4608.0V1@\/%UC:PX\1 M%Z1;BI_7%RILW0."[>S'_?W%S2/Y&< 7U6IUMXFY 9:KD.=_%6* [UUUI>(M/ M ; QH1)S#";X YL5K,ZXAA+F/J]M[E9C=D-S7?ZN/VU8<[#RM #OUM)X.5@: MWU1B5<:+(=9?\,SXOPO_M/?4=BP=VX3@!R- #"_\A*17.*\$"N>7MA:JF@?] M6VGT!\I:P?Q&J$;!*UJ&EPP12JD1 :K^ !A)S@\1\3D[(]^N;F/C57UGT86J M:Z!\+E]YBE#)OJ"8]V@6\EH]_T>EVR3K52T"! PN^ @ S)COO.1;8,)X;5, MC$%?8!7)_=ULOD%UB0N[CX6W+!(C+[RUZ\-VMU,,WDIQ]TR1NZ&P;9G=: M0W$7+- %F2B&WHW4_5/+,!>SFG2EW:*8MT(_<(9U"@9E@3H8/]+=3#4/_RPAM$NUF2,KEFLS ME6-%U_\;8,D2@K54FSF84XXR=(X*WM M*O5AI[5O9U!F8&72^=(#JXTSX7>'Q2M@ZFUA!FM)_;!X5=VDXAS7NCK69ZS@ M,PF>.SB_(:N?KWH>TFQ ZV)4O_7AG*,/.'FSZ5!K#L^I-B4S'SP? V]^6GX?4 MI:CW)/2$@8I!_^@B/8R+-!7*^H"R7D&)/:6X-K-X2"-31"),A()F5F$2>[E]C++L382D0U2/A5;;G8.'5H[NG'*9^GNW?S8*[6L3_G;4 7-1*&Y, M8Y) .$CU85=*'@D[RO"#8DVN#_M2"5, $XF'[&K>4;U+IC7$HBT%U85^4>K" M1\503GI=+ RU,5-.[NWVE);0$CRJ?.6* [A01GS/G<]WAXS$P,QC;1L,KJ#$! M B+*2?XF]/(]U;JU6#LB MC;4UNZ,6&Q$?.18>="+X?TX?*^31%$[_':]6'KM!69(K ZU]]KX-,@1=8@ M!X[(SF./ELZS:>G_IEJD=AIQJ%ZQU;8Y[+!?'W8:K594/'45[/S;1/7> > / MMK#;=C^W5]K=;7NVD^#9;H)G 1EP'NJUMHOXA^BVC6D)K$A_Z=@._ "2HB1* MCHQKLGD5E=31E$S;WY,WAFOMV,F[8)'/7Y.C !T4)^_SWFN_52YA'SA?2CG: MEXKLQ))]>UA5T&JE%?1?]PCZ*R:!XYY+*;(3T>K6;OT;(> [^VICAU5!Z<<". ME\[^:"@9G!,IDP> ,^@!BMQH=Z."\!O(._]J7YT#3M9'@!-W^G>#P#H+[$#\ M0F?O54UA#("?2?0XGM<^)DWM3GCX: (F+J4"%R4H?.Y=7X[,UU1G!]C^P$IFH M"]U19U5E"?]$=W"@*^.,'R<6N@<8D6P,6C\?=V2 V@ 4PEZOT=XCH^PKI6,T MF2SGRQGKAJS1J3[1]J_PX*0PSKNGCJH;5+M0+0.'[P6@=\Z!%R0G&S8%K]A" M5Z"6]SJ-EIQCB#!>W]_JHB^+",@;?6"V=#N- @3S('7VEN%%S2_/='8"H++$6 M)FJ8&O<,T*:6SVQO9+4O(='GZVR050M\8'/H4G8L6SGO8]]JH <#SH;_L!1OIY3O&I MKNA18EMV,A[RB6'C(4F[M_SIH8 Q:7!*I:3<4L;!7 M11FODU(0EN"C17^]D%*.82>T9$CYU/=@RG+TD8P@42C+W1FLG;PJJ14LM%A M[4QA('[DD:&=^P<66'8] (!>C!YHU9_1UCDHH#$[I2%U=@?8J@_HUD$! M/6!QHQANQ>H#NGM 0+=;+:QH&,@Y CJ/4,_^*CK M A3:QV_4@!M^QBX/59OK MAFX[>.._T-7C?*R 89;K1\,2&@4@E@2*I)84Z?!L:G3WNZR/+"&:>Z-EG)L MX[*WBS$/K.&8;+:D@";D?0V[`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

\0CI?"0MUP-M)LRF^QYB7?S5@&?-7-QUS M 0+2(SB+RZ)=O%ONZR3>N#8Z[OWUF1O:46\I(62YE?L%!<$'MCG\S
M;HQCP(/?)GB.+:K^WAQ3$#JP_((A)GCZ;L3I$>ZY0#! DM$;#1X1C^Y3QV%X MA?
U'9:)4_;\6IH/_^ED=%LM(X^%W4UO.5(M\IQI:CPT"INXI;ZM[Y@F:LZ"@ M>?#$"UIV9ZK]3"YGYJL=W2FZL(V?_##4I:;#CC[M^\U7!G&>S:4-%IJ][Y>[
MU%/YKMP;U./<&VS':J 91ZH_Z&_D.RSV;),+8 R-,TG8M1'3K9-[F^)B@2GG M#\PX\V\.WITUS]/N='@5W<$Z8N&ST<-?R.7U[3\>R.7]
[7=R>W=Q/WJ\NOF- MC,X>K_Y^]7AU\; UO!H!L\C@U:8X;6'K%NL>%?*QUXWLU+]D:3VZ&;)9,S W3[S/J6=_>^BP/=+!']]44#"0_$,8E% 5X3 M'1060S
,_A5_GJ!*N42]4S>(N:"6ZJ!MC =YT1V=VE*S\+:]> >$U#2;.9P MT:%8272$ON'/])"I.YE7UN2 M#"1_3A<@V'1.YM@25YV;\))_[R-
YM#!Z#QYJ9&BCP)%B(1"CX)DK"JM'\EG! MAIWE.Q7LL^G55Y:EL#(+[?MM5%<;J :*IVZMLYFJSV,546'#&?GG8X;\X=B. M-
7AA;W="]'UP]JP:3Y0U1%=MFX+JBY?"3%?'^NRHRY94@$4A\LZB"U777-65 MX]%TGJDE$%M9 6=,+ IZV3GE_UX9XJCG=$HMBVH7_,3
L;=XW!$[;2*K%"NP MN[L3DSZWRC M.863,4S&NL1P4$&_O"T6\F:-?('7!^!UJ]NM,NP=FTQP)J%-%NH["^,QXW$R ML;!#B7OI%
(SNXOS%ZZ+0/>\=/R[:1_RPU[YNE$P4#NI#I9-&%*;L[U/&"R8I M5#B*ZB=/C3YL%IKXY=7 M-Z.;LZ,V7C)M'%,7S FEFDVFECDGJM-
TGFESKEJ_PYUJ@Y!@ZKB-63D-S+^N M6D#64['$,2_AE)'#KV-I5BQ!=U#]:>?M77/-*A$5#9,N?:/61+T\$7("?(T2UNL#C&M6BX\,E
MV)#DK:SF&QNWNT9R_&QM!HOS.P0$"DLRB]_)I2-AI5Y/R=&V*Y4&N]O7L!!V M%AF_N^U5/I:_8=_NADL7B-&&ZD9*Q.9VC4&,P<1'N5&LIR$M
I62B)*CGZ%4 M?H;U=Z/LU44."SG11!;+)_3X,I&,.A/[2-&+T!WQ2O[Q3EEDZI M[5CZQ*$:?C RM/ ? D_R3N^K^3X7;Y/9$CD(?F 9J0R^F4SIQ$KD$.Z!]
M=QJ*LKO%W@?*ISP)>0'D9";\UTW24>B.F1,GW3#0.45 M ^^,4#^VZI-E,&\F*1"+J;NH#4_:HXK[
MD05X*D=$>Z=$IUA]&E>65[)W<9;6Q<5S>Q^YO1^CB]5/TBV\N#;4Q>-R@-G(MBK*[9U:.':L_4#?F5$VLEV[SUF,
[ZV3MK+O'=M:)VUFWC^VL#]:3>*6K=6]/ M7:UOSW]C1_A%I#&-KLG#(_SA^\7-XP/_YLF/F]&/\RMX:"]-G[%;HCY]WRR-^&UU
MLYS#4I,UKR3^KAM+JHW@GOV_6^M)-43S*;^;-_SR3;5U^W9Z9X%4-AS^IZ6M M&]2VSZD]L?2%V[Z*EQ;C_&#X\D2G]B.\[ML,6_Q-
6O^'K_L_J4[@.^H""=U: MTM6KO-!-^%>Z+&%OH**P =2%) 3BET6P)1 ^?[D $OI^-[KY)QG=G).'']^_ MC^[_26XOR+>$=E" MGIS 14_.N%;PB;RJV -
I8EH+T\+[O:8;\-(755/1M7\[<4SLH"T-!GU0#> ^ M(OAMI![RC<+2U^KOE-PSGRI2@GC%H_\&\JQJH'C ?D$$H-8P%O3C%FX"N?%T
M#+G5D@G2T(RHBX5EONGXG=E[36Y)/?+Z3$%G<4"A85GZ&E%G,S2T<#LZFZ'- M&__X
[H('\:%#_UMJ=I+2[7Y]AI$)>=TIKZB)N2>''7C$_>Y3PUNWS''L :O MM=F1:VR?6\[MF"2Z;7_E22F(41UT2+*P:-.B+Q0$68/,^6'!EL!N842HG+6I M.6%5
:;!T*11C&XT\"DZ,UE-!:\Q@E6<)7P=DW PD0Q>SF41XDXW#/,%?GO! MG@'V<@94N5C.%S9!.GHB?P>BCZ"Z!CU1+8\0_03*W MT$V!,^9KJ,SK
#/6RV1NPHGX,9UGU4&LHJ#'S;RH^HP]$X:Z2+TX)=_@'#IL M! M6C8S*QH(![X8KJZI[Z"*->$?7)<#=PVB\#)\%C][!3X-'4"C,T"?]>Z2J?S)A;3@=1\5<
MM5WJX@)14(6_5^S 2-&'Q0G. 56Y)A%W14M=Z!ILYLDR7P$$#;C %]BT$BD% MB9A:<1B7P!ML'2*O4KA]"I*(_%4UEBKL$KO\KT!P.9[K#IY9)1VI=?+[
M)T2- !$8COH4.)P3"C_?#T/WAH[8Y-(TN0 ^MY9/9*3- 6] #D*N7IZ//K&F MDSY#X,,-/(@_IF%]4Q:=4$"95H,%R&2&"$4R' M]KA/*9Q$ WQ8CI%?
47*A%"Z9!4&#B# MM[%FPFK H&2RM"PNNY_5%Y3X[')&25-[H@;J6I1[K*LX-7%K M1Z@VCNW>"G98:?8.A)':C:OG0)+CP@L
'9]B9FCX("+)@"240(LZ#,!-"CL0N&S)BB M.0[*Z5(H4PA#>XFB)6)/8':S5KI"K&%XJ,:43M@![$3LR(Z^F M]3LC$'$8'BGF/S-Q#+L']-
C1>Q2X<[\@5A>L+$P#, [_6*J3=_<.\:&+&[!K M09($T,V1;;"\P[1")]A!J(1-"VG2Q3_P?N+!K5MU]1E8T08;#TS'%T"[/(3
MRGK@VK(;WF'C4WWLF67!._HS#T+.GIU+-<5%/61OP>N %'C MF5?Z6,)^9G=GX/[EI ;;!UD1$@Z$B1*7Q!C317,OW)ES,$W'U*,()CF6*(-F MP5?
5UG4!A,7&&YY[%? V%Q2 KJ? #N84G594S.Z!-U!/IR(LA"0D&#46K7E/ON0<]&$(IV'F?*+C7.P;W$@?W.L?@WF%B3R'K]1#1 M)IF[%?
86VTH6<1,O7UGZG?\WL:\EWFI!/TNW7V@,C&T(-8,@=+VPZ)Z<*CM< M*ID0XE)78CSNPQWCZW$Z)CAYMI:-BIAK;2%VF!\$4Z#04<\>.R47^#<+9Q!0
MX>940^MP)=RF(I%'J+P)\G3XXDPC8MI\>(^N/4CX#KE;.[!!>#^&>7#Q$[0E MZ9N*JE3#70=,R([_!A+Q!E0/W5F^6H(DU;7=-5Z;W@1P5,R
ETYX,NH85Z4)2)8&(P;)YTQI6OL3I#1=+F M/K8Q1F;H3)_#/AW/>>7+N=-HW:>*7*>DX[H"?8"/N/<([9QM?">HG-C/%(,L;#LAOFTS!S"#%JBQ&*)Q/2^
$S]_<)=K MRF&V?PT?.25GW%T#F^9)J*YAI($,F9G0QPHM>=WPSH[>$^7@]** [G&$3&H!IS'!M+CR#P=KJ$#0-S-O\'5I\)WVS-
M/52I!%D:0:04)XBN.*N;"[#4N7,1%@);0,2P5\14+56&+=ZK,SIQ6-I+T 5Z MPKSIO.&B:T,&W=C=2COY41?C NXE9%B+")\#B[XRYHX:'F6AGF>\
MMEE/0<\1/H5* ?S4IF27#1-%&F!:J^_;+A30B%:':G%T:GP#AA<4<;1,F"2P'&8RJKI1:\AW<,;,3UF6-@(W+HXLJ%SSLS,>G. MKJP-WW'\
)UKMR11!=V$&[%+X=G'I;P8NLCVX:%4;6FY[G-/G7+E0(!24]W,FF+H1##Y6AY7O12AK M9&CG?B!+#-7DU!27D6,L%63C0:=@-@[$Z +
[*2,O)T/"7CC9NT$WQ3IKP?@X M":28'8CV4W, 2PHT1/[KO6[_?@:' /$!/\6E_"U+!"@>;)-"*3ZT"Y11?!<$ MMU'**RP>Y L#V:6G7>N@-Y"DM3(>R?
H9R[;^%VC'H:H 'J4/0WO"H6TA MM(6ACT[&.;=R67(_&-O/=,9QQ'M[TNJ ML43&<_'F\/-4CH+ENE_"H@@6#9$_Q>]AT$I<]HX;N.);
M'S%C(5)/6"EG[P+9R9U6H]5:+V@_)3J1KW,JPBSK>9Z) !: MMH[*)6:XNHFUD6A!-\\,]GUZT+R/\%_6RE)+E?K1/Z9^)$[]Z!Y3/W[2U]E MKZD?S%0=-
O5S%@R)8,H>M4:Z!/$ MZ_FNHUCS97LHK]]39M@EWK4,#D5W= MT. EK";0C1LW1/" +[WZI4 :]\JD 6^V7EG/ *AAX+7)G@E
MA0'@U410Q4^6=4M3G_UT9O'%ABA56;FFU M\VDZYVFLQ8*232G8!G7[K;$?+H+]A4LGVA)CHC#_;>Y2YP8E@K9C;=7FP[1] MTZ#O7J6M,)!
[&$3/E8-3$4!LO\5C$Z+(FHNP7BE2- 6YMG\E@X'8 SOB"H6 M'KJQ**V)@"_8-K-*N3TW3HY,R8=QUPNQXJ!05KP+SH;U]E-&/DR!C,(
=Q3>5F+3^P_VLFM] M2IOP-8_65^,QVM+:$(^)L7+(LP+W#Q,=JP2(%_O6,[6+W)52'TX!W@GI,QIX M0Y9#:^^NHSFMK5*-1V)8#
[16Z^WZET)Q\D!T/)3?BS[$52""& M[D;G)VX]G"AGY%HM!6'.)DRS]H-S=#QBSQ:/5.UG#+Y;@C9U*XIVIZR "Y]F
M:S$M4*B2?,&H,]K'6,)R*PADL_&0IJHVKN;S:2S:CJ> M-K6T>6T[ZW.#/9Y$^Q%]0JMSOUZJNL5<<;=3S\U^Y6L6R0*+L18+WJPXVKG MFQ7WPQV-
2'Y^&"&PI[*9\EFPXQ9Q),7I7MP ?D7E,\^+)"\N8OP,HJ!.R^]C M-?CLLPX"Q)H\O[N-E703]=Q_BU5U VYR5B:!CW-XLJ)5T)JIS8=I8Z(5WTEP
M8=%@"&X[,K9,5:O-,'YJ?SDT&^=&&DHJTD 3E"?83.AL)AH"LW@,_FXOU(G[M>TIH;'47?P6S1G.><;W6+[B3C2W+894-
*T%&AJ+U5JG.."P_GFXZ:.H'L?Y MN?[_ZS\'W=[@J^>SW]R\/=SH)Y>77R-9UZ0 IS!WE,(U M#HPV$3U>=.RLP?K2B2L2+LS(Q5(^U
M4_&04B8>VM[Y'Q9:;^D?YIIMW=A7GBR49;9-42B*;X@+ISNI>+I]Y.F/PM-*[+MP M:00XC_5(##3K>Y"]-0]\?[-$26WOA_$3P?!-$+1W?B;"?
^0D\O1P[=/T4^7G1+=%%$>-C_%-$#&;_V:>U^PAX65342$869#((X\ZX7X]W9I_Q M/LS>6\-^4B^@OWH [TUV9-FQ.0:,JV[C7U;XQ5<
R>66TNO,_>$5@,]X6TG6 MV!CP[6=[!G#-BYU$MSSWJ$RZU5QUCM=78C?+^7*^^E+/;QP\H2.\NMQ%RERP
MO+2%U/:VYUJ>=1CFJ\&*J7%]YPRVN^R;ZCKH1J MQKQ-2\0Q(IS3?KE:5+TM8,RBS_ FU,"H&S]NC8"7RB.[S4%QNA8LU.N&
P8)XQUI5@ZH%LK;#94=CL/U.@'5NC,=D*"6RE0L8Y5]IH)]'L)2?'R M7*Z@V>G]>1MV;@%Y-'LT%T'A/ZC=J3&'@)3W^;[!9P;(NLO0\B=BW
M/5C"_P_4A"PV;H,IV?!WIG< &8@B?0Z$L':#BK?M:CB@&8U=!=N6 R_B#$#N@*CPN1-^+8N'/K').S/7;&*ZG4CD#O6"L.B,O4OD4S>G
MF.$74A+MAM^(Q<\V#OR1)WY,19,=3NV\H3E7X$#28ZA'8ZD:$702S ?A^'/[M=-X7&'^^($87,6C!))]19ID+Y MCQ>JAGQV+!.\F:1BQ\G!#IIL"X17^97-
90._&[J17QT%09C M5+@FQ* .+US$(4ML:%LHV1$N$L;A6.W 'G.=&YQ!1.THX:.\J=940?JC[FFP MI@XH./Q!
<&@HFH8K$P.SXD[^,7JX_11L[>+>!IO&.-2\]"_6Q7S7R_#.9N8J MGZ*'X].P63N6?J@6WGI\4D-@2WC,Q=):F+:?LHF[Q*:<$]%X[K1VKL\8E"*
M^,22/:GHPV,RYU.P"%G#K[()+6*C8N>!/43 XRYBA5IX!;=2F4UO\TW[G9!Q MIR?0-VR/SCL_A:XOT8?'_]2%74GZ ^3 G4I"[BRR]"*1^3)YIMIR1F^G(_BS
M2Q@/WI"*BS?>BO 2[M@SQMI<* M>--CXQ.FC)A+&S9@?SI=Z[!?I@0Q;G<523,;C/_X?)@P;BY\6&QVQ<*F7XC[M4R@&SKU)<8"*UK./3-
^P#PTV]Z/3(N=^\X@]*I%Q]%AP^B)^G.]6]_F*DKB MK,M[?/2#_D:^?/ZSJY:1 E\<[#OI]X%)8>U%U#/CE3DEN%9#;ZS7L73*OF<-
BYIP*Y@%T\66"0:BAO3^D*L MI_&)W&HW9*7?D#N=3QOS:'K=7Z)R1F_=SHTFJIR39QZA])6TU1.Z$NV7.!DY
M4N0KHQ$MOC)8^0H+>'H:271/EW8GV-2EJ23JZI+Q EKI J,$N\4QK3>D4G3K MPW:CHTAK;6 V@CDQ ,N%F6Y5,-
,#AFX,)"4_S,3GZG6>75_Y!QLR2=FTJ AG MK[O+;:B/B^_$2.Y5!B>!>@#@+D?E6 / !.D@<9@5SLE;CZ[HTZ MQ5G07>'=CZ[O(8/&'38=-
FH9\85TLI5B4=R@(A37:P%;MQIM9;V[6DS]+"Z0 M/Q:".ZVJ(!AL>DEJ] =R,0C.6^IS#BFLQ)?(]6'$['_+G3OCPIVM9WFZIQAK6BN@@ M-2;O?M(Q:_-
M.&Y,=Q%(P7/GQENK:(*78/*2&^$4P4-OC$?TA"+<@&H_U]B MHNKD5IP%D[ROV$B03 ,RXJX79,-!L34VH2V1:],N)1^F0$1Q_+>6^1^HYN!L
MQ48$LGI=3#ISWK&Z0C7XL'5@6ZS3X!TI'7A2#(_AC..5= 2Z)8;F89ZRBALV M:!"K=-?+$$(3<-S<,+&CFK#EC#'&@L%SZ)QO M1&;%A7;+TTI>>:25V,
H;/8 P-#;1&4$!;PUD)ULF0;\R LC[$P"(^FZ <'1 M;K6*OK\I]OPD5Y@7JP4+P<(;+9D\R0EQ;CY7!LP7.1KQ!IN$(6?ZS,ARAG6! MK(@T T] =D>3-
(2(G/+M8[K<^?2%7P@;,7N,Z"4I"5'D"8Y"QM3^ MC54EJ5/L>'8.Y,L !,:) %+@'35W9J(8IY!HJ;98RO%/;E'',EEJ,VY.76#9 MEE?>QS+$F#*W-
JFQMF4.03AG''/WN#8'+$E%D;I((M/AD0F?^LIGHB+H7G7L M&HH*8[@>T,N.T9WP^--:Y"8.+:*+X&TE*V\7F!X&O.W16QS>'C#>YBH3><1Q
M=BY;]]I1;.T_N8F=Z1OVLK9#$X)U0^@WH%H$"PS%##V6<K3=2QN70(7CAHN!/G?<%3@ .].T9U3SY ME^\>5%%>LN)=02[%3M6)5P\B.-
NOCP;%_97BC.3(;< GP4:@_!#> =;N[6"Z M]U9>'<&M.2-\5G OI")L?[;?X"X0N,VQ0$3C><[X)3Z&?&6#8%#5QN+6QD8A
MO&_2PK_09^_AR3_!$:^5KA:4RIBDSEMJ'0N]$Q=Z]X^%WOMGENT>DJW5 TL0 MIL+X^\;;>#Q@%X_
;1GITU"*G7M^<_MX063O2C^[O7FXO;XZ'SU>G)-OH^O1 MS=D%>?C+Q<4C.;]X'%U=NZZ-4GBD4@TUB(9RYR=.PY?+FX;ONEOY_C$E?E^)
M^#R[/'7^_4?%R'1!"+('C$1O"Q*5 \1N\8E5BE ?1BNKDKV^A3'W+)P M]#B1!@8KMN:F[B!CD>NQ.4PZ*N6Q]VJUEGT&D?%G*]'"!7S*TRW# -
Z*#8RE+YE@.V M^O5A;W=292GI/$OR:@Z0PRJ9_NYJLWW*\^@)7P=%4I;*LNQ(ZK?@!LZ*HP-! M+DNY6 Z0DW* 7$EJP&ZG4^P?M]%
^&!%05FJOG(@'!GLB]WW_[&.*UB&D:7& M)@>4*:"R[>;UO55FE4#Z'M9P[#,;O=?)6H-[&-@=UG+K,Z.[V\FJU);D[L(9 M$5^"'9W\%Q0>I6DF;6N.W
M=^23S:[]"9*/>*2HE(].>W!,^2AA@L$QY:-L&%E)^2@_(HZY'LES/48K,R&/ M"1Y)$SQ<"+ZJ3V+>B3OKA(RI0:?Z>@>ODF4@9+12\?07XLC?
Q(G/>,U0'"5G MT (EI[M;Q:E^ID=&DS$KG"6 <[LDG2'"[6E$33!J)I%^0V^&!(RN%63HFD M#B;G)!?&>?AVUGX_\!#-E!X@/IS\EG??,I[X&.8HKT]7ZA1?
3J5XY537%Z.' MBX=]U4R%W&F%S>H9/CZ;EC'7L6^*J6KP;15KONF3V2!G(W9LLI6#@[7=>=0: MN:1C:ZE:[T1JU/S>+OX<;C%"FP\UPSG:
((RP9!GG%/(65S,P)(MZ#IK)?.$BQG8EZ9U'Q2/K2WBL0=W6+?1:JU+2#%HG1?+L\VS#CNJ&&2F+N#4 M;VP&)1QN^YE"TE^.=::YJ6E?
[JB%SARP^7&X$&X$SW7E;L,[8%,.G'"QM&CH MB'U]]KI?@G-A"..64-T1L^I#X\(98,H[07V/T3W-AOPYM;RL/8B#0"4O;38 M/%
VVETT3>,MVDR72@%&-I;1CUB+ VQYP=N: &SCZSOQ@+F-3\[%R^_AW3$! M.@#S9AV@;C^7 &%H"0?%-UC[-C:2TS'=\;(!/L/IK+PP82:4@?=0&X*:.49(
MXVQ7KI4TS6ESZ7UQC6JWLV(K/2?>X\MOIS]L.L(WWXIM71D7;[QU'K!H& VN M=O,>@VN[V(I-
:G2ZK6C&Q:Y\XCV,/+&I@CD&^2NZ9_+AA7P0JTN,#,"GU;]6 M$K79B^('#Q'?50<[&;^'@UQQ.^VE6#J$8:D^O.039%V9Y$JC /JFZD1,)W;? M4V-X;+ IE-.
(AHH-UJ-QIMN![AX\3#>F,_,USO2Y0[8'RH:PBD4DMP44^*U\ MR=O(_1/;R,7U_1_&-A;CS);V!MSV^TMD+Y:,-8Z%- =6TM]LY
M48G\5&R:];%]U/L@(^3XQUE[#DM&9NAL#: !%L(LJZ07$9X5OZ'C(ED"E+O M2IQ6C%X4Q0S0J;9_X0R["+/^P]9[<;;++)$^CM=?NFGA+T0-?<
M]K9[1&-RYWY7:B49^E7\=J3-Y!2-*ZI.GMT>P1[.O#:U"5$7@V([^X6'O&MJ MYWZW@Y/5)"4^>FI!]/"Q+@D1Y#
<@+TN4O"BO=**&O=*Q86_BAKV#8\/>2B65 M//CSJ.P+-D+JQG2HWZ\W,K\$RRR+SB]I>_DE#X^W9__SE]OK\XO[!Q&\)!=_
M^W'U^$^RYT:]Q1UY]/B=W$ZG\!WCJ?A#_>KW&2WZ5=$SB]P8/N-*[ILPB4H> MX&ZT:Z,GN,)8Z[L3?!9!X_WI$\^&N*8(J=]![EB.
91+KJ_/R(GXZR<1F>-A M\.#K<(2:B5#F3?7H;-;@X]$<'0>:F/Q?U<%(;0TD,F4I 18K4VX0/@35'Z$3 M&&,.MZZY?,(L#4:UB?7FQY;] MH-/:#"
@83!E!?,;P,#1%^J,1]M#D/&37UBK_]!J."8%9[C,>$?Q[6!VLSC M>6Y@VJ;6BSZ!KX/(5F?XV':5-
:04Q3.:62Y)\.4/XIT7^,I820]="9,]3]@)VU+46!\Y"KH/'[J'8&1I!T $/AI#*/2CN2&PAL*$?A/D]-LINWS@UAICI(W-(+;YU+DKX]&?
MC1AO(C%/>BQJ;'81^^W6AWU 1T>*<@RNZOD;J%9D/7%:3YA7D\6L$:_$F=+G M=(PEWK=3! 4F6YUA/E4L2Z>7!&,'V6$??
70#):8UYJ9>O:IVS>")3H@MW;99 MO@]+F*)/&(&A4(M@A8'77NT-,\B.#@R5UQ4KLVQ517)^-LCORZ#H6(&OC= =5- M=>"
[PZ$Q2^ZYCH(R?/B>%JFPG>!E&]IF;2M4'808S%=>SE4G@L-TXQPM#E"[9Q'>4OMT/%KV1^!9T49K)-A6D)!O5Q!Z:4;+%:(@M#$?;_?%L445 MB
^\S%4!8;!]G.N[4Q^V3EN[S:A#<&SHOL,V#TW]K?FL:QJ%A_B_< -.G"9> MCBP/0_[JW6A%L'E2D[_<@B!-EGDA@@#GZ+73S+$XB"#
(T&6AS(*@%U.//X@@ MV*)D(S[R4K('T@&5[+)J(J5V=_32M \K1(AA5__*R+ 4;7>J(,,&*,.4"LHP M)3<9UL9X&4T1(DKVS72#LET$@Q2-U0
MVCFV0C=N%(B\UQ18L8:]HF$>"E,FQ*?XDKLB%'O.EHH6(GN/G_=*(!RP65JC'2.5\ #A\P30*QV[=_8844B:)K_#']?? MX(_C/,/,D=!1NT%O?

QE=9"5E_S3)BGFS/TCFCK([4;%TS)\AGW /S-_?HRL^ M7^;OMQ(R_R#H)B]#C*\,K-U/DV:4,VNW6_5AK[M;Z2\;:_>M3?E"FQ@[3;8C7]5#1SPPC>
/,Y_:O)_W/DO_L?'^S\!H6<9_I67 MD,!.VXV65#WUOY\ABK\',=%&,=&MI)AH)Q038.EX@Z#*H@9L=,%NA; 1# M,-AN;:=L+$6MT=9LB/
,W=:I)'=T(^4J5PG]6YP2\BJ1H MHO*L:*_=7J =%.QKLIQY33,CNFZ'&C FZ+Y-1L[.W#*56'1"]1>67\6:6F+3 M3@>[#DZI)5JLE("5K*=;,T6@\TV!/8\W+-
X[29ZV"60#NZSYPW("#?KJ*++8&OP 0V.L%O:*O=.4-=.4/EU*>!SMA5EI&BN=XM@G(? M/?3VV,4XT&LUQLR*FC_X(#RP&%N%[FBKV\W2I!3-
=Z0E&^85WSP?#XX/_LH M>B!>A'!5ZD-EPV!;/-_V8V3)-,CW&&WF%9#7BX4VM51EU_=4U2T^!6F??3IY MMNTEO)O-
'1AI2(#SF',C.IWZL",=8$A,MEUSKTW$IL-30VJLT3)K%^UVNK;L MX]R*R+D5\G%N1>*Y%5+K.+BB=(,KPC4A_E"*VVFP&O*>SE!)8TV=UVHADS>J
MS?B:0'7@H-O-84Z&/Q*C$QZ)T?PV>K@X)V>WW^\N;AY&CU>W-SEJ0OL;?3'G M>I3^4?J,&G>H.;B[R MWH]0S<0 Q U*Y@;U#"=46@@J-KA"-
'0_!8HA(G< ->\6TWA&RR> /?XN,6#7 M5H"M&Q,+Y]K9KLUG>)4PXN61+R/C]QVP[J>'=<"Q?Z8N=$>=<3#?
BYU4AJ*L3QO8K<_W!R4\T8"5&6PZ$__"ZM3_,)DHS%(+!I/# MGA2@&%V2:=5\OH1PFR#4+@"=/0_42$EX1N:;L$73(O/@T WTW+F,+<6
MCB<:XP0;%6<,UU0RMDQ5(ZS7 [-"L:\#K,"]E^B0X"+1Y*T>&N)7I$^ %?=4 MLI &WZ<#*A:ZIMA3#?1/,C #2)IC5&7$^FQ;_N,U=SR.[MC4
MG%Z<7NH&2 0X_;WG//_A;_K:5(U+RN;GQ''N=+%99J/7C1Z?P]"NHS=_P7WF M<.XQ\]J;3P8#D5GCOW=*Z"Y#2>SF!7"
(VE.GL$ZI%#L$/'Y>E:@0O!;=J5'\2S8@VAJYQK M11C5>GPUFSC9CUR>C\C#B?\ M+@G\Z5/8#^^*J#"/ ?%YXV"V*RL9N&NK)<4^7&G;I,755CKUX:
U:'04):XE MU:B)8548$+67XW\!$R(47KCT(UPG6"Y,<9%/GG7ZPB?9X4K4H0P'A(&R.*4Z:HNV0,1O
MG%CBH@&;*\J=AA+1C<=%PXF8##;UW_7)&QR&N'#IDS/$ AD!J5R$FD.4W6#7 M:1!-:Y:+QSYLOB4\ 4S%
.U;QZG@G&)ZW#8XGR$%S6;Q(=T#DZ,M-Y16+PVD M:YL@[;R:T9#FN)FP;:++1;5#%*[I&C%,1\2/'K501%"3 #Y.]>$!=2J]+?B/;?&;&&>P'&Q3?S7PP:\F
] MO]?#-P.2!WCQTC!S"4%7VRSH5CF(873!A5X"I*)T.X>OB\%Q>\!^^S5R-Q M.NWQS(,^PES[M,&3/VT;U]W12Q< A*N! [N 06> M]=.4_^;/8AD9M):?/
MZA-^M_H8[R+&,Q)^K_I@Z"$8UF-G1*/QGB_^AC'N,[I>D/(1(0_J#X8!AOX M_TCX41B76I7'>+^5G? EJ?I@D/*5^/$MCMWVA.<>[G4:R8&54]
M/B9H2NL9-)NX+Q6]EHP]MF'U0^ 4$T?E2)PF0>;G$J/P(.IU5AY M7I[C8W\!>3TIMM(2[EEW:!,#O4#(AOEJJ0OO?8?
FF=)HYIF(IES=1GE8TA*JGNH/ZL/.Z5KYE-?58/MI.B4[S:"%IXGHL/I3.VPV(*];-N1) M64BQ5[;3R$=2C$V*_;
(A3\E"BH.RG:9]),6XI"@E+&@N'GF=#*2(FF^Y3H/% M>+X.FY$47;4UWN#T4C==>GRFJPT.W<(7U6$)U($"&4RNKF&EU)S5IB_1EOBW
MVPR3Y1TU'R;/Y@S6P>5X7O/1Z*&Y\6S:T2SU^C4'U;"HP%L6!<6M^#I7 5N M)H_8O04HE/P36Z*1LZ7U0@E:2?R-BR7;EM_,X,?
IPRDYIU@GB!19$W6"WC*J M[98.!@N,3'X>F]_ENK,K<+TB][99^)[XL"G9$0T'7L<&AIY9YN#!_Y-+9,= M1UT &'%;=*(N;5H+]PJVB4%?
6#FCKGFKN#T6X$.3 XHH27/K>2<3/L >3Q1>$;!EW%'A?9L8DO)L[<4KYD+\Z.D;T=D)?? M)SS>1\"L*,
[\L(@=N1=R8MSN;8LW;J/$\F[1K=TM#9F4IF0$U3Q6]IS/'5:% M(T?+RH][7E:PGM-YBXWW"26XV_ZE/OPFIK2LS6?9&*U,$YO?-N1K0Q ^SM2W
M%'VK,L>-PYUXO'OCTK08?\=LS3/ %.Y&M]UO=",:.,2,%,> ZD^/+F%&!*P(MCL"X>!HP//4'#26BMTLY\+0V!'4[BOAKDOXW/F+WE/2TCMB\&HGT6BS-
O+=[MOFIL?&?)L-XPS)-!1;0?WFIG;$SRV!W;$11SLCU])VWWP-2H9W]E/]D;I/"5 M$7@FB'OLG_SG>G,;S_=:K(MUO[=>9[
-5ARFGPI&17!L"D:+FOI;\UG7-_J/ M\'^;4]AL$X?:L@B4_%5,#=FY]1@F:P[[CT])"88D1E.2O:,E48!$\NY%U&NQ
M7D2=]6RX9'@H5@^,E"Q1HLSUQ8D6;S^9N EK?**YZ5;%+Y:44>K#;E]N*.64 M,WFC(*_[/MP[[#?+M&-VP^RUVED
7DWI6/*6;;U6AXG)]9S9HL1D#D+0&Z1: MEJM^4,ZK/G\Q7G1'\%ZK6Q_V&AUEM^9?:HF\9]G@C3#.7SST6$?']>[%%=2B M-
OHI7;DR<;MYBV$RSM(R^('-R<@0T YMK,S+H4F6ZDHK2*;8K?:1GUD:/<" M[(\F3EH'F&=R_5:8(:U92">W1(E1J/';?BH'"T4>#UDI(= HWU7HL5%]R!_
M=*^5W23'=!&DE96_]WQ'1> TMUM*PDENI]W=2FPJ/*31;8-1G;\N#>JEB1U4 M1\DR3?.@T9J>).;:M1M=97<4H)3&XR& GRWVTI-DD*8-
198:@\R.M*107XNI M9 -X]6,B(+V'RJE208=FB4(E:>?_E#52(K6K'RGIM,KI/HE/2)4.E$@=5)[D M_9GX'R0,LG=14DP41,
(>GGVET>VMMQLI@0S)&0.'#X)(O2SPKJ3@*WL,1.JS MH:59[8K]:%8KIFMBT?FS.SGW+K:+]W%* [C!>^W&H+6;A(].SI+<(.E]G'*K M '1_&"?
G(>^G(GV<\J9975E!KVX'F+$7 MP^K?,Z9COV[-/QSQIHSHK+[/6&:3:93=EF8J+*\VERF\U<%Z^YJUI@OH/ZS5
MA!\Q]$M1O39P7Z$7_4>S22ZQ_"\0TF.&'C8Q;_M4HJ#8Q_7:^9B357,M;-4 #@N6+Z2Q_<%/#&R MU+$^^4IN@*TXZ&Y,!)(D!;_UV?T:@Y_;%0EIPT=Y-
$#'%E5_;XXIMHGY H8S MHB9X_&[$\1'PN8 P2,21&PT>$<_NDT?!!!S86>AUD4U%SG5[,C-MT'!OIT$Q M=T]GV&CIS+0=>TW*V8\TJJ-(0>
<9P;+P*M&5B+4>\A)&"?Q!)1/5?IY1VR9C MU=9M-IMXZZ702NLRB)DEF31)4NYL2I)TN]N84SC!?&X: A;)6MFPKDD6;Z*% MG9>"\ P",[QJ;?
NJRBDY3[2+P!3H8*LH%D2$+^2-L5BIK;>PD]AJ%DME[74B ML(0GV[K_;AGVCZF?]4$6,]4X)9>">&)*A]HZZ<#:)J,=)K.:K!5C^$W8PLZPJ4NH
MMN@()I(34'*JBX5EOK'.@;-W\J<=2)32(W$T@SL1K\UHT^&"[W23PA_$HM+" MUN>-5FN#L-EUB Q6;(Z'0 ^7$GF(%2*LY25ILI)++2&Y9/
WYPAGN3X&,-UF"CUKZ?B. MPMGRUA)J*=((.;E_^/'):_586VGDJ-MD@9U!,5^"C.G,?#VM6K/&])BK6.?& MS8;VQVOIYC7K&UN?
AZ1L#=ZRMG6*!80X#BR_[1]#4T6Z6N5V?!;$:9[#Q*O:\DJ20NMS_UV@/!A^OL5(2%.XIT+...#34'Y]5@5@; M4,SY8R4 Q$0 2@!ODD"B*)#2K0];IX,[ZZ-
^RUQ=* MAQ@E?B@=HMV*R>)[KQ+:<$7\),I#IYK*0UL2RD/RU*0/KCP<8IC[096'MEQ] MY2&4W1BI.OQ,2=!2*XU)4T+MI*V
=M+N@)A*GA&]EGY:9);LAI<5DR.[@MZR MR*BB%)]V2O$4@P#V,IWQ@,%+'_FF(XZP^%]EF[8^H1/;\1(WOW##YX5(CBS MQ@<11L3NQ?3
!$D967M7I=&+=A+HZ.G)HD]P@"L7&(P: \(I3NR[W:D/%;D? M&?WFXPZ7<" 3[KA_K^8R3$S;B;Z+]@OB2]U0#0P\WM,)U5^0]G_X>[XV5>.2
M4DPEC06/;GTX:$>"HV;QK%0L;F74AND-NAV88FF2,65)($\& Y=J>PD?)DZC M5,F":3SK:4$[XO))1LH6(@TW5Q/(A^!.0"Y,^C]XB ?61:9-Y(B
;ZL09L,EIE!<^P^TZ'E,]XZ(][E%S/M:]*UC<^@C""N#B8"[&F+%#((H; MGRR-HY8;+9;JA*&4IIJ;TL1^\?0._FM ^^!_N-:GXLD3W2#_1#WCT\\!&6]H
M(_LM-I%7Y.!!HD\@H2ITPI\6M9Y%RX_GV;7\UQ>>HY;+113//1N15]1N_9+G MH7=8Q5+W)XQSZ\ULD$U#T\$2%XRCL,L6J>#];@,:>
[R"1RDXVJ^I^^T-C9# M#-/P]B2W5$_T-N0BYL>QV['7#V+OZN:R$LTL.KPQ]*#?:'>BG/2%8RT]7K=X M("1ID,R'E,9AF=I3)/L(4-
H=.4\2[9_BD$^!M%6/0+%(S/.2V$YVI6+TZC*RD!+0B:Q+5CA0]^;,2JWJF^.=;%_ MV2"B.
<5.8U26JG_Z7GW8BV[YF=!]M"7%>4^B0I8K:5WVZ\.!HC2D]N[+9!<2 MDB!EFVDH*U4Q#?N#/.FK>]H=[#(-=^)@#U=S:9CL UAV0$"=T\A9?
L7QWD\A M$-,:9MU6?=A7NHU.9.)^0J0$8IL A:FIR/CU6(O1.>\FOPOC).RF_>% / MA-RMHEG1;=>'[<&@(O^3*)#!#US-
@KZJ5/UY$'U3S^(:Q+%K;).4%V? M]GL'O<^55A6-I5YK^[BJ[+C>X[/),P$5J2IV&3H(\R/EWFF_%S<3<*_(WH-* M&)MP#B(XJF\ ]J2-
8]'V*TV.MTQ9K,:>C'GD@VZOT>['SR0]"IZ/*WB*,%![M"@J>]N'5F)V")T=B<[<0?<+JB+(*Y3?VVFGR&W<1D+#S-WY'MPD ?;+D_614NX:=+^C;!*
<(FE/6!P/G(F*3C 5*!>^/P2E\\$/4 M9"SX@C'1%^J,@&J-",#]_DX=WH*&OT@4P(?6YCTU3C<,1CWPZ,@MO56V-3BY
M,@!B]%%]\P=-1O0F43H#N;@!DEBS?/MX0;J$H4CZ2JYNSFZ_7Y#'T?]>//"" MUJJWOWD,#,'2J .FG&[FAJ=4LO"SDCJ&U"Y31W6-*DVT]6Q/M,=G;*AF?
M>54O[W*6_R!%0-8LQA$H_U7*5<0F/;U;9P7\M";YV MBWJ?[K@1 M&)K$^/5+UVYU4VV^>,&G8&2]H:>;? P8ETJPV$1_9;U)'(".DFYB^1MJ9H^U
MHP+D?G;0918U#N4 '(4:_L878H?X7L\#+N+87[%V5-@%Z>5Z(?XCQ.%UCTI- M80LF_)6O4%QL>QC>I;!4@]1]FE342(9*[F++_.^R%BRO:
T#3PQ)1.GJ% M/1^H!2C'Y)((>R+9[!F!.F6MV/FOS4!> UIQ2$*M[@*ODJO5QJRV'3G.(%XS M[Q6IHJAK!DDW-
I,>ST+!!E2>4H]>VW9@N_EAW(&6#DM2[1/1_1[X= M6':+EWQYL<,NP,D?H-C UZ*0GRS'[MDA 2\ :@9@JL,@<;9M5"/T:L4XPG,0 M?ZS68!<#1%D0/?
U-9\.# P3ZE4O#:4\#0MR811/ZH[#K^71L8>XQ%9]*(^A' M2DE(+Z4QW] "XYUD2*5,F\1T(@?F@ G7$@?)#('02PDQ_8* M7[&
(S$4W\OJN&_G\W(H#>*;"?04)IP2>P@08#V MU4JB@T"3L:=+M@6/[2$D=K.#;9OA)5M <2 <)A$.V#=]LOK:OM?CNJ"']([0
M'>E\5)/4TU&4MKH:=8<5C5XYAR$"?*&5X&@E,'YL![@]OM1G/II'NM076]XS M XLUA*>P.7ERT,3,\HS1BN1+8#31^:-"U@Y Q]+PT(AS2)M GY$?
0Z8D@(0 M@+TXD<5*=&Y0P^X[\"%K.B=FFLK:5 CTS2"4.R(S27N($-1I L4W(QP<9Q=V MF:+D]\Q7NQ?UQ(GGCZ;Y!6KIIA. /8
X(BZE(%#.0I@EO!,PR&CTVO ST@E" M-&X77]9!IS)[B'(P96!$V%3;X;69[6QG&0"2-$EB4!D^AF"H+SAZ+V9L)\^- M'\68X/V^A[:7
1($)6=S]"+*D'9]T)8$RZ0[Q)I=!AQS[W4P%7;*KC9# MQ%?@O P?3;)T>J M-1NBOCQF>ZJI#W=?;MM+MJT)=J;\B+8@/X\](#'@CO JJ03?(KO/":R958U^
MF-PLM;3TY/&UU/@TFR1**NQNV6'DO;RYR1!H[8&(L14^DHV$7(J$2$JE+34&8!+WQBN M&H@9ZJ;09BR'3KBW.Q7N.5.Y ZDY>
3U,N!0F>91P$:9R_8H',<>A?N+3\W' MBW/]KGG_^$5_O&_>/#3/'J]N;U;@3H#52*@O>ZJFSOU_>H^)1O&ZY[(QX26- MO;(6'/5GENBD-
NI(.@/]VQNPX1?+^GE$;"/1*6?5)=-,K6_:7#GCJ]7$:N?A M 6]I]A?G(YB@VX$1U'2M/\S.F$9]P^>_>>_5JH=913@P4U.7NUWM2A]RVKA
M<%6/2R<9=4!+P*D#C $"WIV!-,*$QL+C@J:L9:QWT%PDO1?M19_G @!)FD$2 M*K50#0DB?##TM,OFPP>]^7 &^G(?
&$G#."XA%8FHOZC.3\/"BQ8G)ZYU4W>9 M%(G-8ZRD+?$A M/?0&"55:,,<_A!P!Q5WT1A1RM>[G%E[_2H5FJLA,(TA<+T M[Z6P\:)WB\-?
A[OPU_SAK]HN_+5, AY6F]*STA\F<23S?RL5U"8/S-.E+^D* M!)!>+>O7< 7+&#L-):_5A^1WB9;A1:&6 MI-
64U%6:3_"C\/Q2ZB::P5ZDFL(E^AR$F+V&GZ@S8VCSH>*.A(E'6_'FQDZ9O4F! 8VWX&:,526J7&? T-^K%YL?Q&F 7Z(1NVQQG^%,/.T'ZK,5] M9"
[&:_P1W/U&Z4E60CP*T'!2"3B-(NRUG_@Y,9]_-+BP!% M9,>#3US=?Z&0+7*0:N4GF;E7HL]@\XOO,>"%.<5A\I,F?A+)D,-OH)/*M4:^
M[CNF._JE[_V=&@.H/8 E8_0 A@OR8_6*-,\;=TRBJ! M1[LV?6 X-7%N*,@T<>%)K),F(S"+M J.,\%49*Z%F=RY)DHGRFE+UM6.T"\N MXIGD1$?<*
<%!W#B,$N?7Q8_C!Q,#AH[#: 4"V#N&/RD)%!>R[!PZ:-@6 -:&=J5 '84,0$1Z.PMH]Y^@@3AM1).M.
M3X%D*N&$T,6@!IP(22X4(O9X+B4G^!:&8(?.@@:X>.-!\";24UF_PEADIQL* M@ 1L/-(58N)N<1$(3TZ$"-].H-\>S84\U&L!F\?E\J_X1\S-CI.U@4)>0R)U
M'QL8JS]PR0%R00.!TC6?6;*(LO[%BPC4 $E<++-X*K.'1Z2%85*,K0(J;1*S M/(-Z(I2D8@"2UL0+'0![,\YD1_5)HW_'PH+GWL(Y"LA0 JD'\@QVPH\.ILY.
M@!!0! ">ZSQTR@#CE&QA6I; \9!H(MR$(>P^HDLZ2"W S$2>.LBV .5BCN94ZX M-[10D'2,,\W0_(J"5(V?X)K[Y!RA,9[Q0%&R]$2L,*$"I;BY"VJ[D@9?
TE)\ M#DZR+C2*.)>CE"@$^&\U;$Y@5+@HK=_AF=>8;:&N!]4_7- +++XL *;:-N@ MM!:YXU*8!4A:4IPA%L@1A 9&AID&7=? MZ\+*CZ/SW)
(F08W:L.]%'6X5XMMR#2;(#EBJ'KYX^YC"I(/)@UYO&+DD]&*; M\J_9+$BS+_#$:YOS_A&+]@3BK[2M=?@)F;N%U4IS33"44$'V]DLGVOW4XN
MMY'Z*("3.05,[=$%BQQ \X_NJ#*X.U1S%HQT6!#A1/10IJBT-R=P;YZ74N% MHP6,#"^@$>*FI [B95;:,VG>."-H M17W^R6=V[PGS.G'+)=PE'XRR\\S!?
NCMPU\X;@PEC:X!]24?>@'&F%JV!5K4 M,V;X" H3CI G-O#$*P@2#$MY0#+$@00O"R*\9XM["%1NITR&K+N#^6Z8;\A] M02"
(Q10\'T_@EY9*2(#A@#"?/.%*" =]IALQ&_7-OFW!8CH^=;8'8PE])UR9 M1M'#_!ZA3&Q&$FF)CU.-J53C:^#:\T<3##Y8)<]A>B'[J8?J'J:*'!J5=U]_ M0#P(R(
FFB3&":KY[%)ZWT-(5QPO/8\G6)_[44=O6CU $CF0\(UW GJ7YTT! MM1\TZ74B^DX1%!DM:!8IX<1XF>@(LC'I',;26PYB5LADL50B.K2VDL'I[HE
M/[7J\N+YW,HYZ*^Q&X="><*NX#XC5&W16HD=15I\?YNN2W(^!=\AC7,[(_&@ M]B-0< P1!H8YQYAH03J2L$"91HI[;&MG9NBJ'F3N,]'35A-W'*%EC6P
D"'=0K.M MUF*8Z1=HPL)1WD+G*9YFKN"C]X][54LQXB@$#\ GO15T.7@/]FZQ)V0MTAM9 M(@83];EC!S5@;E8D1_'\H(V$
QO1(E=FVM((V?._,'Y=EASXI$.2QPR>!WN* M'SR4&:2"$I=6)#27<2B(108PVE3*)#U %68](@N'<:,6]X$$9(41:0MI8ZEO
M67J^+I!I/H#,FGIF=ACT>M:VG<7?;)AGU:".$GV,I+>5F'?'GL8]Z \]$N MX#Q_P+F^"SCG^Q1D"E$L]HIV%S),M#N:+;K9@Y&K.Z#,5AS3$?
4X1ZI0J0$9'2N*,Y#OU!:N+X M +0#$KVT!KZ39 5/BG*E1O840XN\N&[**RACFP@'2DM'6]?C*D"2&9YR+)8Q M]*S&NS"0()S\4J]*K0QE: R!S"
9GRGQDJLK]'S%Q\D5*[3ZR1C!1^.3JO?5 MDZI,[S.I'3!+2Y0#X7J[H30!P.R92@I).L-#2DN8.U*F#T?**&%?&W.-Q&<* ME;M>'#01CE]:IS$+I/=
MU(!K2NE*.]J;,&"6WC9==4YQ ME.%E9ZY1J+SJY,7;]ADQQL7L%PL&%H2 JHN') JAG-+-'H2;D MX6'U7WMI!4!UKM9]\2!QRS>:)2-N5;_KWG/X63>Q >=
M>M8>AF[R25/@M4,B,T R%'II-*8]%P6K!>_C,/2234'RS@YKBQW$=DTFT6H M1^7#Z4L9HDY9EIH;3_R_C3)4;R?
$@"CC[/[_F[W^3^>EV.&5U.2@S#^7.93> MA@8^3R='CP;^0WI%N)\#(UL.><\LS#'&:F"QU[*'16K_2;[@B8FQ9U*6$=.' MRHA1T![S4=
(AYGZ!IT\@Q$ICFO#;6QWAFY=8G> M.)/&&BIZQ+FG-O;^,&7_^.K5CL#L,26^RR\7\W(O>)58E"!*YJ-(]3[WD+:4 M^O8QFF"0_ZJ4#_6>
[3B4>2FOU^_+S&F.P-$J&)5R5;XEDL3EI"EJ5"8:/X!, MHY=C!!I5F:)B1Q2OQ\P>S%+!M!7QR)0E\9M5X@@EJ*#+RD//);Y&BK8F=+)M
M5)G<:5\+3693FI:B3V6<.2BUGKQONDEB&Z5#S4BK-4TE]J%10M\$%A\O)&&X MXY=DC*5]?
2SMPZPCH*G%E"Q/1HJD53DALPDH%SARG'W*R8_I0M;5Z#+3(L>Z M FM 8+V*Z209%(&A#ZUVDOEKK:QGT1U/*YG&G+
(!=YSB.BIRD8ZUF+ONSUZ= M(5T2@(8UAK@;S--0YY'GA<\BR']D,FW*9+'$;(7CTT9B:*@YF2*E*V 8(M+I M:@ 2\F3%E=O>$JH2\69>(8E7BMXYI?U8)
X.Z:=G3RJ9)()(;^I4GN^%)'& M+D5D_A21PUV*R :=%_OT%^;&;074M-=GMHO(S1N1*YQG?1=V6T,HH8C1IEUL M+0^[W=#8VBZ -E<

39789DIBYSJ$9I2{)R,D5HA-E%&]U.8+YN1EY=6C-H?0-MJH>CD8G5A]!F.&VK"Z)52[7*2#!W]=&K;JEBC!SE-2SC9(;(U6]";/?RT?<'
MT3;*M!Q_;BA^]@M¥%)M*_(R2N+&U1NQUQHX+,IB6*@2#E;#1PREGG!?Y+?R%FN^4Q%5+>0FW(U:-&G<6/^8@'HJ:#DAJC7>
M[SIW!&&H6$@2),+XH^^U>1DKO+R-10-:5,JAY4+H!%TFI\HMXEJ'$OP8%Y;(BH&,!%/$%[6LJ,>8,SY/N&,$(-\5W=!'HQO:-MMD8WZ'I(2W'VD\[]6-2EC
JFDXK;%@X@XZJO6!Z5&1/W9T!-MOX$D*K$007+Q'C*M909=O>UX+P&_U/Z<)-,HTJ0,ZCP5**,$F183M2AD88*X
M*5KRINPBAE5;L>8XF@;*?'C3#H\VW:JR(JH3QAE,//!;/@C+>T-MYBI9/_8.%VU%SJQA.VFQ_E$,=9(P/Q%0;:A1_#17&--=B."&-3D((D^FPZN_-M
6NME4]B_B?"\6:K%?4BSHTMUK9;=E;KEL9API(&':<"2U6@%G1I&"9$UL-M57)!##X%C%&(0905$%DP>,<3%^Q%(<NC"=XE
MN%:@,E:ZV(@_QIR5"A8,;8WXK*@VHDCEI,-!E5F+2-2ZC&<-R-.@7L+39,$B-MK-S6ZF*14Y+>P&YX.8>R".WI?
W29&]^VE#H#78@=4P\CN;"*KT"*[A!CRF1H-M2RF3H;^A3(8VH4R&2+[(&D9P(YD*:%K(JL2M6E[-0;H:B20<$_2CN"Y-?*V6-MMT);;M9J<<7+)VP
CZ6/!0@+T/[@A\6++TZB3:[-,KFC309OY]6NN$(;5Z^A!A1=TY>%:I02-I@P@VQ<-M-
_-8N2&H@)FMLN(WXW/#%UJQ@:S(^KM+)79&!!W+4')2@P%R_D_>6N7.T&-MOE+ZC,%N4MTK3?
V!:NTTX\9<[Y0Z>\W'Z^0766>)LYA/#*P5<<>4"Y6#OST-MZ2RNRB1^C-^@I6M!EW3??,#!&)=6*F74P1;\-O-STD=I!{Y22
MO:*T&*]FDO,RS)=@**,;_92[5TE-M6(C98PUL,-\FI'9$15WDJ[\K)8'+.88/AP;]0D4J$^C0$78)S?S-M4Q@'Q4OMCTI-4.N#OJA"'B5=CXG-
I@>TDFWREG&B7UW*\NAZ+\"(?%Y0-^D<-MFMH%$0E5&Q7'6H#6Q]/QU?5>7*I$)IE(29UY=@#+@F":"?M";CD)2T\,5\A*,1^T*:[-
@DHI[*!.$%L.Y,IZ2'I5%'*G^G5G/>E@W,2@(,0R*F)LHK'84B*R25UR-EI.-MJJH
#:D"RE10I1!625:Z2K).)Y7&TH=*8U%E"M_B1551N:1J@IY0P5>4RHTF-M[XJMUSE,NA(6W,;BH2.VD.+;H:J709?&:MX*1V+A$;BR>/F-OH+R;B).!>G
MEM29QF-J>QH?E74]TC-FZX"3_7W-9W*+*P>*;..PZ;V7=AL)/)X(=C4-M5'?F#-B;X[7F9U?("C'Y"]0DX"/L C8([''--R83(+57F>>AN&+ZFD#?75-M-!-7;=
()G@P0X+SA<(/Y;>)Y9XB'N)+KTT"Z-R?C0ONOFH*+Z;&XA-(0%6]S-M$>]K,F('FN$^_+4O#)]XKG%2ZE@:BMI40[&LS[Q%4-TSKU5-V50--Z4-;VK4-M
L?1T&J5@8.1^LW3+-X,4[=$\\!@L9L+HP/8.)T"-.1TPY=)%QKA6VKTT#Z5-M;>CUI]!L*PK'6LH>'I+UC$]OX,8Z5K2V29Q:R><"_4$SM%Z&.9PL8)^FH5-
MB6)A%REL,D#QC4G#:JEA4[E+]C-[,K->51Q[+>B[:.NY3WP<.[QY6R@3.8&,Q4(-/<<8@-KX'=AD\4"-M!Z.\%^13&TL/$O%V"F]-];?:4-_)$V:3U;9I+E6QG:\
M@)"0YWP@U_D=F[S^=Q47_9*O6:*V\Y'M_^>-1HS**FFD7L9S-MAKTFN69YAZ[M1;)-DPD-U,^$_^L=!8*/[H*%ZDH
PNG="G,G*%H&.9[!FCT-MV$$730\>A[*IH2-96!1("[DRX?-23[QE*4];2R6@\/+D\%I9_\!X(U-*L>[R-M>N1)$(V";%GC)6W(X[$H7(3)+'W*#@IY]D.
(\5=LC*/T,FTZ@8<)PM2GF%<]-M;U,32?9L.E&@B:'T-ME&Q;\0\K:4=DE8H-N\50*1.F9%_T(XVSG^,]Y*![]9/32F7B&3K],?#'UL_5-MEC3=YUB;I59ASW;
<1"&!$.954\-K)8LMH74U.PA_.>O;K*U?O+)61&+QMMT&-M/=87N2XN1AQYKDN:7"BNG2(9V?F5^N:E.XC+52A]=%HJTTD02;$)S"T4S<;O
M(W22SWSA\QWZ@IXU#2WQ*=/LI3>Q%>RC>VP\,>[*7TA!X*#F)JU5(D271-MTS;+ZIQM1[S44-RJC:5,D"EGR=F^DGSL3.5CL1JKW<<|<9.ES-
PI/1IOTX#N-M1-=3&O+*MN831$,B9C@K[9!VA;,B9C@K[9!VA;-?QA%WHN(G$G6G&@W?H5#=[04YX7#49*-M\|\V(.(>+NF\FMGFBZ"=["}H\T?
0&KL(VA+I]^ETTF63(0/,6*(!IJP(7M_77S|>KV9A4&V#1^,@2:ZBIM4Z.L?Z+;>G<|WH+I-M91MME,J[(FAI@&6C)9>&;/?9HP]\-
D3R6;9+4IF@L'D1V69(B,-M0EFVBYX62D\7$6&Q=,ZF\'NJ.XEIDA'V=Q?!L"?/]$%<=U#8NCQ.T0&F."AI-M
7/;^S[KX%4MVCV,))V+|=)C!3[6^CVN]=.F(]+'-M*$4Z[HM.B?<,P$D!@-Z8P4&H818EUVMAGB@HC>1@EX9&&1TW3EY/%H!*M<\H-MZ52X2&U,-
<1R8J3?8Q)UU.I2!U]*LM+P:I)-L,5:W"2:A0Y6'A*?D!$\%P^);,<3U0D-M[A1Z2@]S>64MKCC+!YY,C':O;R9,*;G%DWA]$O8TO@VBB"9PKPU-[TM6FMGI
M+7;@B-1O'];@P_+#KC"K[7'7(7">F$Y[4\,ZF=OZ@M>[/4R^\/%&8[U,7*9-M7!5M[-9.?D/GL;[*\U@MZY]=?BN%;N8\R#21"W[+*?%TD%?
R,W>K"1UAHT]O-M"A,8)*&5-R9C88"B:O;I7M].A0NHI'52NFX5I-7@O"FH,OD478]=S\N19T(-M6VJ?*E/6T$>,G";T;7(-\O2=R+5!#7D!Q43O8/H.-
EWE%W@B7VOV^-E'LKQG-MY(+&=1@-2;I7+F(/U8T[QW2I\6DSZL#&]-I1Y@X]E-M4Y7Y;,51XVO0T4,M1FP-2618*.I%M,&3&QST,)LT-PQL,8J2>
0I!>=I2L7-M1$R/2XA-1O[/]NM[T!MNHAZ\TZ)(#QVS]K_WFO5]W0.A'_OV;.A^[;]RJS]-MMND$;$]WS1ZLA;6L]S>>BR+2J#P=&DW??
_1[;FA=.F9GCU!HOS[OUQO'QA*F-M:EH>]$JCZHM>IYQ&ZKC(76Q,KPZV^F\G]=_M/-P%:I:V05RY@_D-M'.\".\6_=.V0-M[>,"83#?>_'-
_D)/]-.IP!%'D3B06=6B1Q:+SU_N0?G&]7D>_;01?+@J/.&XCTQ_TU$-F6IPS7?9\#_&P_CE(4<'HU9-MR3+X]'[.@I9OD].PV%"5T%L%\#!T-U:6=K;I(5/:7_P?
5!9)4D5"C!&927T-M8CM4:@TW<6Z&4X5D/D-TE;>O-'*_@E:!SMT)PBW>Y1OZW@QO$>RJ16Z@9I2-
M27@>!^$Y.6;&+L89.Z;>]=%IP\Q*%4!S>%@QV&O-V#?^M^=9D6/ZY6[86R@.-MU9%H319KB>)F[RGV!D>#_33\"\;XP
HYPYVI%4SO9!QA-.,_,\!5JU3C^)7I-M/YDN"_9O7QTVD-GUU4]E&J-(_&4N%5N9-E+&\ZOX;F8*6OSA_G-6777Y9[0Z-MSQD="YKE'M!]X0YHB9)KQC
S^IY-/6";8=-=SL(*40*C,91S=)"??>;?Z-M/,=RJ,3;)>W,H\F>_F;0!U3N8,2XY,T>YF?)WG?&=@,B1@,BQ#FI4ZILH2\[H-MQC2E"M#->*K0R/1S,S1UC$?
I[Q*V#?Q,X<.RJR)6'N$\]748>0.S^L#N4&W(H-M4\UFMSCGRMCE7,V?,C#_?@E@?Q.-M\6?P1D%*,YN1ZS1:5L6?DGB17^!Q>3T4L-,&.I6BLG@=
(&&2P31/O.4>H\8W-M-DSSQ*@GZM,@Z;CZ8:8Z,0MQ"J2R!&H3(XBB\?J,SU5.TH_-M-N_:%@@^#+B_5SP-=6Y69FF>"YSUP^#])-UV6DA^D?
1S$!SH'TU\YP(K^-4!-M)E"]G6QF#F@L;@?%?OV8"G4%V\6[''?&-'Q:JEQ0G-1XVLER8Y.R0WYF1HY;-M=UCLK->"EGW5-VZ<'[WR&G8OQOBH_\Z.!.?
2&//]\4UV!.<#(QK(YP,XK-MP+T"U9_T6WXQ_[W^"9M(]UP#L[D&J]7O<-TLT>*>"+0TR?AVIQMF$8R";\L.-M^HXYD*%XO&R)O2Z9?ZKK&GVR+>
K\A,!=>GS@EWIFYA5?IN2/!V/A7'V*.(.M9A3L=TRS_[,Z_5LWE&PZ5I8WA3,*@_]&*)[5!^#AHH":T]_#>SWKNT-]?@1-MVSLXG3)
]-71V8W6S9^R].CP[,.@V\WUF46","539YT&\XQ=UU8Q;\9^ZY/G-M?:!*)+SEA3(]+U"RF)T?KG8%&3-XFF4%MTFCG24!HK&&91B5T74<#Z^#IN<8-MX-
5]!RAR3S3)O[!T_=>DV;ZD=2G+RH#1R=K7U0&I(P13CEI5?2;D.D7HNN9-MM21P&2-<="TKRX+9"(>=M+(+4;+I-W-9VPZQAM)W<\%,>
(WPW¥6O*@M6(]RY-MF?3V??2:<2/K.].VKMPSWF";&-75?C]3.MJJ.+Y'WW)@ATR<#[ZU>];R.BZ-M.ONWP#D$59?G.UD86=$;MRP\,K%1A"?O&-FGC-
E4B-CTA$IL>A)CS,F7;)(-MF"*OLV"_9'DP_XJJN9-%F2N;2Q:-%4._S$)*\U-2=>WFBMZ*Q+:QP-025A8&Y9,-R3FT6M&ISR8&E<+@,6-5&9$!A#E\FD$?
$2&&V-MDXF=$?FS&-=S>-EM1'OLFA>5LN"_0@?7^LF-TPN17SM>R-MX#27#;"4567!:D0&,@819-&Y/B(BK.=#.S41Z3.HEE,(V/2$=FPX$FS-IKA
MON?%Z2]]KY>I,7WW<:S:3N8.0"R.<;NE:L\-UNX9,J>ZAGQ]\HZ43"+)S;#-M%7LXZA-Z*RJ$B%$"4U=N".I-8+=FBUI.6W[&"3L<=2.M??
F9["&F#8O9[ZE9-M!$X\5,3X&,3^*14_'JY*/(T#IH8_X[W#+NV@93I?F.E?N!9RO=1,QM[I_GZE-M!@;AR%RSSW3NM;)>/!6GV$OX+DA-
5=T[_;TZNJ.W3H,[&IVDMG=:K50/OV>;-M"S<$870&$_FF<^5:[/4W-DA-4M\[K50]1]51/VYDP>U-3;?@,_NRN&5P^K-C-MNU_?!ZTNZYDPO?
Y*GWFA!V09^YA:7#FI57E_+KD^^4/;]S4*U4:@?4&'>W#O]&7^P-MWPMPR!?Y=@$NG-?]NGB,$6Q.Z:OX2\I7L]LV\W7:%4M-'+!6N>,]'YQ=_98&
MV_#+\50'0W.I_,XD/SPQ\I\$"D:45_?K\#_]?#);]H87MF+I,QTLE^K)#/S-M7]35Q#.C?E,PFPQ"HQ-@Y/00%1($,XO[)8(PL8Z0)B-AG50/50V
M+WZR8"&OV+3'#]_Y#2[+[F$U&,]5W9>BS=W1]#9X+F49/I]:WNG:O:IL-GY-M6'QA(U,HJSL86EY^&?'QYN-OC,]T"BZ+ALB3S4?
D>/U0"Y,W\6^X)MW&@UA-M?FTT&M?$3Q=B,OXMRV8TM@#QZV;$^;:-ZA90P#HY>+ZQ7UL+]C<,B/4M.$*Y-ML$;.EN0B,PZW-(/K%H,K0N71%J
R/Q;)TM#8*(9@6A$TCK>-J'-BG^7*V6Z<-M;-'BURV83)/LL7]K?!/Y,+TV)9T??J-OA7ULW!5X3*]3A+MH<5-MKPB-.W?-
C!86UZXJKISUZR4IRX3E3MWS4:,.QAH5UM=[X'&P\'V.LC;+H6>MSZ-M.-Z'-3;D3B/^VFQU;9?Y_-7!E5-GY82-AFU#.3QO
MQS$+.@MW.@OI9BPT*I=V*@OMD9P3E0-W/Z)>&%1X5V/Q43E\LZET>%]@P1]P0M)\0&;I'1/#*_IX0?'KN>-M[_9L-[SW3.O!=,]MUO'.FE.Q6+@#69
4K&$?:?4M/E+UI84V92E(*>1T'IL*-MC862U'H<&-]+4H:A'+%922KUTD))]M"N@S/'#(*X9>^M?V]WNN%;HBR+8Z?? M'V09$]4+Q7:A'0N+Q?8\,^?
[6D.N\%'A?9];"_)_?S_]O?U__[C^C]'__/?M?I,ZT>L7]_#$^]?QW/DR<#^?1R^_-/R3QF_5OS_#@*G\=SZI^)\#__"!_;Q-MGT;MZZO1^A16_K]\K#
[\=O#|\^N'L2^79>O#-K\>U\/#N+_NRW7D)/[Y>'@SN-M3AX[[5:O\O%;ZX_P;Z=SP;Y\>GAI?+K^|>3QV^]NWQYTSTS',VI'7O7'QC?_
MZ.Q^_/7/^[^._GAE[<['/UX?+BJ#PY-Z_>'/SQ=_G:W]^I^Z/E<_]/^MWE]]8-MG?W9_4_T]=G[Z]_^M^;5^;>1O>]&)\^O3[?%|+7]^O#&#UK?#D^?
CCQ^16^/RS*G^V#OZ]#_ZVCM\<7;T5M,;X5.&RL&O75]-I7#;0NY-M%3JU+?=:T+)B1(V=+_K[N(18-GF#OL--5#@;M[%S:V\:X>0ZC-+8^;0736^D
MRBC$MFIS;46,:N=#W33"R3>CVCE_ETUQJ[;S5\.HCG=^Y$TCG%PSJN.=-WSI-M]+9:!]&*^-3.D;UA=)-O-K7S8R^;W"Z]R-^P%
(SCG3MZHZ@FWRQJYT1?.K'9-MS],$8N%8U,Z#OE%4DV\656CW.5[*O#%[3+W$]^(]=KTH,%VKZ5H/[!E&9\SE-M0?LKMX4K>6;XXMHL?
J.Q;U04?,Y$!,,O+90("NT*+PX1*/*C-DQ@6?*CT(]F-M0F+3V*\<+PF;)X7V_A82F[7EG>R#YX;!50"RIS:-&*AF!N^H3VWHC3\TB(5I9."7/H?S@@UY@;B
MT$L+!6(1:P74TQ)^9B>+PN(A78M#;&>5-L)3*RX&YZF<\TQR8TF])V^7MT]*-M[18]L;S=LOWI-"^F2)@/&^7)4X*8]@
L;SUF+VI)#.&NPH]VB'#KMM7[F6-M_6Q;D>DH9L0-6!"]ON,-&#NW?=8*/7]ZE-&!3TZ.W1OR0$W*L8.W4L]-MW;G2THU*=8?NI9[N7*GH1]56-
'1/T=:R>]_=/WQ>H_=V65=!-PNFYYFC-SYF03-M<+IN>9HOG!]%=$#EZISFS@XU"NEERM4YS1],"^=**IQO85EW.QCYQ=:?EW%
M7)7[-8S"N9,*@/+5U/PUC,*YC0]-NWQ[E8QM\RK-0U4/7=-G'\R-66KB!GT;M-*.PZ_GV/\SZ[%K,YY6>^C*Q(_@PN'AE?LL.V!T0(%,63-&D?YCOW7FV&]!8
M+J-Z!H_>XPQ_"OZ^P.N"FQAL,+;-X;4CM[626^%\<3M:6!HM%,Z'MX6TD&^7-M877;7(;YH%
(BS)A,L6K!HT=W!A.@[_#R]Q&;AV%5UVUR9.UI;ZT5UL6Z(X3%-M$D)A_;7;0@@Y5Y-*Y_S=" 6)]'0BQP?[%:A1$"B6(.#?X]>_0-??1+NN6CBG
M]48H2MM-Z0$58G-L.<:"+UY83-M6;;^>2YG9#YO>0GA4C.V3.0SA5-H^,3Y34[0"CX4&$]TY%K#R$VH-,T4B"F-MQ\P@\|MFIV
,I),>4OR6SX+#CIX@";^\T>W@[\.I5H_'^\|/YR.BZNH^I,]PQ-M7]E*.A,5&V!#8,41;](>-[1Z0V7@9UY;"LE#-XY,=LY[XM:4-M0\,]M!#O>U88"CH=-I^.2M=-
"'AZ<0&CZ2">ST#-?VZWL-D@<'FP7\-M8Y>9%IT]>!3V?BK_?/*LP2E\UPU[SNG_-5!+-P04-"-"U@&Y9]\C0\$L'-M-!Z(P-'0-&5A,#(R,#0U-3
Q97@S,2TR7VUO9'5L87(N:'1M[9I=;]LV%(;O#?@_$-$V-M)(#RV687B6O-B=W50)IDB0JLE[1T9'.11)64['J_?N^A)%OY<.,U:;=A[D4=
M423/(?GP/8>T.^_\Q?==JOS:M#KXU/POXX_]"\&W#-YL13K-3\3A098+7R5DQ27-Q(U.9,J5!9ZX);.B+31$T^NZ74Z?\UT9
M]W%Z(HP:3_)3D4@S5G@\V.IVSKJ#SQ,U4KEX=;AWU-D_@R/7#[I8UW2CYPQF-MFI8#2G,RSM[/Z/WAYO9#[]\(7_I6X'9RS
M6?'JX&AM=#FYKWZ_&'P4O7,?K\31P<%+3OSWF>2M[M-3 RV*(Q?L]T5?79%+I8>PF5]%#BXOK7K_O/SU
MS=;!EGN^O>Z=U\]?:7(WUUFU]%?!2.>Y3]JRF0KS"?=W\!/FU;^IS4QYX(&,M:PC0RWT]_B@LSPSOQH[?KYM5W1WL'1VK]'Z#F"(,_7/.M#O-
IH\V>E03.24-MA*&IHAF%F']EQ6^%-"QGHL;RK3)A4[%6VT2>+_[F]"1>*_#(I:FW7I/(3OO-MB6$:[(E(&W1(L.\Z%!0&]+'6\IR2D9D+'1(]>GSK/6)
[\&U8K7I7->G_C-M>A^MM]YGTF)-L)]7-RE>A93.";O7'93+G:H,?A4YR+C$B5"IG.19'EIJ!V-MR^82]PFA8@PD1@Y.E(Q%),4&:$3!(!<"U?O4864

K)6FCE72>0=.5P6?5J4 MA? &-F,.,&R#*P3*!$6":BF:PY60@-YLHH*)L 7_M^Q@1H:J7G@(B;(QR5"E M8RQ(/L$0;4:!\[
!:J"Q*IB6T;PY$=\+TQ7+_3]F]]4WLDLB4BG@8,Z6+'@ M%]7Q&K0L*Z@4,@4L%3I2:1 7+%(@KK'R'FA5+'\9>&'6>1/$\1+F"B/[P#8V
M3*BX8X]K%#$J@& -RIPYZ[5;[%(@[41$L9[9&G!#8V5S(V%*FOYL[*="G]J2Q3K584W24:3PN&UWW((/P87R)YJ_N0V@>OM^7.6ESWR:(MB^O"
[O/H>9P2!+*P7VA2,M; %;%Y1,"H,N7"O="%00\0PJFR3F!1BU+7$1\9 MEM+@\W/:F<"SBT ?'E0 S7%-ERB1^CPC<-51$FME5#?
6S&:=FOMK/V4M]=F$[ST4?'X>Q\5W<5M6&\E;REP++A-F)=:QS2N MS87W.&U>N">1.N?:V#J'0 C@$O29)"K/B;X04$8:>0J_#Q4<=+UL WG(M^7P
M@$_.X.N-2I*!?_=IBS2P-VC[&Q.A/^6VO1IJ((@4Z^S&O(^<:.D_\B9K8>L(3(0(\\D!-.
M,.6N_ROXO#+BJG2JXREQV$WEN/H:PU1:2TD6ZSEQ.CN;Z/)K,7F/;:#X=_*2 ME=3N_:<1&6%[D-D-=!S+S-*)J/]Z 9[L'Z0+6,F_Y"AL=J5J1J^LU@&=^)P
M[QA.NMN:A<77CL0/]R@)>2.[;7D"%E+:ZN[;_<[^AWJ:AL\W>/ M-3?N[_^[M5?"YYVHF0SY[[_(X, -[OY1I0>7?+^Q?'S">B$M0X;X-/7Q=?ANZ[(V!^(99
M>^SNTLT%&R]EZWPBE7%T7.-$ID+B.[7SB:)(O%T0?U7F+$XW?19HG-[,.FXM M=L5+[XE]_B%,^64E;MM5ON1=94YU-WKN \A6S -S89=;]=Z
M[W,4GW)-96KOB"]4?'X(2WUWY@TOAOVN-YR,#V%P>CV;7W?''G@3F+M]8Q:: M3@,F%^62=^G"O#OK=3>0+?OX1(T'*?Q$]$=PLE_)$JSY3I_R7A
MC=]L8H)7Q_)].D8>2]3U3$B%@%0 MA!(@_%C3U8)*]+Z%_FV<6$!4N;1D$:YNX,RIGTBF&;J \ #/M0N4%XX3[MC$10:#0:/$F)2J2Q;%
OULA2:2)F09Q(E1"N00NH_UHN7=MSNV\;7YA@0;UY MZAAG 0D$.C%XM+_8]-$Y*X#/B5P03E5U\A#1-71];58,I2TC8;8LJ$I?ADS!
M5R[N,0:W%%=#HEL_C?,%X7-U7K!3HT^IQ?,!>]66'FSH0 65TD$6K9FU7FYFE[@T(L M5^?8C5/&'PM$=(E'K]MXYPTZ6R)
[E7H8BCSMEDF$.>@CYR)#_DU"2/HM89*N MD%_*1&Q>9'"]^8$< Z9:_?1#<+R)_0_R)R=!_6/S)*/2*DW+<[,KA6KN9F]F MKFH3IO\)\$8"-%Y.
;:Q8*Y(FL58HC5A''.<956N8 <6&Z1'C*7&$,$JEW"= M1!&>%8NW*36X$B,UE)6*+30_[?#!(/@Y5S(0IOUMD_)<(+Z>NL6Y*Y[M"7'4U"R%Q'_
M*]1MO)E!B8@%&UC-,\//ZT>D":@OLC"U@ M.*YV:JK5KUX4OAYV=NZU=&W;V MH8A)$#!^6S7G0_89QE[<]-
GQB$#Y%.K7!J+N^RRKI]DE_5W=881;W+;A@+? M 3X]P-;:[O9W ;#3#!0W]TN ;++C[4WB.]V_S!U_^'D_QMR_UF!G=;5"+^U
M0,"AZ\.3,QR^/KRVW3]L"?E1JNZ=%%]IPS-30S:\H%NSWL+WT\;!])W:+.=] M2S&IE$M_=51)G:A"T^-P@;ZF#SY.D,7\@J?!"!3-<0 X33TW^6"G+'"/O&<*
M9[U"TL)1" **_74 V2B:J\H;H728Q5/$0M'M_AOGM#TM]W/MMOU.)7E;X;XO M8#7SM2W[_&:^TOT)4$L#!!0 (+6 ;EEO>O@W]5-!Q?5N81P;\@1/)80U
M/,74O()A6UB5+,T*7VS)(VH!"LE!'I1:,O,LKF<8>.DY&!2)6/T5F?CRNI6 MA25-LS"09KSIP)::Z8FD2FV*%R# "E;D6HE^UV:BZ@\&-QXUN
MBQ'3Q%CU:K51X;='DH'=YHM ^Z>&:%UK-IL5<==M:AE16KAW'"4F+^5NU!8R*N6KOA;Q?L6^Z36$6E"VF13%9^*S C0H'SWO4R]5&N5'S MHB(Q
T6TB,9GI&HZGL3)C M^@PSDP!/GE4@! 1Z;RK*;U=@3*S=K"&7*J?/I,22@)T>J9= (;>W&=8$P9;#R,J@VM>.,!Z('XCV&OG<)/"/D7.C5T MC2A\!SB7-&
[3_0G&X'.(8NO_A7V);+1&X>)8 ;]! ME(*I ?N75RARI"(AUGA7\TD8[151,#Z2KJS'@L"C* VR&5+(5 FX+6-+3V)V + M$UU3(/2__&81<\FEU'76V&
UIMEI$J5[VU#:-W7YT1GP/_\^JM<._XOL@9,I M+CB.-MT+R9A<:?I3I,VN&H19BY_;_6VHY2,@/D1AK5F9'$PPS[4ENI2HTK>F
M4XDM=;5/QA2R75FBYIDLZQ8U(6OOPNS+$.UM$+U-_T3[/@#B6\20-=VP&(8_ M8!3D#(-@'.0,),QZ/11:CX7;GQ.Z-1/=0'@H6? '!=$I,$5]#N 7[,X^I, U$?
W'M4MA./1@)K.2) M.&]#8F% ::CK88W'45V)04;-3\\D6=0Q-GB+;)18(*LU_)PYLI 0AKS2BJTI MD:U@=G2^%+\VXXB89O'.*!:#6Q0(5G2K_S,U1:
(7KL70Q/H@K]=T^>!--)V M3Z(=*4E.%O@/;(;;)]/HM3UL>&FE6!H9DNJ059"J0Z*YA^RI"=EUP6KF+#N$
MO8T;*Z870Q$Z>^PM@V;3U5CQ2[:N!LX3E(YY[# ""$2MK!>=7OC+^WH& M>+KZC_O;CP=__O%)GEF+![K?5+X?SLOW- MX3=V<$$&'S[U/A_<+[
ZOKY?]"^KR_WFWE[_T_#R_N+@P\?KZG#V::]][]0WO MX4^3C];CAS?+>SKL=&=F[TXU6ZW97N6AVC[OC1H3ZT._67O4=6GR\#":?>R# M7@?
ST8H[_1!?]'G\&_9F-"UP:L[!R MN>!ACI.91!A5:-/$HURPI< YU?:VY&! +HC"EZ9/1\/"J\T[:3QC\"C+34GC MHI^"D C[N[),F,5;4&-
J3;O24IQJ#"DDC^8$7TDRT2!Q=)XSI&,QU7$VNK6X MI(I1\+3,3[O/4FTDR(&"7"Q(@$& !KEPT J/+;.PZ>WJ&F'V'=TJA>,.GKS%
MU38*\]_"_.\EQB"S,#J6R5\HXJ^]Q9EW9//$.E7P1"X-ESZ;=H='GO$+NK+;)(YN%3! MKZC^)*18$,*S9MU8!.L=1T)^!?D]8Q"N/"\QD8G B.[9SC5L'Z?HF%
[=K@]X]M$>^#G4GV?< ME0IIR"/N'\#7N\K&AU#X1?O2QB=3Q&6X2J8SG9F(AGX()^(K+,C^)L^-+@MQ M,5WX7V6W7YE?*M?
JY4;M[<)0W*]*9$3!E;8_:Y$-A=MO&Q11W]\)0V"XG]7Q M=AI+TDSTJ6#--%9BQ,<^MIN+T*_I1.%)ZBG^-E9 4JR.\ \'I63$[<"IV%^/
MFIH%_[>&/KZISK3^ HF6<>'+O;X3M^(\9U/BPD)R4W-.]$//9R-C), M!G% "=D?\A'?KCJ&:Q#EM4T\Y;ZXA"2GU4G)9!;_!(]H-<.,Z,I]%,LYFR!
ME&@:C_;=MH#4@'W+XG??,]V:N8,0$.^)>5(C3:6M^]S$V>9#''E4-PGJ>FE' M*1M2V<^CHG$PO2XS2DU/I?
$>,SPT^,=:!H'29QY5SPH]U70X11^P;PJ@#^2P;!DV":JD&0FS8-\;V4\3G91D!IF? MN?WD;*..)V;>>6X(M0W-MTS$M2UGZ 6G8H4^VCVT*5
$Z4\+V_^+9S]Z9#PQ M=1422W"W/W:!*'BTT_I(S_*6_2(\6C # X!"3,E0OGW$>TW*P=X89YK,,&N M[I ='9ONQ1=F/A7.:
(KOK.D(LXYJKP5WN3CNA7\D]_^^M),01EKTY6)&[,%; MDAG2D]"6#I#8*O9-Z^Y_H++9,4=3NY;E\0FYTM&+*Y+&V IITT.'.R+J1J3AVP!82VY3;MB0D!)
MXV>=T"AMLJ]1PS.0$3N2X0YUCWE0A)6S.6;2&+N[39<1&7MCG)FSZ>1B/I]; MS^@-:%O[V(Q&"IV>: M!E13I8=-BU&L#'2G#A.Q%?S,
<[^+VKO&M?'/J_UTP5BL.@D!PBB9NE' 0^G4 M8>\C-OAQQX;'RLNB_ &:Q9W?I*,JY:-R/]T23*=7E._<_FL'N9NO756)V]8W
MWEK,G>8AZ.*4@>A1YD_TC/E!"Z66I/4P3V[LLJ+A"Y%YTTQ.Q'[698="9Q*^ MQ'I V.MGN2,M 6F,PY,][J"/V1S"?2Y!TG9E;G?W'PTM1I^-
Q*6C\@B$897O MIZN"?P[2MC0HMZY4Y7-UQJ.-SS"WB0'L'2H3"=?Y$,9\+6%@# MS*;US9ESY^%G"7VV5SMNO=UALZ-"W*YBPM^+-IQPP,EJ'-;S',]
[QZOZ-SEO>S#*>&@8LS4VT&W6/ZT6(-*IT6' MYH^*-:9(T_&T'DP8SI\.7E0I3&+PI.=/A16F2!I:F(?[;=B\Q_; 9V-0FS?(
MAS:)^**HN>316%'Z@^72FZ4N,6X1AV=29D0]M8I#%^.W!1&=T"GSV M=$GI2[1%\%B_.,N'2O'@XD)[X2O%.KTC%/.-V%F_XAK_.S>[5!:HT<$N>%:8
M+8N'C6=469FJ71)J4U[$ 4G\5"$G6F?%&ZWZD,Y%K;^'>2PKPR^QUPPI,7-B
MFBD0QBUFIS"4FQ4;P!/C7YRV.8JH0A!%KRVW<5YBJ0">F*GGF_/*KPAU$"0 !V !4 !M;V1D+3(P,C0P.3,P7V-A M;"YX;6SM7&MSXK@2_3Z_PI?]USO0]
<%@\,7@;9B!*3#B4P.8>*!ELUS@5&29@A!XH+6Z MOG9%^EI^6\OO'VSS__):NU76MG);V^-7/AW:V'WH(8:M]ME1YD93<,.M;\0 M>J]OY7(%?
=HP,VYY,!0/YMH/"D'K?+%8U(-_?6[*<%A#+C:OWUY>-(TN."B+ M7>8AUQ *&#Y@P<,+8B O0'*E79JTA?A;=MHL*QYE\UO90O[+D)F9,6Z:=DB)
M#0VPM,#R V_4@Z,,PT[/%@8%S[H4K*.,0TPS*Q#,%0LY(>(W\>0'_5$F+B,V M-@7VQ\@676EV ;R,)D2W&V=SG> O^3:B#IC80%R\
(7C414M=*DA/QM@S[I\. M-#W^VP%W,WM?RQJ;K-[F,F+=JDT&&QG[+(1;J<1"XSZ%2^QB MQW?J:"108FW7Y,AUH8H,;&-
O5.N)O,O3\@7PM+!ISV*K#)$]) +-K@>D>TN M>&\G?19J-LX;6@38ZZ)+;(NH=/W;-0!^RCCL^P]0KT? M)<; 8V6?TB!9S'(C[&35$7I.E@>VSZ)* QH#!
<]DOR6-M(M$=KBCXB2/K(%&PU@'L7&).Y+KCG_8*:EXDYM9LLX/.8=I$3GL4#4F-K,?R[X MS/QP.&FA,]]Q
FE9S)/U]'V+$F<%UQY1AC.A/$)XF931!H#ONY[XN0'K=0H] MA*?YA:NN\>BC23IL%(W/P_9[)3$2;!.JMA:IBI]$$LD>[R%BPE .QU.=ZX\K
M@SK/^UYIOCQ0[O-+5,UUX7T1L!PBN7_'XF-^K&\(B36KS:-+F*>8D.6Z)F7A MNZ-C!4(3/@JO^(C#Q05&'5& 84AH%
A1L('K\"J9^'QXY&6D*!$3JK3"E>A? M4PU>.5-SF50"D"2EQN1 S%02]QRYGK2KALA4R'!26S#,9XNIOE$RK*Q0]C&H M6868),'&Y&?&IN22:
[JE74@79_%>$@.JBCP)I5?$-=XR#F;TI5[NK2 E F** M"[^F1XR'+K&Y4"8J3&^DF)00!9M-F2W@2)B!V&MD^Z#8WC -Z=:DS8H7
MD9$&=*Q%*N(XQ$T,^ 7QJ6;/:* O0J(X/$NFB86ER*XC;)ZY9=3#'K)5EW42 M+:FGRV@L2$&2U0QQF&B A[
+9@51ER=HQDM)WQ%X@'D"%C:PZM$L@L*/D)>B MX#;A:5M)FIH98DNNF?CXME+=^YFC+H5#4ALN*PKC#B+8"_;;N#EEXHIJ!UQ# M?2&^3-
,'Y&0I<"M'G8_2R[!6\J6U0_W5-N37!/8F%\X;2+8G-YHA3?>8DYH1 M/QSZ&+' M"UV+@9'=H!)\45_E]HV'3)_KFRCF.?X8+$)AW*Z%AL J0^X.W
KL(CHZXSUD M8NV%O\D[;P<]\H "4UWK)VEIJB'Y!A2$NM2LYRG<9PE.&HQEJX[B&_?NO6Z/G#^__OQNY[1-__M\&V/%O?
^V/K9;HV8O=M@O>#OU[[AJW0^\\UI5']6+K7O+<'+GC\;-]].^K\#=17.P=W'YN=AZ M_-/MX5&WC&R2+^R2K<][CW2WC%NGMXWONS=#L.
[/;X;-2FZT4]S>;MZV*S?E MW=/K\UR[=[M=KS["-MQVK_V'T\^C&[==J_>\QI7EG9STMO6[W-EQHU/H^J?-
M8OZ!$-2]N^OTKIN\7[O]SNEGO]BC_MYM&>T/[IJ%GQ5V5=0O]BW=Q0_?"RYY MW+7J3Z?;U;Q5<_RB?=JI[>L%OU^MW?
H[_JAX>G4"YNBJU;4>!ZV2^;=6;C;$ MH>_T(B'4@69]-]%04;P7\VS#9+]YF60I7S-2J8E];EH1"Y#\%G,23,ER9M, M0%\.CTMFGO$3I!!=IZ2/N:#C49N)V>
[S&%HR>%V;<;HFSDKVKH(J03P-4W'LXP3&_W\Y:$HL/_0HKN1R M421!J4XRXS&T!DH35G84#&.O%9ZYKPYTBL!?.%>HOK".8T2ZZX ;QF%,W"?4
M[ZI87%^T07)"*W&Z97H_8!C' '?"Z9Z:-?E%Q9,K12>3(U2A5XL2ISB2$;]6 M1$?#?<+^OII= 4D?
SMP^L#2FO6&*8W=N>I>W14K&HX\I2&\1J3XV&5WQ^ZSX ME__=\QR#8!ENUD*O;:*75ZKIN"U88KC>RTE!H 9+*.^E-\SARN5G_%=I>^] M+NHLX?
O5W<%5@"IZ=QS(]Y>D%2Z03:K+!AO$SD?*=/R M"T78''@*+X)N]+6".E!,S-*<]>\:Z= F, DAVLJ6$GRF_-1U:[MP;=2HJAH@(.P@+UF53'C?-T!HFGT-
=R0U%>;UG6/N>NX&Q"@MKZ,VHLK'E"M M =A]N"2NUU7^C9VX9J3[09ZD72 4>-E*19+T"]=K#4A*K$^UIWW)^PWH?@9Z MW>64P^/B[
MC3\3V6Z(HB);1217^P='. %BR7/0D06_&EO,DOVKH/EWM'KO:-W/[W&_SG: MNYV<[;U\\?)U]I6__>RY_I<[*T)[&&_>K]?@O1X%WI_#\+[PY<> VF
MO,"/A]D?]PF]]O9^#@,/C=!T+]WB3_%J@=[O1^Y\X1',T]_-0C1]OS\/'.> MD/K%\:L7!-9_D]_\&?YY%OA1X+D.8=*IY9$]CV<(Q?M[9.G;T65EM_A+B6>%
M<^2XMH67MPG##\DG#ZD+'6;2 (GLGS=6B/QXAF*"5J0-]^UU@;9RB75RCL8Q M_GF.P35"?WNM#&4].
(]GF!RSP'.P13G_FKCQ:H(7>1F$KZ119BR58JR=QF=6 M-+OP@H=&Q%TO@G'4@N%DAHB9M?R5Y3OC9#ZWPE4P';OWOCO%F/CQB6T'B1]C
M@WV#D;!=)"_<*C!@>%!6K0&*+=?3IJGY,,%B;P%*&RLSUT]U M!]5OZ[W-5[P]503I*VD[/6L=O4;X4E?3&O6E7M15<1=84N,&:!=W5>QYZZW]
M#2NT19&GO+T43R?DT>7'=$^.B\E&WL8.'#2U$B_>W\O!E'>P7@,?48?X*X?Y M9PYWOYY+-S"NP=QR?654LV]O1 ("V1E>(K23.W2P!BR';]T"I>,&A,
I80[F M:'Z'0DGJ5KX**K*6Y\GA1KZPQ@C+*7;YB8)=8=@Y!N1CC1_Y*CM$CS'";I"3 M/U)BP%Y@5S[AD:?
4("R^YEEWR'N_GT0']Y:U^'/]>C6<7K@^!N):WDT0I8B? MW$5QB(W$+OVB@@Q3*
[I+:9&O=T@,V2'RXJCX36K:4GI*@AAKA#>,/PFKJ&,Y*5#)1496WO-O3\-@KL;"..#2*@BQ*_%^_P7^ M2JH0/]E>@$_K]_LQOJ"7+
(,T;\B+'ODO\5*6ED=.T1'"4%T[?^X[\9WJ+TJ? MU,S#9KB8XS53OLO,;4AL,"&X"='":IT*T MRSEWQ.)<8\L*:5&KTM5=;M33_26=
[FKJDD5U28@C/JF&=K7K"0-43WC")E?. MHE=Z650-W8[<^QD^B&^Q?A*D-?.(#6NS@^YRB$.MG$6O&=9+W7B!6*T^. /%
M]G/J_JC]5+]RK3ORCN$B8-^; :A_#CB+:B+'N)HJ9!'7Z,9:D<@RT(%>#Z2D MOZTSB2^B%8VA4(GK%RNRA+Q][F*HGRL4.$;]7VG.T(@%Y?
I6SZP"\@J&21Q@ M/>(4CVQ\CUG7801^"!GVC^7XPE =4-=X+0'7@6^WJ3LE>'WBDP#U^.YR0P6"
MTQR#_IJRN@!ZT*6GQ9.=%&6]H4\&)),.FJH7S:0<]XQ1>S/9?G('>RFA NK? M;8=%-?[QHQYNGB*LXDX*/WH%@,!##E\VMB/(N>01B_ZH6+O#!^+"S
MO$D-D>'!+EW@[OZ.D](!*ZSE.I?^F;5P8\O3?\DQA4HIF##_B*3@ M^,@YMT(?GUX1ON0F\R1-UQE@0MFN[I-% &!OC)@(\00.&#V> +@'T"LUJJ,/
M^)T%>X'@?.&",^M)R_"(3SGNI8?D.QU6$YXV"61@B5 [G0C*I'W.BV+XP9AP MPS %YZ0N1U'V!.H:4X&:-FAJUQE1BO*]Z>;\S&HY3I)X%H3N-^2 \G$'F-
&0 MM![V[1(0ZBVA#NYE%"6M,"T'U+_8 8MJ(L\(VEA5JM9I@5]E:$^#:17Z@45] M2E?JEHXZ$8B]M)-"I!3(VFG*1^ CC@6IKT%Q*N5$_/GFO
(YU6A0^NE#4FF6 M<^B-7J=Q!QS<:<8$]42857>6O65RK*5+\DZ/.]K%6-$L;ZT/=!VF06G@%ZQ? MU(LV$T"HT^$8]0$X?*O-/=BE%$@*W
A%".^$5*4,T!)Y09JUG0/7'OMFP3(8 M]N:*9S7JS:083-@A:UKK89@GSAP3AZ 7NTL$PR@>-'-7(BE.<8D&GK=88 EM
MYHRZRE(\J2$-6!QA#2NSOZ3/%!0C2A ,VC&5+H.DFP.EED%QC)+S$HPJW.>8X?U%$V#$)5Z?IX_8H0Q-M@O#U>7>!<1 MR7;$W\04\%(IB1'VO&%
<31A,>R$-H*R"R2U>HY);\%-\RDZUYTG0H)B]PDIS MMH9,4#&[:Q2#G7/5M7O#@RV2B.00JU"^R'\IXK) EULJF'YX''0J\8-NFAAS
M:D6N#=]A&%0KW92UBW[:6)'Y-+O#BVI2>94$NU8J\&,L&.=>^JGW^Q&ZS]]! M-<8?
UEADXDF:V09^6H3XZ(*)4"TL*#;5=A9ELJTBD[4LJR<6S&/5%JQ!WLM5 MKYM?"P/JVK73EY;)#99@5AS]>CJ!'/ZUL/Y\T197@(JRW=[&<(PAQ()Z,"RE
MN'RH^"7ZLX(^5!OX&KD,L^P#)?.G(M,'Z#ZHD,05K!A&0SE"7.%0RTQ%[9Q MI28(J$L- *UU(E!N^?5N?I+,1>96L6G_=" OK%WZTXN2'_JE9J57J*L M
5G:\")R1P5%+I!EJ"?_?HB",5EC"EZ2RI2O^63WK*9S]I?XJ2AV^T]4-31:60%*QS%U/(M#/*7A4!_;3&3K-P7?-WJ>XT>TK^T>;)N8/; #Q*CG<#SHG;-
;)EUVT![Z;A;I_#.R.&GU,9R6PB\GOE.,&[WTLXO-<#I%!+>=@0B4N6HJZW;5 MSU$G5,ZR8],L<_U,FJ!8MUZ_LRY-
<\H5%WO=B5(LXWT^7WC!"A7II&3>1HM' M8!WT?A^&M?0L&*L_9,,R[,982P??^\.2R5[]%4GJ M-B(=%M:%B_DP>A>LF8 "
MT(]S!XOJ49T@0&>7[_7@R6ND3S#9KNA(C2*4B. M+=]V/52!/ G,:B<(BEVXK IJ+PR+P$I,ZGTFB!?K72 F;ZB0FK3S\%U#7Y%Y
MPBK\'*!%B&PWA4(:;,R#,':_03"5!>E[X"R3TE"Y)9NXV'9$K/1N.PS//,O5 MGKF#O =M[=!T<%D00L)LW;P.76*+B!@G1#P$A2>I

M+6PV4Z>#:5([HYOV|B2RD-%>+[H8*4$WL&_9S=;\WB) [(S!Q9.K: M+,8)L&9]-7NL'Y,)?\Y3X#X)(Z! ,!@V3^+!*F-A5Z/7/P">RY!](^N]7"+(&\KK%P#
M,Z]/D&SRE 9;C(= MQH#\E\C3TO*(3S["?EGHVGD2'O;%][\H?3)+W]R^\9]_VE[BI*,,I)GEWZ,1 M=B7.IU.DW:E]&?E>.61M,Q9FAEN3371)V+I0L=6&X
A.B@-,(I[,$,GTL?R5 MY3OC9#ZWPE4P';OWOCO%'_;C_+V %0GFN7#C%='1QW(4#E^M$!*2K<,+RW M_#R+9L.C?]!6GI&P^E-B"+,Y^Q72>3Z*
(H&*+)#=U'DX>S@-,$4/?7TW]Q@ M<37K-?)%]#([!99K0MT06ZH+.+4\;;)8I&U'[6\"@TW8*#T5]TP==J,)^]9599]'JE,'POT7GL[ ]VG
ME1]8H1@5D+8NA-=!C#;6",S2"\,U>1WBL97=MY!*R0Z8]11;:C%)G9G76+,"_MI1UL8 TJ-
=9,3!\RUDOG1_]9$,71'OCZP1I(=9IB8SAM6T@B*M4;3:DO\MP$ MJ&JEP8.ZW:CUTAL:@4XTKX>D_-A3LRB4TC!!=6$$$I.)M5,158\6Z!OX?.YF
M]3R6[V3C,.^1SPN>*?=|SV&=;,$"5P@YV,WZVG/A0&F-)'!SKIJ2)&SWR9"*":]#|OGYE>"62@6SV M!)]E=K5GO@1=C9].N\'KTU7Z$ST@\/V]I(R3.]+
[/78M;Q D=_')79#$OP08 M K:+-@I]N/"O,&"C9>M2+RXRU 1)C,M?=K:PSL4>BI6"0/OT="9*1WYFG H7 M;R-
_3V/8G>.S:WNA(6MQ0V^K,BQ9)LH4(,]LB%\([0@C2/:42 QF#TR@V(T M!"G4&:$(X8V1=)0!6B(O2,M%\F+NZO&OS>?C0S3;=D.*>4($%*BG4[P!XV/2
MC\,LZ.=&7\Y"[-G%Y"?MUUTZI/YH&I->6G/OTG)[LBZY,]\29X;,SR)I]$S; M2&E3(+20N1"#&!,D2"*4_]:4!TDB&%M9FJ!GE1C,'FF0& VYHQ\4"R#JJQMA
M62@,MD>GEC@I=4^!*#"XL-PPI9$^C..;Y^I9WZ&,.D_E&HC1S4@QF?Y11D(,< MJ1#]*4!9.@NL_K$@I8=73'H)S'K0EV(P+-)5+U-GR%TB8@5@-
$X%@Z[[,8VH MRQ_^H,+H8BKK#0I3K& 5D@>M+PSD4HT_RD'-C7&#<-VSW[.B**VI2,FT[OA8 M2BS7[LY(@N]3(%*>MB*3$A0?
IQ1]*2(>!CW^T4RN*7)NU^J*^H@O:,$S;RL.5PROC87:BL%39I#JM#?O9]264"%7Z?HLH2[Y"
M%"7S;,HKZ6/6E@O&A&IR,)UT1:0P*87]IN81^X8W[PS':Q;H0$A@U7F#=BO M3G^H]2<|W#;MP%(L;S&IHY,'*W0Z(2BRV/74:FAB#&5^-R2?
Q:)TFF3SV]JC07H8MR)@)7!POD4A'0=.96-;C[7PJLJ7-MF#+UH89]\R#_^<((Y\%YCZ96XL6]8#YA 4SM;LGE_5#QM75&P"OK&TW $#1Q M.\WSJA32&
[M*Z)NTY%2R*F]Z=8QAE*H)K",R0]J"?(+4X6K%RIJD8?V052B MNK;A1$$%A=BB#5!A>T,+?#(GF5;=\HESG PJH,K=2Q,C!*.ZK<1%BI0?]Y3M
MYX='3QET&N]R(0 6M@A*[X$G(NEC%: M(B;4($D>9.VW=4%&&KRLP[%1]-ZMII(?+'N&CXEP508-LHJ%O% QK.F&VC\FXVZ7]|87W6WP8
MC]%OW]Z^^O)X9%_%+_ZXN'@Y_N?A\O'T]/.+I3,.K2_O7L4_WOSA7DSO'^+? MAA>'JYOCR?W4GK_X]:O]*?
[+NS]'GZ_&#V^O/OQP//GZ+W_AKF9GEA<7IZ.[5+/EU?'ST M)0BLV>?/=XN/8[RO-\N[7W](CA=A\O;W,^O=P^?QJ[_.H^OCPZMWTT/?_?+'
M*S_X^F9Z'+W?UQ='T^$\,?9^O1N^.WR5+"\^^+/)\%^37V9HJN/'?YXE7T^F M/WB#_^R=C4<'!YKO2[^$0=1;#",#9K3A@XR-$-
*)G(!@;]*VGROO[G,Q)M]9L7"@53=T/ +K0ZJ3;P9$%?3P!\?]9VVKQ^.NJ_Z]\] F] M\+7W=I-7|^8-?B->,]NB|=DJ&#Y+PA!3
ZZQ!P=>DXS#K.=$=&.M"*FR*4##>(9"*L:Z+]YL8$^!CSQZ0H7YVV+AT^8>GW%,[Z0MY^0BB9,0?<#+ MS9-Y,>
[S%CLC(9:^"\M.FR]4>S)PJW&4C$=UW'4M6H,$:OZ@+'3E'#%FCXL" MT@@1(<4L($V:(R[S\C2'V%61L3L=4%14(0:C7"8 %3)((02WM8UUK3)_*6
MZ$/@QS/= 2%E-,QYOVW)0RWQ0<("HN@0@9P\!(9$H(!N,B[4(N_7Q(:ITQ9% MPQ"SS7IDB@]APF; = PF"MCCPH<,\3M)H,C&'P5)!U?
#P>R!#\U.NG%FNPU M=`77>("ZM!LHO6[4R3"M.E\^ZRY', MN< GV@N0:\^&!56=))QCSY?@:G4FDW!0T=DM:" 9]/4PX%.M&0GS0F):&?%2
M3R>0Y/A:6-K3X:E<,5]OKH&;7:"V#" MZ'!Z9\(8)!/-*M+#)DA;5@O)AC1Y"-3HNOEBC^A:VJWFQCT[D# =%26V_-7NF@+FAK77X6U#NPB24(VZ
MI6^:2S20(VUYL[K+Z'9@N4M%L2U]LS>$+6TV)RQKI]<\80M'1>KPVOF2.7(R M [UKBN[N$]!%8 Y$[KS;^5)/2+E[3FFZS%> 2!Y1-5\S^P L1]*:\XF7-?
O< M.)%M9EE!!G[/Q%;NU*57]S:NU65P'?#=FCX*5Z@"'76O@CY_1*M1N@F=&TT MW&1!Y-/&CMK@)A>'#FJA)/YE-;: 24URN>/"S=,"V5+
[IC0*53_3>,>IP 3 M6!OG7IBD*7R=$)SS62]1P=2"UXX0K7EK](:J7&)PKU5*C[[U(WH(/NL;\WI M:O.9/&,MG:^33^1(PN_1L4NH'S"9%]
(N=DB4+K'E4'5_+6'&-5KC^(/ *UPW,Y:TSZ*K&NP(K6R\A2F6,^X-YZ;13O. MS4S*\Q2B),4X++FC&*]900<$U,S]
(G1VN=!F%)]UFT41C_.2($$$W&P%\HZ0C^UT8_JFN9 MFE0%K2N$^5M4TYW#M%Y>/!8DPI86HC_,![M:6:N0$RC(L[6^6)*$)$4-9$&(MTE-
[=@-9/Z]NU":AU?6,>/04M2LHNK5C"*7_8#W]6IEO4X2M;ICL!1U;-_ M?1*4CH]1&WVY"!&ZQ,=RB*)XA/WYKKB8POB;###K]<1:Y#%(CIA6O$ES-S+L
MZV/@X65(/6+7I9."L<&+?0_$D\9FH(EB*6)W?-SO9'"?H'"N^R4&$%&C049 MD01BJT@65WN-+[.)\^G=+@OCMQ:GRL"=)/@>&;K?D).VM"H-QB1]0Z-
*P#;U MEMJ-735&$C*>Q6&>EM@5#49WXE2ZY$@Z=D4E?^MQJG5UT]A&OA6Z@:;85?VZ M@*S7&\/B&;> 23VM]
<0IG'SY6S_"]X(,!=9$C7D'$XQ1U;4,U0URQ7%.?3A6(M0 (5G);8%X<-QH)AS3@!,"E'<_112S?/F7/B-VW6T+F,\-7X;]:1
M@+NY'+YK.5C#]QJ[XMJEZ[)&S+N7UF1$;'7*0B[.Q]#.9=.[U;J2IBOW9@I" M3]VV&F!Q$1[7/RPCI<%E%"7(&22AZ]]G&I.A5B(0K3A60U-
>:02>N#/9A#6% MH.CO0]#8)#_7ZSXY 6U9) KAUO=,T\R4Y]LXLWP;>1[&VG=&*$Y"'SF38#)# MA*9"+]NZ3^TFB'VG@2)H=A>RR\H7-
7%]QQA.D4O&N:V5L&/7]SH,G[]+"R&+%5 I M"#*]2_T(V6#G.V0;U]8<@8S[$&QA;8+C#$AM;JAYV1GL06H_RD$LMJ'D8!) MD=$A)D8$"6SBR0A%,?
8SL?>96M1;3,X(&TV0KL9L6)W+4=1CDECW).A&)VM(Y!!N8-!;6,M"Z18W;F>+[M(8R\OG,RL?%,1 MWMX2:Q[:OFBGL4S2W7%=']\50=;Y]>
[%98S)N59)T=|H.T7ZCK^O.ZK^1A]3 M[*L9>.*/,P"PGX[TP;)(H/[&MXQJM@U*"+/'EE5V7T]'P+M'6Z%6[:U$ODM^ M$/[?/$)/@DCYSCC]:=K6WN\S#"
[%)!WQ<#& 0"D('0R+"S) 1WS\N6DRB%8H M=4M^[I7\W"M9<[#56*]D#1D%IZO=G *!SD(#/ORK"=MTT#9"C8L36M:2XL/
MATQH0U99>&YN+HL&GQOX*HEAS-@5?YWF.P?,< QU$ MA9UCD/HRWU 8W 08YVM\KTY'$D^"R4/V*_S_YR3Z)3&266*Y[L4DM?@LZW"$
M#&5%]$6>MRG0-0IDMOPD&*,E\M/?D7_+S8&76>\)50M0^"M%7:W7OVST'Y&? M%-38?<20U425[@]6T>(
MD!__BSPX]"RX\3RR%"]0EQ#RV/(.GJJ;%L0!*<+/?>C0?U!*<+]/@]#MD_YT.?RT%N.V!3YK&$:X_.9N,GNCC6S^:O :]]MD)]6R.4%7M]]<"\-
J7#F)@RP%,0KDG,0G_AIG>F"",-M MA*:)=^5.==_O12#V4:N$*"E6B@YXK;Y"5@1S4[X*+#_"^\X@C)"-W"5QL =N
M1#:)A1GJQBP#6369J4(W\=MPS==,7' 5>+,^Z-;M7,/=54G$""I;+Z U5]4 M,% 7 K&++ET$RV:(3B.@=GEU $'JH1B H$YYH9(FGE3RN"-<7]27.]J+A-C|
M,5KLHX=%HH4W"G'9(/3G>&^CP'+&EC]PT7UP=B*5X\Y:P>##!]\ZE"*]3"IH M+S;8H!A%"*TO0RG&!,WAM,!;NZ)P 9KDF)JO($-L*+>_(V+-((?
(>TWS.W5 MC=Y2&K)IAU+Z6Z[=8)\&+VW=H^TQ/>Q|A-(E[X=IB@+V37>&N:N]TU<:BYE MH'+ZZI23($SNN2-\P6W!T%7 F:S$
;!S55(*#+-7ZBI,4D>&I7N(Y-6C>'B' M]P,^Z?QU_FBGD0NLTE6TKESKO7<>*69O4TPZ>\!UXC^8.EH58B%==?,< J0 M'FLQC6S\%"SH]GBD'&P6>!B-
*.O]QXO9*4;F/2N*AM,4'%1\KAZ&7.[6@<.G:B)QYEE?E N5Z2?^VV9PFH3LF M8^LPC8 M#^5(56=V7$910D]J$\SLR++CDE>BZRXI
I(@L)++.#5:"]03*F83 MV@@YT07>PP#=Q=\"[3]'J?A M[:=8MP\,*%%!\[--UI&M7. [G$YF^",$#FX3R5- M#50.JD
&TC3M@.J$TR5GEW;)!52G3K#*#JU!$I*JO72B47:87:.']$_Z0\M" M0'O"-E$2\HN\U8.9F^YOSE])%,_UI^/0X73;! K0*6?,.TXD$_K]D38L@OX&
M:;P!_@[%N]@!_ZKY(RB--9KF<&T>0SLP7DN7*(B-W-+VGJKDG^1SK@%>%RI+ M@\7:-(RBH;XI5(D#,XVC?M"X9A:T-P&#\5A0)VIUU(:=?
E*%HOT1H(;B1L/^ M7(4-DBR/.!#-6"FNE%(YQ2.@UN<:!0RTM"E18:*Q9B80?(3, M]TA,I$WP!P&\L.K:/;,,% (:/29PN]M%M/9V&_Q\!]2A
T'1K%M8*_Q230>5 MV *4< *!;$O3]31(D5%7UX@@:4^'2:WD!]=#41SXZ#3PD^@F#.Y#]J:;$R74 MPOI^]X81Z;&PZV
+DW@@N3/IH5;>$<$0)).&!>DI,U:(TE#NV0B+4^C:,7)2 M\+>8LM%H?
O"8#:L+C<4UL1A#K'U5PU/'H+)+$@BRWQX:B\QB,3:4DQ[:/UI(\\8[R&F_O%\NU*5%I3 MR&G3ZZY'H(.C-EMWNRFL$6CTHG W)N4;V(N;
(I>X<5$.]A>2/[TM#[3L7N) M)\1(2IRLY=U\>V, ^,">UXQSFT6Z%QANBW4E0@ID."M?:!I,X"5N,'*]!700 M%QO=*#YJ)P*6N;DD'G?
FY;ELYZ)+/SO$NC0C5"/F3]L6&I&%(I2H,]@OZEE1 M?%Y6!8+4]D_;S*E2NF'XYMI\%B+#> ;SELX&^*39+T/X@N7:QP&=>.G?D5._ MW_-'\]/N T<0Z/?
R>B3*@T((='<$4':SB@?H",-/3[546BZVY*.9[92RFMK;]_#:TBV* MK[6&V5H#L+:GPE&,(_) M)5[N+;I6ZS7?7.ZL[T;"Y&A?YH>PE1S:O OX^Q[FW^
M!%'?+0W?,,=L2>&N5,G*DQHJ!4*%9BB<@4,C';B5E8491$ [=VM@(G^,G.>Y]RED("4L 3 ;LA+RK%CD$:FD [PGI-GWY$(4OJM2]U+^)4&UK]@6
M'-1M@0M.K=4DAVCB%P:AA8 <"">IE091':W,C1@X-PW,4XTP6EGWL\9[XSB=| M:=<>ZME>WERT189S=.HTL$@_'Y+U21R27'O^'U!+ P04 "
"U@&Y9S2]< M-:Q@ !CW 0 %0 &UO9&0M,C R-X]Y:3;&%B+GAM;.V]:W/DMI4P_/WY M%7BVTI'K4T[Q&K95:GDQ/_>]I&X!&F69C$?_K]]-
N3KP",E\DJC!_^ M]-7=[?']D]FPV^^K__1F__/'_WM\##[&*9!#E?@_AF<)=O=[3($BS2(LW62 M;L'7^?8;< PV>;[[_:M77[Y\^7.;)OLF680]S9)\N889_
8Z/T83EE&W"5/(+3[\#I#[__#OW?";A;G(?)Z^_HT/^SQ^C,/]E/L@@0'#'V9^^ M8E9ZND^C;Y/TX=7KDY,WK\H/OZ)?_OX)_Z+Q_9O2)_K3[-0MZ' M:-
K35W_]>'F[W,!M?'>-? M'9^^/GY$^NU3MOJ*X@V /Z9)]&_@&A#(?Y_[^"?OLK"[2[")'?;5*XY@,2 MI>DK//Y5#!\PZO$B[_BI]_C17Y3_/HRN(?
15P!_>7G>W3%,9Y&RD9@H9 L@ZR>P),,? 5/A>O8)1G MY6^.|6\(=OAS4ZJ40&(H&F"69_0K X3D21Y$!2'4N_M'=!^14X:^PA<,C(_O
M;K_Z\V*^F%R"L[N;F_.K!9C ^6!VE(RCX>\8KK6!+6BZ&48 MW(=1F(=PH&/-6<#'V6Z#H77 +V>3]I/+V6)V[ID-Q'1B64*P2^ZK<15SSLPW'%LX
M/_G,VE(F&"/Q%53O>!OS=;?&;XP@MGB G&,HA@NZ_^W#/>=S - MD]5M'J2Y.?9/..A_'T18;ZFQ_,)0?-(\BSTB^3Q>F:/X5 ?%+X^13_N1?R;Q M:O#
[3]E<[V?2Y#7D@]3[1(+)U73$-Z4NH04/]Q@UM?1BQ'CS'39.A?'#^=,,_MQEGO E9[?O>LU8)!Q$MX(I"47P-8?%[QC =^$=*'91#^!KMRQ"Q>)EMXF62#
M\02SPJL_^V**&@@!6^_ 4R5DC62.&.O$9]!R MB$C_-W'$(B>!8%9HX^#J, 1WSC5_#AXA"#8V<
MN[F>GVD]DP@_A;\C+_^NU^'@!;]FH8SU=8[]";H73@+LLUUFCR& M*]AZ_WR7P=4LKI2@R3(/'X=P(ADL[-[XH0^<1,Q:HAG '@U$N@!C(FJL?YE
M!D/2'P@4)BBRM*L(5IG%CT@9\,">O(5'PYXNV(*' 6Z+H?5670\"]AO@:'BK!DR:%X"?S_ M6'9X#"(L-MR@$Y"&RQRN\!UF]:KY"^;++;R*
[((TQA4$&IY#^]_QI&>U7Q'"^ MW""RP1LDGYROUW#9MS72,?#]^WN51\7M#B7'+2QF 5^OBGF^P>\".85(:Z'_M@/7:7K5;/TS-
'EX/=+/5%SN!.J8#/8QE0FD"Z@2SX,2=B8X5"')P#Q_",,8/ M7;(&%$C?#H1>>*BW\]-V KBS5'4&G&?5DK(#1+_G,<)_V(^Q8O?I:L-4[AGH
M##8OF$O(!"_WJ1V$Y*==S%V3Y3+98W_DPW42A4L<"2/U@IZ%UTE"_7\C,FL MIF(H1-$\&TCLI4'\3'CQ=K_=!NDSOH!NPX.9K'**!46]_"@N/
MX>T&POP&1CAW=!IFRRC)]NE@M[_FH@/(+K+SH0>52&5)X@S=CRN2E%VZ8/R_0\ $N M=YT5^U>F9'RH 9$PP"Y^.+Y$5]0*+-#OP_L(I)*V?+L>F|
]*R7*>+#5O[MCW#^*]CWM2==RD=$G P@63R[7S5;AV):'%3NLG\7D$I#5H'$LX*48XCB K=]KP<%]L8CW'(HP2(,&IQ1545GOT6B!%MI@# ME'D?
8Q%E>,YL,I)P1&\|D8%_<8</>XCV15+B4:J:GM/74P M:5<1=W3:BWV.M-6/81QN]]OKX!E+'MET#P=B#=/5>Q=%9,7?T:8"7\X@M &)
<&XR9/$;_CEF>$<*AXIA@!DA20,6/PTR)I[QI.O,/#7!!2LH*A\7,_"-Q,4.I M$_+%'-\^4F!DFL4Q&07882.*,=2C:*LL@!P3INR5I?D,;G#]B.Y5A 8P'(1^
MJKFG.9<#O;.QH) 1$)*R/%P&$?B(E/Q]2N[V=EZ_4Q[@HAV3NKVEGB\,?"D] M0!HL4G]2&#PF7X)T165!].X127#R&(1HY@A>).D'?*&YN6]Z@SF F]FD
LP M6O)O,/D:5)^#-7HZR8 C\+Y*#.(4?AW/G=<;4VK26N*8@"6N= M*$T6*QU?_8:PN5.A88\L&KOF.E-AC]&,*Z5BN>B%\?M(]>]^'MJE,#IL4V:[JM
^Q&3U[GO"Z_@_C&.':1_+H(%OA)906;,-\/Z[RA"^29SIE MG_8(T2>(#5%P-7F$:? SY[@N@PS>)V&R[YC(5Q!_0)U/+,="B2#<@@HQH!R M$""C.
((".2[X6IBN8[Y D@2@YMRB-* M[OP/?PY'/1]1*>[VQY-S%-SY8HT9+XKQNO1QLC?!)#&%E,8$S>(L3_T>>OOK@=V#&P)-]M=-_^/*?]AM ()8
M)SQ9@]B&+,_ =+$)"LAQYQE<):BN#MX\8M:?!CF]",+TIR#]/>E@%%ORVFG# M\^9U%70R\A@/!7@L((,5_MD7=7T,<$9ZN5[ZIK6W7B.BN3LHO-
W[?).DX:]P11(?27P>!0]7O/S?T0Z.0M,[O93<('=>S M&& +HF8X#:,(()[CIMSP&G](D=U]8B;-7_L*XR-E (L&PEIQG9$D $?$M' M -(EO6IH!&P83$,D'&
'2C@00\L]$M7ENNTT&%Y+9*2D(-5]FY.[KY84F-]46'B MV]OSQ:WO]XE(AT8YI/9FNE1W)[,-7!*/NX;KU& N%**'[.[FYOQ] <;$$$]5 M[81;M/NV(RP!-
Q4C]])K1#9*\&B_ M13JU"=NLU:F'!EN!IUF1AN:MK^_02GB%GCE-OI;S9TH*CDC6(2G"R1]WI00! M_K!9_=5_N2P!"<7%L7@;[_#",74#$;QRMIB=
MWX+)U13H%,SQ41W+D/"-ZE@F&+*]ZIS5))87(_;%>F:B&,-TON4QLW+#.G6& MNS1FR]Z#9YQ%-UB58=XB]LNC\P$1Z7+%Q[A,'_[:;QRMG%"'CV)-
!8.6&^ODIR M"-Y^XYO'-.BIZ7#I\CI>(Y:!B#NIA#]$@")O!>>&!0X08E,5_9*6KCL"_W7R M[DMMZ*S%XV\AN4X82+^G@]J4!3>^H9
M>1H<<%>QD&O3EA@40Y:B;^AXWDP>^51\Q&R\D^^Q-?%P=<95]XV!G]3UQ45, M-4II3$A2%7MQZHQW4"R3>##YOS6]\XKH!P!
(M,8D%DO]IR8]=Z@(@H*6Q$:- DD?XYN0(8+R1*S\B7MJ -Z?T5T< MS;.#2]SB.GH>@\[*8Y5#1;6%[EZXTY'"H+.B!YE- RPY9YMJ#7[YRT1CT$6-
M=>7V>OZ!50792GY,;P)HM%A-IB#XY2X=Y4"U^P[A]XUI!]$*1*OXL'H(8#%A MH0.%P/_SI](('9'ONY)H3#I@RR'94J-
@(K4BP.4DGA8P%G92M;11H<"^8_J M%>) ^B"Z#L+5+#X+=F$>1#WSE&@5'^PD@$4435%]#7#HY$$2G)9T@&>3EX)P MC<@*R8ZM&>
<&YD$8P]5YD.(.!MEDN=QO]R1)8PK7X3+L/SU'N:!SYY(:)G&0 M3ODA6-$O_4I(^N1L9N5H]_^/=L5%T/50:3KB=7Q&[AP"(^"FNG=PN\.YUR *
M$=&XYJ/+$1Q@E.^Q +Y;H_6:2K>7A4I* (TP;I&.('6I5 MC_]]*6D0L7D?]];>X2KZ &/$]1&>]+:AG&(N10;YX9A*M5]KFVI"G@$?%6, M(FP5-
,9Y=5%KDI)E+9W]V]LZ22(1S?KO^V%C9G;-,\S:HI<+?P%"\HGG-ZM- M@<8K=; 5>U)7M1T*SGF/&&O=N[0L6L6'QB6 1>C$2Q[##+?KPPV'*&N '-?S
M]*QQ*0C'K=_!V;&UQE4*V:5A>R!)6+B,'3@5XN M.QA\|)T5I/(6H'O<[1A;IY/M;D]L0;'X/?3 H)T8A&5?>]RY86Z?3.W#6&D$
MH/)%IL/\!K!;D=N:13N9.04K%5?ZT*YBT]7=Q[$80]CQ\!\RZ'CX4T5T#0Z5 MXL4RZH5XK6D,Q'2?HLFN2=EK$]_%?WV1I+2"8!R ;"(

M,,5&DZP8X+72M@W9&_5WC5%C7;J:OQ(;O>.<146+NI;KS< SYE#^F^^GK+05 M%VAPK
Q7';I@28X'4X\Z*RM1]ZW&FZ_OW'YH#**]%GJR!E\"7),_]VV+MJ:^ M[@TKQD^7AK:R ^*1:64 C$I
5(P$LAWINGNJ1M"?]:YE(1[I/ACBRO/:DBR0/(A!7)$X*TC[@T^L] MT=HG94\[=' ^3O'3GVUV4/,/21XL;>#@4E7BKNS>3&$(HZKV!)L -GC*PQUU1 M
"3E(K$+'\8X5 ;LT.?C9& 5)^B*32)D]6L[H0?%&^.*E_?A2S$%L@OSO@SA MJ1L?RQ$WNL=5 "A/;BK.$,%NER:/(]C>SPU<4]7
M73HZS7$)Q15B*@C8"Z35:K?Y1HG*^97/I)O/I4 MF,5G,6UN,5^O(8;@ZK#A#IZ%W!LG[]ZEY7/EQ; !4;; M0RDJBS.Y_1%
<7,X_W8*+F_E',+^OYDL9ECQ7Q>!E&2!7*;1+@99*AW_ME\T% =-_)=H!="*O^5$N!/ %N5B= M4X%^B_^]1,M5]1=)588C]!;ZO?4BUIV=1$&
[[MF>:K>U:IC4" M4!Y6SLUX\'-O69&\43C"&"VV8BMZEU/E]C0!@>GBB MYWP@";4K-)[*FG2!6:2C;=!/D!@@2$MKVLB,Z9#W>Z\.U)[8Y]!82F<\6IK9
M#E:N6W GZSVW[;K(G]8SD5NSKP9$HNZ,I"=CBK\]3M;'57-U+WQG3*?:K*6+ M 6MG>9MQ#WK88F%BN4SWD&7=P6].+2"
<:^]V<&KV.*;2)QW=KH$YBFO2A#?D MMZ,VWC]HSIP[F=_C='@Y0+"NZT1(;;0E&>O<2 MS.)'F/GT$L@ &(^70
EII=@=O73^>WXO00:_#A)5"ARU;=BQW<9(W?/(MQ#(QL/$$B@UF?AB=C6Y.AL]$VOP@P83J]!EW]DR64*XRB[05KA>XYYY5KV>
MGU:^"JC$AW9(_Y 01CQ>G;S7Z$,;CHT[^5-7YK(G'!?M9B7YKTRB+38 M#C(IX8WHEQV"=H,%TU;%@<]'PWB&=U8S70$T?MQZQ3-%PF
&YC5W%]PW'P*+% M8*%.>)7/D$!-LHJ8ZQ ?/5J/KE.(>PQ-BY:O1>UHI-^3-:D9='!]6PL(#^43 M[" 5-PK&0RM3$>W32FK14Z.
[;SI2)IZ0*^G:.M@/KH.GLM$IR4Z*BE$)V@' MT_P9)QKF;"U\@$AOCKYO4?V%^_.PZS.Q/G@BQBU>;2(K[HK!A'MA.=+WM6I, M^L9-
:X:@[HTX/Y(^S#US87M^KQU<*0P:S:\]LXZ0+()6B,R^>K8&:V3U<.'@ M)?"PO2C!S_3;OX^DU;(AFD\&>/AS8R3SJN:P7-Q&\LO"\FF'4&1N5O$@=YQ\
M+0_!P1)PU+T]\:#C60S.VKT]_43M:A!2H\5G\X:TE>8.NSP.PD^"1=P_G'Q M-/IX3@_Z>'K(@&SFE9)T[N6^I60NS]"&(B[#)LR3.DBA#VY^@PF5U-P>_?
QX^3F,YA?@<GUW2Q>QL MSR[G9YX]+T[XM-$Z;G#2V)?I6&[{@:A_!^7]"IE_AZN_A(!R%RWU*0$;G3\MH MOX(K;/@Z(XU%")3S]6$/F:$.Z@
>LC,Z'T3HH#H8B%L'"A[%N"N:#C[!J!) M:.;J;^%F.*9K)(8,@W3+Q[$C#),M/O]]2_"]P.1>TN\#;)$XA^8^+B<'>=)4 M!7PH GWR34-AZ
V+71+T]KM=!+$U+XC>!0%V&]UN(,RG8;;.DFR?#B+R:S2[_U*RTHW[C= M31'4Q9DA,D$/Q9L:"SKG2#5,&C+)->NPJ&8XPC**WVM6G\0';F$=G S!>L-
E M8FDMZ3KX6@7FHY1 K.^Q(%)%_L!@/[HL)?%^8>F0] M8#T5)FP?;!H7*&+DOCUS\L4|\)@<(@&/D4&^N4B/< U7E7]OMEQT";,,PF:&
MZ/<5B'KA(#I&H$1/YY-:OLU2/:BP+:6RT3Q:]DUP/ !CDV8C\/]D+80.!: M1+. 44.EN-BC@1!\#,-PN]^,,DX7W)$>,NC: !?!DBP!]J4!67ML[*O),2]>
MUD&IO5PG7;%$_@W;OFV-UF",ZA*7 "KFXN]]2Z= M6<"8C47H&?A61LOB\[+XDGABWG)U]T9,0PC%S/IVM$*#F,HV_,DBPC;LUDE=
M)DD5)O<*N5'=I2*Z$CSB!E58DA657_*EI.L77%*65[)NM[5)(O3<9S2M^2K) M81U',9@W1GM=UV^O-F0BM6DQ/_N?'^>7T_.;V__^S0^O3]_^
9S_[]UL\=E_ MRU@30K3+R9<@715=8TLXLEE,6^M]@IB=X6KRB$2*!UC^_3H-:]88M$'&8,!]L.V[MW;'@0)7? /(1[SB1WF73)(]"--
(E*0=)#WWL??"V>H&(H,2K^_@79T>I,YW MR2N%4(X!Q2!PR+3%8OH\^Q^6=41,NP+[YT^[,"7038.<\RR&<4';,J]$2_PQ
MG]5MSTIC^(17>CD/(!/)9237$I(U;2N9R0V^]LKE611Z6544L!#I&[Q>5PPL M!?[3GJ4A.QA\F-FL(-443AHU<51BB9_R+5UXI5'BQ1J-7:]
<85U>Y;5Z4&'7 MQ\V1+J?;OAU9KO*3VZ&F .?RZZTZ;FV.(R5W*\G@!I(")6=)EF1UAEAF$C]]/;L^GI%[& ^=7M9#&;7WG5O'IBED8?O1ZPUT&;
NPFS7RY2"&8Y3?HE+DVWG6&=RR-T_LBWH],=)PYV.B68[_]*W]M!O#7G&F0W8A6?? .B< W!U\\P2#/_MQ]!&:]U$H?#=_<$?OY502P9A:>A:$ U
M;%9.#P YCS'K#+)6&0 ZL%36:&R"[X#'_MA'$,C3!:'FS@5BS+-^,VDQ-?PO M:AG))H]!&&&X+1+T S8*SV+F&RT[KC-@W'K57&U+=+#(4%"-
!>LD!63T$3U8 M("##?3Q/7GBPLF0]8S# UHO7;K).>6/>CR#HO4<2GI]PZX=_<]02_B""FX MI-,ID6'5)O:4#T.FB!QACJ!Y^*#1^>@;$]>^2R=;$APH96
5>[Y&%%/EGBL5 MYW$[EF+CFN MN]QH0 W73H"^G@2 3"(V^C/Z2R#T7QP#ZTA4[1X7M)MGXUP_5BVU=@VUJF
M2Q.BEY368@#Y"WD_>W.5J0].+WJ,-(Q'NO^V;O71 %#*KKOPNEXA[*DEN.@ M8%3"D& 5Y$C2"*TKCR0F'+L?WC6 45-W6 #VCRKS(>Q&/T%
+D4%)WOKH,6 MQ\U'-@9(*&4V^-;4/H,-YR)(G2MQ*L;F,_3&*X6R6(#<;U\@2]C MV&/*3C;N?^*X$];=T(C#6
M,,0%45^DYFD*_@M4/PVWV%4'5=\2_Z[*ON51Z%7BMR&VK6%8$69T [,Z-(.*8WHJ3W2Z%RY!> MF*1ZPWC>^^[P>]UF.-
(0"IM@E;55+Q4=B(RB6]IT;YHI3K6/LK4DSCKQ_MC^J[/:!CK'UHO1M1%C6>&!_2IB[^0]F;>8;,$-34I[0359F<64PM^[!*T]; MDJ#?
GR4QZ9]X#R*I*WY?$P[F(U]TC_#&'QN9H!Z M/,Q^2^+R7[-"5.QT/73P$$!"& WE&\N[+(3/>5)IWSN01U*WE&\]_M>P@>ZS.(DH_F#CT3^H-
G3%ZLGJ!^B4'-FGNS\UJ-X?5TQZT#'=S^DW[Z I)Y MUF?H]0[C+%R.RJJMA//EU!I2;474@/SA(84/V,1_*A7V> M2SG^.WBD9O$RV<)%\#1\.RSI4C[>,!E
KZ>79W-/YZ#Q>2O3--J3\^,#NE8 M'E1NU_I"Q^5]PYRX-B;O"]M4B$]AO QA-CQ;&2[N6F,Q T_=HCI/LX6'\^O M%K=@)\"]XG-
XO/8'$SN;J=G.$ZT+>>17(+HK,,:HH9 MZYMTLESNMWNRV!36;B7T[P@2B2%>3;9)FH>_DM]?I\D.(IAP+$^._H8]S3M\ MCGKFW-[
ZL_9^HXR=4RDS)6,K?L"7L#SN!'N[T%0+P)6S"K$N1HPT_NT'?7-M7>P1Z17+E@Y2;4_B.R0]9MDC_/2SI^6Z%,$S[[WHV('0Y_7O?I)L()5>@QF
MV]T^)[73:;EBKQI>)W;0[G4MQ9,W&PDG8'ADUA$>A'Z.P0 [,2[08)2$\R+M M)1*.[--2(B)&AQ)%-A[(JZ09W-
A\U]A$,XMEOS>XCJ/(1!P)_EC8^N]AT'8H,H 99LL[B?Z?"_M>X[W$I&L<5ES]VQ3M_$N?B1\QTO(X+&,X,[4F,9M25\U0 (V*0>"M!I9\,<>
MCVUSB>LK39]BU>VDB0Q[V]XGVF5PD#NF,;+A:N%1BKY7V1GN_SC4*I[2@X);&H1^]5,2>=#AL'X/E)HQA^LR:,P8Y>K*5
MW#_T$F@$A[(:090[6([AO?0^V$:#D"P3J?9O:;S# NL>(7]85A*MXJ7],!\6 M|>/V$V^_@BB9I=L0],\-6Y@=$.JX$V0,K
M29;RPT]B@(1,50\Y#N/C79I@"R;W90+#3FIR-GE*@0)KQB)&WTT2K69;A*1' M6K5A$+Z2K>3^M9- (_0$%"_R-P9R?
VD0<:FY5^^>|NW;KY>ATLX[$O'7]-U M^ L7"IV$EA'PKDX\\,(R45"RKB'=JV="E$-;G,30P@+0&.:U\=KBZ*'R[5$>K
M:H+>'QPIQBL#!G=_=IZ%8JK%E\2Y@YTW2R$!X2.7=&O**=$ M?$5IX?YL/!3,9&:7-G>@1U*K[N\1DUI\=POWUY74AC>X8*@[O4T"A26[_5)<
MZ1Y& ,\DA]LT4Y.8^<+'RT/.C/2 M&[TK$%XBO5N8Y]*[N45C>F=I_H^/81QN[UM]>PL:Q-A:T$^UG:4]G\,WO;6X MR/-$O_%^K0N1CRG-
WXS%%4XF"I[Z)7%C/M?QD-B'O(K$KH ^9@*_^Z^3;=V_M,?BOU]^^_L%_3)HYX2I)PQ 5MJO%9I[6P3+-(KF%CS FO\,_F]F13.9S;DHT M $[$7V^^??
<[S%]OO_W=Z0C,BQ;D]SC,%!M6!DG"IV3"V_)X9V4,VVT,G^H1%;&>>^;S)FC%?G;(L8]&)9$:!]4<)T]AWTV1A,H9P'
G56K$XHEUW4"5Q%1@J=_;D*%C!U\L@%F&.2[O/XE7X&*X0"^F27&$CXL\[M@+C-H[@0
'9R;_FW]IR'N!N/U73XQQM")+IDR!:G^^@A4P$\US%YC>]_^V3' MSLS1N+*L<-CA)2N3=]M*%;?P@42L]LRZXG4\E'H7 B/@R/?[#$FD608R^AVI
M2%G\VW?==24!6?:2;]RVAOE9D&TNIK.S68S+6JT&J9'#7\-Y93X>% *FP=^! MD'Z(RSGM"
[YI5S+UDB4AHUDC/4*X97O%2UC)Z2Z#ZWV$&QOT_7)JK.CA(M(M2\!=YUD>;DGIL#WY%$3A(\S\/H#Z5&T\>9HXL+V=>)68L/@P7Y>*8>_ZOG)!
MYPY -4Q20P"6.SR_<_ID5)7AXNR[BRF 5D3!181N^]^B>#B[CS7]'8+06XR> M-_B$Z\= O[<0GQZ-&X>S(RO/R35$R(]SX
%IF9,X1AHFGF\6+U/,9WHEFU1S M. T/4P CJMQ.O@0I9H&P_!:W\R[F\AH8]DFCR@BM@X(,&:'MZVA:E *\0:^Y M@Y>HL9R/W% Y2 (6*S\!:)@W?
C*EHNHA:NW;TBQ%.DC.UTA>FJ!%OE]'B!U M=36+SY^6&US%"UUT@DJ4?8<]=8#$?5"4/;"B;-1B"A" %$]^C*R/D7@. CR_
M7WVO!QYI!%)UQ%T'@:LY;?F6]\S(@D7D/3,.^6P6J9QEV1[?6DR!_IXO$]J.EW?=X,H!.U"&F#YUMMV!NR[A0Q!=P$-;1 ^:93FO!U-F
ML;308HG^#M:0M89[4A,/<_4!]E=V 91-CHLSM>+#?H77,_C%5R5I1:TA!^= M>5R+01HPB7PC96?/'1Z*RWKC@OB[%![3X75M4\8?
AT4ED.%;WDNO7E-RUC&[MFFBR#7EAK]ABOG+%(1^FUE(^BN/) %(VL1S;IR0BGN@]XF[8VO")G7KY\T40
MI]0%Y63USWV6#]!U2KR.!\^)$!B=A.LU&D;[G_HU'"DIQS*0?,?6\25U1O=9 ML OS(*+2^
W$VBY<723IQ1ZW[RA%I]YC3XS7=RX4&8.H](214;TN+2;P+$M9 ML\!ASTAS)'7I86';F(;\#^ZJ$<8/M"'-:=]VB3Y!I#,_K! MASUC #
]JI8&2")_VH6$788Q.'IKN!BYA^(B[RM_%13-$N+I,@A@I35@U[OD\ MZ*_KFMFU(1-V!:D^!JQU%?V0C2DBT9CR+ >;(81H\P!NX#<(8_?X@5>FUEO+N
2RW29/N-R@]7UD,!P$=CVT&Z,[SF77I MCR>]-Q#K1A[+0TQLK$'5'OZ*WU@>]L[,*5UH%33.':4"8'1]%2[(%^Y2]G78\> M%;-I;-
;&=RR8]JQLL=F%+^I)'%Z@N553G^[32)^G,3-/(MTB"M=R6;S^I8M#6%3]K$=5EU?^^Y-1UK>=(*)_8F!^EZ\WPS3.M9^8+N+UPE M3/+XGY
,]6LETZ9CJQ^M>N,=A(9)1/X.5WPSVSE-FNF9QS07]>%6U0--Q&Z8 M7,?D56I:LP2&+"^<:;$9QEAL-<&/MB[5^^]EW;T;:I9%077(%IN@[_>>;]G
M2%\/XRQ<$C<@H^&/1=CM8RLO1RCN8;>BRC!)'D0@+$=1A[70]/S'_WM\#'[^ M]/&G[__^\U^7N_W3Y_AW[U;_OGU\]^/P?+VR]O+S_^]MWB7_\;
M[\+GS5D0):=OOD]>__;MO]+OS\+%CW^]^=OWGY[@^N$OGYYNST^>?_?NN^]N M_WIW_NGL^Q]_^LO)W>ZOWUU?_M^!_^Z^6G_RX^_??
X4W\VO=_G-U3]?3G?? MO?!\,GM_<_]FL_Q]H?2;#)?]KE_/I_U3NW0?4+Q?VVT,G^]=(VV]?WC_8^_W;,;I?NW?ST+?OCR M^?;-/\^S]W>O+8[KU&#7_[V)D[^]?WZ^M
MS%]]VJ]_>OW+W[[?/K+P^3M;[\\SO_Y\>_@[/;F^-A+7,D8;I!>E)F^#H8/ M'[$2=G/#ZB"VB-'L[<5XJ8?8O3!4D@@4($'#0=#R9[PD7_>0YZ$79_E@9.U0
MB*4H-S6_C*'8(#T%\X"7B(Y6V"H:H\EU9>9YR*'0A+QZH8=;-!>1PB0\!;" M;!*O/B'^Z_UA.)S>^=U\ (DM2Z(GTE.95'#R;=N*;+,0?Y2>W<=#&3[>WPO
MY6$039/]?3ZY3_;YAX1>1TN8Q@OXE+]'<_S2-YOH+^P^,UA!5Z M$DAE33(2%$-].R&,"=[@/C/$6"8FH.J")"ASBP3CJ]QK'^\8Y>4$\,Z$9@5D&-$"%]0-
YA]I;=5F$K>_G\6!R MYX:FYO]BN,*,I%95G_E^&/D48?F"LZTNBCLMG7D#=SC*T,W]H[>FA[=0!RYA MY3 \"$=L@F(:WYQD1-G&RZ>-
!MM*/^AV1AO9(,%N"A]AE.QHB6"BQ-U>N8X MY4]I%9I[&+&>OYM3.@[$%,#.RT\V*=>Q;A^2$H$@ILP^^4LA4AD MQ?_JF=%D*
[F_T"30B!-&ZA'X8:0C ![B^T+3H&(S3T]^>9L 2SP8ZZ-W6 / MQ:)RI)]*TM!1(_61$Z+)NI)+J,\%!R$S4&>PNX-*%2%:^CO7]K81O7M4(+
MX/]@(^IC$&'SZ;"BEMZ;'FXF;AD]<$PMY%_,,.]6OR-J'M8FEP/%?;%#_BE
MJ8=E/>UEQU2Q7(\#R^&$"ZNQXRQ;KL&!1MBPE<&J=/KYNDAS"R+&BS2(V*^W MIOO;3PLN44,&7%&!#,;B634<,..],J(1G1O)C]I(L;P':?
%:4J5QX%=7MI*O M8L5<;&3E\CU[!##6HU:Y,+-ZD;KK133DC*D;X"/'5.SW/@Q1'7&37,"6+#WOQJ59SS9@*>$3B M'4R/R>>]@GR?!-
JDK!1P4ACWUT:'X5)2A,,;N R"K(L7(=+&D!4U4]:PFR9 MAKLAHG%,E_=3=\AG8580'MCL]3SFGLDLJ5OSG0V>K/K:?0PCF.5)#-]G M\3Y#]^-#&FP-
>$XVWG$-' DH CZJ1@ R!!1CVDSDFH$TJ%+QBFK;7>+>2/U4 MQ@@CNI#ZJ9,@6,E#C)L8&D.3G/?[R("4K5()$@Q8%=Y"/+K=1G&7K<'F@(
MTN0AA40X-V_Y22.WR$5/**^EV088,:!:]#_%TF74A6_:&&AP]M$92%\12'& MC/-I@M,F^[;4<]?H^;:)) \1%P!1?
B^5AZN/P<_T]J;2\P@#*MQ005!&I&P)\"\NT(Y%$1A;A.(G7OB))801Q/2(BRP)[N+CI.T]@ M@08/(D3HK-A_>(2,]S0@$L7,)O'#\26Z,59@@7X?
XDS@299!CK+]A]T,R*N5 M'"" $=O8B/K;%:\T]R@6-8M_^F"I4A,,2(>P[R9G])^R+V^XWKDYK_0&LBQ MY4?AU$,]OAH+NK3
J,'1>'_Y"5)'Y#WF/L!CN@^E#[_F>CH8>,YP0.1\3=Q4 M@[RZG 4:AE M!AD-%PDE)L7V[?U/W(F'DI 4B[F5T.7 :,A&Q<@,,(5R1^6_T*.MDLW: I$)
MHV5I_H\;7(M8/R8+#6&X"?U4<]+A;([DG8-E)5ZL,,O#91"!CS#(]FGAT_)K M-Q!0 .,=MR^;L"DB'K72(;;#9"VP >EG;W&R+OP_UPO<
D$.ALCNT&F*"Z4'B"A"CR92W MX:U>VA7PS#*#O5/+/'P,\V=R:&GKM?[?)-$:8WQ_!+#V]M84\Y>GHFCBYU=1 MZY-AC!\0&<+[?
2SH!),]NGS2\%>XNHM7,&7:6I(*%F5OR^LT7$(B,+[]0#H# MZ?U1Z;H#G8=&<(KX&NEH7I2^&%#]RO1"@PZAO]JG+Q.]?>1_L)MV$J]\PD(,%-M
PX"HM.PXP$V(@^P@, '1%3]$=SO/KA+R,1SA;'G7IU]Q_5F]N[\HK@&Z/#+S_+0@[9]+/ ?D> MD $0_2_!1SX\B];2^B[
0,TPKPT<6;+EZ1Z_T%O^$%41,E"#CT^8BAD M;1D ,P+@(>-0U]2T:W9KD&[=TDU/NS\8O]"<82X?W?;RT]X MV5V/3$TKAAP1W9)OR *#B=K<-
=RGW#0!,&>?69\.DF2OOC7##&&1"+,,?I MSK-X%3Z&*R0H?0KSS0VDA5FR3;A;).=($$<O6(F4'I?
M%@S$!FY2^XK8(NN_CZ+F0@<6;;RBEHBTM&/6<^$N*=A,BA;"L97[47?$-XK/AN- ME51)1O86D^/ JL4243)Q:$::/R]2]-X'2Z)S&E]36A.YBB_3-4;8?I
,!60L M8 ?++B?7=Y,)V:J+21LKU]8%P0I#W4W*Y9R6NU)!8\YP8XDVT"4K>U=I8:/G M^V"5+/?
X8@S8OL7LO=!09N;KQ0;]'ZYQ!L:J+.HC4BAQT,B.A%CO8(I#16 M>$U_BWZ3DT_@,9T0?"EF_-9KN*C&EEL7A3;:^I8Y-0BX"VG''OP,(A4V+[JB
M\DA6?PR6Y&N0X<^_]>;&XD+/P;YPC_V+7 88GZ+SG)7T+UD$:5#3)(]"M"IH MK4&-%9ZI.A_525J-@3*:NY10S0A/ X09*$DZBYI]! M4O-
:1$4:P93BCX^3]3'Z' 3X^V_]R4(ZVVF12Q\"LX<[GP=Q/C]96Z 25Q= MOK.BV>I\O88I4FJNO/2;;'&@'WZ=PF)2_&_V.B3:4746PQA ZKY-BLF/0-P@
MKP<"FZ.C36];E+X,\H>%,5?$!E=[7,8-DW[6$QN\ "8HD=(',S01[./61D#, MUQ=)NH9AOD1/%I)O1I!]$- ^K$4R82/V U$VG6&/5-$TZXFP?0*R#0@ MQ7\-
RXD\/E>*+;9(I842#Z2Z";-?E>'(APZ M1C<0B1(Q7"V2!2V,4X2]Z++>_%#*)3=-6LP*\H2^&C,4?G2<[C4YU/Q N/
M,6IGDKZD6Y+|EOPK:^^I$K9F,?,=XLJ<-'CQ ^UB4; T5Q!],>QI@:S^V-*: M4KW[$3UQ(V$E+4YLRMKDCB3,2/]U3^(JEVQ<95"#!NZ?
&]_M*'@@((43Z5_(MOS/)Y8M-4.RG_O1A5Z1PQ.(3?=8&((I MT]$:#DR9^26HS,,-MJQXCS(PE[O V02H8G@4_!=A?!H_+[T\^_^WCZ M9EI\F99O0D8>!?
1CDF((UP@68L&,(7B&08KFPHW)MPC,379$1.]\$Z)/(7;] M/GL.B'!/8OX9\L!E7]YX[%O!#A>XFNZQ,X6>?OHN,S5DY2%V(5,T0YFN 9C@L+

[PHRPN7T_A3)4P)61]Z(Q0YC7NU5E.JKEA_MIZ3SIQU* @)]2 &Q7W1\$KV4628H^G"/7E9T1-P1_Z;;EQ #4/R=R-.A7M78:> MB[+
GY"IT5>8HZOOCFBUPV?P<_%?[, $Q(I.V&ZN2$>TGE;=GBCD+#1C'V* MN3&9Y"OP<_F=WPRT)LP\I/)VY;(<49WP-
CG(IY2H$>+D/Z_8EFR&AWKEWET6 M6,$O?PHWZ/$/'^$L1IH.I%>$9CQ(8SR@$XSXMM'=KH!N!JAZ&>)ZX=1E0OU* M4^Z XOF\E,>99;%!DR[L,REN
#SV*GBKR.6X6G,=:$VT =G-C1B$?'A$],(C M0(U=_]^#Q@Y$UW5]EXY+B5ZGR1+"57:!P*\CW57YC>4H@'?=R!{H1_K6?.7[
MXHK@&IAP>O>>!RFVSE?,)=L&C@'3#C@M(_MI]!'/Y:)%;&&7J(5^0'='.&V7Q]37U;]%?[+(QAEDUAMDQ# +(Q/&+LT^G6Q.&!6)U(LMR
]7U]R4,L!0=URZ VN MPQ##57EH/D)LIA%'Z-"O075+_$P'^);;^=O@45"V87@.AV30%M"%SY)4&5+*35RNJ_&&>*Q;A^J* *]T5'M^
M;84F@37)!__UBSU*+E(N8*X2 M&\JQ1R1\,Z=MELOQ1P#-,!8A06>7 @^%)G8<.Y$.ZZ/-XNL4[H)P-85KF*9P
MA6/XX@PBF$E58AHC(B)D.1LNH4O_]0UQXM(I03$7H2^9#=#I?'N<[)# HW,7 M=+]*PA;6G>1)?4PU1]9EZR^OHF-MS5/'MGY!$@ZXAT5_$S-UXT
EM* 7XST=VIZK_5U M;ISA4A,\R(EQK^B^U^C?R$]PZ5Q 7&]-M^%9.B)FUH58XG-RW9FI F<96/& MMLSDY68PH'?S9M#%D+N74ZM>-
O\=+:J(D['XGB#92N5P7O#-OU$%<3?&E9)Q MBKB Z^_;O1J%:U1C]<*7O5PM/0VRCM;)BAR*S"U)>BFY>(R#.Y)*I&A#G)@ MP '5/.-3/@0;UM,WI-
ARK%R>!=D& S^^LA^#"!N<;N<4_@.I%\7^@OD20_R: M0U_\V1'_PN8KQN>0OH)UC(/?LF.\!UFV@4W/%;H =F.V4/I-N=5&&%CGC\4
M59SU"HWPGF6=Z(A,-W3]0U53NU326G;*IA@PRKZ4@^#?*FJB;_*[E$%H+L@B M>"H,/N]A#->AT)*/P?
H^\I(]G4QY!NO!D_!/@1OD7C+]@WPZ+25,C"0ABA: MQ;TYE@>&0 \LN*96!WE6 09F>T/I R=;>8"A1SE7'Y M>#; 3(<$T:+@T$@<5!8XX!'9&I6.
[TL:2M74>=39&F4XV8%..*8L"_G&>"33 M0863ZU2W)0'7AGX0XE[9Q2K)V5=ZX%"-&5Q?DNB&9]P^:1(GN"_$;>-S&3X
M*6,3E1HSC=5@9KIYWCFS0Z!CK^-^MXL(3$'T/HAP/N3M!L*\[M2@OB39.4 Q M"2"S &8;_I7I0Z QV#)7K#%&F>OL$9LL&.HLF<7HB285_#
{2=;#8!&5RS.3A M(84/2/2>Q3D2YK)P23RO3$#1@(DEA9^* ;\("\D1@+5=I8(15$"6[F\&SC$8 M4SR12&A=\0]LZ4#P- M9?(KX#P-
5>!,!168$&].T=AED=3%/@M%H>ZE<5'VTO">'_Q_U[XNKG6:P^H3 MTMAQ7K&-@P#Q$=3:$,.!2_;JV/9R!7/L140JT&.X@JOWSW>DJ4IU(Q;IA]'Z M.
<"1<\0]6\Z%Y<:O\73H:?Z&,=/44_+?"R\]I2D6^$JE'2Z=VL?EL=^M4&YO M-0ZYTE(ST-JIC;(VF0H-DO4GGLV.-2!<&^/A5EQ'#"A2GYFJ^+B.(NWWO-NE
ME^^ACB!V64#7U4M;'V'2>F>T1 M-E/X"*.$I/@4FH&XO@\=1'B'&5:]1E[%$NF.>%350(%#NP .1B5I-X1[J,1* M79?B5+1B1%F:L%
O#DL3>LD]$VV&1PC5UEV' B;$H+3$)Q8IE;35.E+9G4F:E(:G/JK#.G"7#S*]O)*79ZW(#$$*;<<&VX]+ M_Y<9TZW]$GKEO,MP1ZYWUF])
[]:.^**;"@.C2")GA?J+)"U+&MEDDY<4*_Z* MF^^4T_DMYVBT<^[!L\#=V/)@C/(@/J1))]J*VU.GAG:Z"UG:M),?5]Q_24RH1&NOO*A)1*<^IL-
2X9/EG]\JZH>5EPV5>1[+&?Q(\R:'DM+KV\U$^/U M]=U\47O/!CY>(<:+I#*CDO+F*V[Q;UK/#FTM-4%-1<)),E4NI3**SXI^Q\FB>@F ,<%$8\
M;E9&'$=K5/6.N>XI0WRYJ_V5Q'"{BY)G"*<(K&6>I HW%3,"5$-:MZ+S5"7A M/EIG2[7E,>@D\!*?SPQM.T8/)8E!+#)N+*,V%+TH1Z,X2/>NKQ%HH-!Y!
[NV-MCWJRSS=)&OY]]J*O1_J.()?O2]=;?X@)IWK8QV"Y01I'^LQ>Q0J?2SFD^4IQ-MVU7YH(ID2SR2*#'@TB;/XP\-
L[SHJ(S%,*_8ENY)$9CGW0@,4X@MQ[A;SP.M M.#MY2"%4'QZ*E(*)_F_-%& ?QL@^;-EV';,=%W(Z+RP^194^U>-;UKX]AX%R'(\.OB@A MV9>
(DI,.'EN23!@*01UD@_\A_6R ++HE:P$U<%VJV+7M"GCGGI#B)>;^ V M"+'K]2R)2?KE/H@6,-V^ED8X=VC_7.23,1"UXYLKH #%2!@>4]]=TJ$EBKJ
MBP^<)]4\0$V!Y70,@9IRJZER_\Z\1G?$B0^9 MMU[UWYE5Z.9$N5 MUYV.VWXD#P=:O;G6 =3%A^,#0V*KYVLD!!/->GY/PVIF\?G3>!321,@H4A.(?>A
L<*< MU:'3W:'F28Z>;SN>V>ZYUCD;!+]T%U!#M*CZL_ 04L.\I&*V;WN!?%_< ZB! M";=79)$T5@M4/$VT^&@T;O@&T#PT-MNET.
[R5Y/!0X[=7AH44_#^\KNPW\",@U2F746_LB\/5T\C'";(4LB MZ-*B#E'VRUD*5V&._R6I95(/ ?A+]:!"24<4/&@73/54Y$6V5;Y%18,8EF>J<
MZ_:CK5GVBTEIY\@R\IQUKRGKJAUSSY@AOAQIK>J,I[H(&/IW!(NPULDV2?/P M5WH[F$;?-U/%Z@6.0+4$[0'#+'*D'9_OQQW6"\($CK,>B>&4C2+2;
RN^#*" MHE2;L@I@JV2;'])K;9)+6 /TN&Y;HAQ(T+'8+"\$9.S%9B58Z!84XK/8++^\ MO5ST/2CL?UP7]A^-^BQ=%_=,JA'ALFI0$ 4IYHQX]2EXD!0;P=_13
#\';&\ MSM?K< E3?$TNH_V*.]XSTL3^0Y*L;/%46H@#W";1]S2.P[UR928N/AR[M8AA-MBK01E-OCZ#>>GR<&6J&5C=V,\Y9RZ-G#]9EFVQVZ(6F9-
/FU4PT!]!CNE>.E MJJ%P0S$*_?OU/A<^CPH0UQ*?'*UVZ=HB_HU_OH;OP\V!WZI:^=PFR^AQQ2_
MC,@.8]_CHTY]5(+AJY/HJ&\OR.#859H_1R0CNY:VBPV*80DN_\JC.%%^%AF M_9/?X9_G,93?S&2*HA@"G@3@456EA.
(/Y'>X@H+W2A8&.VZ%W!ACRZDXKU_\ MI*/^QBL;.W;]38(%_U-B47X*4-TV9?I-1,AL5=WF9Q2 M3;$]:2*,F)F2E'?KUU9H9F)L-:25R; =NNP*<7!&T
6XIL'SU[@M?QWG;HKGW@ $@. ,P&<=4%L=4,O0% T.QQ'\-L^ M[2]HZ2QU ,?
^X3Z+\S63SD#,B6E1))96"9^OUQ#'!R+1+RR:+XHXKYP2(*O7.]$=L2A3])(A7A[]LCBA:P90P@:]+ MJ+YAO4Y54@X#8_!H&W-*!&[GE@1.<&B382)6#
!5QB2;=0*"K)-ZER8IV M]_++2I)]\NBN1(NGUB.UI9)G]&E(-2/QL[6-YP=(")"9:@V"F0L4D]5= MU?V5OC7>>4MML,2=:V4!/F FNX$[?&?'#_20T?]5AS;3P:
:K1>"[D6>U]DG M5T;71Q!S 6N9JNN\!,0@>!&D82*9Z")*O@CLTA@3&4(%0<,ZR.X)+HIY7F&# M]2L8Y5GY&V+")N9KK:5N?+"]> PU.;U=I
^ZR\\AT#S_#(%U\2<1AO69MS?%T M ,WG/=[7:/<\BEHAT.7)HW&RB^!I&F;+*,GVJ3J9LP@+1H- /0K\/!HU1[8G MP8.FP('CUZHV;14Y*M21=@,SF#Z2-
JL7^QQ!63KE]&K4E0D\A0N\G(W4-:#S M@7+"L309UMN^PCQH@D-7]36+MQ<=>7G8;2EWH_^]-T(ZA+EE[.%ORF5\BJQ% M,?
DC]1E6YB=AQ(FPBE)Y>N@717'1:CZ?L2.F>V]'@]AAS[7!I,ZMKZ/K<=RN M7B$"W.435Q1D:U\=L2D/TE($?BL1R/;+M:R8H,IE@HPFHV4-
3ALZ9+E3BTT/HLX MZ^RO'6VEC12WDND-)+4JKH,T?UZ@$Y8%Q$^?&2@/Q12 S '82324"2\U7?7W MS#N!QBAK4-0FVK]TLK$1W'8!_K*9W-
T06O!H1/%7WM9&.'\[;-]GX+X&[3BQ M^BJ\^!/1XCQ]\B\A4OT F%C, UG0CH8P@!^M?XK;[N\%)5O$; G?"]DQ5ZIYK10F75 >]G5E48Q MSV)T>O;$.,=-
RAJJ^&02'YX0@P